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SUMMARY 
SAMENVATTING 
 Summary 
 
 Hypertension or high blood pressure is a major risk factor for the development of 
cardiovascular diseases, which are the leading causes of morbidity and mortality in western 
society. Recently, some functional foods have received considerable attention for their 
effectiveness in both the prevention and the treatment of hypertension. This is among others 
due to the presence of food derived bioactive peptides with potential antihypertensive 
properties. Compared to antihypertensive drugs, these peptides, as part of a (functional) food 
or as nutraceutical, have no side effects and are less expensive. Moreover, as a more 
natural product, they appeal to the consumer.   
 Angiotensin I converting enzyme (ACE) inhibitory peptides exert an antihypertensive 
effect by inhibition of the angiotensin I converting enzyme in the cardiovascular system, 
hence preventing the formation of the potent vasoconstrictor angiotensin II and the 
degradation of the vasodilator bradykinin. In order to reduce the blood pressure after oral 
administration, ACE inhibitory peptides have to reach the bloodstream in an active form. 
Therefore, stability against human proteases and intestinal transport of active peptides is 
required. In the current field of ACE inhibitory peptide research, the maintenance of the 
activity in the oral delivery route is often not taken into account. ACE inhibitory peptides have 
mainly been isolated from milk proteins and have not yet been studied from pea protein. 
 The aim of this work was to investigate the release of ACE inhibitory activity from pea and 
whey protein. Moreover, whey protein, from which certain bioactive peptides already have 
been characterised, was compared to the unknown pea protein. Emphasis was placed on the 
in vitro study of the activity of ACE inhibitory peptides after oral administration in the human 
body, from the gastrointestinal tract to their site of action, the cardiovascular system.  
 A diagnostic assay to measure ACE activity was transformed into an ACE inhibition assay 
and subsequently optimised to obtain a more sensitive and less expensive test. This 
spectrophotometric method, where ACE inhibition was measured with the substrate FAPGG 
and rabbit lung acetone extract as ACE source, was validated by the antihypertensive drugs 
captopril, enalapril and its active derivative enalaprilat, and by the lactokinin Ala-Leu-Pro-
Met-His-Ile-Arg. In addition, it indicated the release of ACE inhibitory activity after digestion of 
pea and whey protein. A more delicate and standardised assay was obtained by applying 
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pure ACE from porcine kidney as ACE source. The ACE inhibitory activity of captopril and 
Ala-Leu-Pro-Met-His-Ile-Arg was also verified in this assay. The ACE inhibition assay 
presented a relatively simple and reliable tool to screen for ACE inhibitory peptides from food 
proteins.  
 The activity of the potent ACE inhibitory peptide Ala-Leu-Pro-Met-His-Ile-Arg, originally 
derived from a tryptic digest of β-lactoglobulin, was investigated in vitro in the oral delivery 
route. Protein digestion in the gastrointestinal tract was simulated by digestion of a 4% (w/v) 
protein solution with porcine pepsin at pH 2 for 2 h and subsequent digestion with bovine 
trypsin and bovine α-chymotrypsin at pH 6.5 for 2.5 h at 37°C; all enzymes in an enzyme 
over substrate ratio of 1/250 (w/w). During in vitro gastrointestinal digestion, the heptapeptide 
was partially degraded by α-chymotrypsin, likely to Ala-Leu-Pro-Met and His-Ile-Arg, the 
latter also possessing ACE inhibitory activity. Nevertheless, after hydrolysis by stomach and 
pancreatic proteases, half of the initial peptide concentration and 70% of the initial ACE 
inhibitory activity could still be recovered. The lactokinin was rapidly broken down by rat 
intestinal tissue peptidases, while almost no degradation was observed after incubation with 
Caco-2 homogenates. The intestinal transport of 1 mM of the lactokinin was investigated in a 
Caco-2 Bbe cell monolayer mounted in an Ussing chamber. After 10 min of incubation at 
37°C, substantial ACE inhibitory activity was found in the serosal compartment after threefold 
concentration of the samples. Concomitantly, MALDI-TOF spectrometry detected the 
heptapeptide in the serosal compartment. Under the observed experimental conditions, the 
ACE inhibitory peptide Ala-Leu-Pro-Met-His-Ile-Arg was transported intact through the    
Caco-2 Bbe cell monolayer, although at low concentrations. It seems that the degradation by 
intestinal peptidases constitutes the major barrier in the oral delivery route of this lactokinin.  
 Fermentation by different lactic acid bacteria was studied as a means to release ACE 
inhibitory activity from pea and whey protein. Fermentation of pea protein by Lactobacillus 
helveticus yielded the highest ACE inhibitory activity and was therefore selected for 
subsequent experimentation. Next, pea and whey protein were fermented by Lactobacillus 
helveticus and the yeast Saccharomyces cerevisiae in monoculture and in combination at 28 
and 37°C. Fermentation was always followed by in vitro gastrointestinal digestion and the 
digests of non-fermented protein solutions served as controls.  After fermentation, the ACE 
inhibitory activity (%) of a 2.73 mg/ml sample increased by 18 to 30% for all treatments, 
except for the fermentations of whey protein by Saccharomyces cerevisiae at 28°C, where 
no significant change was observed. After digestion, however, both fermented and non-
fermented samples reached maximal ACE inhibitory activity (%). The degree of proteolysis 
showed only a minor increase after fermentation and augmented sharply after digestion. The 
whey (fermented) digests tended to have lower 50% inhibitory concentrations (IC50) (0.148-
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0.072 mg/ml), hence higher ACE inhibitory activity, than the pea (fermented) digests (0.183-
0.093 mg/ml). The non-fermented digested samples were at least as ACE inhibitory active as 
the fermented ones. The non-fermented whey protein digest showed the lowest IC50 value 
and hence the highest ACE inhibitory activity of all. For pea protein, the non-fermented 
sample had the one but lowest IC50 value. These results suggest that in vitro gastrointestinal 
digestion was the predominant factor controlling the formation of ACE inhibitory activity, 
hence indicating its importance in the bioavailability of ACE inhibitory peptides.  
 Therefore, the formation of ACE inhibitory activity during in vitro gastrointestinal digestion 
of pea and whey protein was investigated more profoundly.  
 Firstly, the conditions during in vitro gastrointestinal digestion of pea and whey protein 
leading to maximal release of ACE inhibitory activity were characterised. In batch 
experiments, three in vitro gastrointestinal digestions varying in pH and incubation time in the 
stomach and the small intestine phase, were compared for pea and whey protein. The 
digestion simulating the physiological conditions of protein hydrolysis in the human body 
sufficed to achieve the highest ACE inhibitory activity, with IC50 values of 0.076 mg/ml for pea 
and 0.048 mg/ml for whey protein. The degree of proteolysis did not correlate with the ACE 
inhibitory activity and pea protein was more susceptible to hydrolysis by gastrointestinal 
proteases than whey protein. In a semi-continuous reactor model of gastrointestinal digestion 
(pre-SHIME), response surface methodology was used to investigate the influence of 
temperature, incubation time in the stomach phase and incubation time in the small intestine 
phase on the ACE inhibitory activity and the degree of proteolysis. For the pea protein, a 
central composite design could constitute a linear model for the degree of proteolysis and a 
quadratic model for the ACE inhibitory activity, expressed as log IC50. Within the model, 
maximal degree of proteolysis was observed at the highest temperature and the longest 
incubation time in the small intestine phase, while maximal ACE inhibitory activity was 
obtained at the longest incubation times in the stomach and the small intestine phase. For 
the whey protein, no significant model for both responses could be designed. Yet, the overall 
results demonstrate that the ACE inhibitory activity of pea and whey protein hydrolysates can 
be controlled by the conditions of the in vitro gastrointestinal digestion.  
 Next, the evolution of ACE inhibitory activity, degree of proteolysis and protein 
degradation was investigated during in vitro physiological digestion. A 2.73 mg/ml pea digest 
showed maximal ACE inhibitory activity (%) already in the early stomach phase and its IC50 
further decreased in the small intestine phase. For whey digest, however, the level of 100% 
ACE inhibitory activity was only attained in the small intestine phase. Subsequent 
supplementation of a rat intestinal acetone powder, which simulated the digestion by brush 
border enzymes, resulted in an increase in IC50 value for both proteins. This decrease in ACE 
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inhibitory activity was less pronounced for pea compared to whey. Yet, a substantial amount 
of peptides were still ACE inhibitory active after digestion of pea and whey protein by 
gastrointestinal and brush border enzymes and the final IC50 values were 0.093 mg/ml for 
pea and 0.128 mg/ml for whey. The degree of proteolysis presented a different evolution and 
augmented more for pea than for whey in both the stomach and small intestine phase, while 
the brush border peptidases caused a smaller increase in the degree of proteolysis of pea 
compared to whey. SDS-PAGE showed that the major part of the proteins in pea was 
already broken down in the stomach phase. The major whey protein β-lactoglobulin was only 
degraded from the small intestine phase onwards. The presence of known ACE inhibitory 
peptides in the pea and whey protein sequences was studied using a dedicated computer 
program. This program makes use of a database of about 500 reported ACE inhibitory 
sequences and their IC50 values, and produces a theoretical score, weighted on the total 
number of amino acids, for the potential of ACE inhibitory peptides in a given source protein. 
For pea, vicilin (VCLC_PEA) and albumin PA2 (PA2_PEA) obtained scores as high as 10 on 
ACE inhibitory activity, compared to 16 for β-casein (CASB_BOVIN) taken as a reference 
protein. β-lactoglobulin (LACB_BOVIN) exceeded all other proteins with a score of 26. To our 
knowledge, this is the first described large ACE inhibitory peptide database that attributes 
scores for the potential of ACE inhibitory activity to protein sequences. In silico digestion of 
these proteins by pepsin, trypsin and α-chymotrypsin directly released two ACE inhibitory 
peptides from PA2, one from vicilin and one from β-lactoglobulin with an IC50 lower than     
100 µM. Furthermore, several less active ACE inhibitory peptides and precursor peptides, 
which may form ACE inhibitory peptides upon further digestion by brush border, enterocyte 
or plasma peptidases, were released. The high ACE inhibitory peptide score of                     
β-lactoglobulin and the fact that this protein resists digestion by pepsin are consistent with 
the substantial decrease in IC50 for the whey digest during the small intestine phase 
digestion. The database and in silico digestion facilitate the efficient release of ACE inhibitory 
peptides and the study of proteins on a large scale.  
The ACE inhibitory activity of pea and whey hydrolysate, obtained by in vitro 
gastrointestinal digestion, with IC50 values of 0.070 mg P/ml and 0.041 mg P/ml, was further 
increased upon purification by ultrafiltration-centrifugation and subsequent fractionation of 
the permeate by RP-HPLC. The most active RP-HPLC fractions eluted at 24-28% acetonitrile 
and therefore contained short, hydrophobic peptides, which is in accordance with the 
structure-activity relationship of ACE inhibitory peptides. The IC50 values of these fractions 
amounted to 0.016 mg P/ml for pea and 0.003 mg P/ml for whey. In this way, the ACE 
inhibitory activity of the pea digest was more than 4 times enriched, while that of the whey 
digest was more than 13 times augmented. This may suggest that in whey hydrolysate very 
Summary 
potent ACE inhibitory peptides were present next to low active peptides, while in pea digest 
all peptides had similar ACE inhibitory activity.  
The intestinal transport of active compounds in the digests and permeates was 
investigated in Caco-2 cell monolayers. All samples retained relatively high ACE inhibitory 
activity after 2 h incubation in the presence of Caco-2 homogenates. Addition of 9 mg P/ml 
digests and 10 mg P/ml permeates in the apical compartments of the Caco-2 cell monolayers 
resulted in the detection of no or only little ACE inhibitory activity in the basolateral 
compartments after 1 h transport experiment, even after concentration of the sample. Some 
ACE inhibitory activity was observed in the transport experiments after addition of               
45 mg P/ml digests and 50 mg P/ml permeates in the apical compartments, but these were 
associated with compromised cell monolayer integrity as indicated by decreased 
transepithelial electrical resistance and increased sodium fluorescein fluxes. Hence, not the 
degradation by intestinal peptidases, but the uptake by the cell monolayer seemed to be the 
decisive factor with respect to the transport of active compounds in the ACE inhibitory 
digests and permeates. As the Caco-2 model is tighter than intestinal mammalian tissue, 
transport of these peptides in substantial quantities might still take place in vivo.  
After intravenous administration of a dose of 50 mg P/kg BW in spontaneously 
hypertensive rats, pea permeate exerted a transient, but strong antihypertensive effect of 
44.4 mmHg. Whey permeate exerted no effect at a dose of 50 mg P/kg BW. Further research 
into potential positive effects in the prevention and treatment of hypertension, for example 
after daily administration over a longer period of time or after addition of a single higher dose, 
is necessary. 
In conclusion, this work presented a profound investigation on the release of ACE 
inhibitory activity from pea and whey protein and the maintenance of this activity in the oral 
delivery route. For the first time, the formation of high ACE inhibitory activity from pea protein 
is described. This knowledge can be applied in functional foods for the prevention and 
treatment of hypertension. 
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Hypertensie of hoge bloeddruk is een belangrijke risicofactor voor de ontwikkeling van 
cardiovasculaire ziekten, die in de Westerse wereld de voornaamste doodsoorzaak zijn. 
Recent hebben een aantal functionele voedingsmiddelen belangstelling gewekt omwille van 
hun effectiviteit in de preventie en behandeling van hypertensie. Dit is onder meer te wijten 
aan de aanwezigheid van uit voedingseiwit afkomstige bioactieve peptiden met potentieel 
antihypertensieve eigenschappen. Vergeleken met de antihypertensieve geneesmiddelen 
hebben deze peptiden, aanwezig in een (functioneel) voedingsmiddel of als nutraceutical, 
het voordeel dat ze geen ongewenste neveneffecten teweegbrengen en minder duur zijn. 
Bovendien spreken deze meer natuurlijke producten de consument aan. 
 Angiotensin I converting enzyme (ACE) - inhibitorische peptiden oefenen een 
antihypertensief effect uit door inhibitie van het angiotensin I converting enzyme in het  
cardiovasculair systeem, wat de vorming van de vasoconstrictor angiotensine II en de 
afbraak van de vasodilator bradykinine bewerkstelligt. Opdat deze ACE-inhibitorische 
peptiden na orale inname een antihypertensief effect zouden uitoefenen, is het noodzakelijk 
dat ze de bloedbaan in een actieve vorm bereiken. Daarvoor is enige stabiliteit ten opzichte 
van proteasen en intestinaal transport van actieve peptiden in het menselijk lichaam vereist. 
In het huidige, wetenschappelijke domein van ACE-inhibitorische peptiden wordt het behoud 
van de activiteit na orale inname in het menselijk lichaam vaak niet in rekening gebracht. 
ACE-inhibitorische peptiden zijn hoofdzakelijk geïsoleerd uit melkeiwitten en erwteneiwit is in 
dit verband nog niet bestudeerd.  
De voornaamste doelstelling van dit onderzoek was dan ook kennis te verwerven over de 
vrijstelling van ACE-inhibitorische peptiden uit erwten- en wei-eiwit. Bovendien werd wei-
eiwit, waarvan reeds een aantal bioactieve peptiden gekarakteriseerd werden, vergeleken 
met het ongekende erwteneiwit. De nadruk werd hierbij gelegd op het nagaan in vitro van de 
activiteit van ACE-inhibitorische peptiden na orale inname in het menselijk lichaam, vanaf het 
gastro-intestinaal kanaal tot aan het cardiovasculair systeem, waar ze hun activiteit 
uitoefenen. 
 Een diagnostische kit voor het meten van ACE-activiteit werd omgevormd tot een ACE-
inhibitietest en vervolgens geoptimaliseerd tot een gevoeligere en goedkopere test. Deze 
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spectrofotometrische methode, waarbij de ACE-inhibitie gemeten werd met FAPGG als 
substraat en konijnenlong-acetonextract als bron van ACE, werd gevalideerd door de 
antihypertensieve geneesmiddelen captopril, enalapril en de actieve verbinding enalaprilat, 
en door het lactokinine Ala-Leu-Pro-Met-His-Ile-Arg. Deze test toonde bovendien de 
vrijstelling van ACE-inhibitorische activiteit aan na vertering van erwten- en wei-eiwit. Een 
gevoeligere en gestandaardiseerde ACE-inhibitietest werd bekomen door het aanwenden 
van zuiver ACE afkomstig uit varkensnieren. De ACE-inhibitorische activiteit van captopril en 
Ala-Leu-Pro-Met-His-Ile-Arg werd eveneens met deze test bepaald. De ACE-inhibitietest 
bleek in staat om op een relatief eenvoudige en betrouwbare manier te screenen naar     
ACE-inhibitorische peptiden uit voedingseiwitten.  
 De activiteit van het krachtige ACE-inhibitorisch peptide Ala-Leu-Pro-Met-His-Ile-Arg, 
oorspronkelijk afkomstig van een trypsine-hydrolysaat van β-lactoglobuline, werd in vitro 
onderzocht in de orale toeleveringsweg. De eiwitvertering in het gastro-intestinaal kanaal 
werd nagebootst door vertering van een 4% (w/v) eiwitoplossing met varkenspepsine bij    
pH 2 gedurende 2 h en vervolgens met rundertrypsine en runder-α-chymotrypsine bij pH 6.5 
gedurende 2.5 h bij 37°C; alle enzymen in een enzym-over-substraatverhouding van      
1/250 (w/w). Tijdens deze in vitro gastro-intestinale vertering werd het heptapeptide 
gedeeltelijk afgebroken door α-chymotrypsine, waarschijnlijk tot Ala-Leu-Pro-Met en His-Ile-
Arg, wat ook ACE-inhibitorische activiteit heeft. Toch bleef er na de vertering met maag- en 
pancreasproteasen nog de helft van de initiële peptideconcentratie en 70% van de initiële 
ACE-inhibitorische activiteit over. Peptidasen uit rat intestinaal weefsel braken het lactokinine 
zeer snel af, terwijl er in de aanwezigheid van Caco-2 homogenaten nauwelijks een afbraak 
werd waargenomen. Het intestinaal transport van 1 mM van het lactokinine werd nagegaan 
in een Caco-2 Bbe celmonolayer gemonteerd in een Ussing kamer. Na 10 min incubatie bij 
37°C werd er na driemaal opconcentratie aanzienlijke ACE-inhibitorische activiteit 
waargenomen in de stalen van het serosale compartiment. Tevens werd het heptapeptide 
door MALDI-TOF spectrometrie in het serosale compartiment gedetecteerd. Onder de 
gegeven experimentele omstandigheden werd het ACE-inhibitorisch peptide Ala-Leu-Pro-
Met-His-Ile-Arg intact getransporteerd doorheen de Caco-2 Bbe celmonolayer, weliswaar in 
een lage concentratie. Blijkbaar vormt de degradatie door intestinale peptidasen het 
voornaamste knelpunt in de orale toeleveringsweg van dit lactokinine.  
Fermentatie door verschillende melkzuurbacteriën werd onderzocht als procedure om 
ACE-inhibitorische activiteit vrij te stellen uit erwten- en wei-eiwit. Fermentatie van 
erwteneiwit met Lactobacillus helveticus bleek het meest effectief en werd daarom 
geselecteerd voor verdere proeven. Daarbij werden erwten- en wei-eiwit gefermenteerd door 
Lactobacillus helveticus en de gist Saccharomyces cerevisiae in monocultuur en in 
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combinatie bij 28 en 37°C. Na fermentatie werd steeds een in vitro gastro-intestinale 
vertering uitgevoerd en verteerde, niet-gefermenteerde eiwitoplossingen dienden als 
controle. De ACE-inhibitorische activiteit (%) van een 2.73 mg/ml staal nam na fermentatie 
toe met 18 tot 30% in alle behandelingen, met uitzondering van wei-eiwit gefermenteerd door 
Saccharomyces cerevisiae bij 28°C, waar geen significante verandering werd vastgesteld. 
Na vertering bereikten echter zowel gefermenteerde als niet-gefermenteerde stalen 100% 
ACE-inhibitorische activiteit. De proteolysegraad vertoonde een beperkte toename na 
fermentatie en steeg aanzienlijk na vertering. De (gefermenteerde) wei-eiwithydrolysaten 
leken te beschikken over een lagere 50% inhibitorische concentratie (IC50) (0.148-           
0.072 mg/ml) en dus een hogere ACE-inhibitorische activiteit dan de (gefermenteerde) 
erwteneiwithydrolysaten (0.183-0.093 mg/ml). Hierbij vertoonden de niet-gefermenteerde, 
verteerde stalen minstens evenveel ACE-inhibitorische activiteit als de gefermenteerde, 
verteerde stalen. Het niet-gefermenteerde wei-eiwithydrolysaat bezat de laagste IC50-waarde 
en dus de hoogste ACE-inhibitorische activiteit. Bij het erwteneiwit had het niet-
gefermenteerde staal de op één na laagste IC50-waarde. Deze resultaten suggereren dat 
hoofdzakelijk de in vitro gastro-intestinale vertering de vorming van ACE-inhibitorische 
activiteit bepaalt, wat wijst op het belang ervan in de bio-beschikbaarheid van ACE-
inhibitorische peptiden.  
 Bijgevolg werd de vrijstelling van ACE-inhibitorische activiteit tijdens de in vitro gastro-
intestinale vertering van erwten- en wei-eiwit meer in detail onderzocht. 
 Eerst werden de omstandigheden nodig voor een maximale vrijstelling van ACE-
inhibitorische activiteit tijdens de in vitro gastro-intestinale vertering van erwten- en wei-eiwit 
gekarakteriseerd. In batch experimenten werden drie in vitro gastro-intestinale verteringen, 
verschillend in pH en incubatieduur in de maag en de dunne darm fase, vergeleken voor 
erwten- en wei-eiwit. De vertering die de fysiologische omstandigheden van de eiwitvertering 
in het menselijk lichaam nabootste, had de hoogste ACE-inhibitorische activiteit, met  IC50 
waarden van 0.076 mg/ml voor erwten- en 0.048 mg/ml voor wei-eiwit. Er was geen verband 
tussen de proteolysegraad en de ACE-inhibitorische activiteit en erwten-eiwit was meer 
onderhevig aan hydrolyse door gastro-intestinale proteasen dan wei-eiwit. In een semi-
continu reactormodel van de gastro-intestinale vertering (pre-SHIME), werd door middel van 
responsoppervlak-methodologie de invloed van temperatuur, incubatieduur in de maagfase 
en incubatieduur in de dunne darmfase nagegaan op de ACE-inhibitorische activiteit en de 
proteolysegraad. Voor het erwteneiwit werd met behulp van een centraal samengesteld 
design een lineair model opgesteld voor de proteolysegraad en een kwadratisch model voor 
de ACE-inhibitorische activiteit, uitgedrukt als log IC50. Binnen de grenzen van het model, 
werd een maximale proteolysegraad waargenomen bij de hoogste temperatuur en de langste 
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incubatieduur in de dunne darmfase, terwijl maximale ACE-inhibitorische activiteit bereikt 
werd bij de langste incubatieduren in de maag en de dunne darmfase. Voor beide responsen 
van het wei-eiwit kon geen significant model worden opgesteld. Algemeen tonen deze 
resultaten aan dat de ACE-inhibitorische activiteit van erwten- en wei-eiwithydrolysaten kan 
bepaald worden door de condities van de in vitro gastro-intestinale vertering.  
 Vervolgens werd het verloop van de ACE-inhibitorische activiteit, de proteolysegraad en 
de eiwitafbraak tijdens de in vitro fysiologische vertering bestudeerd. Een 2.73 mg/ml 
erwteneiwithydrolysaat vertoonde reeds maximale ACE-inhibitorische activiteit (%) in de 
vroege maagfase en zijn IC50 nam verder af tijdens de dunne darmfase. Voor wei-
eiwithydrolysaat werd het niveau van 100% ACE-inhibitorische activiteit pas bereikt in de 
dunne darmfase. Toevoeging van een rat intestinaal acetonpoeder, wat de vertering door 
brushborderenzymen simuleerde, had een stijging in IC50 waarde voor beide 
ewithydrolysaten tot gevolg. Deze afname in ACE-inhibitorische activiteit was minder 
uitgesproken bij erwt dan bij wei. Toch was er nog een aanzienlijke hoeveelheid              
ACE-inhibitorische activiteit aanwezig na vertering van erwten- en wei-eiwit met gastro-
intestinale en brushborderenzymen en de uiteindelijke IC50 waarden bedroegen 0.093 mg/ml 
voor erwt en 0.128 mg/ml voor wei. De proteolysegraad kende een ander verloop en steeg 
meer voor erwt dan voor wei zowel in de maag als in de dunne darmfase, terwijl de 
brushborderpeptidasen een kleinere toename in de proteolysegraad bij erwt veroorzaakten 
dan bij wei. SDS-PAGE toonde dat het merendeel van de eiwitten in erwt reeds afgebroken 
werd tijdens de maagfase-vertering. Het voornaamste wei-eiwit, β-lactoglobuline, werd pas 
afgebroken vanaf de dunne darmfase. De aanwezigheid van gekende ACE-inhibitorische 
peptiden in de verschillende eiwitsequenties in erwt en wei werd bestudeerd door middel van 
een specifiek computerprogramma. Dit programma maakt gebruik van een database van 
ongeveer 500 gekende ACE-inhibitorische peptidesequenties en hun IC50 waarden, en 
berekent een theoretische score, gestandaardiseerd op de totale hoeveelheid aminozuren, 
voor het potentieel aan aanwezige ACE-inhibitorische peptiden in een gegeven eiwit. Bij erwt 
scoorden viciline (VCLC_PEA) en albumine PA2 (PA2_PEA) het hoogst op ACE-
inhibitorische activiteit met een waarde 10, in vergelijking met 16 voor β-caseïne 
(CASB_BOVIN) dat als referentie-eiwit werd genomen. β-lactoglobuline (LACB_BOVIN) stak 
boven alle andere eiwitten uit met een score van 26. Voor zover wij weten is dit de eerste 
beschrijving van een grote ACE-inhibitorische peptidendatabase die scores van potentieel 
aan ACE-inhibitorische activiteit toekent aan eiwitsequenties. In silico vertering van deze 
eiwitten met pepsine, trypsine and α-chymotrypsine stelde rechtstreeks twee                   
ACE-inhibitorische peptiden vrij uit PA2, één uit viciline en één uit β-lactoglobuline met een 
IC50 lager dan 100 µM. Bovendien werden er een aantal minder actieve ACE-inhibitorische 
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peptiden en precursorpeptiden, die ACE-inhibitorische peptiden kunnen vormen na verdere 
vertering met brushborder-, enterocyt- of plasmapeptidasen, vrijgesteld. De hoge             
ACE-inhibitorische peptide score van β-lactoglobuline en het feit dat dit eiwit moeilijk wordt 
afgebroken door pepsine, stemden overeen met de sterke afname in IC50 voor het wei-eiwit 
tijdens de dunne darmfase. De databank en in silico vertering maken een doeltreffendere 
vrijstelling van ACE-inhibitorische peptiden en studie van eiwitten op grote schaal mogelijk. 
De ACE-inhibitorische activiteit van het erwten- en wei-eiwithydrolysaat, verkregen door 
gastro-intestinale vertering, met IC50 waarden van 0.070 mg P/ml en 0.041 mg P/ml, werd 
verder verhoogd door opzuivering met ultrafiltratie-centrifugatie en RP-HPLC. De meest 
actieve RP-HPLC fracties werden opgevangen bij 24-28% acetonitrile en bevatten bijgevolg 
korte, hydrofobe peptiden, wat in overeenstemming is met de structuur-activiteitsrelatie van 
ACE-inhibitorische peptiden. De IC50 waarden van deze fracties waren 0.016 mg P/ml voor 
erwt en 0.003 mg P/ml voor wei. Zo werd de ACE-inhibitorische activiteit van het 
erwteneiwithydrolysaat meer dan viermaal verrijkt, terwijl deze van wei-eiwithydrolysaat meer 
dan dertienmaal toenam. Dit suggereert dat in wei-eiwithydrolysaat zeer krachtige          
ACE-inhibitorische peptiden aanwezig waren naast peptiden met lage activiteit, terwijl in 
erwteneiwithydrolysaat alle peptiden gelijkaardige ACE-inhibitorische activiteit vertoonden.  
Het intestinaal transport van actieve componenten in deze hydrolysaten en permeaten 
werd onderzocht in het Caco-2 celmonolayer model. Alle stalen vertoonden nog hoge     
ACE-inhibitorische activiteit na 2 h incubatie in de aanwezigheid van Caco-2 homogenaten. 
Toevoeging van 9 mg P/ml hydrolysaten en 10 mg P/ml permeaten aan de apicale 
compartimenten van de Caco-2 celmonolayers resulteerde in de detectie van geen of zeer 
weinig ACE-inhibitorische activiteit in de basolaterale compartimenten na 1 h 
transportexperiment, zelfs na opconcentratie. Lage ACE-inhibitorische activiteit werd wel 
waargenomen in de transportexperimenten na toevoeging van 45 mg P/ml hydrolysaten en 
50 mg P/ml permeaten in de apicale compartimenten, maar deze resulteerden in 
beschadiging van de celmonolayer, wat zich uitte in verlaagde transepitheliale elektrische 
weerstanden en verhoogde natriumfluoresceïne fluxen. Vandaar leek niet zozeer de 
degradatie door intestinale peptidasen, maar wel de opname door de celmonolayer het 
transport van ACE-inhibitorische hydrolysaten en permeaten te bepalen. Aangezien de 
cellen in het Caco-2 model dichter bij elkaar aansluiten dan in intestinaal zoogdierenweefsel, 
is het toch mogelijk dat transport van deze peptiden in vivo in voldoende hoeveelheden 
plaatsvindt.  
Na intraveneuze toediening van een dosis van 50 mg P/kg BW in spontaan hypertensieve 
ratten, oefende erwtenpermeaat een tijdelijk, maar sterk antihypertensief effect uit van           
44.4 mmHg.  Weipermeaat oefende geen effect uit bij een dosis van 50 mg P/kg BW. Verder 
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onderzoek is vereist naar potentiële positieve effecten in de preventie en de behandeling van 
hypertensie, na dagelijkse toediening over een langere periode of na toevoeging van een 
enkele hogere dosis.  
Samenvattend bestond dit werk uit een diepgaand onderzoek naar de vrijstelling van 
ACE-inhibitorische activiteit uit erwten- en wei-eiwit en het behoud van deze activiteit in de 
orale toeleveringsweg. Voor het eerst wordt de vorming van hoge ACE-inhibitorische 
activiteit uit erwteneiwit beschreven. Deze kennis kan toegepast worden in functionele 
voeding voor de preventie en behandeling van hypertensie. 
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1. NUTRITION FOR OPTIMAL HEALTH 
 
1.1. Nutrition in relation to health 
 Nowadays, it is well-recognised that nutrition has a major impact on human health. The 
way of looking at nutrition and nutrition science has undergone major changes the last and 
current century, which are associated at least in the Western world with the transformation 
from food scarcity to food abundance for the preponderance of the population and an 
increase in average lifespan that stresses the importance of quality of life.  
 In the first part of the twentieth century, nutrition science made unexpected discoveries 
that completed the understanding of essential nutrients and their concomitant deficiency 
disorders. This led to the recommended dietary allowances for nutrients, which are still in use 
for dietary advice and food consumption surveys today. The diet was attributed merely a 
passive role in that the presence in food products of nutrients in sufficient amounts was 
considered a condition for attaining or maintaining a good health status. Therefore, a strong 
focus was placed on the importance of variety in the diet to fulfil the need for adequate 
nutrition. From the second part of the twentieth century on, human requirements of nutrients 
were defined even more explicitly. Food technology made much progress and this resulted in 
industrially prepared products with defined nutrient composition. Gradually the awareness 
grew that good nutrition is not just a matter of a sufficient supply of nutrients. Epidemiologic 
evidence linked the prevalence of diseases of civilisation or affluence such as cardiovascular 
disease, obesity, hypertension, type 2 diabetes and certain types of cancer to specific dietary 
factors. Diet is not the sole cause, since these diseases are due to interactions of multiple 
factors, including heredity, stress, environmental pollution, smoking and lack of exercise. 
Nonetheless, diet is a factor that is readily amenable to change. A transition in nutrition 
science took place in which nutrition played a more active role focussing on health 
promotion. From ca 1970 on, the search for optimal nutrition began. This resulted in the 
dissemination of dietary guidelines by health authorities in many Western countries. 
Moreover, a new concept in nutrition science, that of functional foods, was introduced to 
make a further contribution to disease prevention (Bender, 1997; Diplock et al., 1999; 
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Schaafsma, 1997). In this respect, a number of bioactive compounds have been 
characterised in natural, modified and novel foods (Table 1).  
 
Table 1. Examples of candidate functional food components for modulation of certain target 
functions (Diplock et al., 1999).  
Target functions Candidate food components 
Skeletal development Calcium, vitamin D, vitamin C 
Immune function Vitamin A, vitamin D, antioxidant vitamins, 
n-3 and n-6 PUFA, trace elements, arginine, 
nucleotides and nucleosides, probiotics 
Defence of DNA, PUFA and (lipo)proteins 
against reactive oxidative species 
Vitamin E, vitamin C, carotenoids, 
polyphenols including flavonoids, selenium 
Control of hypertension Total energy (↓), sodium chloride (↓), 
n-3 PUFA from fish 
Optimal intestinal function and stool formation Non-digestible carbohydrates, probiotics, 
prebiotics, synbiotics 
Cognitive performance Glucose, caffeine, B vitamins, choline 
 
 
1.2. Functional foods 
1.2.1. Definition 
No universally accepted definition for functional foods exists. A rather extensive 
description of the term is given in the Consensus Document of the Functional Food Science 
in Europe (FUFOSE) supported by the European Union and coordinated by the International 
Life Science Institute (ILSI) Europe (Diplock et al., 1999). A food can be regarded as 
‘functional’ if it is satisfactorily demonstrated to affect beneficially one or more target 
functions in the body, beyond adequate nutritional effects, in a way that is relevant to either 
an improved state of health and well-being and/or reduction of risk of disease. Functional 
foods must remain foods and they must demonstrate their effects in amounts that can 
normally be expected to be consumed in the diet: they are no pills or capsules, but part of a 
normal food pattern. A functional food can be a natural or modified food and it might be 
functional for all members of the population or just for a particular group.  
The suggestion that certain foods or their components might offer some unique health 
benefits has blurred the distinction between foods and drugs. Therefore, it is suggested to 
deal with functional foods and their relationship to health at a level that ascribes to 
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prevention, a reduced risk of disease or an improved biological function. Moreover, the 
consumption of food is usually regarded as safe, while for drugs a benefit-risk ratio applies. 
However, scientific studies should not overlook the relative benefits or risks that might accrue 
from the increased ingestion of functional foods (Clydesdale, 1997; Milner, 2000). 
Functional foods are often confused with novel foods and nutraceuticals although these 
terms refer to different food categories. Although functional foods may be novel, this novelty 
is not a strict necessity. Novel foods and novel food ingredients are food products or food 
ingredients not used to date in significant quantities, the method of production or the 
composition of which is different as marketed thus far (ILSI, 1996). Nutraceuticals are 
products produced from food, but sold in pills, powders and other medicinal forms not 
generally associated with food, and which have shown a physiological benefit or a reduced 
risk of chronic disease (Clydesdale, 1997).  
There are a number of distinct types of claims concerning the association between 
nutrition and health, and the definition of them is not the same in all countries. 
 
1.2.2. Japan 
The concept of functional foods was introduced in Japan in the late 1980s. Public 
awareness grew that lifestyle related diseases could be prevented through improved dietary 
practice in the daily life. In 1984, the first national project on functional foods commenced 
under the sponsorship of the Ministry of Education, Science and Culture, which was entitled: 
’Systematic analysis and development of food functions’. One of the functions was newly 
defined as the body-modulating function of non-nutrients that is directly or indirectly related to 
disease prevention. In 1991, the Ministry of Health and Welfare established the world’s first 
policy to legally permit the commercialisation of some functional foods in terms of ‘Foods for 
Specified Health Uses (FOSHU)’. Upon satisfactory submission of comprehensive data 
documenting the scientific evidence of the food product, this policy is able to approve a 
health claim and grant permission to use a label, indicating to the consumer that the food 
product is identified as FOSHU (Arai et al., 2001; Sanders and Huis in 't Veld, 1999). At the 
end of the year 2000, health claims for 192 food products as FOSHU had been permitted 
and most of them contained either oligosaccharides or lactic acid bacteria for promoting 
intestinal health (Arai et al., 2001; Diplock et al., 1999). 
The functional food science in Japan has been progressing strongly to occupy a central 
position in modern bioscience. It is especially characterised by the strength in a product-
driven way of study, which may be influenced by local, traditional or cultural characteristics 
(Arai et al., 2002). 
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1.2.3. United States 
Three US legislative acts have likely had a significant effect on the promotion of the 
concept of functional foods. Firstly, the Nutrition Labelling and Education Act (NLEA), passed 
in 1990, allowed foods to bear a health claim under the condition that the claim was 
approved by the Food and Drug Administration (FDA). A health claim is a statement that 
characterises a relationship between any food substance in a diet and a disease or health-
related condition, e.g. ‘protects against coronary heart disease’ (Sanders and Huis in 't Veld, 
1999). To date, 14 such claims have been evaluated and approved by the FDA (Sanders, 
2002). Secondly, the Dietary Supplement Health and Education Act of 1994 defined dietary 
supplements and created a mechanism for dealing with safety issues, regulation of health 
claims and labelling. Thirdly, the FDA Modernisation Act of 1997 even allowed health claims 
that are not preauthorised by FDA, if they are based on authoritative statements of a Federal 
Scientific Body such as the National Academy of Sciences or the National Institutes of Health 
and a notification to the FDA is made (Milner, 2000).  
A health claim differs from a nutrient content claim, which either explicitly or by implication, 
characterises the level of any nutrient required to be listed on the nutrition label, like ‘reduced 
cholesterol’. These descriptors must be used in accordance with FDA and US Department of 
Agriculture definitions. In addition to this, structure/function claims are allowable on foods 
and dietary supplements; they describe the effect of a food on a structure or function of the 
body e.g. ‘helps maintain cardiovascular health’, for which no prior approval by the FDA is 
required, although notification is necessary (Clydesdale, 1997; Sanders and Huis in 't Veld, 
1999). The road to health claim approval is a long and costly one, not undertaken by food 
companies lightly. Nor in some cases is a disease claim considered to be a marketing 
advantage. An alternative is the use of the structure/function claim (Sanders, 2002). 
 
1.2.4. Europe 
In the European Union, there is no harmonised legislation on functional nutritional or 
health claims, which means that they are dealt with at the national level. The Codex 
Alimentarius from the World Health Organisation (WHO) has recently classified and defined 
four different forms of claims (Codex Alimentarius, 1997). In the European Consensus 
Document two further types of claims are proposed in the context of functional foods: 
enhanced function claims and reduction of disease-risk claims (Table 2). 
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Table 2. Different food claims as classified by the Codex Alimentarius (type 1 to 4) and the 
European Consensus Document on Functional Foods (type A and B) (Codex 
Alimentarius, 1997; Diplock et al., 1999). 
 Definition Example(s) 
1 Claims related to dietary guidelines or healthy diets 
officially recognised by the appropriate national 
authority 
The advice of … is to choose a 
diet high in fibre, low in 
saturated fats, … . 
2 Nutrient content claims Source of calcium, high in fibre, 
low in fat, … . 
3 Comparative claims between the nutrient level of 
two or more foods 
Reduced, less than, increased, 
more than, … . 
4 Nutrient function claims with a reference to the 
physiological role of a nutrient in its relationship to 
growth, development and normal functions of the 
body 
Calcium might help the 
development of strong bones 
and teeth. 
A Enhanced function claims that concern specific 
beneficial effects of (non-)nutrients on physiological, 
psychological functions or biological activities 
beyond their established role in growth, 
development and other normal functions of the body 
Certain non-digestible 
oligosaccharides improve the 
growth of a specific bacterial 
group in the gut. 
B Reduction of disease-risk claims that are related to a 
reduction of the risk of a specific disease or 
condition  
Sufficient calcium intake may 
help to reduce the risk of 
osteoporosis in later life. 
 
These claims are generated from the scientific evidence based on markers relevant to 
functional foods. If evidence for the effects of a functional food is based on a marker for 
target function or biological response, such as changes in body fluid levels of a metabolite, 
protein or enzyme, then an enhanced function claim might be justified. For a reduced risk of 
disease claim, however, evidence for the effect of a functional food should be based on an 
appropriate intermediate endpoint marker of disease, such as the measurement of a 
biological process that relates directly to the endpoint. Claims of type 4 and A correspond 
with the American structure-function claim, while the type B claim is similar to the health 
claim in the USA.  
Hence, contrary to Japan and the Unites States, the European Consensus Document 
prefers a science-based, function-driven approach for functional food science. As the 
functions and their modulations are universal, in this way a better understanding of the 
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effects of food components on target functions in the body is obtained (Diplock et al., 1999; 
Roberfroid, 2000). Recently, a document entitled ‘Guidelines for the Scientific Substantiation 
of Claims on Functional Foods’ has been approved by the Council of Europe and is awaiting 
publication. In the meanwhile, many European Union countries are developing ‘Code of 
Practices’, which are generally referring to the European Consensus on Functional Foods 
(Sanders, 2002). 
 
1.2.5. Perspectives 
There is strong evidence that the European market is becoming increasingly ready for 
functional foods. Consumers now seem to be aware of the relationship between diet and 
health. They generally agree that the three most important factors contributing to health are 
diet, exercise and genetic factors (Hilliam, 1998).  
However, before being considered an economic challenge, it is and must remain a 
scientific challenge. Identification and validation of sensitive and reliable markers will be key 
to adequate assessment of the true effect of foods and their components. These should 
predict potential benefits or risks relating to a target function in the body. Moreover, the dose 
necessary to cause a particular effect should be clearly identified and a safety assessment 
should accompany the demonstration of the effect. It should also be considered that the 
response to functional foods depends on several factors, including genetics, physiologic 
state and the composition of the entire diet (Milner, 2000; Roberfroid, 2000). 
Food regulations should focus in protecting public health, safety, and interests of the 
consumers without impeding innovation in the food industry. From the standpoint of food 
industries, elaborate efforts on research and development are only rewarded if the scientific 
results are exactly and adequately reflected in the health claims, leading to correct 
understanding and support of the product by consumers. In an increasingly global economy, 
these health claims should meet accepted international scientific criteria (Clydesdale, 1997).  
 
1.3. Bioactive peptides 
1.3.1. Introduction 
Biologically active peptides (BAP) or functional peptides are food derived peptides that in 
addition to their nutritional value exert a physiological effect in the body. These bioactive 
peptides are inactive within the original protein, but once released, function as regulatory 
compounds with hormone-like activity that is based on the inherent amino acid composition 
and sequence (Meisel, 1997a; Tome, 1998). In this respect, they may present active 
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ingredients in functional foods and nutraceuticals (Clare and Swaisgood, 2000; Meisel, 
1997b). 
Bioactive peptides usually contain 2 to 20 amino acid residues per molecule. These 
peptides can be liberated from the parent protein during gastrointestinal digestion in the body 
or during food processing (Clare and Swaisgood, 2000). Although these exogenic peptides 
are less active and specific than their endogenic counterparts, they can be effective after oral 
administration. They show partial or total resistance to hydrolysis and may either enter 
peripheral blood intact due to their low molecular size and exert systemic effects, or produce 
local effects in the gastrointestinal tract (Yoshikawa et al., 2000). Mellander (1950) was the 
first to name biologically active peptides, when he suggested that casein-derived 
phosphorylated peptides act as mineral carriers by enhancing vitamin D-independent bone 
calcification in rachitic infants. The knowledge of bioactive peptides has steadily increased 
since 1979 and, at present, numerous peptides exhibiting various activities have been 
reported such as opiate, mineral binding, immunomodulatory, angiotensin I converting 
enzyme (ACE) inhibitory, antithrombotic and antimicrobial peptides (Clare and Swaisgood, 
2000; Meisel, 1998).  
Although other animal, as well as plant proteins contain potential bioactive sequences 
(Dziuba et al., 1999a), milk proteins are currently the main source of a range of bioactive 
peptides. Milk, a basic food in many diets, has shown to contain many compounds with 
biological activity and is recognised as a synergistic mixture of multiple interacting factors 
(German et al., 2002; Xu, 1998). This is somewhat due to the role of milk as an exquisite 
regulation and communication medium between mother and young (Schanbacher et al., 
1997). Most major milk proteins have little or no bioactivity in their native state. Proteolytic 
digestion of milk proteins, however, releases and activates a plethora of bioactive peptides. 
Some regions in the primary amino acid sequence of milk proteins contain overlapping 
bioactive peptide sequences, exerting different biological effects. These regions in the 
multifunctional bioactive peptides are considered as ‘strategic zones’ that are partially 
protected from proteolytic breakdown (Figure 1) (Meisel and Bockelmann, 1999). 
Recently a database of bioactive peptide sequences has been developed that can be 
used to identify potential bioactive peptides within a protein sequence. Furthermore, the 
known cleavage points of proteolytic enzymes like pepsin, trypsin and α-chymotrypsin can be 
inserted into the database, by which the release of bioactive peptides during digestion of the 
protein can be predicted (Dziuba et al., 1999b). 
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Figure 1. Map of some latent bioactive peptides in bovine β-casein, αs1-casein and κ-casein 
PP: mineral binding, ACEI: ACE inhibitory, IMR: immunomodulatory region 
(Schanbacher et al., 1997). 
 
1.3.2. Opiate peptides 
Opiate peptides have opiate-like properties and have affinity for an opiate receptor. Their 
effects are inhibited by naloxone, an opiate antagonist. The individual opiate receptors, which 
are located in the nervous, endocrine and immune systems, as well as in the myenteric 
plexus in the gastrointestinal tract, are responsible for specific physiologic effects, e.g. the   
µ-receptor for emotional behaviour, analgesia and suppression of intestinal motility and 
respiration, the δ-receptor for emotional behaviour and analgesia, and the κ-receptor for 
sedation, food intake and analgesia (Froetschel, 1996). The opiate peptides derived from 
precursor food proteins or exorphins typically have a N-terminal tyrosine and the presence of 
another aromatic residue like tyrosine or phenylalanine in the third or fourth position (for      
α-casein and sometimes κ-casein, an arginine residue precedes tyrosine at the N-terminus). 
The major opiate peptides originate from casein and have been called casomorphins.          
β-casomorphins, derived from β-casein, have been characterised as µ-type receptor 
agonists, while α-casomorphins, derived from α-casein, are δ-type receptor agonists. From 
the bovine whey proteins, α-lactalbumin, β-lactoglobulin and serum albumin respectively the 
opiate µ-type receptor agonists α-lactorphin, β-lactorphin and serorphin were isolated. The 
opiate agonistic peptides modulate social behaviour, increase analgesic behaviour, prolong 
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gastrointestinal transit time, increase the intestinal absorption of amino acids, electrolytes 
and water, stimulate the secretion of insulin and somastotatin and stimulate food intake 
(Meisel, 1997b; Xu, 1998). In neonates and newborne calves, β-casomorphin is transported 
intact through the intestinal wall in the blood, after which it can exert an analgesic effect on 
the nervous system resulting in calmness and sleep (Clare and Swaisgood, 2000). 
Opiate antagonists are found in κ-casein and αs1-casein, the so-called casoxins, with a 
preference for µ- and κ- type receptors, although their potency is rather low compared to 
naloxone. Lactoferroxins are antagonists generated from human lactoferrin, with affinity for    
µ- and κ- type receptors. C-terminally methyl esterified casoxins and lactoferroxins are more 
active (Clare and Swaisgood, 2000; Meisel, 1997a; Pihlanto-Leppälä, 1999). 
 
1.3.3. Mineral binding peptides 
Certain regions of the casein molecules are phosphorylated (αs2 > αs1 > β > κ). After 
release, these casein phosphopeptides (CPP) bind mainly Ca2+ ions, but also Fe2+, Cu2+, 
Mn2+ and Zn2+. Most CCP contain three serine phosphate clusters, followed by two glutamic 
acid residues. The specific amino acid composition associated with the phosphorylated 
binding site influences the degree of calcium binding. CPP are mostly resistant to enzymatic 
hydrolysis in the gut and most often found in a complex with calcium phosphate. The 
complex formation of calcium ions results in a higher solubility, which may enhance the 
intestinal calcium absorption. Hence, CPP may increase the bioavailability of calcium that is 
required for bone calcification. By the entrapment of certain minerals such as iron, these 
CPP may also limit the intraluminal availability and therefore the depression of intestinal 
microbial growth. In addition, CPP may inhibit caries lesions through recalcification of the 
dental enamel and by inhibiting the adhesion of plaque-forming bacteria. As a result, their 
application in the treatment of dental diseases and in tooth paste has been proposed (Clare 
and Swaisgood, 2000; Darragh, 2002; Meisel, 1998).  
 
1.3.4. ACE inhibitory peptides  
The multifunctional enzyme ACE plays an important role in the renin-angiotensin system, 
which regulates both arterial blood pressure as well as salt and water balance. In the 
cardiovascular system, ACE converts angiotensin I to angiotensin II, a potent 
vasoconstrictor, and degrades bradykinin, a vasodilator. Therefore, inhibition of ACE has 
been shown to result in an antihypertensive effect in hypertensive humans and animals. ACE 
inhibitory peptides derived from casein, casokinins, and whey, lactokinins, have been 
isolated (Fitzgerald and Meisel, 2000). These peptides are further discussed in section 2.3.2. 
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1.3.5. Immunomodulatory peptides 
Immunomodulatory milk peptides affect both the immune system and cell proliferation 
responses. Work with animal cell lines has shown that peptides derived from whey and 
casein stimulate phagocytosis of human and murine macrophages and protect against 
Klebsiella pneumonia infection in mice (Migliore-Samour et al., 1989). Lactoferricin B, 
obtained by pepsin hydrolysis of lactoferrin, promotes phagocytic activity of human 
neutrophils (Mijauchi et al., 1998). Both stimulatory and suppressive immune responses, or 
increased and decreased proliferation, of human lymphocytes to milk derived peptides have 
been observed. Feeding peptide fractions from a Lactobacillus helveticus milk ferment to 
mice increases the number of IgA producing cells in the intestine and decreases the size of 
subcutaneously implanted fibrosarcomas (LeBlanc et al., 2002). Immunomodulating milk 
peptides have also shown to inhibit the development of infections in patients with pre-AIDS 
(Meisel, 1998). 
In general, the mechanisms by which these immunomodulatory peptides exert their 
immunopotentiating effects are currently unknown, although opiate receptor pathways have 
been suggested (Clare and Swaisgood, 2000; Meisel, 1998).  
 
1.3.6. Antithrombotic peptides 
Mechanisms involved in the clotting of milk (interaction of κ-casein with chymosin) bear a 
remarkable resemblance to the processes involved in blood clotting (interaction of fibrinogen 
with thrombin) and sequence homologies exist in the fibrinogen γ-chain and κ-casein. As a 
result, peptides derived from casein glycomacropeptide (CMP), the soluble C-terminal 
fragment of κ-casein after splicing by chymosin, have antithrombotic activity. These 
casoplatelines compete with the γ-chain of fibrinogen for the platelet receptors, thus inhibiting 
platelet aggregation (Clare and Swaisgood, 2000; Darragh, 2002).  
 
1.3.7. Antimicrobial peptides 
 Antimicrobial peptides have been derived from the whey protein lactoferrin, an iron-
binding glycoprotein. Lactoferricin, obtained from a peptic digest of lactoferrin, has even 
more potent bactericidal properties than the undigested parent protein, suggesting that its 
much smaller size may facilitate access to target sites on the microbial surface. The 
antimicrobial peptides isracidin and casocidin, are derived from αs1- and αs2-casein 
respectively. The antimicrobial activity of all these peptides seems to be correlated with their 
net positive charge that binds to the negatively charged phospholipids of the cell membrane 
and their large content of hydrophobic residues, both increasing cell membrane permeability 
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and finally killing off sensitive microorganisms. Antimicrobial peptides with bactericidal 
activity against various Gram-positive (Bacillus, Listeria and Streptococcus) and Gram-
negative (Escherichia coli, Klebsiella, Salmonella, Proteus and Pseudomonas) 
microorganisms have been identified. In addition, antifungal properties (Candida albicans) 
have been demonstrated (Clare and Swaisgood, 2000; Darragh, 2002). 
  
1.3.8. Miscellaneous peptides 
 Antioxidative peptides and their synthetic analogues inhibit in vitro the oxidation of 
unsaturated fatty acids. They scavenge free radicals and form complexes with the metal ions 
catalysing free radical reactions. Tyrosine and histidine, which are susceptible to oxidation, 
are typical components of these peptides from soybean. Methionine, lysine and tryptophan 
have similar properties. The antioxidative capacity of peptides is enlarged by the presence of 
proline residues in their sequence, which enhances the interaction with unsaturated fatty 
acids (Dziuba et al., 1999a).  
 Food derived peptide sequences may be involved in the modulation of cancer cell function 
and this sometimes overlaps with an immunomodulation function (LeBlanc et al., 2002). 
Bioactive peptides in yoghurt preparations both suppress proliferation and increase 
apoptosis of cancer cells in animal and human cell lines (Ganjam et al., 1997), whereas 
lactoferricin can inhibit metastasis and angiogenesis. Peptides resulting from the 
fermentation of whey by Lactobacillus helveticus L89 may contribute to the antimutagenic 
effect observed in the Ames test (Matar et al., 1997). Fragments of the hen egg ovomucin 
cause remission of fibrosarcoma cancer in mice after intratumour injection (Watanabe et al., 
1998). Cell growth-promoting peptides are also known: a fragment of lactoferrin and 
casokinins stimulate DNA-synthesis in animal epithelial cells (Darragh, 2002). 
 Several peptides contract smooth muscles, which can be investigated in vitro using 
fragments of pig guinea pig ileum. Examples are albutensin A from bovine serum albumin, β-
lactotensin from β-lactoglobulin and oryzatensin from rye. It is suggested that the action on 
smooth muscles and on immune cells is mediated by the same receptor (Dziuba et al., 
1999a; Shah, 2000). 
 Furthermore, several peptides are known as inhibitory compounds to various enzymes 
like prolyl endopeptidases, which may have an antiamnesic effect (Dziuba et al., 1999a), and 
amino- and endopeptidases of lactic acid bacteria and Pseudomonas fluorescens (Smacchi 
and Gobbetti, 1998).  
 Some peptides exert an antihypertensive effect by other mechanisms than ACE inhibition, 
but these are discussed in section 2.5. 
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1.4. Whey and pea protein 
1.4.1. Whey protein 
Milk proteins consist of 80% casein and 20% whey. Whey proteins remain in milk serum 
or whey after precipitation of casein by acid at pH 4.6 or by rennet at pH 6.7. Compared with 
casein, whey protein is more heat-sensitive, less calcium-sensitive and can engage in thiol-
disulfide interchanges to form oligomeric structures. The major whey proteins are                 
β-lactoglobulin, α-lactalbumin, bovine serum albumin, immunoglobulins and proteose 
peptones (Table 3). β-lactoglobulin and α-lactalbumin are synthesised in the mammary gland 
of the cow, while bovine serum albumin and immunoglobulins are derived from the blood. 
Casein-derived polypeptides include the proteose peptone fraction, present in acid and 
rennet or sweet whey, and the glycomacropeptides, present only in rennet whey (Belem et 
al., 1999; Eigel et al., 1983; Kilara and Harwalkar, 1996; Kinsella and Whitehead, 1989; 
Wong et al., 1996). 
 The main whey protein in milk, β-lactoglobulin, has a very hydrophobic area that is quite 
effective in binding retinol and other hydrophobic molecules. Therefore, it is speculated that 
its biological function is related to vitamin A transport. The B variant is predominant in 
Western cattle. Between pH 3.5 and 5.2, at low temperatures and high protein contents, β-
lactoglobulin associates to form an octamer of 147 kDa. Between pH 5.2 and 7.5, including 
the pH of milk, β-lactoglobulin tends to be found as a dimer of 36.7 kDa. At very low and high 
pH, β-lactoglobulin exists as a monomer. β-lactoglobulin contains one free thiol group per 
molecule, which is of great importance in reactions with other proteins, notably κ-casein and 
α-lactalbumin.  
 In the synthesis of lactose, α-lactalbumin interacts with galactosyltransferase by 
increasing its affinity for the transfer of galactose to glucose. α-lactalbumin is a calcium 
metalloprotein and it is stabilised against heat denaturation and aggregation by calcium. 
Three genetic variants are identified, although only variant B is found in the milk of western 
breeds. The amino acid sequence of α-lactalbumin is very similar to that of lysozyme. 
Recently, α-lactalbumin was shown to regulate the growth of cancerous cells in vitro 
(Sternhagen and Allen, 2001).  
 Bovine serum albumin (BSA) from bovine milk is identical to the blood serum molecule 
and is presumed to be a leakage molecule. In the blood and in milk as well, BSA is a carrier 
for insoluble fatty acids, which protect the molecule against heat. It has specific binding sites 
for hydrophobic molecules and one free thiol group. 
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Table 3. Whey proteins and their properties in milk (Eigel et al., 1983; Kilara and Harwalkar, 
1996; Kinsella and Whitehead, 1989; Wong et al., 1996). 
Component Approximate 
% of total 
whey protein 
Iso-electric 
point pI 
Number of 
amino acids 
Molecular 
weight (kDa) 
β-lactoglobulin 50 5.2 162 36.7 (18.3) 
α-lactalbumin 18 4.8 123 14.2 
bovine serum albumin (BSA) 5 4.7 582 66.3  
immunoglobulin G1 8 5.5 - 6.8  160 
immunoglobulin G2 0.8 7.5 - 8.3  150 
immunoglobulin M 0.8   900 
immunoglobulin A 1.4   400 
proteose peptone 15 3.3 - 3.7  4.1 - 20 
lysozyme 1 9.5 130 18 
lactoferrin 1 8.7  691 76.5 
 
  The immunoglobulins in milk provide passive immunity for the neonate. There are four 
classes found in milk: IgG1, IgG2, IgA and IgM. All of these molecules have a similar basic 
structure composed of two light chains (Lc) with molecular weights of 20-25 kDa and two 
heavy chains (Hc), having molecular weights of 50-70 kDa, linked by disulfide bridges. They 
are very thermolabile. IgG1 is the major immunoglobulin in milk. IgA is the second most 
abundant immunoglobulin in milk, where it exists as a dimer and is usually bound to the 
secretory component, an epithelial glycoprotein of 83 kDa. IgM exists as a pentamer in milk. 
 The proteose peptone fraction is defined as a mixture of phosphoglycoproteins that are 
heat stable at 95°C for 20 minutes at pH 4.7 and are precipitated by 12% (w/v) trichloroacetic 
acid. This fraction is usually designated as component 3 (dimer 40.8 kDa), 5 (13 kDa), 8-fast 
(4.1 kDa) and 8-slow (9.9 kDa) in ascending order of electrophoretic mobility at pH 8.6. 
Proteose peptone component 3 is found in whey only and not in casein. 
 Some minor whey proteins may have important biological functions. Lysozyme is 
considered a significant component of the antibacterial system of milk, possibly affecting the 
general immune system as well. Lactoferrin, an ironbinding glycoprotein, has an 
antimicrobial, antiviral and immunomodulatory function (Shah, 2000; Steijns, 2001).  
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1.4.2. Pea protein 
 Pea protein is mainly composed of water soluble proteins: globulins, which are also 
soluble in salt solutions, and albumins. The insoluble protein is poorly characterised up to 
now. Pea protein is a storage seed protein that serves as nitrogen source for the developing 
embryo during germination (Guéguen, 2000). Pea proteins are distinguished from soy 
proteins by the presence of sulphur-rich albumins.  
 
Table 4. Pea proteins and their properties in pea (Guéguen, 2000; Page and Duc, 1999). 
Component Approximate % of 
total pea protein 
Iso-electric point 
pI 
Molecular weight 
(kDa) 
legumin (11S) 28 5.6 - 6.1 380 
vicilin & convicilin (7S) 32 5.3 & 5.4 – 6.1 170 & 280 
albumins (2S) 25   
insoluble protein 15   
 
 Globulins are products of a multi-gene family with different patterns of synthesis and 
accumulation of these proteins during seed development and the formation of 
heteropolymers. Therefore, the different genes of a globulin usually have high homologous 
sequences (Gatehouse et al., 1984). As in other leguminous seeds, pea globulins are 
composed of two main families, legumin and vicilin, which belong respectively to the 11S and 
7S seed storage protein classes. Legumin, homologous to soybean glycinin, is a closely 
packed hexameric protein. The monomer is constructed from two subunits, the acidic α      
(40 kDa) and basic β (20 kDa) polypeptides, linked by disulfide bonds. The more hydrophilic 
α subunits are situated at the outside, while the β subunits constitute the hydrophobic heart 
of the polymeric protein. Legumins are very variable in terms of composition of subunits αβ: 
in total, 22 different α polypeptides and 11 β polypeptides have been identified. About 10 
genes coding for αβ precursors are known. Vicilin is characterised by a trimeric structure, like 
soybean conglycinin and bean phaseolin. It does not contain cysteine and therefore the 
trimeric structure is only stabilised by weak interactions. Pea vicilins are very complex 
structures in respect of their subunit composition. Up to eight classes of subunits with 
molecular weights from 12 to 50 kDa are known. They seem to be produced by proteolysis 
from a 50 kDa precursor, which can be encoded by 11 different genes. Vicilins and legumins 
have evolved from the duplication of the same ancestral gene, but in legumins a novel        
N-terminal domain has been recruited somewhere in evolution (Gibbs et al., 1989). In 
addition, the trimeric protein convicilin is also present in small quantities. Convicilin subunits 
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have a molecular weight of about 71 kDa and differ only from vicilin by the insertion of a 121 
amino acid sequence near the N-terminus of the protein (Bown et al., 1988; Croy et al., 
1980). This inserted sequence is very hydrophilic and is of similar amino acid composition to 
the sequences found near the C-terminal region of the α subunit in legumin. Up until now, the 
7S proteins remain poorly characterised (Gatehouse et al., 1984; Guéguen, 2000; Page and 
Duc, 1999; Thompson et al., 1991). 
 Albumins mainly comprise proteins with a biological function in the seed, like enzymes, 
enzyme inhibitors and plant defense proteins. Consequently, this protein fraction, which is 
characterised by a high lysine and sulphur amino acid content, is very heterogeneous. It 
contains PA1 albumin, a sulphur-rich protein dimer of 10 kDa, including the two polypeptides 
PA1a of 6 kDa and PA1b of 4 kDa. This fraction is suggested to be a source of sulphur 
containing amino acids for the plant embryo. The larger dimer PA2 albumin of 53 kDa is 
constituted of two similar polypeptides PA2a and PA2b of 26 kDa (Croy et al., 1984). The 
physiological role of this albumin fraction is not yet recognised. 
 
 
2. THE ANGIOTENSIN I CONVERTING ENZYME  
 
2.1. The renin-angiotensin system and the kallikrein-kinin system 
The renin-angiotensin system is a complex regulatory system that plays a key role in 
maintaining blood pressure homeostasis, as well as fluid and salt balance in mammals. In 
the classical pathway of the renin-angiotensin system, activation of a cascade of enzymatic 
reactions results in the generation of the main effector molecule angiotensin II, which acts 
both as a systemic and a locally generated paracrine or autocrine effector peptide (Figure 2). 
The protease renin, which is secreted predominantly in the kidney, cleaves the liver-derived 
precursor peptide angiotensinogen into the decameric peptide angiotensin I. Angiotensin I is 
further hydrolysed into the vasoconstrictor octapeptide angiotensin II by the angiotensin I 
converting enzyme (ACE, EC 3.4.15.1). ACE also inactivates the vasodilator peptides 
bradykinin and kallidin, which explains why ACE is also termed kininase II (Figure 3). Hence, 
activation of the renin-angiotensin system mainly results in a systemic vasopressor response 
by blocking the hypotensive kinin-bradykinin pathway and by generation of the 
vasoconstrictor angiotensin II (Ganong, 1997b).  
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Figure 2. The renin-angiotensin system: the interaction of the different biological active 
peptides with their receptors and effects (ACE = angiotensin I converting 
enzyme, ACE2 = human homologue of ACE, NEP = neutral endopeptidase). 
 
However, the renin-angiotensin system is far more complex than initially thought.  
In addition to the circulating hormone system, the renin-angiotensin system also serves as 
a local tissue hormone system (Campbell, 1987; Johnston, 1992). All components of the 
renin-angiotensin system have been identified in a variety of tissues like the brain, the 
epithelial cells of the intestine, kidneys and eye, the reproductive tract, the cardiovascular 
system and fibroblasts and macrophages. In the brain for example, ACE assists in 
neuropeptide processing. In the intestine, ACE aids in the digestion of oligopeptides and 
angiotensin II controls sodium and water absorption (Levens, 1985; Yoshioka et al., 1987). 
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ACE is also expressed on fibroblasts and in differentiated macrophages and T-lymphocytes 
and may therefore be important in the inflammatory process and the repair of tissues. In the 
reproductive tract, ACE has a crucial role in fertility.  
Angiotensin II mediates a broad array of physiological and pathophysiological effects by 
binding to specific cell membrane receptors. It exerts a direct vasoconstrictor action on the 
vascular smooth muscle cells and stimulates the synthesis and release of aldosterone in the 
adrenal glands, which results in sodium and water retention. Furthermore, it suppresses the 
release of renin in the kidney. In the peripheral nervous system it stimulates the release of 
adrenaline and noradrenaline, thereby enhancing sympathic activity of (heart and arterial) 
muscles. In the central nervous system, angiotensin II stimulates the release of vasopressin 
and antidiuretic hormone and creates a feeling of thirst. Since angiotensin II acts as a growth 
regulator in different cell types, it stimulates (cardiac and vascular) hypertrophy and can 
mediate morphological changes in organs. Moreover, angiotensin II stimulates NO and 
prostaglandin release from endothelial cells, thus antagonising the vasoconstrictor actions of 
the peptide. In some tissues, angiotensin II is synthesised by non-ACE enzymes, for 
example by chymases in the heart (Johnston, 1992; Millatt et al., 1999). 
So far, two distinct types of angiotensin II receptors have been characterised, which are 
heterogeneously distributed in the human body. The AT1 receptor is predominantly 
expressed in the kidneys, adrenal glands, cardiovascular system and brain and it is to this 
receptor that the regulatory actions of angiotensin II on blood pressure and salt-water 
balance have been attributed. The AT2 receptor is present at high density during fetal 
development, while in the adult it is only significantly found in the adrenal glands, uterus, 
ovary, endothelial cells and brain. The AT2 receptor is thought to counterbalance effects 
mediated by the AT1 receptor (Millatt et al., 1999). It is suggested that AT1 and AT2 receptors 
interact physically with each other to antagonise their respective actions (AbdAlla et al., 
2001). 
The renin-angiotensin system involves more angiotensin-derived mediators than 
previously recognised: both angiotensin I and II are further metabolised to other biologically 
active peptides with distinct properties, which can either enhance or compensate the effects 
of angiotensin II: angiotensin III, angiotensin IV and angiotensin(1-7) (Eriksson et al., 2002; 
Turner and Hooper, 2002).  
Recently, two alternative, independent genomics-based strategies have led to the 
discovery of a homologue of human ACE, termed ACE2 or ACEH, which functions as a 
carboxymonopeptidase with a preference for C-terminal hydrophobic or basic residues and 
appears to negatively regulate the activated renin-angiotensin system (Donoghue et al., 
2000; Tipnis et al., 2000).  
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Figure 3. The kallikrein-kinin system: the interaction of the different biological active peptides 
with their receptors and effects (ACE = angiotensin I converting enzyme, NEP = 
neutral endopeptidase). 
 
ACE plays also a functional role in the kallikrein-kinin system.  
The kinins bradykinin and kallidin (Lys-bradykinin) are cleaved from kininogens by 
kallikreins. Tissue kallikrein releases kallidin from low-molecular-weight kininogen and 
plasma kallikrein releases bradykinin from high-molecular-weight kininogen. Kinins are 
degraded by kininases: kininase I type enzymes cleave the C-terminal arginine residue 
(carboxypeptidase N and M) and kininase II type enzymes remove the C-terminal dipeptide 
Phe-Arg (ACE and neutral endopeptidase). The actions of kinins are mediated via B1 and B2 
receptors. Apparently, the B1 receptors are not constitutively present, but are induced by 
certain environmental factors, like in inflamed and injured tissues. Des-Arg9-kallidin is an 
important agonist, in contrast to bradykinin, which is essentially inactive at the B1 receptor. 
Most of the actions of bradykinin and kallidin are mediated through B2 receptors, which are 
expressed in most tissues. Kinins are potent vasoactive peptides that cause vasodilatation 
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and increased vascular permeability. They are responsible for the cardinal signs of 
inflammation, produce pain and have the ability to release cytokines from monocytes. In 
addition, they lower systemic blood pressure, increase capillary permeability and produce 
natriuresis. Kinins also stimulate the secretion of renin from the kidney and the release of 
vasopressin from the brain. In the nervous system, bradykinin is involved in the central 
regulation of the blood pressure, nociception and diuresis, and it increases neuronal 
excitability (Cassim et al., 2002). The kallikrein-kinin system and the renin-angiotensin 
system are not only linked by ACE, but also by the physical interaction between the AT1 and 
the B2 receptor (Abdalla et al., 2000). 
In addition to the renin-angiotensin and the kallikrein-kinin systems, Moskowitz (2002) 
launched a revolutionary theory that ACE functions at the start of a signalling pathway 
common to major diseases that are otherwise unrelated, including cardiovascular disease, 
cancer and psychiatric disease. Although ACE is undoubtedly the primary regulator of 
angiotensin II production and bradykinin inactivation, it is clear that other pathways and 
enzymes also modulate these processes. Furthermore, ACE might have additional 
physiological functions, which are even distinct from its enzymatic activity. It appears that the 
complexity of the renin-angiotensin system guarantees well-tuned adaptation of the blood 
supply of the body compartments and organs to all physiological conditions (Eriksson et al., 
2002; Turner and Hooper, 2002). 
 
2.2. Properties of ACE 
2.2.1. Physical and chemical structure of ACE 
The zinc metallopeptidase ACE is anchored to the plasma membrane through a single   
C-terminal transmembrane domain and is oriented in such a way that the catalytic sites are 
exposed on the extracellular surface of the cell (Figure 4). In mammals, two distinct ACE 
isoenzymes have been described, an abundant somatic form (170 kDa) found on the 
endothelial surfaces of the lungs and on brush border membranes of kidneys, intestine, 
placenta and choroid plexus, and the smaller germinal or testicular form of ACE (100 kDa) 
found only in the testis (Soubrier et al., 1993a). Both ACE isoforms function as ectoenzymes 
which hydrolyse circulating peptides. While germinal ACE has a crucial role in fertility, tissue-
bound somatic ACE controls both blood pressure and renal structure and function. A soluble 
form of ACE, which is derived from the membrane form through the action of a secretase, is 
also present in serum and other body fluids, but its biological significance is not clarified 
(Parvathy et al., 1997; Turner and Hooper, 2002). All forms of ACE are heavily glycosylated 
and it is suggested that various patterns of glycosylation modulate the substrate specificity of 
Chapter 1   
 22
ACE (Orth et al., 1998). Consequently, ACE is one of the glycoproteins that comprise the 
endothelial cell’s unstirred layer. 
Somatic ACE is composed of two highly homologous domains, the N-domain and the C-
domain, suggesting a gene duplication event in the course of evolution. Each domain 
contains the typical zinc-binding motif, His-Glu-X-X-His, at the active site, which is found in 
many zinc peptidases. The two histidine residues provide two of the three zinc-coordinating 
ligands and the carboxyl group of glutamate is the base donor in the catalytic reaction. The 
third zinc co-ordinating residue is another glutamate. The testicular ACE sequence 
corresponds to the C-domain of somatic ACE and therefore contains only one active site and 
one zinc-binding motif (Corvol et al., 1995; Soubrier et al., 1993a).  
 
Figure 4. Structure and conformation of the angiotensin I converting enzyme derived from 
plasma, somatic cell origin and testis, showing the active catalytic sites, zinc 
dependency and the N- and C-terminal ends (Johnston, 1992). 
 
2.2.2. Molecular structure of ACE and phylogenesis 
The somatic and germinal ACE mRNA are transcribed from the same gene, ace, located 
on chromosome 17 in humans, using alternate promoters. The somatic promoter is active in 
several cell types, whereas the germinal promoter is only active in a stage-specific manner in 
male germinal cells. The human ACE gene contains 26 exons. The somatic ACE mRNA is 
transcribed from exon 1 to 26, but exon 13 is spliced during maturation of the somatic ACE 
transcript. The germinal mRNA is transcribed from exon 13 to exon 26. Exons 4-11 and 17-
24, encoding the two homologous domains of the ACE molecule, are highly similar, both in 
Plasma Somatic Testicular 
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size and sequence. This further supports the duplication of an ancestral ACE gene (Soubrier 
et al., 1993a).  
The duplication of the ACE gene occurred early in evolution, since from the origin of the 
Chordata on, the duplicated ACE form is found. Orthologs of ACE are expressed in every 
kingdom, including Archaea and Eubacteria. High levels of ACE are found in the male 
reproductive tracts of several insect species, which indicates that a role for ACE in 
reproduction is evolutionary widespread. ACE is also present in other parts of the insect 
organism and has shown to be important in embryogenesis. It is also suggested that ACE 
could serve as prohormone convertase in insects. Together with the fact that human somatic 
ACE is involved in the processing of neuropeptides further implies an evolutionarily 
conserved role for ACE in the biosynthesis of some regulatory peptides. Unlike mammalian 
somatic ACE, the ACE like enzymes of the housefly Musca domestica and the fruitfly 
Drosophila melanogaster are single-domain proteins without a membrane anchor. However, 
there is still no evidence for the existence of angiotensin I and bradykinin-like peptides in 
insects. Although a single copy of an ACE-like gene is present in the Caenorhabditis elegans 
genome, no enzyme ACE activity has been observed (Isaac et al., 2000). Therefore, it is 
suggested that ACE might have an additional, non-catalytic function. Overall, information on 
invertebrate ACE will increase our knowledge about the functions of the evolutionarily 
conserved human ACE (Turner and Hooper, 2002). 
 
2.2.3. Enzymatic properties of ACE 
The primary specificity of ACE is in acting as dipeptidyl carboxypeptidase that removes 
the C-terminal dipeptide from substrates that have a free carboxyl terminus. It preferentially 
cleaves substrates with hydrophobic amino acids in the antepenultimate position and has 
little affinity for substrates with C-terminal dicarboxylic amino acids (Glu, Asp) or with proline 
in the penultimate position (Cheung et al., 1980). By this mechanism, it catalyses the 
cleavage of angiotensin I to the potent vasoconstrictor peptide angiotensin II and inactivates 
the vasodilator peptides bradykinin and kallidin (Corvol et al., 1995). ACE also hydrolyses the 
inactive angiotensin(1-9) peptide into the vasodilator metabolite angiotensin(1-7) (Eriksson et al., 
2002). Although ACE hydrolyses a wide range of substrates, bradykinin is the most 
favourable substrate for ACE and displays a Michaelis Menten constant Km that is at least ten 
times lower than for angiotensin I (Bunning et al., 1983; Corvol et al., 1995).  
In addition, it degrades enkephalins, C-terminal extended pro-enkephalins and 
neurotensin. ACE may act as endopeptidase on substrates that are amidated at the carboxyl 
terminus like substance P and the luteinising hormone releasing hormone (LHRH). It also 
releases the C-terminal tripeptide from des-Arg9-bradykinin. Moreover, ACE cleaves the 
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tripeptide from the blocked N-terminus of LHRH. However, the tripeptide amide is not 
invariably released from C-terminal blocked substrates; cholecystokinin-8 and various gastrin 
analogues are hydrolysed by ACE to release the dipeptides as the initial and major products. 
While these enzymatic activities have been observed in vitro, there is no convincing evidence 
that they bear any physiological relevance, except maybe for substance P in the brain (Erdös 
and Skidgel, 1987; Soubrier et al., 1993a).  
Chemical modification experiments have identified glutamic acid, tyrosine and arginine as 
catalytic components of the active site (Figure 5). The substrate interacts through its carbonyl 
group with the essential zinc atom to facilitate the nucleophilic attack of the carboxyl group of 
glutamic acid. Subsequent addition of a water molecule completes the cleavage of the 
peptide bond. Tyrosine donates a proton to the scissile peptide NH group, while specificity is 
determined by interaction of the terminal carboxyl group with arginine (Bünning, 1987). 
Crystallisation of the ACE enzyme needs to confirm this model. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Hypothetical model of the active site of ACE and the interaction with a peptide 
substrate (Bünning, 1987). 
 
Two moles of zinc are required per mole ACE due to the two active sites. Chloride ions 
exert an activating effect on the catalytic activity of ACE. Bradykinin is hydrolysed in the 
absence of chloride ions, although the hydrolysis of angiotensin I requires the presence of 
chloride ions. The kinetics of chloride activation are rather complex, being both substrate- 
and pH-dependent. By binding to a lysine residue in the region of the active site, chloride 
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changes the conformation of ACE, thereby improving substrate binding (Bunning, 1983; 
Corvol et al., 1995). 
Both the N- and C-domain of ACE are catalytically active and appear to function 
independently. However, the two domains have some differences in substrate specificity and 
different patterns of chloride activation. For example, the N-domain cleaves the N-terminal 
tripeptide of LHRH much faster than does the C-domain. The haemoregulatory peptide        
N-acetyl-Ser-Asp-Lys-Pro is the most specific substrate identified to date for the N-domain, 
but a specific substrate for the C-domain has not yet been found. The two domains hydrolyse 
angiotensin I and bradykinin at a comparable rate. However, the C-domain requires high 
concentrations of Cl- for optimal activity, a property that seems to be conferred by a single 
arginine residue in this domain. Moreover, the two domains differ in their affinities to bind 
several ACE inhibitors: enalapril for example, preferentially binds to the C-domain while 
ramipril can block both domains. The N-domain of ACE contains a deeply recessed active 
site and therefore the corresponding zinc atom is less accessible to inhibitors (Corvol et al., 
1995; Turner and Hooper, 2002; Wei et al., 1991).  
 
2.3. ACE inhibition 
2.3.1. ACE inhibitory drugs 
ACE inhibitors were first discovered in snake venom of Bothrops jararaca in 1970. These 
inhibitory drugs are oligopeptides with 5 to 13 amino acids per molecule. The nonapeptide 
teprotide, Glu-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro, named for the four proline residues that help 
to confer biological stability, is the most active of the snake peptides in vivo. However, a 
second snake venom peptide, bradykinin-potentiating peptide 5a (BPP5a), Glu-Lys-Trp-Ala-
Pro, or more precisely its Phe3 analogue, is the legitimate progenitor of the huge family of 
ACE inhibitors that has proliferated.  
Structure-activity studies with analogues of snake venom peptides indicate that the         
C-terminal tripeptide residue makes the greatest contribution to their overall binding to the 
active site of ACE. The optimal C-terminal sequence for active site binding is Trp-Ala-Pro, as 
encountered in BPP5a, even though this sequence allows the pentapeptide to be cleaved 
rapidly in vivo, under some conditions by ACE itself, thus preventing its usefulness as an 
antihypertensive drug. Therefore, the tryptophan side chain has usually been replaced by 
that of the more stable amino acid phenylalanine in competitive inhibitors of ACE. As a result, 
all clinical important ACE inhibitors are structurally related to the tripeptide Phe-Ala-Pro. 
These amino acids are shown to produce an optimal interaction with the subsites S1, S’1 and 
S’2 at the active site of the ACE enzyme (Figure 6) (Cushman and Ondetti, 1999). 
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Figure 6. Hypothetical binding of competitive inhibitors to the active site of ACE. The 
subsites S1, S’1, S’2 interact with side chains of terminal, penultimate and 
antepenultimate amino acids or residues of inhibitors. The residue X-H donates a 
hydrogen bond and X accepts a hydrogen bond (Cushman et al., 1987). 
 
The search for drugs that resisted gastrointestinal digestion after oral administration and 
that showed a greater affinity for the active site of ACE resulted in the design of the dipeptide 
analogue inhibitors. Captopril is the major representative of this group. It can be considered 
an analogue of the C-terminal dipeptide Ala-Pro of the snake venom peptide BBP5a, in which 
the amino function of alanine is replaced by a sulfhydryl function that is able to strongly 
interact with the catalytically essential zinc ion of the enzyme. In addition, the terminal 
carboxyl group interacts with the positive charge of arginine at the active site, the carbonyl 
group with the hydrogen bond donor tyrosine, the heterocyclic ring of the prolyl residue with a 
hydrophobic pocket of the enzyme S’2 and the methyl group with the S’1 subsite (Figure 6) 
(Bünning, 1987; Cushman et al., 1987). 
Venom peptide inhibitor 
-Phe-Ala-Pro 
Dipeptide analog 
Captopril 
Tripeptide analog 
Enalaprilat 
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Most of the newer ACE inhibitors are analogous to the C-terminal tripeptide of the BBP5a 
Phe3 analog, and therefore named tripeptide analogue inhibitors. Enalaprilat is the active free 
acid form of the antihypertensive drug enalapril, which is administered as an ester prodrug to 
enhance intestinal absorption (Johnston et al., 1986). Enalaprilat binds to the active site of 
ACE by employing most of the interactions of the C-terminal residue of BPP5a, while 
replacing the weak interaction of the amide carbonyl by a strong interaction of its carboxyl 
function with the zinc ion of the enzyme (Figure 6). The carboxyl function also prevents the 
drug from cleavage by ACE. Under physiologic conditions in vitro, enalaprilat is more active 
than captopril. Another class of tripeptide analog inhibitors employs the hydroxyphosphinyl 
function as the zinc-binding ligand and is represented by phosphinic acids, 
phosphonamidates and phosphonic acids.  
Most of the ACE inhibitors discussed before are remarkably active in vitro. Although 
newer modifications have led to compounds with increasing inhibitory potency, often only 
increased oral effectiveness, increased duration of action, an alternate route of excretion or 
other altered pharmacokinetic properties were obtained. Lisinopril, an analogue of the 
tripeptide sequence Phe-Lys-Pro, is similar to enalaprilat, but has useful oral activity without 
esterification. In ramiprilat, which is more potent than enalaprilat, the C-terminal proline is 
replaced by a proline surrogate, azabicyclo-octane carboxylic acid. Ramiprilat is also dosed 
as an ethyl-ester derivatized prodrug ramipril (Cohen, 1985; Cushman et al., 1987; Cushman 
and Ondetti, 1999). The potencies of some of these ACE inhibitory drugs are displayed in 
Table 5. 
ACE inhibitory drugs are considered as competitive and reversible, slow and tight-binding 
inhibitors of ACE (Bünning, 1987). These drugs are now used clinically to treat hypertension, 
congestive heart failure and myocardial infarction, endothelial dysfunction and renal disease, 
including diabetic nephropathy (Taylor, 2001; Turner and Hooper, 2002). Moreover, ACE 
inhibitors potentiate the effect of bradykinin and its analogues on their B2 receptors 
independently of blocking peptide metabolism (Erdös et al., 1999). Clinical trials are under 
way to test new uses for ACE inhibitors like anti-inflammatory, anti-oxidative and anti-tumour 
effects and improvement of cognitive deficiencies (Bunk, 2002). Adverse side affects related 
to ACE inhibitors include irritating cough, excessive drops in blood pressure, proteinuria, 
neutropenia, hyperkalaemia, pruritic rash and taste disturbance (DiBianco, 1985). When 
administered during pregnancy, ACE inhibitors have potentially harmful effects to the foetus. 
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Table 5. Comparison of the potencies of specific competitive inhibitors against ACE of 
spontaneously hypertensive rats (SHR) (Cushman et al., 1989). 
Inhibitor 50% inhibitory concentration (IC50) (nM) 
Captopril 9.7 
Enalapril 4645 
Enalaprilat 2.8 
Lisinopril 1.4 
Ramipril 616 
Ramiprilat 0.7 
 
2.3.2. ACE inhibitory peptides derived from food proteins 
 The discovery of ACE inhibitory peptides in snake venom indicated the presence of 
inhibiting sequences in natural proteins. This was soon confirmed when ACE inhibitory 
peptides were isolated from a collagenase hydrolysate of gelatine and a trypsin hydrolysate 
of casein (Maruyama and Suzuki, 1982; Oshima et al., 1979). Since then, numerous ACE 
inhibitory peptides have been isolated from food proteins, and more specifically from milk 
proteins (Ariyoshi, 1993; Dziuba et al., 1999a; Yamamoto, 1997). A lot of ACE inhibitory 
peptides are derived from caseins and several of these casokinins are known to exert a 
significant antihypertensive effect after oral administration in SHR (Table 6). In some cases, 
the isolated peptides do not contribute substantially to a blood pressure lowering effect, 
although the hydrolysate they originate from does. For example, the peptide fraction from 8 
month-aged Gouda cheese depressed the systolic blood pressure in SHR by 25 mm Hg, 
while two peptides isolated from this mixture, Arg-Pro-Lys-His-Pro-Ile-Lys-His-Gln and Tyr-
Pro-Phe-Pro-Gly-Pro-Ile-Pro-Asn, showed only a weak antihypertensive effect (Saito et al., 
2000). A similar observation was made by (Gobbetti et al., 2000), who report that the IC50 of 
the crude peptide mixtures from fermented milk are very low, in contrast to the IC50 of the 
individual synthesised peptides. A synergistic inhibitory effect of the peptide mixtures 
compared to the activity of individual peptides is presumed. Whey is less extensively 
investigated and only few studies on antihypertensive effects of lactokinins have been 
reported (Table 7). Table 8 lists some ACE inhibitory peptides derived from other protein 
sources than milk. 
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Table 6. ACE inhibitory peptides derived from bovine casein (CN): casokinins. 
Identified peptides Sequence                       
chemical synthesis         
(fragment released by 
human protease)            
IC50 
(µM)  
Decrease in 
SBP (mm Hg 
at [mg/kg 
BW])° 
Reference 
αs2-CN f(198-202) TKVIP 400 9 [1]  
αs2-CN f(189-192) AMKPW 580 5 [1]  
αs2-CN f(190-197) MKPWIQPK 300 3 [1]  
Maeno et al., 1996 
αs2-CN f(206-207) YL 122  Mullally et al., 1996 
αs2-CN f(25-32) NMAINPSK 60  
αs2-CN f(81-91) (ALNEINQFY)QK 264 
(219) 
 
αs2-CN f(92-98) FPQYLQY 14  
αs2-CN f(174-181) (FALPQY)LK 4 (4)  
αs2-CN f(182-184) TVY 15  
Tauzin et al., 2002 
αs1-CN f(23-34) (FFVAP)FPEVFGK 77 (6) 34 [100] 
αs1-CN f(24-27) FVAP 10  
αs1-CN f(25-27) VAP 2  
Karaki et al., 1990; 
Maruyama et al., 1985 
 
αs1-CN f(28-34) FPEVFGK 140  Maruyama et al., 1987b 
αs1-CN f(32-34) FGK 160   
αs1-CN f(194-199) TTM(PLW) 16 (36) 14 [100] Karaki et al., 1990; 
Maruyama et al., 1987a 
αs1-CN f(197-199) LW 50  Maruyama et al., 1987b 
αs1-CN f(143-148) AYFYPE 106  
αs1-CN f(170-199) QTQYTDAPSFSDIPN
PIGSENSGKTTMPLW 
346  
Yamamoto et al., 1994b 
 
αs1-CN f(104-109) YKVPQL 22 13 [1]  Maeno et al., 1996 
αs1-CN f(157-164) DAYPSGAW 98  
αs1-CN f(194-199) TTMPLW 51  
αs1-CN f(142-147) LAYFYP 65  
Pihlanto-Leppällä et al., 
1998 
 
αs1-CN f(1-9) RPKHPIKHQ 13 9 [7.5] Saito et al., 2000 
β-CN f(177-183) AVPYPQR 15/274 10 [100]/ND Karaki et al., 1990; 
Maruyama et al., 1985 / 
Pihlanto-Leppällä et al., 
1998 
β-CN f(177-179) AVP 340  
β-CN f(177-181) AVPYP 80  
β-CN f(179-181) PYP 220  
Maruyama et al., 1987b 
β-CN f(43-68) DELQDKIHPFAQTQSI
VYPFPGPIPNS 
4 
β-CN f(191-202) LLYQQPVLGPVRGPF
PIIV 
21 
β-CN f(158-175) PPQSVLSLSQSKVLP
VPE 
25 
β-CN f(168-175) SKVLPVPE 39 
 Yamamoto et al., 1994b 
β-CN f(60-66) YPFPGPI 500  
β-CN f(193-202) YQQPVLGPVR 300  
Meisel and Schlimme, 
1994 
β-CN f(74-76)          
κ-CN f(108-110) 
IPP 5 24 [0.3] 
β-CN f(84-86) VPP 9 29 [0.6] 
Nakamura et al., 1995a; 
Nakamura et al., 1995b 
 
°Maximal decrease in Systolic Blood Pressure (SBP) after oral administration in Spontaneously 
Hypertensive Rats (SHR). 
*A hydrolysate of β-CN containing these peptides exerted the antihypertensive effect. 
 22* [15]
Chapter 1   
 30
Table 6. ACE inhibitory peptides derived from bovine casein (CN): casokinins (continued). 
Identified peptides Sequence                       
chemical synthesis         
(fragment released by 
human protease)            
IC50 
(µM) 
(µg/ml)§ 
Decrease in 
SBP (mm Hg 
at [mg/kg 
BW])° 
Reference 
β-CN f(169-175) (KVLPVP)Q 1000 (5) 24 [1] (32 [1])
β-CN f(140-143) LQSW 500 2 [1] 
Maeno et al., 1996 
 
β-CN f(59-64) VYPFPG 221 22 [8] 
β-CN f(59-61) VYP 288 21 [8] 
β-CN f(80-90) TPVVVPPFLQP 749 8 [8] 
Abubakar et al., 1998 
β-CN f(58-72) LVYPFPGPIPNSLPQ 18  Smacchi and Gobbetti, 
1998 
β-CN f(108-113) EMPFPK 423§  
β-CN f(193-198) YQQPVL 280  
Pihlanto-Leppällä et al., 
1998 
β-CN f(60-68)) YPFPGPIPN 15 7 [7.5] Saito et al., 2000 
β-CN f(6-14) LNVPGEIVE 291  
β-CN f(73-82) NIPPLTQTPV 180  
β-CN f(47-52) DKIHPF 194  
Gobbetti et al., 2000 
αs1-CN f(146-147)  
αs1-CN f(159-160)  
β-CN f(114-115) 
κ-CN f(58-59) 
YP 720 27 [1] Yamamoto et al., 1999 
°Maximal decrease in Systolic Blood Pressure (SBP) after oral administration in Spontaneously 
Hypertensive Rats (SHR). 
 
 ACE inhibitory peptides display a lower ACE inhibitory activity in vitro than the ACE 
inhibitory drugs, yet do not have the harmful side effects associated with synthetically 
produced drugs (Fitzgerald and Meisel, 2000). Due to the physiological role of ACE in the 
kallikrein-kinin system, ACE inhibitory peptides may also possess immunomodulatory 
properties (Meisel, 1998).  
As for the ACE inhibitory drugs, structure-activity correlations between different peptide 
inhibitors of ACE indicate that binding to ACE is strongly influenced by the C-terminal 
tripeptide sequence of the substrate. Although the precise substrate specificity is not fully 
understood, ACE appears to prefer substrates or competitive inhibitors containing 
hydrophobic (aromatic or branched side-chains) amino acid residues at the three C-terminal 
positions. However, a C-terminal lysine or arginine, with a positive charge on the ε-amino 
group, seems also to contribute substantially to the inhibitory potency. In this respect, it is 
postulated that the mechanism of ACE inhibition involves inhibitor interaction with an anionic 
binding site which is distinct from the catalytic site. Therefore, it is expected that peptide 
conformation, i.e. the structure adopted in a specific environment, should contribute to ACE 
inhibitor potency. Due to substrate specificity differences between the two catalytic sites of 
ACE, ACE inhibitors may inhibit only one catalytic site.   
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Table 7. ACE inhibitory peptides derived from bovine whey: lactokinins. 
Identified peptides Sequence                       
chemical synthesis         
(fragment released by 
human protease)            
IC50 
(µM)  
Decrease in 
SBP (mm Hg 
at [mg/kg 
BW])° 
Reference 
α-LA f(50-53) YGLF α-lactorphin* 733 23 [0.1] Mullally et al., 1996; 
Nurminen et al., 2000 
α-LA f(105-110) LAHKAL 621  Pihlanto-Leppällä et al., 
1998 
α-LA f(50-52) YGL 409  
α-LA f(99-108) VGINYWLAHK 327  
α-LA f(104-108) WLAHK 77  
Pihlanto-Leppälä et al., 
2000 
α-LA f(52-53)     
β-LG f(104-105) 
LF 349  
β-LG f(102-103) YL 122  
β-LG f(102-105) YLLF β-lactorphin* 172  
β-LG f(146-149) HIRL β-lactotensin 1153  
β-LG f(147-148) IR 696  
Mullally et al., 1996 
β-LG f(142-148) ALPMHIR 43  
β-LG f(146-148) HIR 954  
Mullally et al., 1997b 
β-LG f(9-14) GLDIQK 580  Pihlanto-Leppällä et al., 
1998 
β-LG f(78-80) IPA 141 31 [8] Abubakar et al., 1998 
β-LG f(81-83) VFK 1029  
β-LG f(22-25) LAMA 556  
β-LG f(32-40) LDAQSAPLR 635  
β-LG f(106-111) CMENSA 788  
β-LG f(142-146) ALPMH 521  
β-LG f(94-100) VLDTDYK 946  
Pihlanto-Leppälä et al., 
2000 
BSA f(208-216) ALKAWSVAR 3  Chiba and Yoshikawa, 
1991 
BSA f(221-222) FP 315 27 [8] Abubakar et al., 1998 
°Maximal decrease in Systolic Blood Pressure (SBP) after oral administration in Spontaneously 
Hypertensive Rats (SHR). 
*α-lactorphin can be produced by proteolysis of α-LA with pepsin alone or in combination with trypsin, 
while β-lactorphin can be released from β-LG by pepsin and trypsin (and chymotrypsin) (Antila et al., 
1991). 
 
A detailed knowledge of the mechanism of action of ACE and the conformational behaviour 
of ACE inhibitory peptides should lead to a better understanding of the antihypertensive 
potential of milk derived peptides (Fitzgerald and Meisel, 2000). 
As an example of a structure-activity relationship, the ACE inhibitory activity of dipeptides 
with tyrosine is higher than those with phenylalanine, but less than dipeptides with proline at 
the C-terminal (Cheung et al., 1980). After oral administration in SHR, dipeptides with 
tyrosine at the C-terminal caused slow but prolonged reduction of the systolic blood pressure 
(SBP) compared to dipeptides with phenylalanine at the carboxy-terminus, which produced a 
more rapid decrease and a shorter duration of action (Suetsuna, 1998). 
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Table 8. Some ACE inhibitory peptides derived from other protein sources than milk. 
Protein source Sequence                     
chemical synthesis       
(fragment released 
by human protease)     
IC50 
(µM)  
Decrease in 
SBP (mm Hg at 
[mg/kg BW])° 
Reference 
gelatin GPAGAZ + GPPGAZ 8  Oshima et al., 1979 
α-zein LRP 0.3 15 [30]a Miyoshi et al., 1991a 
porcine muscle MNP 67  Arihara et al., 2001 
human plasma LIY acein-2 0.8  Nakagomi et al., 2000 
chickpea  0.1  Pedroche et al., 2002 
wakame YNKL 21 50 [50] Suetsuna and Nakano, 
2000 
garlic FY 4 25 [200] Suetsuna, 1998 
buckwheat YQY 4 30 [100]b Li et al., 2002 
royal jelly DGL 2 23 [1000] Matsui et al., 2002c 
wheat germ I(VY) 0.5 (5) 19 [5]a (18 [50]) Matsui et al., 1999;   
Matsui et al., 2000 
dried bonito (LKP)NM 2 (0.3) 14 [15] (16 [9]) Fujita and Yoshikawa, 
1999 
swine hemoglobin FQKVVA 6 30 [50] Mito et al., 1996 
bonito bowel IRPVQ 1 19 [100] Karaki et al., 1993 
soy DLP 5 38 [100]b* Wu and Ding, 2001;      
Wu and Ding, 2002 
°Maximal decrease in Systolic Blood Pressure (SBP) after oral administration in Spontaneously 
Hypertensive Rats (SHR). 
aIntravenous injection of the peptide in SHR. 
bA hydrolysate containing this peptide exerted the antihypertensive effect. 
*Oral administration during 1 month. 
 
2.3.3. Determination of the ACE inhibitory activity and the antihypertensive effect 
 For measuring the ACE inhibitory activity in vitro, pure ACE or a concentrated lung extract 
from rabbit, pig, rat or dog is applied as enzyme source. Determination of the ACE inhibitory 
activity implies the determination of the ACE activity. The first methods reported for the ACE 
assay utilised the physiological substrates, but suffered from interference by other 
peptidases that degrade both substrate and products. Based on the physical, chemical and 
enzymatic qualities of ACE, several synthetic substrates with amino-substituted tri- and 
dipeptides were developed that allow a sensitive and direct measurement of the ACE activity 
via radioisotopic, spectrophotometric, fluorometric and chromatographic methods. From the 
ACE activity in the absence and the presence of an inhibitor, the percent ACE inhibition can 
be deduced. When this is done for different concentrations of inhibitor, the IC50 value, which 
is the concentration of inhibitor needed to reduce the ACE activity to half of its initial value, 
can be calculated. The ACE inhibitory activity is usually expressed as IC50 value. 
 The most applied substrate is hippuryl-L-histidyl-L-leucine (HHL). By the action of ACE, 
HHL is degraded to hippuric acid and His-Leu (Figure 7). In the original method of Cushman 
and Cheung (1971), rabbit lung acetone powder extract serves as ACE source and the  rate 
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of production of the extracted hippuric acid, a direct measure for the ACE activity, is 
determined spectrophotometrically. An extraction step is necessary, as both hippuric acid 
and HHL absorb light of similar wavelength.  
Figure 7. ACE catalysed reaction in the method of Cushman and Cheung (1971) with 
substrate HHL. 
 
Later on, some modifications to this method were made by Nakamura et al. (1995a), who 
used pure ACE from rabbit lung. Some compounds in the inhibitor sample may be extracted 
together with hippuric acid into ethyl acetate and consequently interfere with the UV 
determination. Therefore, ACE inhibitory activity assays are described based on RP-HPLC 
separation of hippuric acid, HHL and other interfering compounds (Kim et al., 1999; Mehanna 
and Dowling, 1999). The substrate HHL may also be used to measure ACE activity 
fluorimetrically by formation of the fluorescent adduct of o-phtaldialdehyde and the histidyl 
moiety of the product His-Leu (Friedland and Silverstein, 1976). Another variant is based on 
color development by specific binding of 2,4,6-trinitrobenzene sulfonate (TNBS) to the 
primary amine of His-Leu (Matsui et al., 1992). The latter two methods have the 
disadvantage that fluorescent and colour adducts may be formed with other peptides and 
that His-Leu may be cleaved by proteases, present in the inhibitor sample. An extra blank 
containing all assay components, but where the reaction of ACE was prevented by acid or 
base addition, should correct for this.  
 Another substrate for ACE is 2-furanacryloyl-L-phenylalanyl-L-glycyl-L-glycine (FAPGG). 
By the action of ACE, the dipeptide Gly-Gly is formed and a blue shift of the absorption 
spectrum occurs (Figure 8).  
Figure 8. ACE catalysed reaction in the method of Holmquist et al. (1979) with substrate 
FAPGG. 
 
 In the original method of Holmquist et al. (1979), pure ACE from rabbit lung acetone 
powder serves as enzyme source and the decrease in absorbance at 330-350 nm during 1 to 
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Chapter 1   
 34
10 min is a measure for the ACE activity both at high and low substrate concentrations. ACE 
exhibits high affinity for FAPGG and the kinetic parameters of its hydrolysis are better than 
for HHL. This method was slightly modified by some authors (Ronca-Testoni, 1983; Wong 
and Kinniburgh, 1987). 
 The chromophore- and fluorophore-labelled tripeptide dansyltriglycine can also be used 
as substrate and is cleaved by pure ACE from rabbit lung into dansylglycine and Gly-Gly. 
The product dansylglycine and unreacted substrate are separated and quantified by         
RP-HPLC (Elbl and Wagner, 1991). This method is well suitable for the screening of crude 
plant extracts, where some constituents may interfere with spectrophotometric or fluorometric 
determination.  
 As the substrate specificity of ACE is very broad, many ACE substrates can be present in 
processed food proteins. In any ACE inhibition assay, these substrates show seemingly ACE 
inhibitory activity in vitro, but they fail to produce an antihypertensive effect in vivo.            
Pre-incubation of the pure peptide with ACE before the measurement of the ACE inhibitory 
activity discriminates substrates from true inhibitors. In the case of an ACE substrate, the IC50 
value will increase after pre-incubation with ACE (Fujita et al., 2000). 
 Comparison of IC50 values in literature is hampered by the use of different substrates, 
different sources of ACE, different determination methods, different assay conditions and 
different ways of calculation (Ariyoshi, 1993; Brooks et al., 1990; Buttery, 1985; Nakamura et 
al., 1995a; Weisser and Schloos, 1991). Even when using the same method, different IC50 
values have been reported, like for Ala-Val-Pro-Tyr-Pro-Gln-Arg in Table 6. 
 While the ACE inhibitory activity is a marker for a biological response, the demonstration 
of an antihypertensive effect represents an intermediate endpoint marker for cardiovascular 
disease. Antihypertensive effects are usually measured in spontaneously hypertensive rats 
(SHR), which are genetically predisposed to have a high blood pressure (Yigal et al., 1998). 
The change in blood pressure is monitored in conscious and anesthetised rats by the tail-cuff 
method (Widdop and Li, 1997) or via a catheter in the artery, after administration of the 
product orally, intravenously or intraperitoneally (Fujita and Yoshikawa, 1999; Miyoshi et al., 
1991b). Normally ACE inhibitory peptides only produce an antihypertensive effect in SHR, 
while no effect is observed in normotensive or Wistar Kyoto (WKY) rats. Previously, ACE 
inhibitory peptides were administered intravenously to normal rats and the antagonism to an 
elevated blood pressure response after intravenous injection of angiotensin I was measured 
in vivo (Maruyama et al., 1989). ACE inhibitory peptides have also been tested on stroke-
prone spontaneously hypertensive rats, which are strongly predisposed to hypertension and 
stroke (Mizutani et al., 2000). 
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2.4. Hypertension  
 Hypertension is defined as a sustained increase in blood pressure, more specifically a 
systolic blood pressure of 140 mm Hg or more and/or a diastolic blood pressure of 90 mm Hg 
or more. Hypertension is one of the most common chronic medical conditions in the 
developed world and is rapidly becoming a major problem in developing countries. It is 
estimated that about 20% of the world’s adult population suffers from hypertension. The 
prevalence of high blood pressure increases with age, affecting approximately 65% of the 
population aged 65-74 years in Western nations (Alper et al., 2001; Duprez et al., 2002). 
 High blood pressure is a haemodynamic disorder in which increased arterial pressure may 
be associated with an increased cardiac output or increased peripheral resistance. Most 
cases of hypertension result from the interplay of genetic and environmental factors, with    
25-40% of blood pressure variation being genetically determined. Hypertension has clearly 
been demonstrated to be a leading risk factor for stroke, coronary heart disease, heart failure 
and renal failure. As there are often no clinical manifestations other than increased blood 
pressure, hypertension is also named the ‘silent killer’.  
 Lifestyle modifications are recommended in the prevention, but also in the treatment of 
hypertension. Not only do these measures help to lower the blood pressure, they also help to 
reduce the need for pharmacological treatment. In this respect, it is advised to lose weight if 
overweight, to limit alcohol intake to no more than one or two drinks per day, to increase 
aerobic physical activity, to reduce sodium intake, to increase the intake of fresh fruits and 
vegetables, which should increase the intake of potassium, calcium and vitamins, and to stop 
smoking. Several recent clinical trials have demonstrated the benefits of dietary modification 
in blood pressure control (Groziak and Miller, 2000; Hermansen, 2000). Hypertensive 
subjects enrolled in the Dietary Approaches to Stop Hypertension trial (DASH), a diet rich in 
fruits, vegetables and low-fat dairy products, were shown to have a blood pressure reduction 
of 11.4/5.5 mm Hg, compared with a normal American diet and despite dietary sodium and 
subject weight being held constant.  
 The goal of antihypertensive therapy is to reduce cardiovascular morbidity and mortality 
and to prolong life by the least intrusive means possible. Seven different classes of 
antihypertensive drugs are currently in use:  
(1) diuretics, which cause the body to excrete water and salt. 
(2) β-blockers and α-blockers, which block the effect of adrenaline, thus easing the 
heart’s pumping action and widening blood vessels. 
(3) ACE inhibitors, which reduce the production of the vasoconstrictor angiotensin II. 
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(4) calcium channel antagonists, which help decrease the contractions of the heart and 
widen blood vessels. 
(5)  angiotensin II receptor blockers, which block the effect of the vasoconstrictor 
angiotensin II, have similar benefits as ACE inhibitors and may have fewer or less 
severe side effects, because they do not interfere in the kallikrein-kinin system. 
(6) vasodilators, which widen blood vessels. 
It is important to ensure continuous administration of the antihypertensive drugs. As first-line 
treatment, experts generally recommend β-blockers or diuretics, which are inexpensive, safe, 
and effective for most people with hypertension who have no complicating problems. 
Individuals, however, may have special requirements that call for specific drugs or 
combinations (Alper et al., 2001). Combining low doses of drugs with different mechanisms 
of action, is suggested to result in an additive or synergistic effect on blood pressure 
(Messerli, 1999; Taylor, 2001). 
 The role of ACE in the pathology of hypertension remains obscure. However, in human 
subjects an ACE gene insertion/deletion (I/D) polymorphism has been observed. This 
insertion consists of a 287-bp-long alu repetitive sequence located inside intron 16 of the 
ACE gene. In subjects who are homozygous for the D allele, the mean serum ACE is nearly 
twice as high as that of subjects with the II genotype (Soubrier et al., 1993b). Furthermore, 
the DD genotype is associated with an increased risk for cardiovascular diseases (Soubrier 
et al., 1993b), and even cancer and psychiatric disease (Moskowitz, 2002). 
 
2.5. The role of peptides in the treatment of cardiovascular diseases 
 Food derived peptides are known to lower the blood pressure by other mechanisms than 
ACE inhibiton.  
 The opiate and ACE inhibitory peptide α-lactorphin (Table 7), originally derived from 
bovine α-lactalbumin, dose-dependently lowers the blood pressure of both SHR and 
normotensive Wistar Kyoto rats (WKY) upon subcutaneous administration. The reduction in 
blood pressure can be reversed by nalaxone, a specific opiate receptor antagonist, providing 
evidence for the involvement of opiate receptors in the antihypertensive effect          
(Nurminen et al., 2000).  
 Single oral administration of an extract from autologous lysate of Lactobacillus casei 
significantly lowers the blood pressure in spontaneously hypertensive rats and long-term oral 
administration even suppresses the development of hypertension in these animals (Furushiro 
et al., 1990). The active substance of this extract, a polysaccharide-glycopeptide complex, 
enhances only after oral intake prostaglandin synthesis, which resulted in a decrease of 
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peripheral vascular resistance and hence an antihypertensive effect (Furushiro et al., 1993). 
Furthermore, oral administration of the Lactobacillus casei cell lysate extract to hypertensive 
patients reduces both the systolic and diastolic blood pressure, in addition to the total 
cholesterol and fasting plasma glucose level (Nakajima et al., 1995). 
 Two peptides, the ovokinin Phe-Arg-Ala-Asp-His-Pro-Phe-Leu and Arg-Ala-Asp-His-Pro-
Phe, isolated from a pepsin and α-chymotrypsin digest of ovalbumin respectively, exert a 
dose-dependent vasodilatation in an isolated mesenteric artery in SHR, which is 
preconstricted by phenylephrine. The vasorelaxing activity is attributable to the binding to B1 
receptors and the subsequent release of prostaglandin and NO respectively. Following oral 
administration, Arg-Ala-Asp-His-Pro-Phe lowers the blood pressure in SHR (Fujita et al., 
1995; Matoba et al., 1999). An even more potent and long-lasting hypotensive activity is 
obtained by oral administration of the synthetic analogue Arg-Pro-Phe-His-Pro-Phe (Matoba 
et al., 2001). 
 Pepsin digests of bonito and beef inhibit the endothelin converting enzyme, which 
produces the potent vasoconstrictor endothelin (Okitsu et al., 1995). 
 
 
3. PRODUCTION OF ACE INHIBITORY PEPTIDES 
 
3.1. Introduction 
 Sometimes, ACE inhibitory peptides are present as such in foods, for example in garlic 
(Suetsuna, 1998) and the mushroom Grifola frondosa (Choi et al., 2001). However, most of 
the time, they need to be specifically released from the food protein by the action of 
enzymes, heat, base or acid. Hence, ACE inhibitory peptides are usually formed during food 
processing or during gastrointestinal digestion in the human body.  
 
3.2. Fermentation  
3.2.1. Introduction 
 Several ACE inhibitory peptides have been isolated from fermented products, mostly milk 
derived products. The proteolytic system of lactic acid bacteria can contribute to the 
liberation of bioactive peptides (Law and Haandrikman, 1997). The cell wall bound proteases 
release oligopeptides from the milk proteins with a rather broad substrate specificity. 
Transport systems specific for amino acids and peptides up to 18 amino acids are present in 
lactic acid bacteria for nitrogen uptake. Longer oligopeptides, not transported into the cells, 
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can be a source of bioactive peptides in fermented milk products when further degraded, for 
example by the intracellular peptidases of lactic acid bacteria after cell lysis. As casein 
contains a lot of proline, especially the peptidases associated with the hydrolysis of proline-
containing peptides have received considerable attention: aminopeptidase P, prolidase, 
proline iminopeptidase, prolinase and X-prolyl-dipeptidyl aminopeptidase. However, the 
specificities of the known peptidases suggest that almost all peptide bonds in caseins can be 
cleaved in theory (Christensen et al., 1999; Kunji et al., 1996). In this respect, the formation 
of bioactive peptides by lactic acid bacteria in fermented milk products seems to be a rare 
event. Nevertheless, bioactive peptides are isolated from fermented milk products, 
suggesting limited proteolysis conditions and/or resistance towards proteolysis (Meisel and 
Bockelmann, 1999). 
 
3.2.2. The success story of Lactobacillus helveticus and Calpis milk 
 The lactic acid bacterium Lactobacillus helveticus is particularly well-known for the 
production of ACE inhibitory peptides. This microorganism possesses efficient protease and 
peptidase activities towards milk proteins (Matar et al., 1996). Compared to other lactic acid 
bacteria, milk ferments obtained from most strains of L. helveticus show high ACE inhibitory 
activity and a significant blood pressure lowering effect. Furthermore, the fermented milks 
with higher ACE inhibitory activity show a better growth of the lactic acid bacterium 
associated with a larger pH decrease, a higher peptide content and a higher protease activity 
(Yamamoto et al., 1994a).  
 Milk fermented for 24 h at 37°C with the Calpis starter, including L. helveticus and 
Saccharomyces cerevisiae, contains the highly potent ACE inhibitory peptides Val-Pro-Pro 
and Ile-Pro-Pro derived from β-casein and κ-casein (Table 6) (Nakamura et al., 1995a). It 
seems that these peptides are processed by the extracellular protease of Lactobacillus 
helveticus followed by some peptidase action during fermentation (Yamamoto et al., 1993; 
Yamamoto et al., 1994b). Both the sour Calpis milk and the isolated peptides demonstrate 
an antihypertensive effect in SHR of at least 20 mm Hg from 4 to 8 h after a single oral 
administration of 5 ml/kg BW for the Calpis milk, equalling 0.6 mg Val-Pro-Pro/kg BW and 
0.3 mg Ile-Pro-Pro/kg BW, and 5 mg/kg BW for Val-Pro-Pro and Ile-Pro-Pro respectively. 
Moreover, the antihypertensive effect of the peptides is dose-dependent. In contrast, a single 
oral administration of either sour milk or tripeptides does not change the systolic blood 
pressure of normotensive WKY rats (Nakamura et al., 1995b). Val-Pro-Pro and Ile-Pro-Pro 
are also detected in the abdominal aorta of SHR 6 h after oral administration of the sour milk. 
The ACE inhibitory activity in the aorta is lower in rats fed with the sour milk compared to 
control rats (Masuda et al., 1996). This clearly indicates that the peptides resist 
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gastrointestinal digestion, are absorbed intact into the blood and exert an antihypertensive 
effect by ACE inhibition.  
 In a placebo-controlled study, hypertensive patients ingest daily 95 ml of the sour milk or a 
placebo for 8 weeks, in addition to their antihypertensive medication. Both the systolic and 
diastolic blood pressure decrease significantly in the treatment group and these decreases 
are maintained 4 weeks after treatment (Figure 9). The dose of sour milk is approximately    
2 ml/kg BW, which corresponds to a dose of 0.033 mg Val-Pro-Pro and 0.025 mg Ile-Pro-Pro 
per kg BW (Hata et al., 1996). In a similar study, these results are confirmed in untreated 
hypertensive subjects and no effect is observed in healthy individuals with normal blood 
pressure (Itakura et al., 2001).  
Figure 9. Changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP) of 
hypertensive subjects by treatment for 8 weeks with Calpis sour milk (white) and 
artificially acidified milk as placebo (black). Significant difference from initial value: 
*p < 0.05, **p < 0.01 (Takano, 2002). 
 
 In addition to the beneficial effects of Calpis milk in the treatment of hypertension, it may 
also have a function in the prevention of hypertension (Takano, 1998). In this respect, in 
young SHR fed with the Calpis milk for 15 weeks, the ACE inhibitory activity of the aorta is 
lower and the systolic blood pressure increase is inhibited compared to rats fed a normal diet 
*
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(Nakamura et al., 1996). Based on all this evidence, a functional food product containing 
sour milk as a significant component is approved as “Food for Specified Use” in Japan with 
an appropriate health claim on the label (Takano, 2002).  
 In a yoghurt-like product fermented by L. helveticus CPN4 for 10 h, the casein-derived 
peptide Tyr-Pro yields significant antihypertensive activity in SHR (Table 6). As this 
sequence is found at more C-terminal regions of bovine caseins and the protease of this 
strain preferentially hydrolyses casein at the C-terminus, it is suggested that this peptide is 
likely to be formed at the beginning of fermentation. As this product does not contain        
Val-Pro-Pro and Ile-Pro-Pro, a longer fermentation time would be necessary to release these 
peptides (Yamamoto et al., 1999).  
 Other research groups have also used L. helveticus to produce fermented milk with 
antihypertensive properties (Fuglsang et al., 2002; Leclerc et al., 2002; Seppo et al., 2002; 
Seppo et al., 2003). In a long-term study, the development of hypertension in SHR is 
significantly and dose-dependently attenuated when Calpis milk or Evolus milk, 
containing the double dose of Val-Pro-Pro and Ile-Pro-Pro, or the tripeptides itself, are 
administered daily (Sipola et al., 2001; Sipola et al., 2002).  
 
3.2.3. Other fermented products 
 High ACE inhibitory activities are obtained in fermented milks started by Lactobacillus 
delbrueckii ssp. bulgaricus SS1 and Lactococcus lactis ssp. cremoris FT4, respectively. The 
IC50 of the crude peptide fractions are very low, 8-11 mg/l, while the isolated peptides display 
a considerable lower ACE inhibitory activity (Gobbetti et al., 2000). When milk whey and 
casein protein are fermented by different lactic acid starters on the other hand, digestion with 
pepsin and trypsin is necessary to observe ACE inhibitory activity. The starters were 
Streptococcus salivarius ssp. thermophilus, bifidobacteria and Lactobacillus acidophilus for 
the yoghurt; Lactococcus lactis ssp. lactis, L. lactis ssp. cremoris, L. lactis ssp. lactis biovar. 
diacetylactis and Leuconostoc mesenteroides spp. cremoris for the ropy milk; and L. lactis 
ssp. lactis, L. lactis ssp. cremoris, L. lactis ssp. diacetylactis and Leuconostoc mesenteroides 
spp. cremoris for the soured milk. These results may be due to the low proteolytic activity of 
the used starters or the specificity of the enzymes in the lactic acid bacteria (Pihlanto-
Leppällä et al., 1998). Aged fermented milk prepared by culturing with various lactic acid 
bacteria and yeast exhibits a significant antihypertensive effect in SHR following oral intake, 
despite its weak ACE inhibitory activity in vitro (Kuwabara et al., 1995). In fed-batch 
fermentation by Kluyveromyces marxianus var. marxianus of whey protein, several peptides 
are isolated that contain the sequences of known ACE inhibitory peptides (Belem et al., 
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1999). These peptides may be released upon oral administration and lower the blood 
pressure. 
 ACE inhibitory peptides have been isolated from several natural and modified cheeses 
(Haileselassie et al., 1999; Ryhänen et al., 2001; Smacchi and Gobbetti, 1998). Upon 
assessment of different milk products, ACE inhibitory activity is especially observed in 
ripened cheeses. In these products, the ACE inhibitory activity increases during cheese 
maturation, but decreases when the proteolysis exceeds a certain level (Figure 10) (Meisel et 
al., 1997).  In agreement with this observation, the free peptides from 8 month-aged Gouda 
cheese exert the strongest depressive effect in the systolic blood pressure after oral 
administration in SHR, compared to 24 month-aged Gouda, Emmental, Blue, Camembert, 
Edam and Havarti cheeses (Saito et al., 2000). 
Figure 10. ACE inhibition index (%) of extracts from ripened cheese in dependence on 
proteolysis as measured by the ratio of free to peptide-bound amino acids 
(Meisel et al., 1997). 
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 The ACE inhibitory peptide His-His-Leu (IC50 = 5 µM) is present in Korean fermented 
soybean paste and triple intravenous injections of this peptide in SHR at a total dose of         
5 mg/kg BW results in a significant decrease of the systolic blood pressure by 61 mmHg 
(Shin et al., 2001). Potent ACE inhibitory peptides are also isolated from sake and sake lees. 
An antihypertensive effect is observed with Ile-Tyr-Pro-Arg-Tyr at 100 mg/kg BW in SHR that 
continues for 30 h after oral administration. This peptide maintains its inhibitory activity when 
digested with pepsin and pancreatin in vitro and three dipeptide fragments of this 
pentapeptide, which may be released by brush border and plasma peptidases, have 
hypotensive effects in SHR as well (Saito et al., 1994). Furthermore, ACE inhibitory peptides 
with IC50 of 17.5-83 µM are found in red wine (Takayanagi and Yokotsuka, 1999). 
 
3.3. Digestion  
3.3.1. Introduction 
 Digestion of proteins is usually performed by microbial enzymes or gastrointestinal 
proteases. ACE inhibitory peptides may be released by one enzyme or by a combination of 
enzymes in batch or in a continuous process (Table 9). 
 
3.3.2. Fermentation related enzymes 
 When the research group of the Calpis milk hydrolyses β-casein with an extracellular 
protease from L. helveticus CP790, they cannot isolate Val-Pro-Pro or Ile-Pro-Pro, but find 
the antihypertensive peptide Lys-Val-Leu-Pro-Val-Pro-Gln (Table 6) (Maeno et al., 1996). 
This also demonstrates that a longer incubation time and/or other peptidase action is 
required to release these tripeptides. Maybe they are produced by peptidases of 
Saccharomyces cerevisiae. This yeast has been shown to contain several proteolytic 
enzymes, such as protease A, protease B, carboxypeptidase Y, carboxypeptidase S, 
aminopeptidase Co and dipeptidyl aminopeptidase B (Jones, 1991). Potent ACE inhibitory 
activity is identified in skimmed milk digested with cell-free extract of S. cerevisae and the 
active enzyme is characterised as protease B (Roy et al., 2000). 
 
3.3.3. Comparison of different proteases 
 Often different enzymes are compared for their ability to release ACE inhibitory peptides 
from a certain food protein. When trypsin, α-chymotrypsin, proteinase K and thermolysin 
hydrolyse ovine and caprine β-lactoglobulin for 24 h, the highest ACE inhibitory activity is 
obtained with the microbial enzymes proteinase K and thermolysin. Apparently, these 
proteases yield peptides of lower molecular masses than the digestive enzymes. 
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Table 9. Some proteases used in the production of ACE inhibitory peptides (less specific 
cleavage). 
Protease Origin Specificity 
Gastrointestinal:   
pepsin (A or C) porcine stomach (C-) and N-terminus of Phe, Leu, Tyr, (Trp)  
trypsin bovine pancreas C-terminus of Arg, Lys 
α-chymotrypsin bovine pancreas C-terminus of Trp, Tyr, Phe, (Leu, Met, His) 
elastase bovine pancreas C-terminus of uncharged, non-aromatic 
amino acids: Ala, Val, Leu, Ile, Gly 
carboxypeptidase A bovine pancreas cleaves C-terminal aromatic or aliphatic 
(neutral) amino acids 
carboxypeptidase B bovine pancreas cleaves C-terminal basic amino acids 
pancreatin porcine/bovine 
pancreas 
endo- and exopeptidases 
Others:   
thermolysin  Bacillus 
thermoproteolyticus 
N-terminus of Leu, Phe, (Trp, Tyr, Ile, Val, 
Met) 
proteinase K Tritirachium album C-terminus of aromatic or aliphatic 
(hydrophobic) amino acids 
alkalase Bacillus licheniformis endopeptidase (subtilisin A), broad, 
preference for C-terminus of large 
uncharged amino acid 
neutrase Bacillus subtilis endopeptidase 
flavourzyme Aspergillus oryzae endo- and exopeptidase (carboxy-, amino- 
and X-prolyl dipeptide aminopeptidase) 
pronase E Streptomyces 
griseus 
broad, endoprotease 
actinase E Actinomyces spp. broad, endoprotease 
newlase F Rhizopus spp. broad, endoprotease 
papain Carica papaya broad, endoprotease  
ficin Fig tree latex broad, endoprotease 
collagenase  N-terminus of Gly in Pro-X-Gly-Pro 
protease of                    
L. helveticus 
L. helveticus CP790 broad specificity, N-terminus of Leu, Phe, 
Ser, Lys, Glu, and Gln 
Industrial enzymes from Novo Nordisk. 
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Ovine and caprine β-lactoglobulin hydrolysates have similar effects, but sweet whey results 
in a considerable lower IC50 than acid whey with the exception of the digestion by                
α-chymotrypsin. This points to the release of potent ACE inhibitory peptides from casein 
glycomacropeptide, only present in sweet whey (Hernandez-Ledesma et al., 2002).  
 When porcine skeletal muscle protein is digested by eight different proteases, the 
thermolysin digest has the highest ACE inhibitory activity, followed by proteinase K, papain 
and pronase E. α-chymotrypsin and ficin are less effective and trypsin and pepsin produce 
only little ACE inhibitory activity (Arihara et al., 2001).  
 In another study, wheat germ is digested by pepsin, α-chymotrypsin, trypsin, alkalase and 
protease from Aspergillus niger for 5 h under various pre-treatment conditions. For all pre-
treatments, hydrolysis by alkalase is the most favourable in producing potent ACE inhibitory 
activity. A pre-treatment consisting of defatting the wheat germ followed by α-amylase 
digestion results in a higher ACE inhibitory activity upon digestion compared to intact wheat. 
By removing lipids and sugars from the matrix, the susceptibility of the wheat germ protein to 
proteolysis increases (Matsui et al., 1999). 
 Alkalase is also the most effective protease to release ACE inhibitory peptides from blood 
plasma proteins, followed by trypsin, while neutrase, pepsin and papain are less effective. 
Trypsin on the other hand produces in a lower enzyme concentration higher ACE inhibitory 
activity from casein than alkalase (Hyun and Shin, 2000).  
 This indicates that the capability of an enzyme to produce ACE inhibitory peptides is 
dependent on the food protein sequence.  
 Upon oral administration of seven different whey digests to SHR, significant 
antihypertensive activity is observed after 6 h for the digests with trypsin, proteinase K and 
actinase E (Table 10) (Abubakar et al., 1998). The non-digested whey protein shows already 
an antihypertensive effect, but no ACE inhibitory activity. This may be explained by the 
formation of ACE inhibitory peptides during gastrointestinal digestion and/or an 
antihypertensive effect by another mechanism than ACE inhibition. For the different digests, 
the ACE inhibitory activity does not always correspond with the antihypertensive effect.  
 The thermolysin-digest of ‘Katsuo-bushi’, a Japanese traditional food processed from 
dried bonito, possesses potent ACE inhibitory activity and demonstrates antihypertensive 
activity after oral administration in hypertensive subjects.  One of the isolated peptides, Leu-
Lys-Pro-Asn-Met, is hydrolysed by ACE to Leu-Lys-Pro, a very potent ACE inhibitory and 
antihypertensive peptide. The digest has been officially approved as FOSHU in Japan (Fujita 
and Yoshikawa, 1999). 
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Table 10. ACE inhibitory activity (%) and antihypertensive effect in SHR from whey protein 
after digestion with one of seven proteases (Abubakar et al., 1998). 
Sample1 ACE inhibitory activity (%) Decreased SBP2 (mm Hg) 
whey protein (control) 0.0 -38 ± 2 
pepsin 83.7 -47 ± 3 
trypsin 56.7 -51 ± 4* 
α-chymotrypsin 76.0 -40 ± 4 
proteinase K 95.7 -55 ± 3** 
actinase E 55.7 -55 ± 4** 
thermolysin 98.6 -42 ± 4 
papain 86.5 -47 ± 4 
1Dose was 8 mg/kg BW. 
2The decrease in systolic blood pressure (SBP) 6 h after gastric intubation is shown as    
mean ± SE (n = 3). 
*Different from control (p < 0.05). 
**Different from control (p < 0.01). 
 
3.3.4. Gastrointestinal proteases  
 ACE inhibitory peptides have also been produced by gastrointestinal proteases in 
sequential digestion. The ACE inhibitory activity of buckwheat protein is not enhanced by 
pepsin treatment, but a digest produced by pepsin, followed by trypsin and α-chymotrypsin, 
results in a significant increase in the ACE inhibitory activity and is able to lower the systolic 
blood pressure of SHR (Li et al., 2002). The digestion of α-lactalbumin and β-lactoglobulin by 
pepsin, trypsin, α-chymotrypsin, elastase or carboxypeptidase A and B alone and in 
combination, reveals that trypsin is necessary to release high ACE inhibitory activity from 
whey protein (Pihlanto-Leppälä et al., 2000). The gastrointestinal protease elastase, on the 
other hand, is associated with a low production of ACE inhibitory peptides from α-lactalbumin 
and β-lactoglobulin (Mullally et al., 1997a; Pihlanto-Leppälä et al., 2000). Pepsin digestion 
raises the ACE inhibitory activity of royal jelly protein considerably and subsequent hydrolysis 
by trypsin and α-chymotrypsin further reduces the IC50 to 0.099 mg protein/ml. Single oral 
administration of this gastrointestinal hydrolysate at 1 g/kg BW in SHR results in a significant 
lowering of the systolic blood pressure by 23 mmHg (Matsui et al., 2002c). Three novel ACE 
inhibitory peptides have also been isolated from a tryptic digest of human αs1-casein, which 
was expressed in E. coli and purified (Kim et al., 1999). 
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3.3.5. Membrane reactors 
 A more industrial approach for the enzymatic production of ACE inhibitory and other 
bioactive peptides is the digestion in membrane reactors. In enzymatic membrane reactors, 
hydrolysis of the food proteins is combined with the purification of the bioactive peptides from 
the reaction mixture by filtration or precipitation. Moreover, a complete retention of the 
enzyme within the system makes the continuous operation of the membrane reactor feasible. 
Ultrafiltration membranes (1-100 nm or MWCO 500-100 000 Da) are most adequate for the 
retention of the majority of enzymes (Prazeres and Cabral, 1994). The major advantages of 
membrane reactors are the higher productivity due to the continuous process and the 
improved conversion in product-inhibited reactions, and the control of the molecular weight of 
the hydrolysates. A major disadvantage is the reduction in membrane filtration capacity 
during operation due to concentration polarisation and fouling and enzyme inactivation 
(Perea and Ugalde, 1996). 
 Tryptic hydrolysis of CMP is carried out in a continuous membrane reactor for the 
preparation of casoplatelines. An ultrafiltration membrane with MWCO 3000 Da continuously 
extracts four small bioactive peptides from the reactor and new substrate is fed in at the 
same rate. Compared to the batch reactor, the productivity of the continuous system is three 
times higher after 3.5 h of hydrolysis. However, CMP hydrolysis is about 50%, necessitating 
the optimisation of substrate concentration and flux and the insertion of a bleeding step for 
the membrane (Bouhallab et al., 1992). In another study of the same group, the 
immunomodulatory peptide β-casein (193-209) is selectively isolated from the chymosin 
digest of β-casein. When the reactor is equipped with a cellulosic type membrane, the most 
satisfactory transmission of the peptide is obtained (Bouhallab et al., 1993). It appears that 
continuous isolation of specific peptide(s) from reaction mixtures requires the use of a highly 
specific enzyme, the rapid release of the desired peptide, a large molecular weight difference 
between bioactive peptides and others to promote selective separation and a high 
transmission rate of the bioactive molecules through the ultrafiltration membrane.  
 In batch, oligopeptides of 1000 Da or less are obtained by hydrolysis of chicken egg yolks 
with the crude enzyme Newlase F and by subsequent dialysis with a semi-permeable 
membrane filter. In a long-term study, these extracted oligopeptides suppress the 
development of hypertension after oral administration in SHR (Yoshii et al., 2001).  
 Using a three-step ultrafiltration membrane reactor, ACE inhibitory peptides are produced 
from skin gelatine from cow and Alaska Pollack by sequential protease treatment in the order 
of alkalase, pronase E and collagenase (Figure 11).  
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3.4. Chemical synthesis 
 
 
3.5. Other techniques 
 
Figure 11. Schematic diagram of the three-step recycling membrane reactor for the 
production of enzymatic hydrolysates of gelatine. TI: temperature indicator; PI: 
pressure indicator; FI: flow indicator; P1: recycling pump; P2: feed pump; P3: 
NaOH pump; PCV: pressure control valve; pHIC: pH indicator controller; FH: 
first hydrolysate; SH: second hydrolysate; TH: third hydrolysate (Byun and Kim, 
2001). 
 
 The ultrafiltration membranes from the first to the third reactor have a decreasing MWCO 
in the order of 10 000 Da, 5000 Da and 1000 Da. The combination of different enzymes 
results in a high degree of hydrolysis. For the fragmented hydrolysate, the ACE inhibitory 
activity markedly increases with decrease of MWCO of the membranes. For Alaska Pollack 
skin gelatine, the IC50 value of the third hydrolysate (0.63 mg/ml) is increased twofold 
compared with the value of the first hydrolysate (1.40 mg/ml). The third hydrolysate contains 
the ACE inhibitory peptides Gly-Pro-Met and Gly-Pro-Leu (Byun and Kim, 2001). For bovine 
skin gelatine, similar IC50 values are obtained for the hydrolysates and two potent ACE 
inhibitory peptides, Gly-Pro-Val and also Gly-Pro-Leu are purified from the third hydrolysate 
(Kim et al., 2001). 
 
3.4. Chemical synthesis 
 Based on known peptide sequences in food proteins, ACE inhibitory peptides may be 
synthesised chemically, which is expensive and not relevant for industrial production 
processes. However, recent advances in the design and construction of synthetic peptides 
enable the investigation of modifying functional activities (Mayo, 2000), which may have 
important implications for biotechnology.  
 
  
alkalase pronase E collagenase 
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3.5.  Recent techniques 
 Production and isolation of bioactive peptides may be combined in one step. 
Chromatographic media together with in situ enzymatic hydrolysis and followed by selective 
elution enable the release of specific peptide sequences from a crude protein (Figure 12). 
Therefore it is essential to know the structural properties of these peptides. Anionic and 
cationic peptides with different biological activities can be isolated in this way. For example, 
lactoferrin is selectively bound when cheese whey is filtered through a cation-exchange 
membrane. Subsequently, it is directly hydrolysed in situ with pepsin. Inactive fragments are 
washed off the membrane with ammonia and a fraction enriched in the antimicrobial peptide 
lactoferricin is obtained by further elution with NaCl. This method has also proven to be 
effective in the isolation of phosphopeptides from milk proteins. Major advantages of this 
method are that the precursor protein does not need to be purified separately and that the 
other proteins in the crude mixture remain intact for other applications (Recio and Visser, 
1999; Recio et al., 2000).  
Figure 12. Method for the combined in situ hydrolysis and isolation of bioactive peptides 
(Floris, 2000). 
 
 Another approach is to chemically synthesise the oligonucleotides encoding ACE 
inhibitory peptides and express them in microorganisms. For example, oligonucleotides 
encoding the ACE inhibitory peptides Ile-Tyr and Val-Lys-Tyr are chemically synthesized and 
designed to be multimerised due to isoschizomer sites. The cloned gene, named ap3, is 
multimerised up to 6 times in a plasmid and expressed as a fusion protein, which is easily 
membrane 
enzyme
active peptide 
1. Concentration 2. Hydrolysis 3. Selective elution 
Literature review 
 49
purified. The digest of AP3 by chymotrypsin exhibits an IC50 value of 18.53 µM. Therefore, 
potent ACE inhibitory peptides may be released upon oral ingestion of AP3 (Oh et al., 2002). 
 
3.6.  Isolation and characterisation of ACE inhibitory peptides 
 Various procedures are available to further purify and characterise bioactive peptides from 
hydrolysates. Firstly, usually a fractionation based on selective precipitation, ultrafiltration, 
chromatography or solid phase extraction is carried out to obtain a potent bioactive peptide 
mixture. Then, this is further purified to pure peptides by reversed phase - high performance 
liquid chromatography (RP-HPLC) (Herraiz, 1997). Different methods of mass spectrometry 
facilitate the detection and identification of peptides (Léonil et al., 2000). 
 Precipitation of large peptides and proteins is performed with solutions containing organic 
solvents (methanol, ethanol or acetone) or acids (trichloroacetic acid), also by high 
concentration of salts (ammonium sulphate) or by adjusting the pH to the iso-electric point. 
Ultrafiltration is a reliable and simple method for fractionating peptides in function of their 
molecular size. Size exclusion chromatography or gel filtration also separates peptides 
according to molecular size. Ion exchange chromatography selects peptides based on their 
ionic character. Peptides containing very specific functional or active groups can be isolated 
by affinity chromatography. Solid phase extraction uses cartridges and columns with several 
bonded phases that isolate peptides by non-polar, polar and ion exchange mechanisms 
(Herraiz, 1997). 
 From a tryptic casein hydrolysate, hydrophobic peptides can be precipitated by a 
combination of pH and salt. As these peptides are often bitter, this procedure may be 
applicable to improve the taste of protein hydrolysates. On the other hand, it can be used to 
isolate bioactive peptides (Léonil et al., 1994). 
 After tryptic digests of β-lactoglobulin and whey protein concentrate are subjected to 
ultrafiltration, the highest ACE inhibitory activity is present in the 3 kDa permeates as 
opposed to 1 and 10 kDa permeates and the unfractionated hydrolysates (Mullally et al., 
1997a). In the characterisation of whey protein hydrolysates digested by gastrointestinal 
proteases, the ACE inhibitory activity in the 1 kDa permeate is in many cases higher than in 
the retentate (Pihlanto-Leppälä et al., 2000). Hence, ultrafiltration may be exploited to enrich 
for ACE inhibitory peptides. 
 When characterising oligopeptides from yoghurt, which contain bioactive peptide 
sequences, cation exchange separates uncharged and anionic compounds such as sugars 
or lactic acid, while subsequent ultrafiltration permits to isolate oligopeptides with molecular 
weight < 2 kDa. Final separation of oligopeptides is carried out by RP-HPLC on C18 silica 
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columns using gradient elution with an aqueous trifluoroacetic acid/acetonitrile mixture and 
UV detection (Schieber and Brueckner, 2000).  
 Two potent ACE inhibitory peptides were purified from skin gelatine hydrolysate by 
sequential chromatographic methods including size exclusion chromatography, ion exchange 
chromatography and RP-HPLC. During the successive purification steps the IC50 value of the 
active fraction decreased by a factor 400 (Byun and Kim, 2001; Kim et al., 2001).  
  
 
4. BIOAVAILABILITY OF ACE INHIBITORY PEPTIDES 
 
4.1. Introduction 
To exert physiological effects in vivo after oral ingestion, it is of crucial importance that 
ACE inhibitory peptides remain active during gastrointestinal digestion and absorption and 
reach the cardiovascular system. ACE inhibitory peptides may be released and degraded in 
the human body. Figure 13 shows the potential barriers in the human body where bioactive 
peptides can be (in)activated. This partially explains the discrepancy that is often observed 
between the ACE inhibitory activity of a food protein hydrolysate and its antihypertensive 
effect after oral administration (Table 6, 7 and 8). It is also suggested that ACE inhibitory 
peptides may exert an additional antihypertensive effect by inhibition of chymase and the 
endothelin converting enzyme (Okitsu et al., 1995; Yamamoto et al., 1999). 
 
4.2. Gastrointestinal digestion 
 Digestion of proteins starts in the stomach by the action of pepsins at acidic pH. In 
humans the endopeptidases pepsin A and C are present, which exhibit similar substrate 
specificity (Table 9). In the luminal phase of the small intestine, the polypeptides are further 
cleaved by the pancreatic proteases trypsin, α-chymotrypsin, elastase, carboxypeptidase A 
and B at more alkaline pH (Table 9). This results in a mixture of oligopeptides and free amino 
acids, of which oligopeptides constitute a major portion. The free amino acids are absorbed 
as such into the enterocytes across the brush border membrane via distinct amino acid 
transport systems. The oligopeptides undergo further hydrolysis by the action of a battery of 
brush border peptidases resulting in a mixture largely consisting of free amino acids, di- and 
tripeptides. The intestinal brush border membrane is particularly rich in aminopeptidase 
activity, which provides functional complementation to the carboxypeptidases present in the 
pancreatic juice. Aminopeptidase N and A are the major representatives and cleave             
N-terminal neutral and anionic amino acids, respectively.  
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Figure 13. The potential activation and inactivation of ACE inhibitory peptides in the human 
body during gastrointestinal digestion, absorption and in the blood. 
  
In addition to these enzymes, the intestinal brush border contains endopeptidase and 
dipeptidase activity. ACE or dipeptidyl carboxypeptidase cleaves dipeptides from the           
C-terminus of oligopeptides with Pro, Phe or Leu in the ultimate position. Dipeptidyl 
aminopeptidase IV releases dipeptides from the N-terminus of oligopeptides with Pro or Ala 
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in the penultimate position. Hence, the dipeptides released by these enzymes are generally 
of the X-Pro type (Ganapathy and Leibach, 1999; Ganong, 1997a). 
Proline and hydroxyproline containing peptides are generally resistant to degradation by 
digestive enzymes. Furthermore, tripeptides containing C-terminal Pro-Pro are reported to be 
resistant to proline specific peptidases (Fitzgerald and Meisel, 2000; Vanhoof et al., 1995). 
This stresses the fact that several bioactive peptides that have been shown to exert an in 
vivo effect, are isolated from casein and gelatine, as these proteins contain a high amount of 
proline. 
 Bioactive peptides have already been characterised from in vivo digests. When diets 
containing bovine casein are given to minipigs, the opiate peptide β−casomorphin-11 and the 
CPP αs1-casein f(66-74) are isolated from small intestinal contents (Meisel and Frister, 1989). 
In another study, β-casomorphin-7 immunoreactive material is detected in small intestinal 
contents of adult humans after bovine milk ingestion (Svedberg et al., 1985). In adult 
humans, after milk or yoghurt ingestion, the appearance of bioactive peptides in the stomach, 
small intestine and blood has been investigated. Many peptides derived from αs1-, β- or       
κ-caseins have been detected in the stomach, smaller peptides derived from casein and 
lactoferrin have been recovered from the small intestine. Two long peptides, CMP, κ-casein 
f(106-117) and the N-terminal peptide f(1-23) of αs1-casein, are absorbed and detected in 
plasma (Chabance et al., 1998). Hence, casoplatelines (CMP fragments) are released during 
gastrointestinal digestion and absorbed intact into the blood, which supports the concept that 
they exert an antithrombotic effect in vivo. The peptide Phe-Val-Ala-Pro-Phe-Pro-Glu-Val-
Phe-Gly-Lys-Glu, αs1-casein f(24-35), and f(25-32) are released in the human stomach. The 
latter fragment and f(28-35) are also detected in the duodenum. As these contain sequences 
of ACE inhibitory peptides (Table 6) (Karaki et al., 1990; Maruyama et al., 1987b), they might 
exert a physiological effect after absorption in the blood. The peptide αs1-casein f(1-23) is the 
antibacterial peptide isradicin with immunomodulatory capacities. This includes the fragment 
αs1-casein f(1-9), Arg-Pro-Lys-His-Pro-Ile-Lys-His-Gln, which has shown to have a small 
antihypertensive effect in SHR (Table 6) (Saito et al., 2000). 
 To investigate if ACE inhibitory peptides resist gastrointestinal digestion, they are usually 
subjected in vitro to hydrolysis by pepsin, trypsin, α-chymotrypsin or pancreatin. For 
example, ACE inhibitory wheat germ hydrolysate and the peptide Ile-Val-Tyr isolated from it, 
are hydrolysed by pepsin, trypsin and α-chymotrypsin alone and in combination. The ACE 
inhibitory activity of the wheat germ hydrolysate increases with 27% after a combined 
digestion, indicating that any active peptides must be newly produced by action of these 
proteases, in particular trypsin. The IC50 value of Ile-Val-Tyr does not change during 
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digestion, signifying that this peptide would resist in vivo gastrointestinal digestion (Matsui et 
al., 1999). Another example of activation of ACE inhibitory peptides during gastrointestinal 
digestion is the following. The antihypertensive peptide Lys-Val-Leu-Pro-Val-Pro-Gln shows 
only low ACE inhibitory activity in vitro. However, the potent ACE inhibitor Lys-Val-Leu-Pro-
Val-Pro is formed after pancreatic digestion due to the action of carboxypeptidase A. In the 
same study, an αs1-casein derived peptide, Tyr-Lys-Val-Pro-Gln-Leu, with strong ACE 
inhibitory activity, fails to exert an antihypertensive effect due to pancreatin degradation 
(Maeno et al., 1996).  
 After the small intestine, the non-digested and/or non-absorbed food peptides enter the 
large intestine or colon, where they can be metabolised by the intestinal microbiota. Here, 
hundreds of bacterial species interact with one another and the host, forming an integral and 
biologically important component of the body. The normal intestinal microbiota may possess 
a range of beneficial features from an impact on the morphology and physiology of the 
intestinal tract (Falk et al., 1998), over the suppression of colonization by pathogens and 
opportunistic microorganisms (Anonymous, 1999), the metabolisation of a variety of 
compounds and  the production of certain vitamins and fatty acids, to the stimulation of the 
immune system (Iijima et al., 2001). However, the normal microbiota is also involved in the 
metabolism of some potentially harmful substances leading to intestinal putrefaction and an 
increased risk of colon cancer (Knasmuller et al., 2001). To study the gastrointestinal 
microbial ecosystem and its impact on the health and well-being of the host, in vitro systems 
have been designed to reproduce the main nutritional and environmental conditions that 
affect the composition and functionality of the complex ecosystem (Rumney and Rowland, 
1992). One example is the SHIME, Simulator of the Human Intestinal Microbial Ecosystem 
(Molly et al., 1994). This semi-continuous in vitro system consists of five reactor vessels, 
simulating the different parts of the gastrointestinal tract, respectively stomach, small 
intestine, caecum + colon ascendens, colon transversum and colon descendens. At the start-
up the system was inoculated with fecal material. By addition of an adapted diet, pancreatic 
juice and bile, and by controlling pH, temperature and retention time in the different vessels, 
the microbiota of the human individual can be mimicked. The first two vessels work semi-
continuously with a fill-and-draw system, while in the last three vessels, simulating the large 
intestine, the suspension is continuously transferred. By selective adaptation of the system, a 
simulator for the infant (baby-SHIME) (De Boever et al., 2001) and pig (SPIME) microbial 
community have also been created. Recently the SHIME apparatus was extended by a 
computer control system. The SHIME has been demonstrated to be very useful in examining 
the intestinal microbial ecology and in studying the effect of functional foods on the 
gastrointestinal microbial community (De Boever et al., 2000). 
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4.3. Intestinal absorption  
 Peptides consisting of two or three amino acids are absorbed intact across the brush 
border membrane by a specific peptide transport system. The peptide transporter PepT1 
uses a transmembrane electrochemical proton gradient as the driving force and has broad 
substrate specificity (Yang et al., 1999). Small peptides are absorbed more rapidly than free 
amino acids and their transport is favoured (Webb, 1990). Once inside the enterocyte, these 
peptides are usually hydrolysed to free amino acids in the cytoplasm by various intracellular 
peptidases. Among these, aminotripeptidase, which releases the amino acid from the          
N-terminus of tripeptides, and several dipeptidases with different substrate specificity 
towards specific amino acids, are present. Here, iminodipeptidase or prolidase is of special 
interest because of its restricted specificity toward dipeptides of the X-Pro or                        
X-hydroxyproline type. Via specific amino acid transport systems, the amino acids cross the 
basolateral membrane and enter the portal circulation (Ganapathy and Leibach, 1999). 
 Transport of intact peptides and proteins from the intestinal lumen into the blood 
circulation is a unique phenomenon, which differs from the regular process of food digestion 
and absorption. The concept that significant amounts of small peptides can escape total 
digestion to amino acids and enter the circulation in intact form is rather new, but is gaining 
acceptance (Gardner, 1988; Grimble, 2000). Apart from the peptide transporter route, 
peptides can be absorbed intact across the intestinal mucosa via other mechanisms     
(Figure 14) (Gardner, 1998). There is evidence in support of both paracellular and 
transcellular routes for passage of intact peptides, but there is still debate as to the relative 
importance of these. Paracellularly, large water-soluble peptides pass via the tight junctions 
between cells. Highly lipid-soluble peptides appear to be able to diffuse via the transcellular 
route. Peptides may also enter the enterocytes via endocytosis which entails membrane 
binding and vesiculisation of the material (Ziv and Bendayan, 2000). The intestinal 
basolateral membrane also possesses a peptide transporter, which facilitates the exit of 
hydrolysis-resistant small peptides from the enterocyte into the portal circulation (Gardner, 
1984).  
 Biologically active peptides generated in the diet can be absorbed intact through the 
intestine and produce biologic effects at the tissue level. However, the potency of the 
administered peptides decreases as the chain length increases (Roberts et al., 1999). As in 
infants the gastrointestinal barrier is not yet completely mature, intact peptides and proteins 
are much better absorbed in infants than in adults (Walker, 1985). Together with the limited 
gastrointestinal proteolysis in infants, this explains why milk contains several bioactive 
proteins and peptides that are presumed to have a physiological role in the young. 
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Figure 14. Different mechanisms for intestinal transport of peptides: 1) paracellular, 2) 
passive diffusion, 3) endocytosis, 4) carrier-mediated transport.  
 
 In this respect, β-casomorphin immunoreactive material is detected in the plasma of 
newborn calves after milk intake (Umbach et al., 1985). Higher plasma levels of CMP are 
found in 5-day old infants compared to human adults after ingestion of milk (Chabance et al., 
1995; Chabance et al., 1998). In the latter study, it is demonstrated that a peptide containing 
24 amino acids is absorbed intact into the blood stream of human adults after milk ingestion 
(see above) (Chabance et al., 1998). Intestinal transport of β-casomorphins and synthetic 
analogues is investigated in isolated rabbit ileum mounted in Ussing chambers. While natural 
β-casomorphins are degraded by the intestinal mucosa and no intact transpepithelial 
passage is detected for these peptides, the synthetic analogue Tyr-D-Ala-Phe-D-Ala-Tyr 
crosses the epithelium intact (Tome et al., 1987). 
 When the intestinal transport mechanism of the antihypertensive peptide Val-Pro-Pro is 
studied in a Caco-2 cell monolayer, a low but significant amount of intact Val-Pro-Pro is 
transported through the cell monolayer. The transport is not mediated by the peptide 
transporter PepT1 and it is suggested that paracellular transport is the main mechanism of 
absorption (Satake et al., 2002). In another paper, the transepithelial transport of the 
oligopeptides bradykinin, β-casomorphin Tyr-Pro-Phe-Pro-Gly, ovokinin Phe-Arg-Ala-Asp-
His-Pro-Phe-Leu, Pro-Phe-Gly-Lys and Gly-Gly-Tyr-Arg is investigated in the Caco-2 model. 
The susceptibility to the brush border peptidases is one of the factors that decide the 
transport rate. Bradykinin and Gly-Gly-Tyr-Arg are hardly degraded, while β-casomorphin 
and ovokinin are hydrolysed substantially. The transport rate is greatest for Gly-Gly-Tyr-Arg 
and smallest for β-casomorphin. Furthermore, the transport mechanism is studied for 
bradykinin and Gly-Gly-Tyr-Arg. While adsorptive transcytosis through hydrophobic 
interaction with the cell membrane is suggested to be involved in the transport of bradykinin, 
Gly-Gly-Tyr-Arg is believed to be transported mainly via the paracellular pathway. It seems 
1 2 3 4 
Chapter 1   
 56
that molecular size and other structural properties like hydrophobicity determine the major 
transport way for peptides (Shimizu et al., 1997). 
 The antihypertensive peptide Val-Tyr, derived originally from sardine muscle, is dose-
dependently detected in human plasma and reaches a maximum 2 h after a single oral 
administration in normotensive human subjects. At the highest dose, more than a tenfold 
higher increment in Val-Tyr plasma concentration is measured compared to the baseline 
concentration. The low absorption ratios are explained by the fact that most of the 
administered dipeptide is hydrolysed by membrane-bound peptidases. Therefore, it is 
suggested that saturation of the peptide transporter enables the entry of excess Val-Tyr into 
peripheral blood (Matsui et al., 2002a). 
 
4.4. Stability in the blood 
 Blood contains substantial activities of peptidase enzymes. The half-life of certain 
peptides in plasma is very short, with an order of magnitude of 1 minute (Gardner, 1998). 
Angiotensin II degradation occurs even within seconds (Moskowitz, 2003). 
 First of all, oligopeptides with an ACE inhibitory activity in vitro, need to resist ACE to exert 
an antihypertensive effect in vivo. In this respect, the ACE inhibitory peptides can be 
classified in three groups: the inhibitor type, of which the IC50 values are not affected by 
preincubation with ACE; the substrate type, peptides that are hydrolysed by ACE to give 
peptides with a weaker activity and the prodrug-type inhibitor, which are converted to true 
inhibitors by ACE or other gastrointestinal proteases. Only peptides belonging to the inhibitor 
or pro-drug type exert antihypertensive activities after oral administration in SHR (Fujita et 
al., 2000). 
 After intravenous administration of the ACE inhibitory peptide Ile-Val-Tyr, isolated from 
wheat germ hydrolysate, to SHR, the tripeptide is observed to be metabolised by the action 
of aminopeptidase in plasma to form a subsequent ACE inhibitor, Val-Tyr. The latter peptide 
exerts an acute depressor effect in SHR and the blood pressure returns about 5 min after 
injection to the normal state. On the other hand, after injection of Ile-Val-Tyr, the reduction in 
blood pressure is much stronger and is held for 15 min. Therefore, it is suggested that the 
intake of Ile-Val-Tyr as a physiologically functional food would serve in lowering the blood 
pressure by the combined action of itself and its metabolite after absorption (Matsui et al., 
2000). Val-Tyr has been administered orally to mild hypertensive subjects. Although the 
peptide is present in plasma and the absorption is comparable to the one observed in 
normotensive subjects (see above), no marked decrease in blood pressure is seen, 
suggesting that the peptide exerts no acute hypotensive effect (Matsui et al., 2002b). 
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 In conclusion, the bioavailability of ACE inhibitory peptides is predominantly determined 
by the resistance to peptidase degradation and intestinal absorption. In vivo experiments and 
clinical trials are necessary to demonstrate their physiological effects. 
 
 
5. GOALS AND OUTLINE OF THE STUDY 
 
 Hypertension or high blood pressure is a major risk factor for cardiovascular diseases, 
which are the leading causes of morbidity and mortality in western society. Lifestyle 
modifications and diet therapy, such as the DASH diet, have been shown to be effective in 
both the prevention and the treatment of hypertension. In this respect, bioactive peptides with 
antihypertensive properties like ACE inhibitory peptides may play a functional role as part of 
a functional food or as nutraceutical. As they are less active than their drug counterparts, 
they have not yet demonstrated any side effects. Moreover, they are less expensive. 
 ACE inhibitory peptides have mainly been isolated from milk proteins and have not yet 
been studied from pea protein. Whey has high biological value and originates as by-product 
from milk during the cheese making process. Pea is a long established and significant crop in 
Europe, but is nowadays mainly used in animal nutrition, although it has some advantages 
for human nutrition as well. Pea protein has a well balanced profile of amino acids, and 
especially a high content in lysine. Moreover, in accordance with today’s consumer 
demands, it is environment-friendly produced: not only can it present a non-GMO alternative 
to soy protein, but it is also a low input crop due to symbiotic nitrogen fixation.  
 This thesis aimed to investigate the formation of ACE inhibitory activity from pea and whey 
protein and to compare whey protein, from which certain bioactive peptides already have 
been characterised, to the unknown pea protein. Emphasis was placed on the in vitro study 
of the activity of ACE inhibitory peptides after oral administration in the human body, from the 
gastrointestinal tract to their site of action, the cardiovascular system. This was done by 
means of an in vitro gastrointestinal digestion, by simulation of the brush border phase and 
intracellular enterocyte enzyme activity and by in vitro intestinal transport studies. Literature 
review indicated that the maintenance of biological activity during the oral delivery route is 
often neglected.  
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 More specifically, the goals of this work were: 
• To optimise and validate an ACE inhibition assay, which is used to measure the 
biological activity of ACE inhibitory peptides in vitro and facilitates the screening of 
such peptides from food proteins (Chapter 2). 
• To study the activity of the potent lactokinin Ala-Leu-Pro-Met-His-Ile-Arg in the oral 
delivery route in vitro: stability towards gastrointestinal proteases and peptidases in 
the brush border and enterocytes, intestinal transport and antihypertensive effect 
(Chapter 3). 
• To release ACE inhibitory activity from pea and whey protein by fermentation with 
GRAS microorganisms and to study the influence of an in vitro gastrointestinal 
digestion on this activity (Chapter 4). 
• To characterise the conditions during in vitro gastrointestinal digestion of pea and 
whey protein leading to maximal ACE inhibitory activity release. This was investigated 
in batch by comparing three different in vitro digestions and in a semi-continuous 
reactor model by response surface methodology (Chapter 5). 
• To study the evolution of ACE inhibitory activity and protein degradation during an in 
vitro gastrointestinal physiological digestion, subsequently supplemented with rat 
intestinal acetone powder. Via an ACE inhibitory peptide database, protein databases 
and protein cleavage software, the ACE inhibitory activity and protein degradation 
during gastrointestinal digestion was also investigated in silico (Chapter 6). 
• To enrich the ACE inhibitory activity in pea and whey digests by ultrafiltration and RP-
HPLC fractionation, investigate the in vitro intestinal transport of these digests and 
permeates and examine the antihypertensive activity of pea and whey permeate in 
SHR (Chapter 7).  
The major findings of this work are summarised and discussed in Chapter 8. In addition, 
some perspectives for ACE inhibitory peptides are mentioned.  
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CHAPTER 2 
 
 
 
 
AN ANGIOTENSIN I CONVERTING 
ENZYME INHIBITION ASSAY FOR 
THE SCREENING OF BIOACTIVE 
PEPTIDES  
 
 
 
 
Redrafted after VERMEIRSSEN, V., VAN CAMP, J. & VERSTRAETE, W. 
(2002b). Optimisation and validation of an Angiotensin Converting 
Enzyme (ACE) inhibition assay for the screening of bioactive peptides. 
Journal of Biochemical and Biophysical Methods, 51:75-87. 
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Chapter 2
An angiotensin I converting enzyme inhibition assay
for the screening of bioactive peptides 
 
ABSTRACT 
 
 Angiotensin I converting enzyme (ACE) plays a major role in the regulation of blood 
pressure. A diagnostic assay to measure ACE activity was transformed into an enzyme 
inhibition assay and optimised, which led to a more sensitive and less expensive assay. By 
this spectrophotometric method, ACE inhibition is measured using the substrate 
furanacryloyl-Phe-Gly-Gly and rabbit lung acetone extract as ACE source. The optimised as 
well as the original ACE inhibition assays were used to verify the ACE inhibitory activity of 
captopril. The ACE inhibition assay was further validated by enalapril, its active derivative 
enalaprilat and the ACE-inhibitory peptide Ala-Leu-Pro-Met-His-Ile-Arg, corresponding to a 
tryptic fragment of bovine β-lactoglobulin. Sigmoid curves could be fit adequately to the data 
points representing ACE inhibition in function of inhibitor concentration. IC50 values for these 
compounds corresponded well with literature data. Futhermore, pea and whey protein 
hydrolysates obtained by digestion with trypsin showed ACE inhibitory activity in the ACE 
inhibition assay. Hence, this optimised assay is suited for the screening of ACE inhibitory 
peptides derived from food proteins with a possible antihypertensive effect in vivo. Later on, 
a more delicate and standardised assay was obtained by applying pure ACE from porcine 
kidney. This assay was also validated by captopril and Ala-Leu-Pro-Met-His-Ile-Arg. For most 
experiments done in this work, ACE inhibitory activity was measured by the latter assay. 
 
Keywords:  Angiotensin I Converting Enzyme (ACE), ACE inhibition assay, bioactive 
peptides, IC50, whey protein, pea protein 
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INTRODUCTION 
 
 Angiotensin I converting enzyme (ACE; EC 3.4.15.1) is a non-specific dipeptidyl 
carboxypeptidase associated with the blood pressure regulating renin-angiotensin system. 
This enzyme increases blood pressure by converting the decapeptide angiotensin I into the 
potent vasoconstricting octapeptide angiotensin II. Angiotensin II brings about several central 
effects all leading to a further increase in blood pressure. ACE is a multifunctional enzyme 
that also catalyses the degradation of bradykinin, a blood pressure lowering nonapeptide 
(Erdös and Skidgel, 1987; Johnston, 1992). Therefore, inhibition of the angiotensin I 
converting enzyme results in an overall antihypertensive effect.  
 Synthetic ACE inhibitors are one group of drugs in the treatment of hypertension.  
However, these synthetic drugs can have significant side effects due to their high activity and 
specificity (Messerli, 1999). On the other hand, peptides with ACE inhibitory activity have 
already been isolated from different food proteins (Ariyoshi, 1993; Dziuba et al., 1999a; 
Yamamoto, 1997). These so-called 'biologically active peptides' could represent a healthier 
and natural alternative treatment of hypertension.   
 To measure ACE activity and inhibition in vitro, the method of Cushman and Cheung 
(1971) is often used. In this spectrophotometric assay, the extent of hippuric acid release 
from hippuryl-L-histidyl-L-leucine (HHL) is directly related to the ACE activity. Rabbit lung 
acetone extract is the enzyme source. Nakamura et al. (1995a) later modified this assay by 
using pure ACE from rabbit lung instead of rabbit lung acetone extract. However, a major 
drawback of this method is that the absorbance to determine the hippuric acid concentration 
can only be measured after extraction with ethyl acetate. Additionally, an incubation time of 
30 min is necessary to yield a significant amount of product, which further prolongs the 
experiment. Sigma-Aldrich distributes a relatively fast ACE assay, based on the method of 
Holmquist et al. (1979) (Wong and Kinniburgh, 1987). Here, the ACE activity is determined 
by the blue shift of the absorption spectrum that occurs upon hydrolysis of a furanacryloyl 
tripeptide (FA-Phe-Gly-Gly, FAPGG) leading to the production of the corresponding amino 
acid (FA-Phe, FAP) and dipeptide (Gly-Gly, GG). The release of these peptides decreases 
the absorbance at the predescribed wavelength. The angiotensin I converting enzyme used 
in this assay originates from porcine kidney and is dissolved in human serum.  
We have modified this assay to determine ACE inhibition by the addition of an inhibitory 
compound in the reaction mixture and optimised it by using rabbit lung acetone extract as 
ACE source and applying the appropriate enzyme-substrate ratio, which increased the 
sensitivity of the assay. The optimised and original ACE inhibition assays were both used to 
determine the well-known ACE inhibitory activity of captopril, an antihypertensive drug. The 
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optimised ACE inhibition assay was further validated with enalapril, an antihypertensive 
prodrug, its active derivative enalaprilat and Ala-Leu-Pro-Met-His-Ile-Arg, an ACE inhibitory 
peptide isolated from a tryptic digest of  bovine β-lactoglobulin with an IC50 of 42.6 µM 
(Mullally et al., 1997b). Digests of pea and whey protein obtained with trypsin (EC 3.4.21.4) 
were also assessed for ACE inhibitory activity by this protocol. Afterwards, this assay was 
slightly modified by using pure ACE from porcine kidney as enzyme source. The ACE 
inhibitory activity of captopril and Ala-Leu-Pro-Met-His-Ile-Arg were also measured by this 
method. 
 
 
MATERIALS AND METHODS 
 
Products 
ACE reagent (305-10), ACE control-E (A 7040), rabbit lung acetone powder (L 0756), 
elastase (E 1250), trypsin (T 1426), Angiotensin I Converting Enzyme from rabbit lung         
(A 6778), captopril (C 4042), enalapril (E 6888) and Gly-Gly-Gly (G 1377) were purchased 
from Sigma-Aldrich (St.-Louis, MO, USA). The inhibitor solutions were prepared from 10-3 M 
stock solutions of captopril and enalapril in demineralised water and stored at -20°C. 
Angiotensin I Converting Enzyme from rabbit lung, reconstituted with demineralised water 
(0.1 U/ml), was kept at 5°C. The ACE inhibitory peptide Ala-Leu-Pro-Met-His-Ile-Arg was 
synthesised by solid phase peptide chemistry and FMOC protection at the Biotechnology 
Center of the University of Illinois, Urbana-Champaign, IL, USA.  
The pea protein isolate Pisane HD and the (rennet) whey protein isolate Lacprodan   
DI-9213 were obtained from Cosucra SA (Fontenoy, Belgium) and Acatris Belgium NV 
(Londerzeel, Belgium), respectively. Non-specified products were analytical grade from VWR 
International (Zaventem, Belgium). 
 
Sigma ACE assay transformed into an ACE inhibition assay: assay 1 
The ACE reagent contains 0.005 mmol FAPGG with stabiliser and buffer to ensure that 
the reaction takes place at pH 8.1-8.3. It was reconstituted with 5 ml instead of 10 ml 
demineralised water in order to maintain the substrate concentration of 4.6 .10-4 M in the final 
reaction mixture after addition of a volume of inhibitory compound. ACE control-E was 
reconstituted with 1 ml demineralised water according to the distributor. This solution 
contains an assigned activity of porcine angiotensin I converting enzyme in a buffered human 
base with stabilizers and preservatives. Five hundred µl ACE reagent and 500 µl 
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demineralised water (blank) or inhibitor solution were mixed and pre-incubated for 2 min at 
37°C. After addition of 100 µl enzyme (ACE control-E) to this suspension, the reaction 
mixture was incubated for 5 min at 37°C. Subsequently, the absorbance was measured 
against demineralised water in a heated cuvet holder (37°C) of an UV/VIS double beam 
spectrophotometer (Uvikon 922, Kontron Instruments, Watford Herts, UK) at 340 nm over a 
time interval of exactly 5 min. The pH of the reaction (8.1-8.3) was verified by means of 
indicator paper.  
 
ACE inhibition assay with rabbit lung acetone extract: assay 2 
The rabbit lung acetone extract was prepared by dissolving 1 g rabbit lung acetone 
powder in 10 ml 50 mM potassium phosphate buffer, pH 8.3 and ultracentrifuging the mixture 
for 40 min at 40 000 g (L 7-55 ultracentrifuge, Beckman, Fullerton, CA, USA). The clear wine 
red supernatant possessed high ACE activity and was kept at 5°C (Cushman and Cheung, 
1971). Prior to the assay, the supernatant was diluted 10 times in 50 mM potassium 
phosphate buffer, pH 8.3. 
ACE inhibitory activity was assayed with a variant of the above-described transformed 
Sigma assay. The reaction mixture contained 500 µl ACE reagent, 300 µl demineralised 
water (blank) or inhibitor solution and 300 µl ten times diluted rabbit lung acetone extract. 
The incubation and spectrophotometric determination of the mixture was identical to assay 1. 
 
ACE inhibition assay with pure ACE from porcine kidney: assay 3 
Instead of 300 µl ten times diluted rabbit lung acetone extract, 300 µl reconstituted ACE 
control-E was added as enzyme source. All other conditions were identical to assay 2. For 
most experiments done in this work, ACE inhibitory activity was measured by the latter 
assay. The concentration of the analysed inhibitory ferments and hydrolysates in the assay 
was 2.73 mg/ml when determining a percent ACE inhibitory activity (see next chapters).  
 
Standard curve 
The decrease in absorbance over 5 min corresponds to an ACE activity as determined by 
the standard curve. This curve was constructed using different dilutions of the ACE control-E 
as enzyme source. In assay 1 up to 100 µl pure ACE control-E was added, while in assay 2 
and 3 this was 300 µl. Data were fitted by a linear regression model using the Marquardt-
Levenberg algorithm (minimisation of the sum of the squared differences between the values 
of the observed and predicted values of the dependent variable) (Sigmaplot 8.0, SPSS Inc., 
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Chicago, Illinois, USA). The activity of the angiotensin I converting enzyme is expressed in 
U/l, whereby 1 unit is defined as the amount of enzyme that catalyses the formation of           
1 µmol FAP per min under the assay conditions of the Sigma-Aldrich ACE assay. Pure rabbit 
lung angiotensin I converting enzyme (0.1 U Cushman & Cheung/ml) was also once applied 
as enzyme source in assay 2 in order to compare the FAP units with the Cushman & Cheung 
units. 
 
Inhibition 
Inhibition was expressed as the concentration of inhibitory compound in the assay that 
inhibits 50% of ACE activity (IC50), assuming that the activity of the blank is 100%. When 
ACE inhibitory activity exceeded 80%, dilution series were made to determine the IC50 value. 
Dose-activity curves were generated for doses of inhibitor (abscissa) versus ACE activity 
(ordinate). The data were fitted by a 4 parametric logistic model using the Marquardt-
Levenberg algorithm (Sigmaplot 8.0, SPSS Inc., Chicago, Illinois, USA). The IC50 value was 
obtained from the parameters of the fitted function. 
[ ] slopehillxICy .log 50101
minmaxmin −+
−+=  
In this equation y represents the ACE inhibitory activity (%) and x the logarithm of the 
concentration of inhibitor (M or mg/ml). Parameter min equals the baseline of 100% 
inhibition, max the plateau of 100% activity. Parameter IC50 gives the transition center. The 
hill slope determines the slope of the curve at the transition center. 
 
Chloride ion determination in the ACE reagent 
Chloride ion concentration of thousand fold diluted ACE reagent was determined by the 
spectrophotometric LCK 311 assay on the ISIS 9000 apparatus (Dr. Lange, Düsseldorf, 
Germany).  
 
Effect of elastase on FAPGG  
Elastase solutions of 10 mg/1.5 ml and a tenfold dilution (1 mg/1.5 ml) in 50 mM 
potassium phosphate buffer, pH 8.3, were used as enzyme source in the ACE inhibition 
assay with rabbit lung acetone extract (assay 2). Instead of using 300 µl of the ten times 
diluted rabbit lung acetone extract, 300 µl of elastase solution was added in assay 2. 
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Chemical hydrolysis of enalapril to enalaprilat 
Four ml 1 M NaOH was added to 10 ml 10-3 M enalapril solution in demineralised water 
and the reaction mixture was placed at room temperature overnight. Afterwards, the pH was 
adjusted to 8 with 1 M HCl and the solution was diluted to 20 ml with demineralised water. 
Assuming complete conversion, the final concentration enalaprilat in the solution amounted 
to 5 .10-4 M. Different dilutions of this solution were used in assay 2. 
 
Preparation of ACE inhibitory samples 
Pea protein and whey protein isolate (4% (w/v) in demineralised water) were digested with 
trypsin (E/S = 1/250 (w/w)) for 2 h at 37°C and pH 7. Samples were taken before trypsin 
addition and after digestion. In both cases, the pH was adjusted to pH 5 with 10 N and 1 N 
HCl or NaOH while heavily stirring the solution and samples were centrifuged for 15 min at 
10 000 g. Before freezing the supernatant at -70°C, the protease was inactivated by cooling 
in liquid nitrogen for 25 s. After minimum 12 h the samples were lyophilised.  Ten mg of the 
lyophilised powder was dissolved in 1 ml demineralised water and used as ACE inhibitory 
solution in ACE inhibition assay 2 (concentration of 2.73 mg/ml in the assay). 
 
Statistical analysis 
Values are reported as mean ± standard error (SE). Statistical analysis of the parameters 
was performed by the F-test (p < 0.05) to verify equality of variances and by the appropriate 
two-tailed Student t-test (p < 0.05; 0.01; 0.001) to determine whether two samples are likely 
to have come from the same two underlying populations that have the same mean. 
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RESULTS 
 
Standard curve 
In our ACE inhibition assays, ACE catalyses the degradation of the substrate, so that the 
ACE activity could be derived from the decrease in absorbance during the reaction. In the 
standardised assays, the absorbance was measured at 340 nm 5, 7.5 and 10 min after the 
addition of the enzyme. The decrease in absorbance for a given ACE concentration occurred 
linearly in time during the 5 min measurement. A standard curve was constructed using 
different dilutions of the ACE control-E (Figure 1). Regression analysis revealed a linear 
model with a slope of 0.0031 ± 0.0001, an intercept of 0.0110 ± 0.0013 and a correlation 
coefficient of 94% (n = 62). The detection limit is defined as the concentration that yields a 
decrease in absorbance that is still significantly different from the background signal. The 
detection limit of the ACE inhibition assays, predicted with 99.7% confidence, was 2.9 U/l. 
This corresponded to a decrease in absorbance of 0.02. 
 
Figure 1.  Standard curve for the ACE control-E, which links the decrease in absorbance 
over 5 min at 340 nm with the ACE activity in the reaction mixture (U/l) (n = 62).  
The 95% confidence and prediction lines of the standard curve are also shown. 
This standard curve was used in all assays. 
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Diagnostic assay transformed into an ACE inhibition assay: assay 1 
Since in assay 1 only 100 µl ACE control-E enzyme was added, a maximum decrease in 
absorbance of 0.038 could be obtained for the ACE control-E during the 5 min measurement 
period (Figure 2). This corresponded to an ACE activity of 8.7 U/l. Taking the detection limit 
into account, this means that the reduction of the ACE activity to a value lower than 33% 
cannot be distinguished significantly from a reduction to 0% (p = 0.003).  
The decrease in absorbance for a given ACE concentration occurred linearly in time 
during the 5 min measurement. Extending the measurement period to 11 min increased the 
decrease in absorbance, and thus the sensitivity, but the linearity of the decrease was not 
maintained: the decrease in absorbance during the last 6 min was on average 20% lower 
than expected from the linearity during the first 5 min of the measurement. Therefore it was 
decided to measure the ACE activity over a period of 5 min (data not shown).  
Figure 2. The decrease in absorbance over the 5 min measurement period for the three ACE 
inhibition assays (assay 1: 100 µl ACE control-E, assay 2: 300 µl ten times diluted 
rabbit lung acetone extract, assay 3: 300 µl ACE control-E) (n = 3). 
 
In order to validate the ACE inhibition assay, captopril was added in different 
concentrations and ACE activity was determined. When the activities of the inhibited ACE 
solutions were plotted against the captopril concentration, a sigmoid curve was obtained 
(Figure 3). In the small concentration range of 10-10 M to 10-8 M there was a transition from 
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no to total inhibition of the ACE enzyme. Captopril is a very strong inhibitor, since its IC50 
value was situated around 1.60 nM (Table 1).  
Figure 3. ACE inhibition (%) when captopril was added as inhibitory compound in assay 1 
(●), assay 2 (▼) and assay 3 (□). Data were fitted by a 4 parametric logistic model 
(n1 = 30, n2 = 36, n3 = 23).  
 
ACE inhibition assay with rabbit lung acetone extract: assay 2 
The ACE activity in the rabbit lung acetone extract is not known. Diluting the extract 
increased the linearity of the absorbance decrease over 5 min, while it reduced the sensitivity 
(Figure 4). Certain compounds in the extract also seemed to absorb at 340 nm. The ten 
times diluted rabbit lung acetone extract had about the same ACE activity as ACE control-E. 
The modified enzyme assay with ten times diluted rabbit lung acetone extract showed a good 
linear decrease in absorbance over the 5 min measurement period. The measurement range 
was also considerably increased compared to assay 1: an average decrease in absorbance 
of 0.09 was obtained, which slightly differed per batch rabbit lung acetone extract prepared 
(Figure 2). This corresponded with an ACE activity of 25.5 U/l in the standard curve of ACE 
control-E, which is approximately 3 times higher than the start ACE activity in ACE inhibition 
assay 1. Hence, a reduction of the ACE activity to 11% can still be distinguished from a 
reduction to 0% (p = 0.003). Batches of rabbit lung acetone extract were only used if the 
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decrease in absorbance for the blank was within the range of 0.07 to 0.11. Under these 
conditions no significant difference in IC50 for a given inhibitor was obtained with different 
batches. 
Figure 4. Deviation of the decrease in absorbance during the 5 min measurement from the 
initial rate of decrease (dashed line) for the ten times diluted rabbit lung acetone 
extract (inset: six and fifty times diluted rabbit lung acetone extract) (n = 3). 
 
A spectrophotometric assay revealed the presence of about 606 mM chloride ions in the 
ACE reagent itself; the latter is diluted approximately a factor 5/11 in the assays. When pure 
elastase was used as enzyme source in the ACE inhibition assay, no significant decrease in 
absorbance was observed during the 5 min measurement at enzyme concentrations of       
6.7 mg/ml and 0.67 mg/ml elastase. 
Applying 300 µl pure angiotensin I converting enzyme (0.1 U Cushman & Cheung/ml) 
from rabbit lung in this ACE inhibition assay, revealed that 1 U of Sigma equals 1 U of 
Cushman & Cheung. In this respect, ACE inhibitory activities in different units can be 
compared. 
With captopril a sigmoid curve was obtained similar to this of assay 1 (Figure 3, Table 1). 
In the concentration interval of 10-10 M to 10-7 M there was a change from 0 to 100% 
inhibition of the ACE enzyme. Here, captopril had an IC50 of 8.91 nM, which was significantly 
different from the one in assay 1 (p < 0.001). When enalapril, enalaprilat or the ACE 
inhibitory peptide Ala-Leu-Pro-Met-His-Ile-Arg were dosed in the ACE inhibition assay with 
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rabbit lung acetone extract, sigmoid inhibition curves were observed as well (Figure 5). 
Enalaprilat is the active antihypertensive drug, which was obtained by chemical hydrolysis 
from the prodrug enalapril. This conversion resulted in a decrease in the IC50 value from    
1.56 µM to 4.96 nM, which corresponds to an augmentation of the ACE inhibitory activity with 
a factor 1000. The food derived ACE inhibitory peptide was less active, with an IC50 value of 
32.5 µM (Table 1).  
Figure 5. ACE inhibition (%) when enalaprilat (▲), enalapril (●) and Ala-Leu-Pro-Met-His-Ile-
Arg (■), whey digest (▼) an pea digest (○) were used as inhibitory compound in 
assay 2. Ala-Leu-Pro-Met-His-Ile-Arg in assay 3 (□) is also plotted. Data were 
fitted by a 4 parametric logistic model (nenalapril = 16, nenalaprilat = 22, npeptide = 22, 
npeptide-assay3 = 36, nwhey = 31, npea = 21). 
 
Whey and pea protein isolate were subjected to a digestion with trypsin (E/S =            
1/250 (w/w)) for 2 h at 37°C and pH 7. Before digestion, the measured ACE inhibitory activity 
in whey and pea protein was 9 ± 4% and 35 ± 4% respectively. After digestion, these values 
increased to 97 ± 2% and 99 ± 1% for whey and pea protein respectively. When fitting a 4 
parametric logistic model to dose-activity data, IC50 values of 0.24 mg/ml for whey and      
0.37 mg/ml for pea protein digest were observed (p < 0.01) (Figure 5, Table 1). 
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ACE inhibition assay with pure ACE from porcine kidney: assay 3 
ACE control-E has an assigned ACE activity, which differs slightly per lot product. During 
our experiments, this value ranged from 88 to 102 U/l at 37°C, which corresponds with a 
concentration in the assay from 24 to 27.8 U/l and an absorbance decrease from 0.085 to 
0.097. This is very similar to assay 2 (Figure 2). 
 
Table 1. Parameters of the fitted 4 parametric logistic dose-activity curves for the following 
inhibitors: captopril, enalapril, enalaprilat, the ACE inhibitory peptide Ala-Leu-Pro-
Met-His-Ile-Arg and the tryptic digests of whey and pea protein in assay 11, assay 
22 and assay 33.  
 Min (%) Max (%) Log IC50 (M) Hill slope R2 N 
Captopril1 3.9 ± 2.7 103.0 ± 3.3 -8.80 ± 0.05 1.5 ± 0.2 0.97 30 
Captopril2 -0.4 ± 2.4 103.0 ± 3.7 -8.05 ± 0.04*** 1.5 ± 0.2 0.96 36 
Captopril3 5.0 ± 1.9 102.3 ± 3.7 -8.13 ± 0.04 1.7 ± 0.2 0.99 23 
Enalapril2 2.5 ± 1.9 100.3 ± 1.7 -5.81 ± 0.02 2.3 ± 0.3 0.99 16 
Enalaprilat2 0.0 ± 2.5 101.0 ± 3.0 -8.30 ± 0.03 1.8 ± 0.2 0.99 22 
Peptide2 0.0 ± 1.5 102.4 ± 1.8 -4.49 ± 0.02 1.5 ± 0.1 0.99 22 
Peptide3 -1.4 ± 3.0 101.8 ± 2.6 -4.84 ± 0.03*** 1.5 ± 0.2 0.99 36 
Whey digest2  0.2 ± 2.6   99.4 ± 2.3 -0.61 ± 0.03 1.8 ± 0.2 0.99 31 
Pea digest2 -1.3 ± 4.2 108.6 ± 6.3 -0.43 ± 0.05**  1.2 ± 0.2 0.99 21 
Values are expressed as mean ± standard error.  
Significant differences (*p < 0.05, **p < 0.01, ***p < 0.001) verified by t-tests between 
captopril1 and 2, and captopril2 and 3, peptide2 and 3 and whey and pea digest respectively. 
IC50 of whey and pea digest is expressed in mg/ml. 
 
 When compared to the curve of assay 2, inhibition with captopril showed an almost 
identical sigmoid curve (Figure 3). An IC50 value of 7.41 nM was calculated, which was not 
significantly different from the one obtained in assay 2 (Table 1). Ala-Leu-Pro-Met-His-Ile-Arg 
displayed an IC50 value of 14.5 µM in assay 3, which was significantly different from the one 
in assay 2 (p < 0.001) (Table 1, Figure 5). The repeatability of the log IC50 of this lactokinin, 
expressed as variation coefficient (standard deviation over mean), was 7.5% in assay 3           
(n = 3). The reproducibility, expressed as variation coefficient, amounted to 3.6% (n = 3). 
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Furthermore, the peptide Gly-Gly-Gly at a concentration of 2.73 mg/ml in the reaction mixture 
had an ACE inhibitory activity of 97 ± 3%. 
Table 1 shows a good fit to the 4 parametric logistic model for all inhibitory compounds in 
all assays: regression coefficients were higher than 95%. In all cases the ACE inhibitory 
activity increased from 0 to 100% in function of the concentration. The hill slope was always 
higher than 1.2, which corresponds to an angle of more than 50°.  
 
 
DISCUSSION 
 
Most ACE inhibitory drugs and peptides inhibit the ACE enzyme in a competitive way 
(Meisel, 1997a; Weisser and Schloos, 1991). Above a given concentration a saturation effect 
appears: ACE inhibitory activity is then 100% and independent of the inhibitor concentration. 
Below a given concentration ACE inhibitory activity is absent. Between 0 and 100% the ACE 
inhibitory activity changes according to a sigmoid curve in function of the logarithm of the 
concentration. A 4 parametric logistic model can fit the data points, from which the IC50 value, 
the concentration of inhibitor that inhibits the ACE enzyme for 50%, is calculated. This model 
efficiently described the ACE inhibitory activity in function of the inhibitor concentration, 
regardless of assays or inhibitory compounds. The calculated hill slope is an indication of the 
rate of change of the sigmoid curve. For all inhibitory compounds a steep slope was 
observed. 
Measuring the ACE activity with FAPGG as a substrate is a sensitive method for substrate 
concentrations above the Michaelis-Menten constant Km (3 .10-4 M), to give classical zero-
order kinetics, and below Km, to give first-order kinetics (Holmquist et al., 1979; Ronca-
Testoni, 1983). In our assays the substrate concentration was 4.6 .10-4 M, hence higher than 
Km, for which the reaction obeys zero order kinetics in the substrate concentration under 
steady state conditions. The reaction rate, which is expressed as the ACE inhibitory activity, 
is then independent of the substrate concentration and approaches vmax in the enzyme 
saturation kinetics, which is directly proportional to the enzyme concentration. Under these 
conditions substrate hydrolysis occurs linearly with time over at least 15% of total hydrolysis 
(Holmquist et al., 1979). Provided that the absorbance decreases linearly with time during 
the 5 min measurement period, the decrease in absorbance is a measure for the reaction 
rate or the enzyme activity (µmol.l-1.min-1) (Weisser and Schloos, 1991). Furthermore, 
FAPGG is the substrate of choice since it exhibits one of the highest activities with ACE. Its 
kinetic parameters are better than those of Hip-His-Leu, the most commonly used ACE 
substrate (Cushman and Cheung, 1971; Meisel et al., 1997a; Mullally et al., 1997a; 
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Nakamura et al., 1995a; Pihlanto-Leppällä et al., 1998). FAPGG has a Km = 3 .10-4 M and   
kcat = 19 000 min-1 which compare favourably with values of 2.4 .10-3 M and 15 600 min-1 
respectively for Hip-His-Leu (Bunning, 1983; Bunning et al., 1983; Holmquist et al., 1979). 
The diagnostic Sigma reagent kit is already validated for measuring ACE activity. Wong and 
Kinniburgh (1987) have shown that the reaction is linear up to 160 U/l ACE, which 
corresponds with a concentration in assays 2 and 3 of 43.6 U/l. 
The sensitivity of the diagnostic ACE inhibition assay (assay 1) could not be increased by 
prolonging the incubation time, because zero order Michaelis-Menten kinetics were no longer 
applicable under these conditions. The switchover to the ACE inhibition assay with rabbit 
lung acetone extract (dilution 1/10) and applying the appropriate enzyme-substrate ratio 
(assay 2), increased the useful measurement range of the assay three times. Since in    
assay 2 rabbit lung acetone extract replaced the pure porcine ACE-control E, it is less 
expensive. Moreover, less inhibitor was needed in this assay. Cushman and Cheung (1971) 
stated an optimal ACE activity of the rabbit lung acetone extract at pH 8.1-8.3 and in the 
presence of 300 mM NaCl. Chloride ions are necessary for the activity of the enzyme. In our 
reaction mixtures a chloride ion concentration of about 275 mM was present, which 
approximates the optimal chloride ion concentration. The concentration of chloride ions in the 
reagent itself is in agreement with the value of 651 mM, reported by Wong and Kinniburgh 
(1987). Holmquist et al. (1979) mentioned with furanacryloyl tripeptides as substrate and 
purified ACE from rabbit lung acetone powder a maximal hydrolysis rate at pH 7.5. Since in 
the Sigma diagnostic assay the ACE reagent is buffered at pH 8.2, the reaction in our 
experiments also took place at this pH. According to Cushman and Cheung (1971) this is 
also the pH where the rabbit lung acetone powder extract shows optimal ACE activity. Rabbit 
lung acetone powder is sold by Sigma as a source of angiotensin converting enzyme and 
elastase, a non-specific protease. Pure elastase was used in assay 2 as enzyme source to 
verify that elastase was not able to cleave the substrate FAPGG. As this was not the case, 
rabbit lung acetone powder is specific enough to search for ACE inhibitory activity with 
FAPGG as substrate. 
Later batches of the rabbit lung acetone extract failed to give a satisfactory absorbance 
decrease of at least 0.07. Therefore, assay 2 was modified by using ACE control-E as 
enzyme. This decreased the cost-efficiency of the assay, but on the other hand resulted in a 
more standardised assay. 
The active inhibitory group in captopril is a sulfhydryl (SH) group that chelates the zinc ion 
contained in the active site of the ACE enzyme (Bunning, 1983; Bünning, 1987; Cushman et 
al., 1987; Shapiro and Riordan, 1984). The obtained IC50 values for captopril, 1.60 .10-9 M in 
assay 1, 8.91 .10-9 M in assay 2 and 7.41 .10-9 M in assay 3, correspond well with literature, 
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where values from 7.5 .10-10 M to 2.2 .10-8 M are mentioned (Cushman et al., 1987; 
Cushman et al., 1989; Elbl and Wagner, 1991; Fujita and Yoshikawa, 1999; Hiwada et al., 
1990; Ino et al., 1989; Mullally et al., 1997a; Williams et al., 1993). The difference in IC50 for 
captopril in the Sigma diagnostic assay (assay 1) and the ACE inhibition assay with rabbit 
lung acetone extract (assay 2) can be explained by the different test conditions, a different 
origin of the ACE enzyme and the complex composition of the rabbit lung acetone extract. 
However, captopril demonstrated in assay 3 with ACE from porcine kidney a similar IC50 as in 
assay 2 with rabbit lung acetone extract. Ariyoshi (1993) emphasised that any ACE inhibitor 
may act differently against ACE obtained from different sources. Some researchers include 
another blank, which contains the inhibitory compound, but no ACE enzyme, resulting in a 
different calculation of the ACE inhibitory activity (Nakamura et al., 1995a). Furthermore, 
when comparing to literature data, one has to consider that different substrates are used in 
the determination of ACE inhibitory activity, which result in different IC50 values (Brooks et al., 
1990; Weisser and Schloos, 1991).  
  Enalaprilat is dosed as prodrug, enalapril, to improve the absorption after oral intake. In 
enalapril the active inhibitory group, a COOH-group, is esterified with an alcohol and the 
release of the active compound enalaprilat occurs after absorption by esterases in the 
plasma (Chevillard et al., 1994). Enalapril on its own exerts a certain inhibitory capacity that 
is about thousand times less potent than that of enalaprilat. The IC50 value of enalapril,     
1.56 .10-6 M, reported here, corresponds well with literature data, where values between            
2.1 .10-7 M and  7 .10-5 M are mentioned (Chevillard et al., 1994; Hiwada et al., 1990; Udupa 
and Rao, 1997). Enalaprilat further confirmed the validity of our assay. The observed IC50 of 
4.96 .10-9 M falls in the range of  1 .10-10 M to 6 .10-9 M found in literature (Allan et al., 1987; 
Hiwada et al., 1990; Inada et al., 1988; Tillman and Moore, 1989; Weisser and Schloos, 
1991). This may indicate that the assumption of a complete conversion of enalapril to 
enalaprilat during alkaline hydrolysis was correct.  
Not only ACE inhibitory drugs, but also the food derived ACE inhibitory peptide Ala-Leu-
Pro-Met-His-Ile-Arg, inhibited the ACE enzyme in assay 2 and 3 in a similar way as reported 
elsewhere. The IC50 of 32.5 µM for the peptide in assay 2 corroborates well with the value of 
42.6 µM found by Mullally et al. (1997b). In assay 3, a slightly higher ACE inhibitory activity 
(IC50 = 14.5 µM) for this ACE inhibitory peptide was obtained. In fact, the ACE inhibition 
assay with pure ACE (assay 3) generally gave slightly higher ACE inhibitory activities 
compared to assay 2. This may be due to an increased sensitivity as a result of the purity of 
the enzyme source. 
Trypsin digestion of whey and pea protein produced ACE inhibitory activity in assay 2. 
Before enzyme addition a relatively high ACE inhibitory activity was detected in the pea 
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protein solution, which can be due to some acid or basic hydrolysis during pH setting. IC50 
values for the hydrolysates were about 0.3 mg/ml, which corresponds to 0.3 mM assuming 
an average molecular weight of 1000 Da for the ACE inhibitory peptides. There were 
significant differences between the fitted curves of the whey and pea digest, indicating 
different ACE inhibitory peptides. Mullally et al. (1997a) obtained ACE inhibitions of 80-90% 
and IC50 values ranging from 130-201 mg/l for ultrafiltrated tryptic digests of β-lactoglobulin 
and whey protein concentrate. Pihlanto-Leppällä et al. (1998) found about the same ACE 
inhibitory activity in a peptic and tryptic digest of whey: IC50 values ranging from 80-314 mg/l 
for different chromatography fractions. An isolated peptide from this digest, β-lactoglobulin 
f(9-14), released by trypsin, had an IC50 value of 580 µM. In a later article, where                 
α-lactalbumin and β-lactoglobulin are digested by trypsin, an IC50 value of 345 respectively    
457 mg/l is mentioned for the total hydrolysate, while after fractionation higher ACE inhibitory 
activities are observed (Pihlanto-Leppälä et al., 2000). These values are similar to the ones 
for the tryptic pea and whey protein hydrolysates reported here.  
Gly-Gly-Gly showed potent ACE inhibitory activity in ACE inhibition assay 3, however, this 
peptide is known to be a substrate for ACE (Ohkubo et al., 1994). As ACE prefers this small 
tripeptide substrate over FAPGG, no decrease in absorbance is observed. This is the 
limitation of all spectrophotomectric ACE inhibition assays. A distinction between a real 
inhibitor and a substrate can be made by pre-incubation with ACE, follow-up of the 
degradation by HPLC and measurement of the ACE inhibitory activity before and after (Fujita 
et al., 2000). Otherwise, an overestimation of the ACE inhibitory activity is obtained in vitro. 
Though, few authors in literature take this fact into account and prefer not to complicate the 
assay. Our peptide mixtures also hamper HPLC analysis. In addition, as heat treatment is 
necessary to inactivate the ACE from the pre-incubation before ACE inhibition can be 
measured, degradation of the peptides is risked.  
 
In conclusion, two ACE inhibition assays, one with rabbit lung acetone extract and another 
with pure ACE from porcine kidney as ACE source, were demonstrated to be relative rapid 
and reliable tools for the screening of food derived bioactive peptides. 
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Chapter 3
Stability of the lactokinin Ala-Leu-Pro-Met-His-Ile-  
Arg in the oral delivery route in vitro 
 
ABSTRACT 
  
ACE inhibitory peptides derived from food proteins during food processing or 
gastrointestinal digestion, could function as efficient agents in treating and preventing 
hypertension. However, in order to exert an antihypertensive effect by inhibition of the ACE 
enzyme, they have to reach the systemic circulation. The aim of this research was to assess 
if the known ACE inhibitory peptide Ala-Leu-Pro-Met-His-Ile-Arg, derived from a tryptic digest 
of β-lactoglobulin, could resist digestion by gastrointestinal proteases and peptidases from 
the intestinal brush border and enterocytes. In addition, it was investigated if this peptide 
could cross a Caco-2 Bbe cell monolayer mounted in an Ussing chamber and reach the 
serosal side intact. The heptapeptide was partially degraded during digestion with                
α-chymotrypsin; at the end of 4.5 h in vitro gastrointestinal digestion, more than half of the 
initial peptide concentration could still be recovered. The lactokinin was rapidly broken down 
by rat intestinal brush border peptidases, while almost no degradation was observed after 
incubation with Caco-2 homogenates. In the transport experiment, samples of the mucosal 
compartment showed high ACE inhibitory activity 10 min after the addition of 1 mM of the 
heptapeptide. No or only little ACE inhibitory activity was detected in the serosal 
compartment, although a substantial ACE inhibitory activity was registered after threefold 
concentration. Concomitantly, HPLC and MS clearly showed the presence of Ala-Leu-Pro-
Met-His-Ile-Arg in the mucosal compartment, whereas in the serosal compartment only MS 
was able to detect the heptapeptide. Hence, under the observed experimental conditions, the 
ACE inhibitory peptide Ala-Leu-Pro-Met-His-Ile-Arg was transported intact through the    
Caco-2 Bbe cell monolayer, although at concentrations too low to exert an ACE inhibitory 
activity in vitro. In conclusion, it seems that the degradation by intestinal brush border 
peptidases constitutes the major barrier in the oral delivery route of this lactokinin.  
 
Keywords: ACE inhibitory peptide, lactokinin, gastrointestinal digestion, intestinal transport, 
Caco-2, whey protein, Ussing Chamber  
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INTRODUCTION 
 
Bioactive peptides are food derived peptides that have, besides their nutritional, also a 
functional effect in the human body: they can behave as regulatory components with a 
hormone like activity (Clare and Swaisgood, 2000). In this respect, stability to human 
proteases and intestinal transport of active peptides are often prerequisites.  
ACE inhibitory peptides are bioactive peptides with possible blood pressure lowering 
effects in vivo. By inhibiting the angiotensin I converting enzyme (ACE; EC 3.4.15.1), the 
concentration of the vasoconstrictor angiotensin II decreases, while the concentration of the 
vasodilator bradykinin increases. This results in an antihypertensive effect (Lüscher and 
Yang, 1993). ACE inhibitory peptides have already been found in several food protein 
hydrolysates and ferments (Dziuba et al., 1999a; Yamamoto, 1997) and have been shown to 
lower the blood pressure in spontaneously hypertensive rats (SHR) and hypertensive patients 
(Hata et al., 1996; Yoshii et al., 2001). Therefore, there is a growing interest in using these 
bioactive peptides as efficient agents in treating and preventing hypertension.  
ACE inhibitory peptides can only exert an antihypertensive effect if they reach the 
bloodstream intact after oral administration. Therefore, they have to show some resistance to 
gastrointestinal proteases and brush border peptidases and they have to be absorbed 
through the intestinal wall with preservation of their physiological activity. Hence, either the 
orally administered ACE inhibitory peptide or an active metabolite has to enter the systemic 
circulation. The peptide in the present study, Ala-Leu-Pro-Met-His-Ile-Arg, is a lactokinin, a 
whey protein derived ACE inhibitory peptide, corresponding to a tryptic fragment of bovine   
β-lactoglobulin, with an IC50 value of 42.6 µM (Mullally et al., 1997b). According to this study, 
this peptide is resistant to further digestion with pepsin and is only hydrolysed to a very low 
extent by α-chymotrypsin. Thus, this peptide may reach the brush border membrane intact. 
Passage of intact peptides across the intestinal mucosa may occur via both paracellular and 
transcellular routes (Grimble and Backwell, 1998). It is generally accepted that di- and 
tripeptides are transported, because these are the substrates for the intestinal peptide 
transporter PEPT1 (Grimble, 2000; Yang et al., 1999 ). There is also evidence that larger 
peptides may be absorbed through the small intestine (Chabance et al., 1998; Gardner, 
1984; Roberts et al., 1999), although it remains to be established to which extent this occurs 
and what the transport mechanism is.  
In this study, the temperature-dependent chemical degradation of Ala-Leu-Pro-Met-His-Ile-
Arg was studied. Subsequently, the peptide was exposed to an in vitro gastrointestinal 
digestion with pepsin (A, EC 3.4.23.1), trypsin (EC 3.4.21.4) and α-chymotrypsin (EC 
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3.4.21.1). Furthermore, the resistance of the lactokinin to degradation by intestinal brush 
border and intracellular peptidases was tested. In an Ussing chamber experiment we 
investigated if the ACE inhibitory heptapeptide could cross a monolayer formed by a Caco-2 
cell clone, the Caco-2 Bbe (morphologically homogeneous, brush border expressing cells) 
cell monolayer, which is a good model for the small intestinal epithelium (Peterson and 
Mooseker, 1992; Wilson et al., 1990). The presence of the peptide was measured by an in 
vitro ACE inhibition assay and by HPLC and MS. Preliminary experiments assessed the 
antihypertensive activity of the lactokinin after intravenous administration in SHR.  
 
 
MATERIALS AND METHODS 
 
Products 
The ACE inhibitory peptide Ala-Leu-Pro-Met-His-Ile-Arg (836.5 g/mol) was synthesised by 
solid phase peptide chemistry and FMOC protection and evaluated by HPLC-MS (purity: 
batch1 = 84.37%, batch2 = 86.99%, batch3 = 80.97% (w/w)) at the Biotechnology Center of 
the University of Illinois (Urbana-Champaign, IL, USA).  
Pepsin (P 6887), trypsin (T 1426) and α-chymotrypsin (C 4129) were purchased from 
Sigma-Aldrich, St.-Louis, MO, USA. 
Krebs buffer was composed of 111.9 mM NaCl, 5 mM KCl, 1.2 mM CaCl2, 1.2 mM MgCl2, 
0.4 mM NaH2PO4, 1.6 mM Na2HPO4, 25 mM NaHCO3, 4.9 mM Na-(L-)glutamate, 4.9 mM Na-
pyruvate, 5.4 mM Na2-fumarate and 11.5 mM glucose at pH 7.4. Transport buffer contained 
Hanks’ Balanced Salt Solution supplemented with HEPES (both from Invitrogen Life 
Technologies, Carlsbad, CA, USA) and D-glucose (Sigma-Aldrich, G 7021) at a final 
concentration of 10 mM and 25 mM, respectively at pH 7.4. Modified Krebs buffer consisted 
of 140 mM Na+, 119.8 mM Cl-, 25 mM HCO3-, 1.2 mM Mg2+, 1.2 mM Ca2+, 4.8 mM K+, 2.4 mM 
HPO42-  and 0.4 mM H2PO4- at pH 7.4. 
Non-specified products were analytical grade from VWR International (Zaventem, 
Belgium). 
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Stability and digestion experiments 
Chemical stability  
The peptide, dissolved at a concentration of 60 mg/l (72 µM) in Krebs buffer (pH 7.4) was 
incubated at 4°C, 25°C (room temperature) and 37°C, respectively. The degradation was 
monitored by RP-HPLC. 
 
In vitro gastrointestinal digestion 
 A 125 µM (105 mg/l) Ala-Leu-Pro-Met-His-Ile-Arg solution in MilliQ water (Millipore, 
Bedford, MA, USA) was subjected to a digestion by pepsin for 2 h at pH 2 (E/S =                  
1/200 (w/w)), followed by a hydrolysis by trypsin and α-chymotrypsin for 2.5 h at pH 7.5         
(E/S = 1/200 (w/w)) at 37°C. The concentration of the peptide during incubation was 
determined by RP-HPLC and the ACE inhibitory activity was analysed by the ACE inhibition 
assay (assay 3, Chapter 1). This experiment was performed twice. As a control, a pepsin 
solution and a solution containing pepsin, trypsin and α-chymotrypsin, at a concentration ten 
times the one in the digestion experiment, were also analysed by RP-HPLC. The lactokinin 
was theoretically cleaved by the program Peptide Cutter at www.expasy.ch. The degradation 
products of the peptide were determined by Matrix Assisted Laser Desorption / Ionization - 
Time Of Flight (MALDI-TOF) spectrometry (Bruker Reflex III, Bruker Daltonik, Bremen, 
Germany) (Gevaert et al., 2001). 
 
Stability towards peptidases from the intestinal brush border and enterocytes 
 The peptide was added to the buffer solution that originated from the mucosal and serosal 
chamber respectively of an Ussing chamber transport experiment with rat intestinal tissue. 
Both buffer solutions, which contained released enzymes from the rat intestinal tissue in 
Krebs buffer, were kept for 16 days at -80°C. The initial peptide concentration was about          
30 mg/l (36 µM). The solutions were incubated for 4 h at 37°C. 
 Moreover, 100 µM Ala-Leu-Pro-Met-His-Ile-Arg dissolved in transport buffer (pH 7.4), 
was incubated in the presence of Caco-2 homogenates in an E/S of 1/6 (w/w) for 3 h at 37°C. 
These Caco-2 homogenates were prepared as described by Augustijns et al. (1998). In brief, 
freshly scraped Caco-2 cell monolayers grown in a 75 cm2 flask were homogenised in 5 ml 
transport buffer using a cell disrupter (Branson Sonifier B15, Branson Ultrasonics, Frankfurt, 
Germany) for 10 s at 4°C. After centrifugation of the crude Caco-2 homogenates at 14 000 g 
for 5 min, the supernatants were harvested and the protein content was determined by the 
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method of Lowry (Lowry et al., 1951). The Caco-2 homogenates were kept for 6 months at        
-80°C. 
 The concentration of the peptide at different time intervals, as well as the mucosal and 
serosal buffer solution, and the Caco-2 homogenate in transport buffer, were analysed by 
RP-HPLC. 
  
HPLC 
The lactokinin was analysed by reversed-phase HPLC on a Prosphere 300 Å C18 column 
(250 x 4.6 mm, 5 µm) (Alltech Associates, Deerfield, IL, USA) and a Dionex (Sunnyvale, CA, 
USA) HPLC with an autosampler ASI-100, pump series P580, STH585 column oven, UV-VIS 
detector UVD340S operating at 210 nm and Chromeleon 6.0 software. Elution was at 25°C 
with a flow rate of 1 ml/min. A linear gradient was applied from 90% solvent A (H2O +           
0.1% (w/v) TFA) to 50% solvent B (acetonitrile + 0.085 % (w/v) TFA) in 30 min, again to 90% 
solvent A in the next 20 min and remaining at 90% solvent A during the last 10 min. 
Quantitative determination of Ala-Leu-Pro-Met-His-Ile-Arg was done by injection of 100 µl 
sample and using an external standard ranging from 0.01 to 0.2 mM. The peptide eluted at a 
retention time of 13.8-14.1 min with a detection limit of 5 µM. The precision of the injection of 
0.1 mM of the lactokinin had a variation coefficient (standard deviation over mean) of 3.5%  
(n = 10). 
 
Transport experiments 
Cell culture 
Caco-2 Bbe (Peterson and Mooseker, 1992) cells were routinely grown in T-75 cell culture 
flasks in Dulbecco's Modified Eagle Medium (DMEM), containing 10% (v/v) fetal bovine 
serum,  0.25 mg/l fungizone and 0.5% (v/v) penicillin-streptomycin, supplemented with non-
essential amino acids (all from Invitrogen Life Technologies) and 10 mg/l transferrin (Sigma-
Aldrich, T 5391), in an atmosphere of 20% O2 and 5% CO2 at 37°C. For the Ussing Chamber 
experiments, 105 cells/well (passage 95) were inoculated in Costar Brand Snapwell culture 
plates (3 µm pore diameter, 12 mm diameter, Costar, Cambridge, MA, USA) and maintained 
for 23 days with daily medium refreshment.  
 
Electrophysiological studies  
The Snapwell inserts with the Caco-2 Bbe monolayer were mounted in modified Ussing 
chambers (Physiological Instruments Inc., San Diego, CA, USA) (Figure 1) with an exposed 
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area of 1.13 cm2 (Kles et al., 2001). Cells were bathed on each side with 4 ml oxygenated 
(95% O2/5% CO2) modified Krebs buffer (pH 7.4) maintained at 37°C and short circuited 
after appropriate correction for fluid and system resistance, using dual channel 
voltage/current clamps (VCC MC2, Physiological Instruments) connected with a computer 
interface (Acquire & Analyze Software, Physiological Instruments).  
 
Figure 1. Schematic overview of an Ussing chamber set-up. Indicated are the intestinal 
tissue or cell insert (1), water-jackets (2), gas-inlet (3), potential difference (4) and 
short-circuit current (5) measurement. 
 
Serosal solutions were supplemented with 10 mM glucose while mucosal solutions were 
supplemented with 10 mM mannitol for osmotic balance. The transepithelial potential 
difference (PD) and the current required for nullifying the spontaneous transepithelial 
potential difference (Ic) were monitored. At PD = 0 mV, respective short-circuit currents (Isc) 
were calculated. Periodic measurements of potential difference and current deflections 
induced by bipolar pulses of 1 s duration and 66 µA amplitude, served to calculate the 
transepithelial electrical resistance (R) based on Ohmic relationship. Ala-Leu-Pro-Met-His-
Ile-Arg was added to the mucosal bathing solution at a final concentration of 1 mM while 
equimolar amounts of mannitol were added to the serosal side (n = 6). One Ussing chamber 
served as a control. After 10 min, samples were taken from both the mucosal and serosal 
side for the ACE inhibition assay and HPLC-MS. Samples were freeze-dried and redissolved 
prior to analysis. In the Ussing chambers, samples were replaced by equal volumes of buffer 
and 10 mM L-glutamine was added to the mucosal compartments together with 10 mM 
mannitol to the serosal compartments, to check for an Isc increase indicating cell monolayer 
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viability and integrity during the incubation period. Responses to substrate supplementation 
were expressed as differences between basal value and maximal response (∆Isc).  
 
ACE inhibitory activity and ACE activity 
Lyophilised samples were redissolved to the original volume in demineralised water, exept 
for the concentrated analysis on two Ussing chambers, where the lyophilised powder was 
dissolved in a volume threefold smaller than the original one. The ACE inhibitory activity was 
measured by the ACE inhibition assay with ten times diluted rabbit lung acetone extract 
(assay 2 in Chapter 2) (Vermeirssen et al., 2002b). To assess the ACE activity in the control, 
which accounted for the enzyme released by the cell monolayer in the buffer solution, 300 µl 
of mucosal and serosal bathing solution respectively, was used as enzyme source in the ACE 
inhibition assay. Demineralised water was added instead of an inhibitory compound. 
 
HPLC and MS 
The bathing solutions of two Ussing chambers in which the heptapeptide was 
supplemented, were analysed by HPLC and MS. Reversed-phase HPLC analysis was 
performed on a Beckman C18 Ultrasphere column (150 x 4.6 mm, 5 µm) and a Beckman 
HPLC equipment model 126 (Fullerton, CA, USA) with an UV detector operating at 215 nm. A 
40 µl aliquot of 1 mg/ml lyophilized powder in 0.1% (w/v) TFA in water was loaded onto the 
column and eluted at a flow rate of 0.5 ml/min with a linear gradient from 100% solvent A 
(0.06% (w/v) TFA in water) to 80% solvent B (0.052% (w/v) TFA in acetonitrile) in 60 min at 
25°C. Samples were also analysed by MALDI-TOF spectrometry on a Voyager-DE STR 
(Applied Biosystems, Foster City, CA, USA) using positive reflectron mode with 100 ns 
delayed extraction, an accelerating potential of 20 kV (76% grid voltage, 0% guide wire 
voltage) and external calibration to convert the time-of-flight to mass. Prior to analysis, the 
samples were acidified with aequous TFA to pH < 4 and a final TFA concentration between 
0.1%-1%, subsequently concentrated and desalted using C18 ZipTip (Millipore, Bedford, MA, 
USA) and finally crystallised with α-hydroxycinnamic acid (Sigma-Aldrich). The detection limit 
of the MALDI-TOF spectrometer was about 1 µg/l. 
 
Antihypertensive activity 
 
The lactokinin was injected intravenously at a dose of 5 mg/kg BW in the femoral vein of 
Spontaneously Hypertensive Rats (SHR) (n = 2). The complete procedure and the 
measurement of the Mean Arterial Blood Pressure (MAP) are described in Chapter 7. 
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RESULTS 
 
Chemical stability of Ala-Leu-Pro-Met-His-Ile-Arg 
 The temperature-dependent degradation of the lactokinin is illustrated in Figure 2. After  
24 h at 4°C, the peptide was still intact. Upon incubation at 37°C, the initial peptide 
concentration was maintained for 7 h, but after 24 h the peptide was completely degraded. At 
room temperature, the peptide remained more or less stable for 16 h, after which a very fast 
degradation was observed and after 20 h incubation at 25°C the peptide could not be 
detected anymore.  
Figure 2. Recovery of the lactokinin Ala-Leu-Pro-Met-His-Ile-Arg in function of incubation 
time at 4°C, 25°C and 37°C, respectively. 
 
In vitro gastrointestinal digestion 
 Theoretically, the lactokinin Ala-Leu-Pro-Met-His-Ile-Arg can be cleaved by both pepsin 
and α-chymotrypsin (Figure 3). Experimentally, the peptide was mainly degraded during the 
small intestine phase with trypsin and α-chymotrypsin hydrolysis at 37°C (Figure 4). 
However, at the end of the 4.5 h in vitro gastrointestinal digestion, 54 ± 4% of the lactokinin 
still remained intact. The major degradation products appeared to be two peptides that eluted 
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at 5.1-5.4 min and 12.2-12.4 min, respectively. The first peptide was identified by MALDI-TOF 
spectrometry as His-Ile-Arg: a peak with molecular mass 425 represented the tripeptide plus 
a proton, while 441 was the mass of the peptide plus proton in which methionine has been 
oxidised. The second peptide was not recovered (data not shown). Before digestion, 28.5-
39.9% of the total peak area consisted of Ala-Leu-Pro-Met-His-Ile-Arg. His-Ile-Arg and the 
non-identified peak were only present for 0.6-1.0% and less than 0.3% respectively. After 
digestion, the lactokinin formed 13.6-32.0% of the total peak area; His-Ile-Arg and the other 
degradation product constituted respectively 5.8-7.0% and 4.0-5.6% of the total peak area. 
The control chromatograms of the pepsin solution and the pepsin-trypsin-α-chymotrypsin 
solution showed no peaks beyond a retention time of 4 min. 
Figure 3. Possible cleavage sites (and probability of cleavage) of Ala-Leu-Pro-Met-His-Ile-
Arg by gastrointestinal proteases (Peptide Cutter at www.expasy.ch) and brush 
border peptidases (Ganapathy and Leibach, 1999). 
 
 The ACE inhibitory activity of the peptide decreased over incubation time: after the 
stomach phase 92% of the initial ACE inhibitory activity was measured, while after the small 
intestine phase this value was reduced to 70% (Table 1). 
 
Table 1. ACE inhibitory activity (%) during in vitro gastrointestinal digestion of Ala-Leu-Pro-
Met-His-Ile-Arg: at the start (0 h), after the stomach phase (2 h) and after the small 
intestine phase (4.5 h) (n = 2). 
Digestion time (h) ACE inhibitory activity (%) 
0 75 ± 2 
2 69 ± 3 
4.5 53 ± 8 
 
Ala  Leu  Pro  Met  His  Ile  Arg 
pepsin                  
(high and low specificity) 
α-chymotrypsin
(low specificity)
aminopeptidase N1 dipeptidyl  peptidase IV2
58.3% 28.7% 
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Figure 4. RP-HPLC chromatograms during in vitro gastrointestinal digestion of Ala-Leu-Pro-
Met-His-Ile-Arg: at the start (0 h), after the stomach phase (2 h) and after the small 
intestine phase (4.5 h). The percent recovery of the peptide is mentioned (n = 2). 
 
Stability towards peptidases from the intestinal brush border and enterocytes  
 A very rapid degradation of the lactokinin was observed in the presence of rat intestinal 
tissue peptidases. After 1 h incubation at 37°C in both the mucosal and serosal buffer 
solutions of an Ussing chamber experiment with rat intestinal tissue, the peptide was almost 
completely degraded. In the presence of Caco-2 cell homogenates for 3 h at 37°C, on the 
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contrary, no significant degradation of the lactokinin was observed (data not shown). In 
theory, brushborder peptidases like aminopeptidase N and subsequently dipeptidylpeptidase 
IV, which are also expressed in Caco-2 cells, are able to cleave the heptapeptide (Figure 3). 
 
Transport experiments 
Addition of 1 mM peptide to the mucosal compartment evoked a substantial increase in 
short-circuit current ∆Isc of 0.4 ± 0.2 µA/cm2. The transepithelial electrical resistance was 
about 300 Ω.cm2 and remained constant throughout the experiment. Addition of 10 mM L-
glutamine to the mucosal bathing solution at the end of the experiment induced an increase 
in short-circuit current ∆Isc of 1.4 ± 0.9 µA/cm2.  
In the Ussing chamber without added peptide, neither ACE activity nor ACE inhibitory 
activity was observed in the mucosal or serosal compartment. The mucosal bathing solutions 
of all 6 Ussing chambers in which the ACE inhibitory peptide was supplemented, showed 
high ACE inhibitory activity (Figure 5).  Only minor or no ACE inhibitory activity was detected 
in the serosal bathing solutions. However, when the samples were concentrated threefold, 
the ACE inhibitory activity in the serosal bathing solutions increased to 30%. Hereby, the 
effect of the increased chloride concentration in the threefold concentrated modified Krebs 
buffer on the ACE inhibitory activity was taken into account. 
Figure 5. ACE inhibitory activity (%) observed in the mucosal and serosal compartments of 
the Ussing chambers with Caco-2 Bbe cell monolayer upon administration of the 
ACE inhibitory peptide Ala-Leu-Pro-Met-His-Ile-Arg (1 mM), analysed as such 
(n=6) and three times concentrated (n=2) in the ACE inhibition assay. 
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HPLC analysis of the mucosal samples yielded three significant peaks (not shown): peaks 
1-2 with a retention time around 4 min and an area of 28% of the total peak area and peak 3 
with a retention time of 29 min and an area of 59%. In the serosal samples only peaks 1-2 
were detected after 4 min elution with a total area of 99%. Peaks 1-2 correspond to 
hydrophilic compounds present in the buffer solution like glucose and mannitol, while the last 
peak represents the heptapeptide. This peak closely resembled the one in the control HPLC 
chromatogram of the heptapeptide after synthesis (data not shown). MALDI-TOF 
spectrometry of both the mucosal and serosal samples revealed the presence of a peak at 
mass 837, which is the molecular mass of the heptapeptide (836) plus a proton (Figure 6). 
The mucosal sample contained a few other high molecular mass peaks: 859 is the mass of 
the heptapeptide plus sodium, while 881 represents the heptapeptide plus disodium. The 
peak with mass 853 in the serosal sample represents the peptide plus proton in which 
methionine has been oxidised. 
 
Antihypertensive effect in SHR 
 During preliminary experiments, Ala-Leu-Pro-Met-His-Ile-Arg failed to reduce the blood 
pressure in SHR at a dose of 5 mg/kg BW. 
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Figure 6. MALDI-TOF mass spectrometry profile of the mucosal and serosal compartment of 
the Ussing chamber upon administration of the ACE inhibitory peptide Ala-Leu-Pro-
Met-His-Ile-Arg (1 mM).  
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DISCUSSION 
 
Several in vivo studies have demonstrated the antihypertensive effect of orally 
administered food derived ACE inhibitory peptides (Hata et al., 1996; Yoshii et al., 2001). In 
vitro experiments may provide an outcome as laboratory-scaled alternatives for 
experimentation with humans or animals in the screening process for ACE inhibitory 
peptides. In this respect, the gastrointestinal digestion and intestinal transport of ACE 
inhibitory peptides are important facets in the in vitro investigation of the maintenance of ACE 
inhibitory activity through the oral pathway.  
 
Stability towards chemical degradation and digestion 
Ala-Leu-Pro-Met-His-Ile-Arg showed a rather good stability, which decreased of course 
with increasing storage temperature. Since the heptapeptide exhibited a thermal stability of   
7 h at 37°C, and our digestion experiments at 37°C were shorter, the degradation observed 
during these experiments could be mainly attributed to the action of proteases.  
Theoretically, the lactokinin, derived from a tryptic digest of β-lactoglobulin, can be cleaved 
by pepsin with high (pH lower than 2) and low specificity and by α-chymotrypsin with low 
specificity (Figure 3). The cleavage by pepsin is prevented in practice, however, by the 
unfavourable presence of proline. The same proline also impedes the action of                     
α-chymotrypsin on the peptide bond between leucine and proline. His-Ile-Arg appears to be a 
major degradation product after α-chymotrypsin hydrolysis as the presence of methionine 
blocks the cleavage after histidine (Peptide Cutter at www.expasy.ch). At least half of the 
initial peptide concentration remained present after in vitro gastrointestinal digestion, which 
indicates a rather good stability of the peptide in the stomach and small intestine. Mullally et 
al. (1997b) also observed no hydrolysis of the peptide following incubation with pepsin and 
only a low degree of chymotryptic hydrolysis, which creates two extra peaks in the 
chromatogram at similar positions as in Figure 4. His-Ile-Arg and Ile-Arg display ACE 
inhibitory activity as well, although their IC50 values are rather high (954 µM and 696 µM) 
(Mullally et al., 1996). We assume that the non-identified peptide is the longer and more 
hydrophobic fragment Ala-Leu-Pro-Met, which eluted at retention time 12.2-12.4 min. 
However, the degradation by brush border peptidases and the intestinal transport of these 
degradation products were not investigated; Ala-Leu-Pro-Met-His-Ile-Arg was the peptide 
under scrutiny. The ACE inhibitory activity was reduced to only 70% after the hydrolysis by 
stomach and pancreatic proteases, which can be due to the logistic relation between the ACE 
inhibitory activity and the inhibitor concentration, but also can indicate that the degradation 
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products contributed to the total ACE inhibitory activity. Consequently, the lactokinin resisted 
well the in vitro gastrointestinal digestion, although it is known that the luminal pancreatic 
proteases may be a metabolic obstacle in the oral delivery of even small peptides (Krondahl 
et al., 2000). 
 The heptapeptide was very susceptible to hydrolysis by rat intestinal tissue peptidases, 
while in the presence of Caco-2 homogenates no significant breakdown was observed. 
Theoretically, aminopeptidase N, abundant in the intestinal brush border, can cleave alanine 
from the lactokinin, after which it can be further degraded by dipeptidyl peptidase IV, also a 
major brush border peptidase (Ganapathy and Leibach, 1999). These peptidases are 
normally also expressed in the Caco-2 cell monolayer, although it is known that certainly at 
the beginning of cell differentiation, the brush border membrane associated enzyme activities 
of Caco-2 cells are much lower than in the mammalian small intestine (Bolte et al., 1998; 
Wilson et al., 1990). Furthermore, species-specific differences in the enzymatic inactivation of 
biological active peptides in the intestine have been observed (Drucker et al., 1997). On the 
other hand, it is suggested that the enzyme activity in the intestinal brush border of the rat is 
higher than in humans (Augustijns et al., 1998). These facts, together with the lower 
concentration and longer storage time of the Caco-2 cell homogenates compared to the 
buffers containing rat peptidases, could explain the stability of the heptapeptide incubated in 
the presence of Caco-2 cell homogenates. Hence, compared to rat intestinal tissue, a less 
severe degradation of the lactokinin could be expected in the human intestine, increasing its 
potential to reach the cardiovascular system intact. 
 
Intestinal transport  
In this in vitro study, the mass spectrometry results combined with the electrophysiological 
and ACE inhibition data show that transport of intact Ala-Leu-Pro-Met-His-Ile-Arg through the 
Caco-2 Bbe monolayer took place within 10 min after administration. 
The small increase in short-circuit current ∆Isc after addition of the peptide to the mucosal 
compartment reflects the transport of the positively charged heptapeptide (Arg), transport of 
its charged degradation products or ion transport induced by the heptapeptide. As was the 
case in our study, addition of L-glutamine to the mucosal compartment leads in a viable and 
functional small intestinal cell monolayer to an increase in short-circuit current as a result of 
the cotransport of sodium. The transepithelial electrical resistance of 300 Ω.cm2 reflects the 
structural integrity of the cell monolayer (Wilson et al., 1990).  
The Caco-2 Bbe cell monolayers did not secrete ACE enzyme or ACE inhibitory 
compounds. The ACE inhibition assay indicated a high ACE inhibitory activity in the mucosal 
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compartments of the Ussing chambers. This could be due to the heptapeptide or to active 
degradation products. Substantial ACE inhibitory activity was only detected in the serosal 
compartments of the Ussing chambers after concentrating the samples.  
HPLC analysis clearly detected the pure peptide in the mucosal compartments. The peak 
of the heptapeptide was not retrieved in the analysis of the serosal compartments. However, 
the highly sensitive MALDI mass spectrometry demonstrated the presence of the 
heptapeptide in both the mucosal and serosal samples.  
Although it cannot be excluded that some degradation of the heptapeptide occurred or that 
transport of degradation products took place, these results show that the ACE inhibitory 
heptapeptide is transported intact, be it at very low concentrations. As samples were taken  
10 min after addition of the ACE inhibitory peptide to the mucosal compartment, there may 
have been insufficient time for the transport to occur completely. However, longer sampling 
times could increase the risk of degradation. Few studies describe the in vitro transepithelial 
transport of bioactive oligopeptides. They show that the susceptibility to brushborder 
peptidases controls the transport rate, which is in agreement with our findings, and that 
several transport mechanisms may participate in oligopeptide passage across the intestinal 
epithelium (Matsui et al., 2002a; Shimizu et al., 1997). Another study in the Caco-2 cell model 
illustrates that, although the ACE inhibitory peptide Val-Pro-Pro is detected in the aorta after 
oral administration and exerts an antihypertensive effect, less than 2% of the peptide 
concentration added to the apical chamber is transported to the basolateral side in 60 min 
(Satake et al., 2002).  Hence, despite the low transport of the lactokinin observed in vitro, it 
may reach the systemic circulation in vivo in substantial amounts to exert a biological activity. 
 
Antihypertensive activity 
In some preliminary experiments, the lactokinin did not produce antihypertensive activity at 
a dose of 5 mg/kg BW upon intravenous injection in SHR. Either the peptide is rapidly 
degraded by plasma peptidases or just inactive in vivo at this dose, which both indicate that 
aministration of a higher dose may lead to a reduction in blood pressure. Further research 
needs to elucidate this.  
 
In conclusion, Ala-Leu-Pro-Met-His-Ile-Arg resisted in vitro gastrointestinal digestion well, 
but is susceptible to degradation by peptidases from the rat intestinal brush border and 
enterocytes. Furthermore, it is transported intact trough a Caco-2 cell monolayer, although at 
a very low concentration.  
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ACE inhibitory ferments and in vitro digests 
of pea and whey protein 
 
ABSTRACT 
 
Pea and whey protein were fermented by Lactobacillus helveticus and Saccharomyces 
cerevisiae in monoculture and in combination at 28 and 37°C in order to release Angiotensin 
I Converting Enzyme (ACE) inhibitory peptides. The fermentation products were subjected to 
in vitro gastrointestinal digestion and the digests of non-fermented protein solutions served 
as controls. After fermentation, the ACE inhibitory activity (%) of 2.73 mg/ml samples 
increased by 18 to 30% for all treatments, except for the fermentations of whey protein by 
Saccharomyces cerevisiae at 28°C, where no significant change was observed. After 
digestion, however, both fermented and non-fermented samples at a concentration of      
2.73 mg/ml reached maximal ACE inhibitory activity (%). The whey digests tended to have 
lower 50% inhibitory concentrations (IC50) (0.148 to 0.072 mg/ml), hence higher ACE 
inhibitory activity, than the pea digests (0.183 to 0.093 mg/ml). The non-fermented samples 
were at least as ACE inhibitory active as the fermented ones. The non-fermented whey 
protein digest showed the highest ACE inhibitory activity of all. For pea protein, the non-
fermented sample had the one but lowest IC50 value. These results suggest that in vitro 
gastrointestinal digestion was the predominant factor controlling the formation of ACE 
inhibitory activity, hence indicating its importance in the bioavailability of ACE inhibitory 
peptides.  
 
Key words: ACE inhibitory peptides, fermentation, gastrointestinal digestion, Lactobacillus 
helveticus, Saccharomyces cerevisiae 
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INTRODUCTION 
 
Hypertension is a major risk factor for the development of cardiovascular disease, which is 
one of the main causes of mortality in Western countries (Duprez et al., 2002). Diet and 
lifestyle modification represent effective tools in the prevention of hypertension. In the 
treatment of the disease, these diet and lifestyle changes can decrease requirements of 
antihypertensive medication, as well as have beneficial effects on the metabolic aberrations 
related to hypertension not remedied by most drugs (Hermansen, 2000). In this respect, 
functional foods with blood pressure lowering properties have recently received considerable 
attention.    
Angiotensin I converting enzyme (ACE; EC 3.4.15.1) is a dipeptidyl carboxypeptidase that 
elevates blood pressure by producing the vasoconstrictor angiotensin II and degrading the 
vasodilator bradykinin (Campbell, 1987). ACE inhibitory peptides have already been isolated 
from many food proteins (Dziuba et al., 1999a; Fitzgerald and Meisel, 2000). Fermentation 
and/or digestion are popular food processing steps to release these bioactive or functional 
peptides from food proteins (Abubakar et al., 1998; Gobbetti et al., 2000). After oral 
administration, the ACE inhibitory peptides may exert an antihypertensive effect, provided 
they pass the gastrointestinal digestive and absorptive system and reach the cardiovascular 
system in an active form.  
Recently, certain functional foods containing ACE inhibitory peptides have been shown to 
act as an additional or alternative treatment in hypertension. Daily administration of Calpis 
sour milk to hypertensive human subjects significantly reduces their blood pressure. The 
antihypertensive effect of this milk fermented by a starter containing Lactobacillus helveticus 
and Saccharomyces cerevisiae, is due to the presence of the ACE inhibitory peptides Val-
Pro-Pro and Ile-Pro-Pro, contained in the primary structure of β-casein, and β-casein and     
κ-casein, respectively (Takano, 1998). Moreover, long-term intake of Val-Pro-Pro and         
Ile-Pro-Pro, or a sour milk containing these tripeptides attenuates the development of 
hypertension in spontaneously hypertensive rats (SHR), suggesting a preventive role of ACE 
inhibitory peptides in hypertension as well (Sipola et al., 2001). 
 Pea protein is a valuable protein for human nutrition with the advantage of a good 
balanced profile of amino acids, a high content in the essential amino acid lysine                
(82 g/kg protein) and a rather good solubility. In addition, it is an environmentally friendly, low 
input crop and may represent an alternative to soy. ACE inhibitory peptides derived from pea 
protein have not yet been reported in literature. In a previous study high ACE inhibitory 
activity in a tryptic digest of pea protein isolate was found, suggesting that pea may be an 
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alternative source of ACE inhibitory peptides (Vermeirssen et al., 2002b).  Fermentation was 
investigated as a means to produce ACE inhibitory peptides and the ACE inhibitory activity 
derived from pea protein was compared to the one of whey protein, a known source of ACE 
inhibitory peptides (Pihlanto-Leppälä, 2001). Eight lactobacilli and Saccharomyces 
cerevisiae, microorganisms already used in food processing and consequently generally 
recognised as safe (GRAS), were used to inoculate the protein media. The combination of 
yeast and lactic acid bacteria is often used in fermented milk based products as several 
synergistic interactions may occur (Viljoen, 2001). The importance of the gastrointestinal 
proteases pepsin (A, EC 3.4.23.1), trypsin (EC 3.4.21.4) and α-chymotrypsin (EC 3.4.21.1) 
on the formation and/or degradation of ACE inhibitory peptides was also assessed. 
 
 
MATERIALS AND METHODS 
 
Products 
The pea protein isolate Pisane HD and the (rennet) whey protein isolate Lacprodan  
DI-9213 were obtained from Cosucra SA (Fontenoy, Belgium) and Acatris Belgium NV 
(Londerzeel, Belgium), respectively. Thiamin, pyridoxine, D-pantothenic acid, inositol,         
D-biotin, nicotinic acid, riboflavin, pepsin (P 6887), trypsin (T 1426), α-chymotrypsin            
(C 4129), trichloroacetic acid solution (490-10), ACE reagent (305-10), ACE control-E         
(A 7040), 100% (w/v) trifluoroacetic acid solution (30,203-1) were purchased from Sigma-
Aldrich (St.-Louis, MO, USA). Non-specified products were analytical grade from VWR 
International (Zaventem, Belgium)  
 
Fermentation  
The following lactobacilli were used in the screening fermentations: Lactobacillus 
fermentum LMG8900 (intestine from 8 day old breastfed baby), Lactobacillus gasseri 
LMG9203 (human), Lactobacillus oris LMG9848 (human Italian saliva), Lactobacillus reuteri 
LMG9213 (human intestine), Lactobacillus acidophilus LMG7943 (human), Lactobacillus 
plantarum LMG9211 (human saliva), Lactobacillus plantarum LMG9212 (human saliva), 
Lactobacillus helveticus LMG 11474 (Swiss cheese starter) (LMG Culture Collection, Ghent 
University, Belgium). In the subsequent fermentations, Saccharomyces cerevisiae 
(commercial baking yeast) was also used. Lactobacilli were propagated in MRS broth (de 
Man, Rogasa, Sharpe) (Oxoid, Basingstoke, UK) under micro-aerophilic conditions at 37°C 
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for 24 h and baking yeast in YPD broth (10 g/l Yeast extract (Oxoid), 10 g/l Peptone 
bacteriological (Oxoid), 20 g/l D-glucose) under aerobic conditions at 28°C for 24 h.  
The screening fermentations were carried out with the lactobacilli described above on pea 
protein only, for 48 h at 37°C. Fermentations with L. helveticus and S. cerevisiae occurred in 
monoculture at their optimal temperature (37 and 28°C respectively) and in combination (37 
and 28°C) for 48 h on both pea and whey protein. At the start of the fermentation the 
selected microorganisms were added to the fermentation medium under sterile conditions in 
a concentration of 6.3 log10 CFU/ml for L. helveticus and 5.7 log10 CFU/ml for S. cerevisiae. 
The inoculated fermentation medium was incubated at 28 or 37°C for 48 h. Fermentation 
experiments with L. helveticus or/and S. cerevisiae were repeated at least three times. 
Samples were taken before and after fermentation and after in vitro gastrointestinal 
digestion. 
The fermentation medium was composed as follows: 40 g/l (4 % (w/v)) protein, 20 g/l      
D-glucose, 10 ml/l vitamin solution, 10 ml/l salt solution, 0.1 M sodium phosphate buffer, pH 
6 to 6.5. To avoid the Maillard reaction, the protein solution and the rest solution, consisting 
of D-glucose and salt solution in sodium phosphate buffer, were autoclaved separately for   
15 min at 121°C, 101.3 kPa overpressure. The salt solution contained 5 g/l MgSO4.7H2O,     
5 g/l KH2PO4, 1 g/l CaCl2.2H2O and 0.5 g/l MnSO4.H2O. The vitamin solution consisted of    
40 mg/l thiamine, 40 mg/l pyridoxine, 40 mg/l D-pantothenic acid, 200 mg/l inositol, 2 mg/l   
D-biotin, 40 mg/l nicotinic acid, 40 mg/l riboflavin. It was added to the autoclaved 
fermentation medium after sterilisation by 0.22 µm filtration (Millipore, Bedford, MA, USA). 
Prior to inoculation the pH of the 100 ml whey protein fermentation medium was adjusted to 
pH 6 to 6.5 by addition of 450 µl 10 M NaOH.  
  
Digestion 
 Fermented and non-fermented protein solutions were subsequently digested. The 
conditions of the physiological digestion were based on literature (De Boever et al., 2000; 
Ganong, 1997; Gauthier et al., 1986). To simulate the digestion in the stomach, the pH of the 
fermented medium was adjusted to 2 with 10 M and 1 M HCl under rigorous mixing. 
Subsequently, pepsin was supplemented in an E/S of 1/250 (w/w) and the medium was 
incubated on a shaker for 2 h at 37°C. Next, the small intestinal digestion was simulated by 
setting the pH at 6.5 with 10 M and 1 M NaOH under rigorous mixing and by addition of 
trypsin and α-chymotrypsin, both in an E/S of 1/250 (w/w), followed by another incubation for 
2.5 h on a shaker at 37°C. At the end of digestion the pH was adjusted to 5 with 10 M and    
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1 M HCl. As this is near the iso-electrical point for both proteins (pea: pH 4.5, whey: pH 4 to 
5), a standardised and clear separation was obtained by subsequent centrifugation.  
 
Follow up of the fermentation 
At the start and the end of the fermentation, pH was measured using a 744 pH Meter 
(Metrohm, Herisau, Switzerland) and plate counts were performed after 72 h incubation at 
37°C on Rogosa agar (Oxoid) and at 28°C on YPD agar (YPD broth + 20 g/l agar) for 
lactobacilli and S. cerevisiae, respectively. 
 
Degree of proteolysis 
The degree of proteolysis was determined by the ratio of the non-protein Kjeldahl nitrogen 
to the total Kjeldahl nitrogen. Samples for non-protein nitrogen determination were treated 
with trichloroacetic acid solution to a final concentration of 6% (w/v), shaken for 5 min and 
then centrifuged at 12 000 g for 10 min at 4°C. This supernatant and a sample for total 
nitrogen determination were stored at -80°C prior to analysis.  
 
ACE inhibitory activity 
Samples for ACE inhibition were centrifuged at 10 000 g for 15 min at 4°C, the 
supernatant was frozen in liquid nitrogen and stored at -80°C. Freezing in liquid nitrogen was 
preferred over heating at 98°C for 10 min to inactivate the proteases and to maintain the 
bioactivity of the peptides. Next, the frozen samples were lyophilised to obtain a dry powder, 
which was analysed by the ACE inhibition assay 3 as described in Chapter 2.  
 
Protease activity 
The protease activity was determined on the supernatant and the redissolved precipitate 
of the 24 h propagated culture of L. helveticus and S. cerevisiae respectively, after 
centrifugation at 5000 g for 10 min (n = 3). Activity was assessed by means of a commercial 
available Universal Protease Substrate spectrophotometric assay (Roche Diagnostics, Basel, 
Switzerland). 
 
HPLC  
Samples for the HPLC analysis were treated as for the ACE inhibition assay. Twenty 
milligram lyophilised powder was dissolved in 2 ml milli-Q water (Millipore) and ultrafiltrated-
centrifuged in Centricon YM-3000 tubes (MWCO = 3000 Da) (Millipore) for 2 h at 7500 g. 
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The permeate was analysed by reversed-phase HPLC on a Prosphere 300 Å C18 column 
(250 x 4.6 mm, 5 µm) (Alltech Associates, Deerfield, IL, USA) and a Dionex (Sunnyvale, CA, 
USA) HPLC with an autosampler ASI-100, pump series P580, STH585 column oven, UV-VIS 
detector UVD340S operating at 210 nm and Chromeleon 6.0 software. The temperature was 
controlled at 25°C and the flow rate was maintained at 1 ml/min. The permeates were eluted 
by a linear gradient from 90% solvent A (H2O + 0.1% (w/v) TFA) to 50% solvent B 
(acetonitrile + 0.085% (w/v) TFA) in 30 min, again to 90% solvent A in the next 20 min and 
remaining at 90% solvent A the last 10 min. 
 
Sonication 
Sonication (Sonicator 250, Branson, G. Heinemann, Schwäbisch Gmünd, Germany) was 
performed in the ice-cooled 24 h propagated culture of L. helveticus, S. cerevisiae or a 
combination of both (1/1 (v/v) propagated culture of both microorganisms) to release the 
intracellular proteases from the lysed cells in the medium. Operational parameters resulting 
in the highest protease activity as obtained with the commercial protease assay were found 
to be: time 12 min, output control 3 and duty cycle 70%. A 4% (w/v) whey or pea protein 
solution in demineralised water was incubated with 1% (v/v) lysed cell suspensions of          
S. cerevisiae at 28°C or L. helveticus or both at 37°C for 24 h. 
 
Statistical analysis 
 All values are reported as mean ± standard error (SE) of the mean (nmin = 3). Some 
missing values (2% of the dataset) were replaced by the average of the treatments. A 
(paired) Student t-test studied the significance of changes in pH, lactobacilli and yeast counts 
during fermentation. To exclude the initial effect of the protein itself, the statistical analysis 
was performed on the changes in degree of proteolysis and ACE inhibitory activity after 
fermentation, and after fermentation and digestion. By means of the General Linear Model 
procedure (Minitab 11.21, State College, PA, USA) significant differences in type of protein 
(pprot) and type of fermentation (pferm) were assigned. When there was a significant type of 
protein × type of fermentation interaction, for both proteins a Oneway ANOVA analysis was 
carried out in type of fermentation. All data used in the variance analysis met the 
homogeneity of variance requirement assessed by Bartlett's test for normal and Levene's 
test for not-normal distributions. Normality was tested by means of the Anderson-Darling 
criterion. Indication of subgroups was done by Tukey post hoc test (p < 0.05). The statistical 
analysis was performed on the log IC50 value, as this value is calculated from the logistic 
model and is normally distributed. 
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RESULTS 
 
Screening of lactobacilli 
Eight different GRAS lactobacilli were screened for the production of ACE inhibitory 
activity during fermentation and subsequent in vitro gastrointestinal digestion of pea protein 
(Table 1). Fermentation by L. helveticus yielded the highest ACE inhibitory activity and was 
therefore selected for subsequent experimentation. After in vitro digestion all ferments 
reached high to maximal ACE inhibitory activity.  
 
Table 1. ACE inhibitory activity (%) after fermentation of pea protein medium by different 
lactobacilli at 37°C and subsequent in vitro digestion. The data represent the result 
of a single experiment. 
Strain After fermentation1,2 After in vitro digestion1,3 
Lactobacillus fermentum LMG8900 12 90 
Lactobacillus gasseri LMG9203 12 96 
Lactobacillus oris LMG9848 16 100 
Lactobacillus reuteri LMG9213 9 96 
Lactobacillus acidophilus LMG7943 13 93 
Lactobacillus plantarum LMG9211 7 83 
Lactobacillus plantarum LMG9212 11 99 
Lactobacillus helveticus LMG11474 37 96 
1 The concentration of ferment or digest in the assay was 2.73 mg/ml. 
2 The initial ACE inhibitory activity of the pea fermentation medium was 16 ± 2%. 
3 The ACE inhibitory activity of non-fermented digested pea fermentation medium amounted 
to 99.3 ± 0.7%. 
 
Fermentation by Lactobacillus helveticus or/and Saccharomyces cerevisiae 
Autoclaved pea and whey protein medium were fermented by L. helveticus at 37°C,        
S. cerevisiae at 28°C or a combination of both microorganisms at 28 or 37°C in order to 
produce ACE inhibitory active ferments. Fermentation was always followed by an in vitro 
gastrointestinal digestion with pepsin at pH 2 and a combination of trypsin and                  
α-chymotrypsin at pH 6.5. Non-fermented autoclaved pea and whey protein medium, 
subjected to in vitro gastrointestinal digestion, served as control experiments.  
The presence of L. helveticus at its optimal temperature of 37°C initiated a large pH 
decrease during fermentation (pferm < 0.001) (Table 2). The pH after fermentation was lower 
Chapter 4 
 106
for pea than for whey (pprot < 0.001). L. helveticus’ counts increased during fermentation in 
monoculture on both protein media. However, this lactic acid bacterium hardly grew in the 
presence of the yeast, both at 37 and 28°C, for pea and whey protein (Table 2).                   
S. cerevisiae's counts increased during fermentation at 28°C, whether or not in the presence 
of L. helveticus. A higher, non-optimal temperature, e.g. 37°C, was disadvantageous for the 
yeast. Hence, the growth of both microorganisms was affected by the type of fermentation 
(pferm < 0.001), but in a different manner. The counts of both microorganisms did not differ 
significantly between the two proteins (L. helveticus: pprot = 0.209; S. cerevisiae: pprot = 0.938). 
 
Table 2. pH and plate counts (log10 CFU/ml) of Lactobacillus helveticus and Saccharomyces 
cerevisiae at the start and after 48 h fermentation for the different types of 
fermentations (LH37: L. helveticus at 37°C, Y28: S. cerevisiae at 28°C, LHY37: L. 
helveticus and S. cerevisiae at 37°C, LHY28: L. helveticus and S. cerevisiae at 
28°C), for both pea and whey protein (nmin = 3).  
  pH L. helveticus S. cerevisiae 
Pea Start 6.1 ± 0.0 6.3 ± 0.1 5.7 ± 0.1 
 LH37 3.5 ± 0.1***a 7.8 ± 0.4**a  /  
 Y28 5.5 ± 0.2b /  7.1 ± 0.2**a 
 LHY37 3.6 ± 0.1**a 6.5 ± 0.3b 5.6 ± 0.5b 
 LHY28 5.4 ± 0.3b 6.6 ± 0.4b 7.7 ± 0.2*a 
Whey Start 6.3 ± 0.0 6.3 ± 0.1 5.7 ± 0.1 
 LH37 3.9 ± 0.1***c 7.4 ± 0.3**a  /  
 Y28 6.1 ± 0.0**d /  7.6 ± 0.1**a 
 LHY37 4.3 ± 0.2***c 6.3 ± 0.3b 5.1 ± 0.2**b 
 LHY28 5.9 ± 0.1*d 6.3 ± 0.2b 7.6 ± 0.3***a 
/  = not applicable. 
Significant from the start value: *p < 0.05, **p < 0.01, ***p < 0.001. 
Different letters indicate significant differences in ‘type of fermentation’ (and ‘type of protein’) 
(p < 0.05). 
 
Degree of proteolysis and ACE inhibitory activity in ferments and digests 
At the start of the fermentation process the degree of proteolysis for pea, 6.7 ± 0.4%, was 
lower than for whey, 17.9 ± 0.5% (p < 0.001).  The ACE inhibitory activity of the fermentation 
medium of pea amounted to 16 ± 2%, while for whey this was 63 ± 2% (p < 0.001). Figure 1 
shows the degree of proteolysis and Figure 2 the ACE inhibitory activity, after fermentation 
and after fermentation and digestion for both proteins. The statistical analysis, however, was 
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performed on the changes of these parameters during fermentation, and fermentation and 
digestion, in order to exclude the initial degree of proteolysis and ACE inhibitory activity of 
the protein itself. 
Figure 1. Degree of proteolysis (%) after fermentation, and after fermentation and digestion 
of pea (P) and whey (W) protein (nmin = 3). (LH37: Lactobacillus helveticus at 
37°C, Y28: Saccharomyces cerevisiae at 28°C, LHY37: L. helveticus and            
S. cerevisiae at 37°C, LHY28: L. helveticus and S. cerevisiae at 28°C, n-ferm: 
non-fermented). Straight, dashed lines indicate the initial degree of proteolysis of 
the pea and whey medium. Different letters indicate significant differences in the 
change (p < 0.05). 
 
The change in degree of proteolysis during fermentation was significantly different 
between the two proteins (pprot = 0.033) and between the different types of fermentation   
(pferm < 0.001). The degree of proteolysis increased during fermentation maximally by 15%, 
namely in the monoculture fermentation by L. helveticus (Figure 1). The fermentation by both 
L. helveticus and S. cerevisiae at 37°C also augmented the degree of proteolysis, and more 
in the pea than in the whey protein medium. In the presence of S. cerevisiae at 28°C, no 
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significant change could be observed, except for the monoculture fermentation by                
S. cerevisiae on whey protein (W-Y28), where the degree of proteolysis slightly decreased 
after fermentation (p < 0.05).  After in vitro digestion, the degree of proteolysis augmented 
sharply in all samples to 75 ± 2% for pea and 67 ± 1% for whey and the degree of proteolysis 
in the non-fermented media did not differ from the fermented ones (pferm = 0.625). The less 
pronounced increase in degree of proteolysis for the whey protein during digestion, 
compared to the pea protein (pprot < 0.001), may partially be explained by the higher initial 
degree of proteolysis for the whey protein fermentation medium.  
Figure 2. ACE inhibitory activity (%) after fermentation, and after fermentation and digestion 
of pea (P) and whey (W) protein (nmin = 3). (LH37: Lactobacillus helveticus at 
37°C, Y28: Saccharomyces cerevisiae at 28°C, LHY37: L. helveticus and S. 
cerevisiae at 37°C, LHY28: L. helveticus and S. cerevisiae at 28°C, n-ferm: non-
fermented). Straight, dashed lines indicate the initial ACE inhibitory activity of the 
pea and whey medium. Different letters indicate significant differences in the 
change (p < 0.05). 
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For the pea protein, the type of fermentation did not influence the increase in percent ACE 
inhibitory activity of a 2.73 mg/ml sample after fermentation (pferm = 0.539) (Figure 2). For the 
whey protein, on the other hand, the presence of L. helveticus and a temperature of 37°C 
resulted in increased ACE inhibitory activity after fermentation, whereas the presence of       
S. cerevisiae and a temperature of 28°C did not (pferm < 0.001) (pinteraction = 0.008). In vitro 
digestion augmented the ACE inhibitory activity significantly and both non-fermented and 
fermented samples reached the maximal level of 100% (pferm = 0.959). Somewhat due to the 
high initial ACE inhibitory activity of the whey protein, the increase during digestion was 
smaller compared to the pea protein (pprot < 0.001). The degree of proteolysis did not 
correlate with the ACE inhibitory activity: although the pea ferments at 28°C showed a lower 
degree of proteolysis compared to the pea ferments at 37°C, the ACE inhibitory activity of 
both groups did not differ. The IC50 value enabled to further distinguish the ACE inhibitory 
activity of the digests (Table 3).  
 
Table 3.  IC50 (mg/ml) and their log values on which the statistical analysis was performed, 
for the different types of fermentation for pea and whey protein after in vitro 
digestion (nmin = 3). (LH37: Lactobacillus helveticus at 37°C, Y28: Saccharomyces 
cerevisiae at 28°C, LHY37: L. helveticus and S. cerevisiae at 37°C, LHY28:         
L. helveticus and S. cerevisiae at 28°C, n-ferm: non-fermented). 
   IC50 Log IC50 ± SE 
Pea LH37  0.183 -0.74 ± 0.02a 
 Y28  0.158 -0.80 ± 0.02a 
 LHY37  0.162 -0.79 ± 0.00a 
 LHY28  0.093 -1.03 ± 0.07b 
 n-ferm  0.121 -0.92 ± 0.08ab 
Whey LH37  0.148 -0.83 ± 0.02c 
 Y28  0.078 -1.11 ± 0.01de 
 LHY37  0.109 -0.96 ± 0.03cd 
 LHY28  0.094 -1.03 ± 0.02de 
 n-ferm  0.072 -1.14 ± 0.07e 
Different letters indicate significant differences (p < 0.05). 
 
The type of fermentation influenced the (log) IC50 values after in vitro digestion for both 
proteins in a dissimilar way (pinteraction = 0.012). The pea digest with the combined 
fermentation at 28°C showed the lowest IC50, although this did not differ significantly from the 
Chapter 4 
 110
non-fermented pea digest (pferm = 0.018). With the exception of this fermented pea digest, the 
whey digests tended to have a lower IC50, hence a higher ACE inhibitory activity, than the 
corresponding pea digests. The presence of the yeast at 28°C seemed to decrease the IC50 
value. The lowest IC50 value was obtained in the non-fermented whey protein medium, 
although this value was not significantly different from whey digests fermented by the yeast 
at 28°C (pferm = 0.004). Hence, the non-fermented samples were at least as ACE inhibitory 
active as the fermented ones. 
 
Protease activity 
Protease activity in the 24 h propagated culture of L. helveticus and S. cerevisiae was 
measured on the supernatant and the cell precipitate in order to identify the origin of 
protease activity. The protease activity in the supernatant measured 0.80 ± 0.01 U/L for        
L. helveticus and 0.53 ± 0.07 U/L for S. cerevisiae. The cell precipitate of L. helveticus had a 
protease activity of 0.39 ± 0.03 U/L, whereas the one of S. cerevisiae had an activity of     
0.55 ± 0.13 U/L.  
 
HPLC profiles 
The HPLC profile of the samples provided a fingerprint of the small peptides (MWCO 
ultrafiltration-centrifugation = 3000 Da) present in the digests. No striking differences 
between the chromatograms of the fermented and the non-fermented digests were observed. 
For both proteins, the HPLC chromatogram of one fermented digest and the non-fermented 
digested medium are displayed in Figure 3.  
 
Contribution of intracellular proteases 
Non-autoclaved 4% (w/v) pea and whey protein solution had a degree of proteolysis of 
respectively 2.4 ± 0.4% and 12.9 ± 0.7% (p < 0.001), and an ACE inhibitory activity of 
respectively 10.0 ± 0.7% and 15 ± 2% (p = 0.083). After 24 h incubation with a suspension of 
lysed cells of L. helveticus at 37°C, S. cerevisiae at 28°C and a combination of both at 37°C, 
the degree of proteolysis only augmented for the pea protein and amounted to 30% at the 
end of digestion for all suspensions. Similarly, only for the pea protein an increase in ACE 
inhibitory activity was observed. The ACE inhibitory activity of a 2.73 mg/ml sample reached 
after incubation 80% for S. cerevisiae's, 30% for L. helveticus' and 40% for the combination's 
lysed cells. In the whey protein digests no change in degree of proteolysis, nor ACE 
inhibitory activity, could be detected. 
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Figure 3. HPLC-profile of the digested non-fermented pea (P-n-ferm) and whey (W-n-ferm) 
medium, pea medium fermented by L. helveticus at 37°C (P-LHY37) and whey 
medium fermented by S. cerevisiae  at 28°C (W-LHY28). 
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DISCUSSION 
 
In this study, pea and whey protein were fermented by lactobacilli and yeast in order to 
release ACE inhibitory peptides that could lower the blood pressure in vivo. Subsequently, 
the impact of an in vitro gastrointestinal digestion on the ACE inhibitory activity was 
evaluated.  
 
Screening of lactobacilli 
From the eight GRAS lactobacilli selected, only L. helveticus produced considerable ACE 
inhibitory activity after fermentation of pea protein medium. L. helveticus, whether or not in 
combination with S. cerevisiae, is known for its capacity to form ACE inhibitory peptides from 
milk proteins (Nakamura et al., 1995a; Yamamoto et al., 1999). Fermented milk prepared by 
most strains of L. helveticus significantly lowers the blood pressure in SHR upon oral 
administration, while milk fermented by other species of lactic acid bacteria, including a         
L. acidophilus strain, does not display significant antihypertensive effects (Yamamoto et al., 
1994a).  According to the same study, ACE inhibitory activity in most of the whey fractions of 
the milk fermented by L. helveticus is also higher than in the other fermented milks.  Another 
feature of L. helveticus is that it can survive passage through the gastrointestinal tract, where 
it may act as a probiotic (Shinoda et al., 2001). Nevertheless, ACE inhibitory peptides have 
been isolated from different dairy products started by various lactic acid bacteria: e.g. 
Lactobacillus delbrueckii subsp. bulgaricus SS1, Lactococcus lactis subsp. cremoris FT4, 
Lactobacillus acidophilus,  bifidobacteria, Streptococcus thermophilus, … (Gobbetti et al., 
2000; Ryhänen et al., 2001; Saito et al., 2000).  
Based on the results from the screening and literature, L. helveticus and S. cerevisiae 
were used to initiate fermentations in monoculture and in combination on pea and whey 
protein. The ACE inhibitory activity after fermentation is not a good selection criterion, 
because the physiological transformations in the human body, which determine the 
bioavailability of the ACE inhibitory peptides, are not taken into consideration. However, often 
only the food-processing step is envisaged (Haileselassie et al., 1999; Kim et al., 2001). By 
incorporation of the in vitro gastrointestinal digestion, the measured ACE inhibitory activity 
relates more closely to the ACE inhibitory activity in the human body. To exert an 
antihypertensive effect, the peptides also have to pass the intestinal barrier to arrive in the 
blood in an active form, yet this has been the scope of another paper (Vermeirssen et al., 
2002a). From this study, it was hard to make a selection after in vitro digestion in the 
screening, since almost all fermented digests reached maximal ACE inhibitory activity.  
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Fermentation by Lactobacillus helveticus or/and Saccharomyces cerevisiae 
The lactic acid bacterium L. helveticus was metabolically more active at 37°C, which 
resulted in more lactic acid production and hence a larger pH decrease. Although                  
L. helveticus and S. cerevisiae have complex nutritional requirements for growth (Hebert et 
al., 2000; Walker, 1998), both microorganisms were able to grow on the pea and whey 
protein medium in monoculture at their optimal temperature. The type of protein did not 
influence their growth, showing that pea and whey protein both could serve as a nitrogen 
source for L. helveticus and S. cerevisiae. Furthermore, it cannot be excluded that the 
(autoclaved) protein isolates contain a minor amount of small peptides and free amino acids.  
A positive interaction of the yeast towards the lactic acid bacterium would be translated in 
the provision of essential growth factors like amino acids and vitamins, CO2 production or 
growth stimulation by increasing the pH due to the utilisation of organic acids. However, in 
the combined fermentations, the yeast did not favour the growth of L. helveticus, which could 
be due to the production of organic acids, antibacterial compounds, ethanol, … or 
competition for nutrients (Viljoen, 2001). The counts of S. cerevisiae on the other hand, 
decreased slightly in the presence of L. helveticus at 37°C; which can either be attributed to 
the high acid production or the high temperature.  
 
Degree of proteolysis in ferments and digests and protease activity 
The increase in degree of proteolysis observed in the ferments with L. helveticus was 
induced by the action of its proteases, possibly supplemented by a slight acid hydrolysis as 
the pH decreased maximally to 3.5. L. helveticus is known to possess a cell-wall-associated 
protease, capable of forming antihypertensive peptides from casein (Yamamoto et al., 
1994b), and several peptidases (Christensen et al., 1999). However, the protease activity 
assay found a higher activity in the supernatant than in the cell precipitate, indicating that the 
cell-wall-associated protease has been released from the cell wall or that other secreted 
proteases played a major role. Also, the peptide rich propagation medium may inhibit the 
synthesis of the cell-wall-associated protease in L. helveticus (Hebert et al., 2000). The total 
potential protease activity of S. cerevisiae was similar to that of L. helveticus, but this did not 
induce an increase in degree of proteolysis after fermentation. Generally, S. cerevisiae has 
no extracellular proteases or peptidases to cleave oligopeptides or proteins in the medium, 
only some specialised strains have (Walker, 1998). However, it seems that the strain used in 
this study did possess some extracellular protease activity. A non-significant increase and 
even decrease in degree of proteolysis by the yeast can be explained by the consumption of 
peptides and amino acids present in the medium and by an increase in total protein content 
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due to yeast growth. The gastrointestinal proteases drastically incremented the degree of 
proteolysis, which simulated well the conditions during physiological digestion. The specificity 
and purity of pepsin, trypsin and α-chymotrypsin led to the formation of numerous peptides 
and amino acids. The pea protein was more susceptible to hydrolysis than the whey protein. 
 
ACE inhibitory activity in ferments and digests 
Comparing the ACE inhibitory activity of the whey protein at the start of the fermentations 
with that at the start of the digestion by intracellular proteases revealed that autoclaving had 
a major impact on the ACE inhibitory activity of the heat labile whey protein. This was also to 
a lesser extent observed for the ACE inhibitory activity of pea and was reflected in the 
degree of proteolysis for both proteins. This may be caused by heat and by the presence of 
natural proteases in the (whey) protein isolate, which are initially activated by the 
temperature increase during autoclaving (Huyghebaert, 1999). Yet, no proteolysis is 
observed during heat treatment of whey protein isolate at 85°C for 30 min at pH 4.6 
(Mutilangi et al., 1995). The higher initial degree of proteolysis of whey compared to pea 
protein can be explained by a higher concentration of peptides, like CMP, in this protein 
isolate. 
In vitro gastrointestinal digestion released significant ACE inhibitory activity from pea and 
whey protein medium and ferments. However, despite the growth of the microorganisms, the 
increase in degree of proteolysis and the increase in ACE inhibitory activity after 
fermentation, the fermented samples did not show higher ACE inhibitory activity after in vitro 
digestion than the non-fermented samples. The fact that fermentations are ineffective in 
producing ACE inhibitory activity has been reported in literature. Pihlanto-Leppällä et al. 
(1998) observed ACE inhibitory activity in whey and casein fermented by different lactic acid 
starters only after digestion by trypsin and pepsin. They attribute their results to the low 
proteolytic activity of the starters or the specificity of the enzymes in lactic acid bacteria. In a 
study where milk, either supplemented with 5% (w/w) sodium caseinate or whey protein 
isolate, is fermented by two L. helveticus strains for 24 h under constant stirring and CO2 
circulation at 42°C and pH 6, the caseinate-enriched milk allows better growth conditions and 
shows a higher degree of proteolysis and ACE inhibitory activity than the milk containing 
whey protein isolate (Leclerc et al., 2002). This suggests that casein is a better substrate 
than whey proteins for the extracellular proteinases of lactic acid bacteria. This may be 
another reason why there was no high ACE inhibitory activity obtained after fermentation of 
pea or whey protein. The formation of bioactive peptides by lactic acid bacteria seems to be 
a rare event and is recently being debated (Meisel and Bockelmann, 1999).  
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The IC50 values not only confirmed this observation, but even pointed out that 
fermentation may sometimes adversely affect the ACE inhibitory activity as the non-
fermented whey protein digest showed the highest ACE inhibitory activity. The tendency 
towards higher IC50 values in the fermented digests can be enlightened by the hypothesis 
that the microbial enzymes splice within the sequence of bioactive peptides in the food 
protein, thereby preventing the gastrointestinal proteases to release them. Therefore, there 
exists an optimal degree of hydrolysis, above which more ACE inhibitory peptides are 
degraded than new peptides are formed, decreasing the overall ACE inhibitory activity 
(Mullally et al., 1997a; Pedroche et al., 2002). Hence, no direct relationship between the 
degree of proteolysis and the ACE inhibitory activity is possible, especially in the later stages 
of hydrolysis. After fermentation of the whey but not the pea protein, some correlation 
between the degree of proteolysis and the ACE inhibitory activity was observed. After 
fermentation and digestion, however, the whey samples fermented by S. cerevisiae at 28°C, 
which showed the lowest degree of proteolysis and ACE inhibitory activity after fermentation, 
exhibited the lowest IC50 values and hence the highest ACE inhibitory activity. This further 
illustrates our hypothesis. The IC50 values of the digests ranged from 0.072 to 0.183 mg/ml, 
which are slightly more active than the values reported for whey digests by gastrointestinal 
proteases of 0.345 to 1.733 mg/ml (Pihlanto-Leppälä et al., 2000). Differences in assay 
conditions make it somewhat difficult to compare these values. The tendency towards lower 
IC50 values for the whey compared to the pea digests was due to the intrinsic amino acid 
sequence of the protein.  
 
HPLC profiles of the digests 
The HPLC chromatograms of the peptide fraction with MWCO < 3000 Da, did not differ 
between fermented and non-fermented digests. The type of protein and the digestion step 
determined the HPLC profile and hence the formation of small peptides with possible ACE 
inhibitory effects. Fermentation had only minor influence on the small peptide profile. Matar 
et al. (1996), however, concludes that there is a major impact of milk fermentation by           
L. helveticus on subsequent gastrointestinal digestion. The HPLC elution profiles of that 
study show that fermentation may contribute to the formation of new peptides during in vitro 
digestion, provided that the pH is controlled at 6.0 during the fermentation, which favours the 
growth and proteolytic activity of L. helveticus. Nevertheless, in other fermentation studies 
with L. helveticus and other lactic acid bacteria that are effective in producing ACE inhibitory 
peptides, pH is never controlled (Gobbetti et al., 2000; Nakamura et al., 1995a; Yamamoto et 
al., 1999). 
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Contribution of intracellular proteases 
In the case of the pea protein, the preliminary study on the production of ACE inhibitory 
activity from lysed cells pointed to the importance of the intracellular proteases from             
S. cerevisiae. Lysis of the cells made these proteases readily available for cleaving the 
bioactive peptide sequences from the food proteins, leading to an increased ACE inhibitory 
activity. Intracellular proteases and peptidases of both L. helveticus and S. cerevisiae will 
most likely contribute to degradation of proteins after cell lysis during fermentation (Jones, 
1990; Law and Haandrikman, 1997; Meisel and Bockelmann, 1999). This may both positively 
or negatively affect the ACE inhibitory activity. 
High ACE inhibitory activity is identified in skimmed milk digested with cell-free extract of 
S. cerevisiae and the hydrolysate obtained with the purified protease B shows an IC50 of    
0.42 mg protein/ml (Roy et al., 2000). Another vacuolar protease of S. cerevisiae, 
carboxypeptidase Y, is ineffective in releasing the potent ACE inhibitor Val-His-Leu-Pro-Pro 
from γ-zein (Maruyama et al., 1989). An extract of autologous Lactobacillus casei cell lysate 
demonstrates an antihypertensive effect in hypertensive patients, but this is due to the 
presence of polysaccharide-glycopeptide complexes (Nakajima et al., 1995). 
 
In conclusion, we were able to produce ACE inhibitory active digests from pea and whey 
protein. Nevertheless, a fermentation step by L. helveticus or/and S. cerevisiae did not 
improve the release of ACE inhibitory activity after in vitro gastrointestinal digestion.  
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Chapter 5
ACE inhibitory in vitro gastrointestinal digests:  
from batch experiment to semi-continuous model 
 
ABSTRACT 
 
Gastrointestinal digestion is of major importance in the bioavailability of angiotensin I 
converting enzyme (ACE) inhibitory peptides, bioactive peptides with possible 
antihypertensive effects. In this study, the conditions of in vitro gastrointestinal digestion 
leading to the formation and degradation of ACE inhibitory peptides were investigated for pea 
and whey protein. In batch experiments, the digestion simulating the physiological conditions 
sufficed to achieve the highest ACE inhibitory activity, with IC50 values of 0.076 mg/ml for pea 
and 0.048 mg/ml for whey protein. The degree of proteolysis did not correlate with the ACE 
inhibitory activity and was always higher for pea than for whey. In a semi-continuous reactor 
model of gastrointestinal digestion (pre-SHIME), response surface methodology studied the 
influence of temperature, incubation time in the stomach and incubation time in the small 
intestine phase on the ACE inhibitory activity and the degree of proteolysis. For the pea 
protein a linear model for the degree of proteolysis and a quadratic model for the ACE 
inhibitory activity could be constituted. Within the model, maximal degree of proteolysis was 
observed at the highest temperature and the longest incubation time in the small intestine 
phase; while maximal ACE inhibitory activity was obtained at the longest incubation times in 
the stomach and the small intestine phase. These results show that ACE inhibitory activity of 
pea and whey hydrolysates can be controlled by the conditions of the in vitro gastrointestinal 
digestion.                                 
  
Keywords: ACE inhibitory peptides, pea protein, whey protein, response surface 
methodology 
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INTRODUCTION 
 
Angiotensin I converting enzyme (ACE, EC 3.4.15.1) inhibitory peptides are food derived 
bioactive peptides with possible antihypertensive effects in vivo (Fitzgerald and Meisel, 
2000). A high blood pressure is a major risk for cardiovascular disease, one of the most 
important causes of mortality in the developed world. In a recent study performed in 5 
European countries, 34% of the adult population had a blood pressure higher than       
140/90 mmHg, the treatment of which contributes substantially to health care costs (Hansson 
et al., 2002). Recently, foods containing ACE inhibitory peptides have shown to be effective 
in both the prevention and treatment of hypertension (Sipola et al., 2002; Takano, 1998).  
Research on ACE inhibitory peptides has mainly concentrated on milk proteins, but 
vegetable and other animal proteins have been studied as well (Yamamoto, 1997). To our 
knowledge, pea protein has not been the subject of study for ACE inhibitory activity yet. In a 
previous paper, we observed a large impact of in vitro gastrointestinal digestion on the 
formation of ACE inhibitory activity from pea and whey protein (Vermeirssen et al., 2003a). 
The scope of this paper was to further investigate the conditions of in vitro gastrointestinal 
digestion leading to the formation and/or degradation of ACE inhibitory peptides. Firstly, this 
is of physiological importance, since, upon oral administration, these bioactive peptides have 
to reach the blood stream in an active form to exert an antihypertensive effect (Masuda et al., 
1996). Gastrointestinal digestion and transport are the major barriers in the bioavailability of 
ACE inhibitory peptides (Pihlanto-Leppälä, 2001). Secondly, digestion by gastrointestinal 
proteases can be used as a production process for ACE inhibitory peptides, with the 
advantage that the formed peptides will resist the physiological digestion after oral intake 
(Matsui et al., 2002).  
Few studies have been performed on the conditions necessary during digestion to release 
ACE inhibitory activity. Some hydrolysis of the proteins is required in order to free the 
bioactive peptide sequences. At some point during hydrolysis however, no further increase in 
ACE inhibitory activity is observed (Mullally et al., 1997a). Meisel et al. (1997) reported that 
the ACE inhibitory activity in ripened cheese increases during cheese maturation, but 
decreases when the proteolysis exceeds a certain level. At this point the degradation of 
bioactive peptides starts to dominate the formation of new ones. Digestion of bovine skin 
gelatine independently by different proteases at incubation times up to 24 h also 
demonstrated an optimal incubation time for maximal ACE inhibitory activity (Kim et al., 
2001). Hence, there seems to be an optimal and not always maximal hydrolysis for maximal 
ACE inhibitory activity. Moreover, the specificity of the enzymes plays a major role in the 
formation of ACE inhibitory peptides (Mullally et al., 1997a; Vermeirssen et al., 2003a). ACE 
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inhibitory peptides are most commonly produced by trypsin (EC 3.4.21.4) (Pihlanto-Leppälä, 
2001). This readily available enzyme forms peptides with a terminal lysine or arginine, the 
latter being reported in structure-activity studies of ACE inhibitory peptides (Fitzgerald and 
Meisel, 2000). The digestion of α-lactalbumin and β-lactoglobulin by pepsin (EC 3.4.23.1), 
trypsin, α-chymotrypsin (EC 3.4.21.1), pancreatin, elastase (EC 3.4.21.36) or 
carboxypeptidase A (EC 3.4.17.1) and B (EC 3.4.17.2) alone and in combination, revealed 
that trypsin is necessary to release high ACE inhibitory activity from whey protein. The 
gastrointestinal protease elastase, on the other hand, is associated with a low production of 
ACE inhibitory peptides from α-lactalbumin and β-lactoglobulin (Mullally et al., 1997a; 
Pihlanto-Leppälä et al., 2000). 
 The physiological conditions of the gastrointestinal protein digestion are more or less 
known. The gastric pH is between 1.5 and 2 during fasting and it can increase up to 5 after 
ingestion of a meal due to the diluting and buffering effect of the food components (Charman 
et al., 1997). Proteins are cleaved in the stomach by the endopeptidase pepsin with rather 
broad substrate specificity and an optimal pH in the range of 1 to 2 (Ganapathy and Leibach, 
1999). The fasting pH of the overall small intestine is situated around 6.5, while for the 
postprandial pH this is around 5.5 (Charman et al., 1997). In the duodenum, the 
endopeptidases trypsin, chymotrypsin and elastase, and the carboxypeptidases A and B 
continue the splicing of the polypeptide chain at more alkaline pH with an optimal activity in 
the range 7 to 8. At the brush border membrane, the oligopeptides are further cleaved by 
amino-, di- and endopeptidases, resulting in a mixture of amino acids and small peptides 
which can be absorbed by the enterocytes (Ganapathy and Leibach, 1999). The half-
emptying time for the stomach is 0.5 to 3 h for fed conditions, while the residence time in the 
duodenum and jejunum is 2 to 2.75 h and in the ileum 5 to 7 h (Oomen et al., 2002).  
In our study, digestion was first simulated in batch, where the enzyme over substrate ratio 
was set at 1 over 250 (w/w) (Gauthier et al., 1986). A non-optimal, physiological and 
prolonged optimal gastrointestinal digestion, varying in pH and residence time in stomach 
and small intestine, were compared for the formation of ACE inhibitory activity, degree of 
proteolysis and HPLC profile. Subsequently, a semi-continuous model based on the batch 
physiological digestion, was developed. In this reactor, the influence of temperature, 
incubation time in stomach and small intestine phase on the formation of ACE inhibitory 
activity and degree of proteolysis was investigated by means of an experimental design.  
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MATERIALS AND METHODS 
 
Products 
The pea protein isolate Pisane HD (90% protein on dry matter) and the whey protein 
isolate Lacprodan DI-9213 (minimal 90% protein on dry matter) were obtained from 
Cosucra SA (Fontenoy, Belgium) and Acatris Belgium NV (Londerzeel, Belgium), 
respectively. Pepsin (P 6887), trypsin (T 1426), α-chymotrypsin (C 4129), trichloroacetic acid 
solution (TCA) (490-10), ACE reagent (305-10), ACE control-E (A 7040), 100% (w/w) 
trifluoroacetic acid solution (TFA) (30,203-1) were purchased from Sigma-Aldrich (St.-Louis, 
MO, USA). Non-specified products were analytical grade from VWR International (Zaventem, 
Belgium). 
 
Batch gastrointestinal digestion 
A 100 ml 4% (w/v) protein isolate solution was brought to the desired pH for the stomach 
digestion with 1 N and 10 N HCl and NaOH under rigorous mixing. Pepsin was added in an 
E/S of 1/250 (w/w) after which the incubation at 37°C on a shaker started. After a defined 
residence time, the pH was set at the desired value for small intestine digestion and trypsin 
and α-chymotrypsin were supplemented both in an E/S of 1/250 (w/w). Then the solution was 
again incubated at 37°C. When samples were taken at the start and the end of digestion, the 
pH was adjusted to 5. As this is a pH near the iso-electrical point for both proteins (pea: pH 
4.5, whey: pH 4 to 5), a standardised and clear separation was obtained by subsequent 
centrifugation. Incubation time and pH in stomach and small intestine phase varied in the 
three types of in vitro gastrointestinal digestion: the non-optimal, physiological and prolonged 
optimal digestion (Table 1).  
 
Table 1. pH and incubation time (h) in stomach and small intestine phase for the non-
optimal, physiological and prolonged optimal digestion. 
Type of digestion Stomach Small intestine 
 pH Incubation time pH Incubation time 
Non-optimal 4 0.5 5 0.5 
Physiological 2 2 6.5 2.5 
Prolonged optimal 2 4 7 4.5 
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For the preliminary experiments preceding the experimental design, other protein 
concentrations (2 and 8% (w/v)) and enzyme over substrate ratios (1/50, 1/100, 1/400, 
1/1000) were applied in the batch gastrointestinal digestion. 
 
Experimental design in a semi-continuous model for gastrointestinal digestion  
Figure 1 shows the reactor set-up for the semi-continuous digestion. This model was called 
the pre-SHIME, because it can precede the SHIME, the Simulator of the Human Intestinal 
Microbial Ecosystem (Molly et al., 1993). By means of double jacketed vessels and a warm 
water bath, the content of the vessels was kept at a defined temperature. The pH in the two 
vessels was controlled by a pH stat (Consort R305, Turnhout, Belgium) and the content was 
mixed by magnetic stirring. A peristaltic pump brought 200 ml 4% (w/v) protein solution in the 
first reactor vessel that simulated the stomach. The pH was adjusted to 2 (lower and upper 
limits: 1.85 and 2.15) with 1 N HCl and NaOH. Pepsin was supplemented in an E/S of     
1/250 (w/w). After the stomach phase the solution was pumped to the second reactor vessel, 
where the pH was set at 6.5 (lower and upper limits: 6.35 and 6.65). Subsequently, trypsin 
and α-chymotrypsin were added in an E/S of 1/250 (w/w) and the solution was incubated for 
the small intestine phase. At the end of the in vitro digestion the hydrolysate was pumped to 
an erlenmeyer flask and brought to pH 5. Samples for analyses were taken. 
Figure 1. Experimental set up for the semi-continuous digestion. 
Protein 
pH 
2
pH 
6.5
Stomach Small intestine Hydrolysate 
 pre-SHIME 
trypsin + α-chymotrypsin pepsin 
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The experimental design was created and analysed by Design-Expert 6.0.3 (Stat-Ease, 
Minneapolis, USA). Response Surface Methodology linked the digestion parameters 
temperature, incubation time in stomach phase and incubation time in small intestine phase 
(3 factors) via a polynome to the degree of proteolysis and the 50% ACE inhibitory 
concentration (IC50) (2 responses). A central composite design was chosen, where the 
factors vary round a central point, here the conditions of the physiological digestion (Table 1, 
Figure 2). This design contains 5 levels for each digestion parameter, coded by -α, -1, 0, +1 
and +α (Table 2). In this way, the factors are standardised and vary in the same range, which 
facilitated the interpretation of the effects and interactions.  
 
Table 2. The different factors of the central composite design with their codes and values. 
Factor Code 
 -α -1 0 +1 +α 
Temperature (°C) 18.5 26.0 37.0 48.0 55.5 
Incubation time stomach (min) 19 60 120 180 221 
Incubation time small intestine (min) 0 60 150 240 301 
 
The design exists of three experiment subsets. Firstly, at the central point, all the factors 
are at level 0. Secondly, the factorial points have all combinations of the factors set at the 
levels -1 and +1 and indicate the range where the design is valuable. These points give 
information about the linear effects and the interaction effects. Thirdly, for the axial points, all 
factors are set at level 0, except for one, which adopts the levels –α or +α, an extreme value. 
These points determine the estimation of the quadratic effects. The value of α was chosen so 
the design was rotatable, which guaranteed that the precision of the estimated values 
(standard error) is only influenced by the distance to the central point and not by the 
direction. The final experimental design consisted of 20 experiments for both proteins: 6 
repetitions of the central point, 8 factorial points and 6 axial points. Based on the repetitions 
of the central point, the experimental error was estimated. 
 
Degree of proteolysis 
 The degree of proteolysis was determined as in Chapter 4. 
 
ACE inhibitory activity  
Samples for the determination of ACE inhibitory activity were treated as described in 
Chapter 4 and analysed by the ACE inhibition assay 3 in Chapter 2.  
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Figure 2. Central composite design for three factors: position of factorial and axial points 
relative to central points. 
 
HPLC 
Samples for the HPLC analysis were treated as for the ACE inhibition assay. Ten 
milligram lyophilised sample was dissolved in 1 ml milli-Q water and 20 µl of this solution was 
analysed by RP-HPLC on a Prosphere 300 Å C18 column (250 x 4.6 mm, 5 µm) (Alltech 
Associates, Deerfield, IL, USA) and a Dionex (Sunnyvale, CA, USA) HPLC with an 
autosampler ASI-100, pump series P580, STH585 column oven, UV-VIS detector UVD340S 
operating at 210 nm and Chromeleon 6.0 software. Elution was at 25°C with a flow rate of     
1 ml/min with solvents A (H2O + 0.1% (w/v) TFA) and B (acetonitrile + 0.85% (w/v) TFA). 
Whey was analysed by a linear gradient from 90% solvent A to 50% solvent B in 30 min, 
again to 90% solvent A in the next 20 min and remaining at 90% solvent A in the last 10 min. 
For pea a linear gradient from 95% solvent A to 30% solvent B in 30 min was applied. 
Subsequently, the gradient went linearly up to 95% solvent A the next 20 min and remained 
at 95% solvent A in the last 10 min. A control solution containing 16 mg of pepsin, trypsin 
and  α-chymotrypsin in 100 ml MilliQ, centrifuged for 15 min at 10 000 g, was also eluted by 
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the HPLC programs for pea and whey respectively. Only an injection peak could be observed 
on these chromatograms. 
 
Statistical analysis 
  All values are reported as mean ± standard error (SE) of the mean (nmin = 3). For the 
comparison of the three in vitro digestions, significant differences in type of protein (pprot) and 
type of digestion (pdigest) were assigned by means of the General Linear Model Univariate 
Analysis of Variance procedure (SPSS 11.0.1, Chicago, Illinois, USA). To exclude the initial 
effect of the protein itself, the statistical analysis was performed on the changes in degree of 
proteolysis and ACE inhibitory activity during digestion. When there was a significant type of 
protein × type of digestion interaction, for both proteins a Oneway ANOVA analysis was 
carried out by type of digestion. All data used in the variance analysis met the homogeneity 
of variance requirement assessed by Levene's test. Indication of subgroups in type of 
digestion was done by Tukey post hoc test (p < 0.05). Differences between the digestion in 
the semi-continuous reactor model and the physiological digestion in batch were assigned by 
an independent Student t-test. A hierarchical cluster analysis by average linkage and with the 
Pearson correlation coefficient as measure of inequality, was performed on the relative 
squares of the peaks for different intervals of retention times of the digests HPLC 
chromatograms. An independent Student t-test compared the log IC50 values of the 
preliminary batch experiments of the experimental design and the batch physiological 
digestion. 
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RESULTS 
 
Comparison of three different in vitro gastrointestinal digestions  
Before digestion, the pea protein solution showed a lower degree of proteolysis than 
whey, respectively 2.4 ± 0.4% and 12.9 ± 0.7% (p < 0.001), while the ACE inhibitory activity 
of both proteins did not differ and was 10 ± 0.7% and 15 ± 2%, respectively (p = 0.083). IC50 
values were 16 mg/ml for pea and 18 mg/ml for whey protein. 
To investigate the conditions during gastrointestinal digestion leading to the release of 
ACE inhibitory activity, we compared three different in vitro digestions (Table 1). The non-
optimal digestion was carried out at non-optimal pH in stomach and small intestine phase for 
short incubation times, minimizing protein hydrolysis. The physiological digestion simulated 
the in vivo conditions of protein digestion. The prolonged optimal digestion combined optimal 
pH in stomach and small intestine phase with long incubation times in order to get ideal 
conditions for protein hydrolysis.  
The degree of proteolysis after the three in vitro digestions is depicted in Figure 3. The 
statistical analysis, however, was performed on the change in degree of proteolysis during 
digestion, to exclude the initial degree of proteolysis of the protein itself. For both proteins, 
the increase in degree of proteolysis was significantly different between the three digestions 
(Oneway Anova, pdigest < 0.001). For all digestions, pea showed a higher increase in degree 
of proteolysis than whey. For the whey protein, the degree of proteolysis increased 
proportionally between the three digestion types, while for the pea protein, the prolonged 
optimal digestion contributed only a little more to the degree of proteolysis than did the 
physiological digestion (pinteraction = 0.003). In the physiological digests, the degree of 
proteolysis amounted to 72 ± 1% for pea and 58 ± 2% for whey. 
The increase in percent ACE inhibitory activity did not vary significantly between the three 
in vitro gastrointestinal digestions (pdigest = 0.078) and amounted to 89.8 ± 0.3% for pea and 
83.8 ± 1.2 % for whey digest respectively (pprot < 0.001). As the maximal level of 100% ACE 
inhibitory activity was reached after all digestions, the (log) IC50 value or 50% inhibitory 
concentration was determined (Figure 3). A higher IC50 indicated a lower ACE inhibitory 
activity. The three digestions had a different effect on the log IC50 value for the pea in 
comparison to the whey protein (pinteraction < 0.001). For pea, the only significant difference 
was found between the non-optimal and the physiological digestion, where the IC50 of the 
first was double the one of the latter (Oneway Anova, pdigest = 0.015).  
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Figure 3. Degree of proteolysis (%) (bars, a, b, …) and log IC50 (mg/ml) (bullets, 1, 2, …) 
after the non-optimal, physiological and prolonged optimal digestion and the semi-
continuous digestion of pea (P) and whey (W) protein (nmin = 3). Straight, dashed 
lines indicate the initial degree of proteolysis of the pea and whey protein. Different 
letters and numbers indicate significant differences (p < 0.05). The semi-
continuous digestion was compared to the physiological digestion by means of an 
independent samples t-test. 
 
For the whey, on the other hand, a relatively high IC50 was obtained after non-optimal 
digestion, which displayed a tenfold difference from the IC50 of the physiological and 
prolonged optimal digestion (Oneway Anova, pdigest < 0.001). IC50 values as low as           
0.076 mg/ml for the physiological digestion of pea and 0.032 mg/ml for the prolonged optimal 
digestion of whey protein were observed (Table 3).  
The soluble fraction of the non-digested proteins and the digests of both proteins after 
non-optimal, physiological and prolonged optimal digestion were eluted by RP-HPLC    
(Figure 4a and b). The chromatograms clearly differentiated both proteins. For the pea 
protein, the chromatograms of the prolonged optimal digests had remarkably higher initial 
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peaks compared to the ones of the non-optimal and physiological digests, while apart from 
that no major differences were noticed. For the whey protein, it is clearly shown that the                  
β-lactoglobulin peak was only substantially degraded in the prolonged optimal digests (this 
peak was confirmed by elution of pure β-lactoglobulin). Moreover, in the non-optimal digest a 
remainder of another whey protein at a retention time of 30 min is present. From the non-
optimal to the physiological and to the prolonged optimal digestion, more intense peptide 
peaks were observed, as the degree of proteolysis increased. The relative squares of the 
peaks for different intervals of retention times clustered separately for the pea and whey 
digests (Figure 5). Furthermore, the data of the different pea digests were more closely 
related with each other than the data of the different digestions of whey. 
 
Table 3. IC50 (mg/ml) of pea and whey protein and after non-optimal, physiological, 
prolonged optimal digestion and after digestion in the semi-continuous reactor. 
Digestion type Pea Whey 
None 16 18 
Non-optimal 0.142          0.377      
Physiological 0.076      0.048      
Prolonged optimal 0.108           0.032      
Semi-continuous 0.068            0.044    
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Figure 4a. HPLC chromatograms of the soluble fractions of the non-digested PEA protein 
and after a non-optimal, physiological and prolonged optimal digestion. 
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Figure 4b. HPLC chromatograms of the soluble fractions of the non-digested WHEY protein 
and after a non-optimal, physiological and prolonged optimal digestion. The 
recovery of β-lactoglobulin is also indicated (nmin = 3). 
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Figure 5. Dendrogram of the hierarchical cluster analysis using average linkage and 
Pearson correlation coefficient of the relative squares of the chromatogram peaks 
for different intervals of retention times (W = whey protein, P = pea protein, non-
opt = non-optimal, phys = physiological, prol = prolonged optimal digestion). 
 
Experimental design in a semi-continuous reactor model 
When the physiological digestion was simulated in the semi-continuous reactor, no 
significant differences in change in degree of proteolysis (pea, p = 0.13, whey, p = 0.38) and 
log IC50 value (pea, p = 0.20, whey, p = 0.60) were observed in comparison to the batch 
physiological digestion (Figure 3, Table 3). From the HPLC chromatogram, it was observed 
that 65% of β-lactoglobulin was recovered (data not shown).  
First some preliminary experiments were designed in batch to study the influence of 
protein concentration and enzyme over substrate ratio on the formation of ACE inhibitory 
activity from pea and whey protein (Table 4). No significant differences between the log IC50 
values of the whey digests with 2%, 4% or 8% (w/v) protein concentration were found. A     
2% (w/v) pea protein solution gave a significantly lower ACE inhibitory activity compared to 
the other pea protein concentrations. Although the log IC50 values of digests with a higher 
enzyme over substrate ratio tended to be lower for pea protein, the differences were non-
significant. The influence of the incubation time in stomach and small intestine phase was 
already suggested in the previous experiments. In addition, it is known that pepsin A has an 
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optimal activity at 42°C (Ryle, 1984), while for trypsin this is at 45°C (Venkatesk and 
Sundaram, 1998). The optimal hydrolysis temperature for α-chymotrypsin is 50°C (Angelo et 
al., 1982). 
 
Table 4. IC50 (mg/ml) of the preliminary experiments for the experimental design (batch 
physiological digestion). The other conditions were the same as during an in vitro 
physiological digestion. 
Condition tested Pea Whey 
2% (w/v) protein      0.191*** 0.047 
4% (w/v) protein§ 0.076 0.048 
8% (w/v) protein 0.079 0.046 
E/S = 1/1000 0.082 / 
E/S = 1/400 0.075 / 
E/S = 1/250 0.064 / 
E/S = 1/100 0.057 / 
E/S = 1/50 0.052 / 
/ Data not available. 
Statistical analysis performed on the log IC50: *p < 0.05, **p < 0.01, ***p < 0.001 (n = 9). 
§The values were compared to the mean value of all batch physiological digestions. 
 
Based on these data, temperature and incubation time in stomach and small intestine 
phase were chosen as parameters in the experimental design in the semi-continuous 
reactor. The aim of this design was to establish, for both pea and whey protein, a relation 
between the responses, the degree of proteolysis and the ACE inhibitory activity, expressed 
as log IC50 value, and the variables, temperature (from 26 to 48°C), incubation time in the 
stomach phase (from 1 to 3 h) and incubation time in the small intestine phase (from 1 to 4 h) 
within a certain degree of freedom around the physiological digestion parameters (37°C, 2 h 
and 2.5 h) (Table 2).  As the IC50 was calculated by means of the four parametric logistic 
model, only the log IC50 is normally distributed. Moreover, the Box Cox plot for power 
transformation in the Design Expert analysis program indicated that a log transformation for 
the IC50 data was necessary. 
The statistic properties of the data points in the experimental design were investigated for 
the two responses for both proteins (Table 5). Both for the degree of proteolysis and the log 
IC50 value of the pea digests, the range of all data points included the range of the central 
points, the only replicates in the design. Moreover, the standard error on the average of the 
central points was smaller than the one on the average of all data points. This indicated a 
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good reproducibility of the semi-continuous digestion of the pea protein. Hence, the large 
standard error on the average of all pea digests and the large range were probably not due 
to experimental error, but to variation in the process parameters. This justified the creation of 
a response surface model for the pea protein in the two responses. For the whey protein 
however, the central points showed a rather large variation for both responses, which 
indicated a poor reproducibility of the semi-continuous digestion of the whey protein. Since 
the standard error on the average of all samples was about as large as the one on the 
average of the central points, it could not be explained by a variation in process parameters 
and was merely due to experimental error. As a result, neither for the degree of proteolysis 
nor for the log IC50 of the whey protein, a significant model could be established.  
 
Table 5. Average ± standard error and range of all points in comparison to the central points 
for the degree of proteolysis (%) and the log IC50 (mg/ml) in the central composite 
design (n = 20). 
  Degree of proteolysis (%) Log IC50 (mg/ml) 
  All points Central points All points Central points 
Pea Average 73 ± 9 77 ± 3 -1.24 ± 0.04 -1.19 ± 0.01 
 Range 49 to 86 65 to 85 - 0.90 to -1.66 -1.16 to -1.23 
Whey Average 53 ± 4 64 ± 4 -1.32 ± 0.06 -1.42 ± 0.04 
 Range 32 to 82 40 to 81 -0.37 to -1.66 -1.23 to -1.66 
 
For the pea protein, the best fitting model equation of the degree of proteolysis and log 
IC50 were respectively calculated as a linear and quadratic polynomial equation of 
temperature, incubation time in stomach and incubation time in small intestine phase.     
Table 6 shows the coefficients of the obtained response equations and the corresponding 
model validation parameters.  
For a good model, lack of fit should be non-significant, R2 values high (predicted R2 in 
reasonable agreement with adjusted R2), adequate precision above 4 and PRESS values 
low. The adequate precision value measures the signal over noise ratio, while the PRESS 
statistic points to the lack of predictive value of the model. Reduced models could be 
obtained by omitting the non-significant model terms (p > 0.1), taking into account the 
hierarchy of the model, but responses and validation parameters did not change much (data 
not shown).  Both the linear model for the degree of proteolysis and the quadratic model for 
the log IC50 were significant. Furthermore, the model validation parameters demonstrated 
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that the equations were representative for the observed data and useful to navigate the 
design space. Figure 5 shows the response surface plots of the degree of proteolysis and the 
ACE inhibitory activity of the pea digest. 
 
Table 6. Coefficients in terms of actual and coded factors and their p values, and validation 
parameters of the linear and quadratic model equations of respectively the degree 
of proteolysis (%) and the log IC50 value (mg/ml) of the pea protein digest as a 
function of temperature (°C) (A), incubation time in stomach (min) (B) and 
incubation time in small intestine phase (min) (C). 
 Degree of proteolysis (%) Log IC50 (mg/ml) 
Model Linear (p = 0.0232) Quadratic (p < 0.0001) 
Factors actual coded p-value actual coded p-value 
Constant 43.441 73.2  -2.438 -1.19  
A 0.536 5.90 0.0124 0.039 -0.017 0.1494 
B 0.023 1.39 0.5152 0.010 -0.096 < 0.0001 
C 0.047 4.27 0.0589 1.7 .10-3 -0.094 < 0.0001 
A2    -1.4 .10-4 -0.017 0.1286 
B2    -1.8 .10-5 -0.066 0.0002 
C2    4.1 .10-6 0.033 0.0120 
AB    -1.6 .10-4 -0.100 0.0001 
AC    -7.4 .10-5 -0.073 0.0014 
BC    -1.1 .10-5 -0.057 0.0056 
Lack of fit 
Adjusted R2 
Predicted R2 
Adequate precision 
PRESS 
0.65 
0.33 
0.16 
6.68 
1442 
0.20 
0.95 
0.80 
27.05 
0.08 
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Figure 5. Response surface plots of the degree of proteolysis (%) and the log IC50 (mg/ml). 
The non-displayed parameter is set at the central point.  
 
Results are displayed as perturbation plots of the non-reduced models and contour plots 
(Figure 6 and 7). A perturbation plot shows how the response changes as each factor, 
expressed as coded value, moves from the central point of the design towards the borders, 
while all other factors are held constant at the central point. The degree of proteolysis 
showed the major deviation from the central point when the temperature varied, while the log 
IC50 changed substantially from the central point when the incubation time in the stomach 
increased and the incubation time in the small intestine phase decreased.  
-1.5  
-1.4  
-1.3  
-1.2  
-1.1  
   
 
  60
  90
  120
  150
  180
60  
105  
150  
195  
240  
    
    Incubation time              
in intestine (min) 
Incubation time in 
stomach (min) 
Log IC50 (mg/ml) 
63.0  
68.1  
73.2  
78.3  
83.4  
  26.0
  31.5
  37.0
  42.5
  48.0
60  
105  
150  
195  
240  
    
    
Temperature (°C) Incubation time              
in intestine (min) 
Degree of proteolysis (%)
From batch experiment to semi-continuous model 
 137
Figure 6. Perturbation plots for degree of proteolysis (%) and log IC50 (mg/ml) as a function 
of temperature (A), incubation time in stomach (B) and incubation time in small 
intestine phase (C). 
 
A contour plot is a two-dimensional representation of the response for selected factors. 
The contour plot for the degree of proteolysis indicates that this response increased as the 
pea protein was digested at higher temperatures and with longer incubation times in the 
small intestine phase, when the incubation time in the stomach was set at 120 min. At a 
temperature of 37°C, the log IC50 lowered when both the incubation time in stomach and 
small intestine phase increased. In the contour plots for the log IC50, where the temperature 
is displayed in the X axis, the rather horizontal lines point to the limited importance of the 
temperature.  
At the central point, the observed degree of proteolysis and log IC50 value were 
respectively 77 ± 3% and -1.19 ± 0.01 mg/ml (IC50 = 0.065 mg/ml), while their predicted 
values were respectively 73% and -1.19 mg/ml. From the three-dimensional plot of the 
standard errors it can be found that the model for the log IC50 is more reliable than the one 
for the degree of proteolysis: the central composite design provided relatively precise 
predictions over a broader area around the central point (Figure 8). The circular contours 
confirmed the rotatability of the design. 
The central composite design was used to optimise towards a maximal degree of 
proteolysis on one hand and a minimal log IC50 on the other hand, when all the parameters 
were in the design space. For both criteria, this resulted in maximal parameters: maximal 
temperature (48°C), maximal incubation time in stomach (3 h) and maximal incubation time 
in small intestine phase (4 h). The maximal degree of proteolysis amounted to 85% and the 
minimal log IC50 was -1.66 mg/ml (IC50 = 0.022 mg/ml). As this maximum was situated at the 
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edge of the design space, it was associated with a relatively large standard error. Hence, the 
optimisation results have to be interpreted with caution. Because of the non-significance of 
the factor incubation time in stomach in the model of the degree of proteolysis, maximal 
degree of proteolysis was also attained when only the temperature and the incubation time in 
the small intestine phase were maximised in the model. When the temperature, the least 
important factor in the model of the log IC50, was set at 37°C, a slightly lower maximal ACE 
inhibitory activity (log IC50 = -1.47 mg/ml, IC50 = 0.034 mg/ml) was obtained for maximal 
incubation time in stomach and maximal incubation time in small intestine phase. 
Figure 7. Two-dimensional contour plots for the degree of proteolysis (%) and                      
log IC50 (mg/ml). The non-displayed parameter is set at the central point.   
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Figure 8. Three-dimensional plot of the standard error of the degree of proteolysis (%) (A) 
and the standard error of the log IC50 (mg/ml) (B) in function of the most significant 
parameters of the model, while the other parameter was set at the central point. 
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DISCUSSION 
 
Gastrointestinal digestion is of major importance in the bioavailability of ACE inhibitory 
peptides. After oral administration gastrointestinal proteases may splice the ACE inhibitory 
peptides, thereby increasing or decreasing their activity. For example, after oral 
administration in spontaneously hypertensive rats (SHR) the nonapeptide Ile-Val-Gly-Arg-
Pro-Arg-His-Gln-Gly, isolated from a thermolysin digest of chicken muscle, is hydrolysed by 
trypsin to Ile-Val-Gly-Arg-Pro-Arg, which then exerts the antihypertensive effect (Fujita et al., 
2000). Similarly, the ACE inhibitory activity of Lys-Val-Leu-Pro-Val-Pro-Gln, derived from     
β-casein, is increased by pancreatin digestion and the derivative Lys-Val-Leu-Pro-Val-Pro 
lowers the blood pressure of SHR (Maeno et al., 1996). In the same study, an αs1-casein 
derived peptide, Tyr-Lys-Val-Pro-Gln-Leu, with strong ACE inhibitory activity, fails to exert an 
antihypertensive effect due to pancreatin degradation.   
Our previous study demonstrated the high ACE inhibitory activity of pea and whey protein 
after gastrointestinal digestion (Vermeirssen et al., 2003a). Here, the process of digestion 
was investigated more in detail with respect to the formation of ACE inhibitory activity. During 
a first set of experiments, the gastrointestinal digestion was simulated in batch, while for the 
experimental design a semi-continuous reactor model was developed. In literature different in 
vitro models are reported: from simple batch experiments (Oomen et al., 2002; Pihlanto-
Leppällä et al., 1998), dialysis bags (Gauthier et al., 1986) to more complex computer-
controlled models like artificial stomach (Yvon et al., 1992), TIM (Minekus et al., 1993), 
SHIME (Molly et al., 1993) and models coupled to cell cultures (Glahn et al., 2002). Although 
some of them use pancreatin as a small intestinal enzyme source, we preferred to use 
relatively pure trypsin and chymotrypsin.  
 
Comparison of three different in vitro gastrointestinal digestions 
Three different in vitro batch gastrointestinal digestions were compared to elucidate the 
conditions required for protein hydrolysis and release of ACE inhibitory activity. From the 
non-optimal over the physiological to the prolonged optimal digestion, protein hydrolysis 
increased significantly, due to a more optimal pH for the gastrointestinal proteases and 
longer incubation times. The degree of proteolysis of the pea digest levelled off from the 
physiological to the prolonged optimal digestion, suggesting that liberation of peptides from 
the pea protein reached a saturation point. Yet, the prolonged optimal digestion of the whey 
protein still contributed substantially to protein hydrolysis. In addition, pea protein displayed 
higher increases in degree of proteolysis than whey, showing that the latter is less prone to 
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gastrointestinal digestion. Indeed, the major whey proteins α-lactalbumin and β-lactoglobulin 
partially resist gastrointestinal digestion. Pepsin degrades α-lactalbumin and only 
denaturated β-lactoglobulin, trypsin slowly cleaves α-lactalbumin and denaturated                
β-lactoglobulin, while α-chymotrypsin hydrolyses both α-lactalbumin and β-lactoglobulin to a 
limited extent (Guo et al., 1995; Schmidt and van Markwijk, 1993).  
All three digests of both proteins reached 100% ACE inhibitory activity, but the 50% 
inhibitory concentrations differed. Both pH and incubation time had an influence on the 
formation of ACE inhibitory activity. A physiological digestion sufficed for both proteins to 
obtain minimal IC50 and hence maximal ACE inhibitory activity. The formation of ACE 
inhibitory activity reached a saturation level, after which no major breakdown occurred or 
equilibrium existed between the formation and degradation of ACE inhibitory peptides.  
Apparently, a certain degree of proteolysis was necessary to exert high ACE inhibitory 
activity, as the non-optimal digestion resulted in lower ACE inhibitory activity than the other 
two digestions and this effect was larger for whey than for pea. This may be of physiological 
importance since a higher, non-optimal pH in the stomach can occur in humans with 
increasing age (Morihara et al., 2001). The higher ACE inhibitory activity of the whey protein 
after a physiological or prolonged optimal digestion compared to those of pea can be 
attributed to the amino acid sequence of the proteins which determines the presence of 
bioactive peptide sequences and enzyme splicing sites. The IC50 of the physiological and 
prolonged optimal whey digests are lower than the IC50 ranges of 0.130-0.201 and 0.345-
1.733 mg/ml reported respectively by Mullally et al. (1997a) and Pihlanto-Leppälä et al. 
(2000) for whey protein digested by gastrointestinal proteases. However, differences in the 
ACE inhibition assay and the way of calculation of the ACE inhibitory activity complicate the 
comparison of IC50 values reported in literature (Ariyoshi, 1993). No IC50 values for pea 
hydrolysates are reported in literature. 
Compared to the ACE inhibitory activity produced after in vitro gastrointestinal digestion of 
autoclaved pea and whey protein (Chapter 4), higher activity is obtained after digestion of the 
native proteins (this chapter). Denaturated proteins are usually more prone to hydrolysis 
(Guo et al., 1995; Pihlanto-Leppälä et al., 2000), although sometimes the formation of 
irreversible disulfide interactions may lead to polymerisation and consequently a reduced 
susceptibility to hydrolysis (Angelo et al., 1982). No differences in change in degree of 
proteolysis were observed between the autoclaved and the native protein digests. An 
increased or decreased hydrolysis in the heat treated proteins may only be reflected at the 
level of soluble peptides and amino acids.   
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The HPLC chromatograms confirmed the difficult degradation of β-lactoglobulin in the 
whey digests. The higher initial peaks in the prolonged optimal pea digest present short 
hydrophilic peptides or amino acids. The higher similarity between the chromatograms of the 
different pea digests compared to the whey digests corresponds with the higher similarity 
observed in the IC50 values of the different pea digests. This can partially be explained by the 
higher susceptibility of pea protein for hydrolysis by gastrointestinal proteases. 
 
Experimental design in a semi-continuous reactor model 
A semi-continuous reactor model was developed with the aim to produce high ACE 
inhibitory activity from pea and whey protein by means of gastrointestinal proteases. As a 
result, the formed peptides resist the physiological digestion after oral administration (Matsui 
et al., 2002c). The process conditions of the semi-continuous reactor differed slightly from 
the batch experiments in the continuous and more rigorous pH and temperature control and 
a slight dilution effect due to the pH control with only 1 N HCl and 1 N NaOH. 
  Preliminary experiments excluded the protein concentration and the enzyme over 
substrate ratio as parameters in the experimental design. This is in agreement with a 
previous study on the hydrolysis of heat-denatured whey proteins by trypsin, α-chymotrypsin, 
alkalase and neutrase, where different protein concentrations have no significant influence 
on the reaction rate (Mutilangi et al., 1995). It is expected that a protein concentration of 4% 
or higher is sufficient to provide substrate saturation conditions. In the same work, increasing 
enzyme over substrate ratios augment the degree of proteolysis. This may explain the slight, 
but non-significant decrease in IC50 for increasing enzyme over substrate ratios. For fish 
protein hydrolysates, increase in enzyme concentration and/or hydrolysis time is shown to 
result in improved ACE inhibitory activity (Matsui et al., 1993). A similar evolution is obtained 
during the digestion of blood plasma albumin by alkalase, while during digestion of casein by 
trypsin the high ACE inhibitory activity obtained the first hour, decreases temporarily and 
then increases gradually with hydrolysis time and increasing enzyme concentration (Hyun 
and Shin, 2000). Since the optimal temperatures of the different gastrointestinal enzymes 
were slightly higher than the physiological temperature of 37°C (Angelo et al., 1982; Ryle, 
1984; Venkatesk and Sundaram, 1998), the effect of this parameter was investigated in the 
design. The batch physiological digestion sufficed to achieve maximal ACE inhibitory activity 
and therefore served as a central point in the experimental design. Consequently, the 
digestion was performed at physiological pH, which is close to the optimal pH for the 
gastrointestinal proteases (Ganapathy and Leibach, 1999). 
From batch experiment to semi-continuous model 
 143
For the whey protein, high experimental error prevented the design of a significant model 
for both responses. The higher variability of the whey protein in comparison to the pea 
protein is also observed in higher standard errors for the degree of proteolysis and the        
log IC50 in the comparison of the three batch digestions. This can partially be explained by 
the lower susceptibility to hydrolysis, resulting in higher variations when slightly different 
conditions are applied.  
By means of the central composite design for pea, a linear model for the degree of 
proteolysis was established, where the incubation time in the stomach phase was of non-
significant importance. Gauthier et al. (1986) found that the degree of proteolysis of a casein 
hydrolysate increases with longer incubation times in the presence of pancreatin, while a 
short or long pre-incubation with pepsin has the same effect. Higher temperature exerted a 
major effect, which can be attributed to the optimal temperatures of the enzymes, which are 
above 37°C (Angelo et al., 1982; Ryle, 1984; Venkatesk and Sundaram, 1998). For the ACE 
inhibitory activity, expressed as log IC50, a quadratic equation described the relationship 
between temperature, incubation time in stomach and incubation time in small intestine 
phase. Here, the temperature and its quadratic term exerted no significant influence, but it 
could not be omitted in the model because of the hierarchy and the significant interaction 
terms. As seen from the contour plots longer incubation times in the stomach yielded higher 
ACE inhibitory activity and this effect was more pronounced for a long incubation time in the 
small intestine. This is somewhat contradictory to the results obtained for the batch 
prolonged optimal and physiological digestion for pea, but there the lack of pH control may 
have resulted in lower ACE inhibitory activity for longer incubation times. The fact that two 
different models were obtained for the two responses indicates that no straight forward 
relationship exists between the (log) IC50 and the degree of proteolysis during digestion, 
which was also observed for the comparison of the three batch digestions and was already 
reported in literature (Mullally et al., 1997a).  
During the redaction of this paper, one very recent study appeared on the optimisation of 
ACE inhibition by response surface methodology (van der Ven et al., 2002). In this paper, a 
quadratic model for the IC50 of a pancreatic whey digest is obtained. Whereas we studied 
both the stomach and small intestine phase of the gastrointestinal digestion, this study 
focusses only on the small intestine phase as a production process for ACE inhibitory 
peptides. Moreover, the authors included pH, enzyme over substrate ratio and pre-treatment 
temperature of the protein as process parameters, in addition to temperature and hydrolysis 
time. They found maximal ACE inhibitory activity at rather low pre-treatment temperature of 
the protein and for hydrolysis at high enzyme over substrate ratio, long hydrolysis time 
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(optimally 5 h), pH 8-9 and a temperature of 45°C. Hence, their findings on hydrolysis time 
and temperature are in agreement with our results for the pea digest.  
 
In conclusion, gastrointestinal digestion is physiologically important after oral 
administration of ACE inhibitory peptides. The normal physiological process resulted in 
maximal ACE inhibitory activity release from pea and whey protein. When performed in a 
semi-continuous reactor model, it could be used as a production process for ACE inhibitory 
peptides from pea and whey protein. For pea, a response surface model indicated the 
process parameters necessary to release maximal ACE inhibitory activity. 
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ACE inhibitory in vitro gastrointestinal digests:  
time course study and protein degradation 
 
ABSTRACT 
 
In vitro gastrointestinal digestion simulating the in vivo conditions of protein digestion 
produced high ACE inhibitory activity from pea and whey protein. A 2.73 mg/ml pea digest 
showed maximal ACE inhibitory activity already in the early stomach phase and its IC50 value 
further decreased in the small intestine phase. For a 2.73 mg/ml whey digest, however, the 
level of 100% ACE inhibitory activity was only attained in the small intestine phase. 
Subsequent supplementation of a rat intestinal acetone powder, which simulated the 
digestion by brush border enzymes, resulted in an increase in IC50 value for both proteins, 
and more for whey than pea. Nevertheless, a substantial amount of peptides were still ACE 
inhibitory active after digestion by gastrointestinal and brush border enzymes and the final 
IC50 values were 0.093 mg/ml for pea and 0.128 mg/ml for whey. SDS-PAGE showed that 
the major part of the pea proteins was already broken down in the stomach phase. The major 
whey protein β-lactoglobulin was only degraded from the small intestine phase onwards. The 
presence of known ACE inhibitory peptides in the pea and whey protein sequences was 
studied using a dedicated computer program. This program makes use of a database of 
about 500 reported ACE inhibitory sequences and their IC50 values, and produces a 
theoretical score, weighted on the total number of amino acids, for the potential of ACE 
inhibitory peptides in a given source protein. For pea, vicilin (VCLC_PEA) and albumin PA2 
(PA2_PEA) obtained scores as high as 10 on ACE inhibitory activity, compared to 16 for     
β-casein (CASB_BOVIN) taken as a reference protein. β-lactoglobulin (LACB_BOVIN) 
exceeded all other proteins with a score of 26. In silico digestion of these proteins by pepsin, 
trypsin and α-chymotrypsin directly released two ACE inhibitory peptides from PA2, one from 
vicilin and one from β-lactoglobulin with an IC50 lower than 100 µM. Several less active ACE 
inhibitory peptides and precursor peptides, which may form ACE inhibitory peptides upon 
further digestion by brush border, enterocyte or plasma peptidases, were also released.   
 
Keywords: ACE inhibitory peptides, brush border, SDS-PAGE, pea protein, whey protein, 
ACE inhibitory peptide database 
Chapter 6 
 148
INTRODUCTION 
 
Foods containing angiotensin I converting enzyme (ACE, EC 3.4.15.1) inhibitory peptides 
have shown to be effective in both the prevention and treatment of hypertension (Sipola et 
al., 2002; Takano, 1998). As hypertension indirectly contributes to cardiovascular mortality in 
the developed world, food derived ACE inhibitors may provide an alternative or an additional 
cure to antihypertensive drugs (Fitzgerald and Meisel, 2000). Besides, ACE inhibitory 
peptides have not shown any side effects yet, which makes them attractive in the prevention 
of a high blood pressure as well.  
Many ACE inhibitory peptides have been characterised from both vegetable and animal 
proteins (Yamamoto, 1997). To exert an antihypertensive effect in vivo, these bioactive 
peptides have to reach the blood stream in an active form upon oral administration (Masuda 
et al., 1996). Gastrointestinal proteases may metabolise the ingested ACE inhibitory 
peptides, resulting in either the release of more active peptides or inactive fragments (Maeno 
et al., 1996). It is generally accepted that potent ACE inhibitory peptides exhibit partial 
resistance to complete degradation by human peptidases (Meisel, 1998). In addition, ACE 
inhibitory peptides have to cross the intestinal enterocytes to reach the blood stream. In this 
respect, di- and tripeptides are most easily absorbed (Webb, 1990).  
Although their precise structure-activity relationship is not fully understood, competent ACE 
inhibitory peptides contain hydrophobic (aromatic or branched side-chains) amino acid 
residues at the three C-terminal positions. However, a C-terminal lysine or arginine, with a 
positive charge on the ε-amino group, also seems to contribute substantially to the inhibitory 
potency (Fitzgerald and Meisel, 2000). The amino acid sequence of a given protein not only 
determines the potential of ACE inhibitory peptides inactively present, but also their specific 
release by enzyme cleavage. Therefore, it is possible to predict the biological activity of 
protein fragments using sequence alignments between proteins and known ACE inhibitory 
peptides collected in a database (Dziuba et al., 1999b). Such a database can be combined 
with information on recognition sequences of proteolytic enzymes, which are available on the 
World Wide Web (e.g. PeptideCutter at http://www.expasy.org), in order to estimate the 
specific release of bioactive peptides.  
Pea protein isolate contains the globulin proteins legumin, vicilin and convicilin and the 
albumin fraction that comprises proteins with a biological function in the pea seed. The major 
representatives of the latter fraction are PA1 and PA2 albumin (Guéguen, 2000). Whey 
protein isolate contains in order of importance β-lactoglobulin, α-lactalbumin, 
immunoglobulins, BSA and some minor proteins (Wong et al., 1996) (Chapter 1). 
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In previous studies, high ACE inhibitory activity has been produced by different in vitro 
gastrointestinal digestions of pea and whey protein (Vermeirssen et al., 2003a; Vermeirssen 
et al., 2003b). An in vitro digestion simulating the physiological conditions in vivo is adequate 
for the formation of maximal ACE inhibitory activity. Moreover, whey hydrolysates are more 
ACE inhibitory potent than pea hydrolysates (Vermeirssen et al., 2003b). In this paper, this 
physiological digestion was studied over time and followed by a rat intestinal acetone powder 
digestion to observe the evolution of the ACE inhibitory activity in the different stages of 
gastrointestinal digestion. Hence, the formation and stability of the ACE inhibitory peptides 
released from pea and whey protein up to the brush border barrier were investigated. 
Moreover, the degradation of the different proteins in pea and whey protein was followed by 
means of sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). These 
experimental data were combined with the information obtained from a database for ACE 
inhibitory peptides, a protein database and a protein cleavage program. In this way, the 
proteins in pea and whey protein containing potent ACE inhibitory peptides could be 
distinguished and the theoretical release of these bioactive peptides by gastrointestinal 
proteases was studied.  
 
 
MATERIALS AND METHODS 
 
Products 
The products used during in vitro gastrointestinal digestion, HPLC analysis and the ACE 
inhibition assay are described in Chapter 5. Rat intestinal acetone powder (I 1630) was 
purchased from Sigma-Aldrich (St.-Louis, MO, USA). Non-specified products were analytical 
grade from VWR International (Zaventem, Belgium). 
 
In vitro gastrointestinal digestion followed by brush border phase 
The experimental conditions of the in vitro physiological digestion are mentioned in 
Chapter 5. A 150 ml 4% (w/v) protein solution was used and the brush border phase was 
simulated by addition of rat intestinal acetone powder in an E/S of 1/10 (w/w) and incubation 
for 1 h at 37°C. This rat intestinal acetone powder contains all enzymes from rat intestinal 
tissue that do not phase separate into acetone. Samples were taken at the start and after   
0.5 h, 1 h, 2 h, 2.5 h, 3.5 h, 4.5 h, 5 h and 5.5 h incubation. 
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Degree of proteolysis and ACE inhibitory activity 
For the treatment of the samples and the analyses, reference is made to Chapter 4. The 
measurement of the ACE activity and ACE inhibitory activity in 4 mg/ml rat intestinal acetone 
powder solution was done as described in Chapter 2.  
Another way to indicate a degree of proteolysis is by analysing the number of free amino 
groups as a measure of the number of peptide bonds cleaved. The TNBS method, where 
trinitrobenzenesulfonic acid reacts with primary amines to form a chromophore, was applied 
in this case (Adler-Nissen, 1979; Panasiuk et al., 1998). 
 
 SDS-PAGE 
Samples were diluted five times in 10 mM Tris buffer, pH 8, containing 2.5% (w/v) SDS, 
5% (w/v) β-mercapto-ethanol and 1 mM EDTA and boiled for 5 min. The low molecular 
weight (LMW) electrophoresis calibration kit (Amersham Pharmacia Biotech, Uppsala, 
Sweden) was used as standard: phosporylase b (97 kDa), BSA (66 kDa), ovalbumin          
(45 kDa), carbonic anhydrase (30 kDa), trypsin inhibitor (20.1 kDa) and α-lactalbumin (14.4 
kDa). The standard was boiled for 1 min. Gel electrophoresis was performed with a 
Phastsystem (Pharmacia). Phastgel SDS buffer strips, containing 0.55% (w/v) SDS in 0.2 M 
tricine and  0.2 M Tris buffer at pH 8.1, were used. One microlitre diluted sample or standard 
was spotted on Phastgel Homogeneous 20 gels to analyse the protein/peptide fraction 
between approximately 1 and 100 kDa. Electrophoretic conditions programmed into the 
Phastsystem were 15°C, 250 V, 3 W and 10 mA for 1 Vh, subsequently 1 mA for 1 Vh and 
finally 10 mA for 95 Vh. For the detection of the protein bands in the gel, Coomassie blue 
staining was applied. The gels were scanned and analysed by means of Image Master 
TotalLab v1.00 (Pharmacia).  
 
HPLC 
The HPLC procedure for the samples taken at different times during the digestion of pea 
protein and of pea and whey protein subjected to only a stomach or small intestine phase 
digestion is equal to the one mentioned in Chapter 5. A control solution containing 16 mg of 
pepsin, trypsin and α-chymotrypsin and 400 mg rat intestinal acetone powder in 100 ml 
MilliQ, centrifuged for 15 min at 10 000 g was also eluted by the HPLC programs for pea and 
whey, respectively (Chapter 5). 
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In silico screening of the ACE inhibitory peptide potential  
 A theoretical analysis of ACE inhibitory peptides present in the sequences of pea and 
whey proteins was performed using a database and data-mining software developed by the 
Institute for Agronomical and Technological Research (ATO) (Wageningen, The 
Netherlands). The database contains 498 ACE inhibitory peptides published in literature. The 
data-mining software screens this database against a second database in SwissProt format, 
containing the sequences of source proteins of interest, in this case from pea and whey. For 
more than 95% of these peptides an IC50 value is also available. The inclusion of the latter 
enables the program to add up the total activity of the peptides identified in a certain protein 
sequence, after which the summed score is ‘weighted’ to compensate for the relative size of 
the examined protein (i.e. the total number of amino acids). ACE inhibitory peptide scores 
are attributed to the proteins in two ways. When scoring on high ACE inhibitory activity, the 
peptides in the database are ranked from high to low ACE inhibitory activity and in this order 
the program searches for homologous peptide sequences in the food protein. When scoring 
on peptide size, the database is first sorted on the number of amino acids within a specific 
peptide and then on ACE inhibitory activity. Subsequently, sequence alignments between the 
food protein and the database are discovered. When ACE inhibitory peptide sequences 
overlap, depending on the scoring method, the peptide with the highest activity or the 
shortest peptide with the highest activity is chosen. 
 Protein sequences from pea and whey protein were found on the World Wide Web in the 
protein databases SwissProt and TrEMBL at the ExPASy Molecular Biology Server 
(http://www.expasy.org/sprot) and in the National Center for Biotechnology (NCBI) protein 
database (http://www.ncbi.nlm.nih.gov). Complete sequences were preferred over fragments, 
because most sequence fragments are not representative for actual mature proteins. Signal 
peptides and propeptide sequences were removed from precursor protein sequences from 
the SwissProt and TrEMBL database. Several proteins were used as entry in the ACE 
inhibitory peptide database search (Table 1). Caseins were used as reference proteins as 
already many ACE inhibitory peptides are derived from these food proteins (Fitzgerald and 
Meisel, 2000). For the proteose peptone C5/8 fraction (Kinsella and Whitehead, 1989)  and 
casein glycomacropeptide (CMP) fragments of proteins were used in the screening. The 
protein monomers of the pea albumin PA1 fraction were separated by a propeptide in the 
precursor protein sequence ALB1_PEA in the SwissProt database.  
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Table 1. Proteins from pea and whey with their entry names in the protein databases. 
Protein Entry name Protein database 
PEA   
vicilin VCLC_PEA SwissProt 
legumin J LEGJ_PEA SwissProt 
legumin A2 LEG2_PEA SwissProt 
legumin A LEGA_PEA SwissProt 
legumin B O24294 TrEMBL 
legumin K S26688 NCBI 
albumin PA2 ALB2_PEA SwissProt 
vicilin 47 kDa Q43626 TrEMBL 
vicilin 14 kDa VCL1_PEA SwissProt 
convicilin Q9M3X6 TrEMBL 
convicilin A CVCA_PEA SwissProt 
albumin PA1B (leginsulin) ALB1_PEA [part2] SwissProt 
albumin PA1A ALB1_PEA [part1] SwissProt 
WHEY   
β-lactoglobulin LACB_BOVIN SwissProt 
β2-microglobulin B2MG_BOVIN SwissProt 
serotransferrin TRFE_BOVIN SwissProt 
lactotransferrin TRFL_BOVIN SwissProt 
bovine serum albumin (BSA) ALBU_BOVIN SwissProt 
proteose peptone C5/C8 CASB_BOVIN [f(1-107)] SwissProt 
lactoperoxidase PERL_BOVIN SwissProt 
α-lactalbumin LCA_BOVIN SwissProt 
lysozyme LYCN_BOVIN SwissProt 
IgG1/2 heavy chain precursor S22080 NCBI 
proteose peptone C3 LCTN_BOVIN SwissProt 
casein glycomacropeptide (CMP) CASK_BOVIN [f(106-169)] SwissProt 
CASEIN   
β-casein CASB_BOVIN SwissProt 
αs2-casein CAS2_BOVIN SwissProt 
αs1-casein CAS1_BOVIN SwissProt 
κ-casein CASK_BOVIN SwissProt 
Time course study and protein degradation 
 153
In silico gastrointestinal digestion  
Some protein sequences were cleaved by the combination of pepsin, trypsin and            
α-chymotrypsin with the software PeptideCutter at http://www.expasy.org. In parallel, the 
protein was cleaved by trypsin and α-chymotrypsin respectively, for which specific cleavage 
probabilities could be reproduced. In our figures a cleavage probability less than 60% for 
these enzymes is indicated by a dotted arrow.   
The hydrolysis preference of the proteases in the program was the following:  
• pepsin high specificity (pH 1.3): C-terminus of Phe and Leu 
• pepsin low specificity (pH ≥ 2): N- and C-terminus of Phe, Tyr, Trp and Leu 
• trypsin: C-terminus of Arg and Lys 
• α-chymotrypsin high specificity: C-terminus of Trp, Tyr and Phe 
• α-chymotrypsin low specificity: C-terminus of Trp, Tyr, Phe, Leu, Met and His 
The release of ACE inhibitory sequences from the proteins by these gastrointestinal 
enzymes was investigated.  
 
Statistical analysis 
 All values are reported as mean ± standard error (SE) of the mean (nmin = 3). The degree 
of proteolysis, ACE inhibitory activity and log IC50 of the pea and whey protein were 
compared by an independent Student t-test after the stomach, small intestine and brush 
border phase. For the log IC50, a General Linear Model Univariate Analysis of Variance 
procedure (SPSS 11.0.1, Chicago, Illinois, USA) was carried out with type of protein (pprot) 
and the phase of digestion (pphase) as factors. When there was a significant type of protein × 
phase of digestion interaction, for both proteins a Oneway ANOVA analysis was carried out 
by phase of digestion. All data used in the variance analysis met the homogeneity of 
variance requirement assessed by Levene's test. Indication of subgroups in phase of 
digestion was done by Tukey post hoc test (p < 0.05).  
 
 
 
 
 
 
 
 
 
Chapter 6 
 154
RESULTS 
 
Formation of ACE inhibitory activity over time 
The physiological digestion that simulated the in vivo conditions of protein digestion was 
studied over time. To investigate the influence of brush border peptidases on the ACE 
inhibitory activity, the digests were subsequently incubated in the presence of rat intestinal 
acetone powder. The evolution of the degree of proteolysis in comparison to the percent 
ACE inhibitory activity of a 2.73 mg/ml sample is plotted in Figure 1, together with the log IC50 
value after the different phases in digestion. The IC50 values can be found in Table 2. 
Figure 1.  Evolution in the degree of proteolysis (%) (●) and ACE inhibitory activity (%) (▲) 
during the physiological digestion of pea (white) and whey (black) protein followed 
by a rat intestinal acetone powder digestion, and the log IC50 (♦) after the 
stomach, small intestine and brush border phase (nmin = 3). An independent 
samples t-test indicated the significant difference between both proteins (*p < 
0.05, ***p < 0.001) at the start and after stomach, small intestine and brush border 
phase. Different letters separate significantly different (p < 0.05) digestion phases 
in log IC50. 
 
During digestion with pepsin, the degree of proteolysis climbed the first hour of digestion 
to 30% for both proteins and remained at that level the next hour. After the addition of trypsin 
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and α-chymotrypsin, the degree of proteolysis increased sharply the first half hour and 
thereafter only marginally to a value of 72% for pea and 52% for whey at the end of the small 
intestine phase (p < 0.001). The degree of proteolysis augmented more for pea than whey in 
both the stomach and small intestine phase. The peptidases from the rat intestinal extract 
caused only a small increase in degree of proteolysis for pea, while for whey a substantial 
augmentation was obtained the first half hour. Although in the mucosal phase no spectacular 
increases in degree of proteolysis were observed, the TNBS method indicated here major 
releases of free α-amino-groups for both proteins (data not shown). Final degrees of 
proteolysis were 73 ± 2% for the pea and 61 ± 3% for the whey digest (p = 0.017).  
The ACE inhibitory activity presented a different evolution during digestion. For the pea 
protein, maximal ACE inhibitory activity (100%) at a concentration of 2.73 mg/ml was 
reached early in the stomach phase and this level was maintained during the small intestine 
and brush border phase. For the whey protein on the other hand, the ACE inhibitory activity 
reached 79% after half an hour of pepsin digestion and 95% at the end of the stomach phase 
(p = 0.029). Maximal ACE inhibitory activity of the whey protein was only obtained in the 
small intestine phase and then maintained for the remainder of the digestion. The IC50 values 
gave more information of the evolution of the ACE inhibitory activity. The IC50 value of whey 
changed drastically over the different digestion phases (pphase < 0.001), while for pea slight 
variations occurred (pphase = 0.025) with a significant difference between the ACE inhibitory 
activity of the stomach and small intestine phase (pinteraction < 0.001). At the end of the 
stomach phase, a relatively high IC50 value of 0.496 mg/ml was found for whey compared to 
0.117 mg/ml for pea (p < 0.001). The IC50 decreased to 0.052 mg/ml for whey and           
0.071 mg/ml for pea (p = 0.063) during the small intestine phase. In the mucosal phase, the 
IC50 values increased again, more for whey than pea, to final values of 0.093 mg/ml for pea 
and 0.128 mg/ml for whey (p = 0.18).  
The angiotensin I converting enzyme is also present in the brush border, where it 
contributes to the digestion of oligopeptides (Yoshioka et al., 1987). To account for a 
possible under- or overestimation of the ACE inhibitory activity in the mucosal digests, the 
ACE activity and the ACE inhibitory activity of 4 mg/ml rat intestinal acetone powder, the 
concentration used in the digestion, were studied. The rat intestinal acetone powder showed 
an ACE activity of 7 ± 1 U/l, compared to the ACE enzyme in the assay which was 28 U/l, 
and an ACE inhibitory activity below the detection limit of the assay. Due to a possible 
presence of ACE in the inhibitory samples, an underestimation of the ACE inhibitory activity 
may have occurred in the ACE inhibition assay. As the digests were further manipulated by 
centrifugation and lyophilisation, the maximal underestimation of the ACE inhibitory activity in 
the brush border phase samples was 25%.  
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Table 2. IC50 (mg/ml) of the non-digested proteins and after the stomach, small intestine and 
brush border phase of the in vitro physiological digestion of pea and whey protein. 
Digestion phase Pea Whey 
None 16 18 
Stomach 0.117 0.496 
Small intestine 0.071      0.052      
Brush border 0.093           0.128     
 
Follow-up of the protein degradation over time 
The degradation of the pea and whey protein over time was studied by means of SDS-
PAGE (Figure 2) (LMW = Low Molecular Weight Standard and C = control containing 16 mg 
pepsin, trypsin, chymotrypsin and 400 mg rat intestinal acetone powder in 100 ml, the 
concentrations present in the digests). Pepsin alone and in combination with trypsin and 
chymotrypsin gave no visual bands (data not shown). 
The SDS-PAGE of the pea protein at the start presented the proteins released from the 
albumin and globulin fraction by β−mercapto-ethanol (Guéguen, 2000). At the start, about 14 
bands were visible with average molecular weights of approximately 96 and 72, 46, 38, 33, 
30, 28, 26, 22, 17, 15, 14 and approximately 11 and 8 kDa. Based on literature, these bands 
could be assigned to the major pea proteins (Figure 2). The band of 96 kDa is probably 
lipoxygenase, which has a reported molecular weight of 91 kDa (Crevieu et al., 1997). 
Convicilin appears as one major band at 70-72 kDa, the molecular weight of its monomer 
(Croy et al., 1980). The characteristic bands of vicilin are around 46, 33, 30, 20, 17 and 14 
kDa (Crevieu et al., 1997; Guéguen et al., 1984; Nielsen et al., 1988). The acidic and basic 
monomers of legumin correspond with bands around 40 and 20 kDa, respectively (Guéguen 
et al., 1984). The monomer of the albumin PA2 fraction has a reported molecular weight of 
26-28 kDa (Crevieu et al., 1997; Croy et al., 1984). The albumin PA1 fraction consists of 2 
monomers of 6 and 4 kDa respectively (Guéguen, 2000). After 2 h digestion in the stomach 
phase, 7 major bands and on some gels (between parentheses) 3 additional bands with 
average molecular weights of 72, (48), (38), 28, 20, 16, 15 and approximately 13, 11 
(overlapping) and (10) kDa were observed. Although already a substantial degradation of the 
proteins by pepsin took place, convicilin, PA2 and to a lesser extent vicilin and legumin 
resisted this hydrolysis. The proteins were almost completely broken down after the small 
intestine phase and the most intense bands were overlapping below 14 kDa, with sometimes 
bands at (30), (25) and (18) kDa. Addition of brush border peptidases did not change this 
band profile much: (25), (18) kDa and overlapping bands below 14 kDa. 
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Figure 2. SDS-PAGE of pea and whey during in vitro physiological digestion (nmin = 4).  
LMW      whey     0 h           2 h           4.5 h        5.5 h        C 
kDa 
kDa 
LMW      pea         0 h          2 h        4.5 h       5.5 h       C       
kDa 
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Before digestion of whey, bands with average molecular weights of (82) (secretory 
component associated with IgA), 64 (bovine serum albumin and heavy chain (Hc) of the 
immunoglobulins), 35, 29 (light chain (Lc) of the immunoglobulins), 18 (β-lactoglobulin), 14 
(α-lactalbumin) and approximately (12) (proteose peptone fraction) kDa were observed 
(Figure 2) (Kilara and Harwalkar, 1996). After the stomach digestion the bands of 35 and 18 
remained clearly present, while a fraction below 14 kDa appeared. Hence, β-lactoglobulin 
resisted pepsin digestion, while the other whey proteins were almost completely degraded. 
After the small intestine phase, bands with average molecular weights of 17, 15 and 
approximately 12 and 11 kDa were clearly visible in addition to smaller bands at 33 and 
approximately 8 kDa. Apparently, β-lactoglobulin was spliced by the action of trypsin and      
α-chymotrypsin into 3 smaller proteins. Finally, upon the addition of the rat intestinal acetone 
extract a similar profile was observed with 4 major bands at 18, 15 and approximately 12 and 
11 kDa and a smaller one at approximately 8 kDa.  
The HPLC profiles of the pea and whey digests after the stomach, small intestine and 
brush border phase were also studied. They were compared with the start profiles found in 
Chapter 5. A remarkable change in the peak profile from the stomach to the small intestine 
phase was observed. The intensity of the peaks that eluted first, increased, while the 
intensity of the peaks that eluted at the end of the gradient, decreased. This is due to the 
action of trypsin and α-chymotrypsin that degrade the proteins to smaller oligopeptides. The 
degradation of β-lactoglobulin mainly took place during the small intestine phase, which is in 
accordance with the SDS-PAGE profiles. After the stomach phase, 94% of β-lactoglobulin 
could be recovered, after the small intestine phase this was 51% and after the brush border 
digestion still 50% of β-lactoglobulin was present. The higher degradation of β-lactoglobulin 
during these digestion experiments compared to the ones in Chapter 5, may be explained by 
small differences in experimental conditions. When the lactokinin Ala-Leu-Pro-Met-His-Ile-
Arg was added to a physiological digest sample and eluted by HPLC, its retention time was 
14.1 min, which was about the same as in the standard curve (13.8-14.1) (Chapter 3). In 
many, although not in all, physiological digests, a small peak at this retention time could be 
observed. Therefore, the lactokinin may be released during the physiological digestion, 
although in small quantities.  
 
In silico screening of the ACE inhibitory peptide potential and release 
 Complete amino acid sequences of proteins were screened for ACE inhibitory peptides by 
means of the ACE inhibitory peptide database and data-mining software developed by ATO 
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(Wageningen, The Netherlands). The proteins were scored by the total ACE inhibitory activity 
and by the presence of short ACE inhibitory peptide sequences (Table 3).  
For the pea proteins, vicilin (VCLC_PEA) scored the best on shortest ACE inhibitory 
peptide sequences and its score for total ACE inhibitory activity was slightly higher. Hence, 
vicilin contained several potent ACE inhibitory peptides. The albumin PA2 (ALB2_PEA), 
however, had the highest score for total ACE inhibitory activity, while its score on ACE 
inhibitory peptide size was much lower. This signifies that this protein consisted of longer 
ACE inhibitory peptides that contained smaller peptides with lower ACE inhibitory activity. 
For albumin PA1 (ALB1_PEA), the pea protein that scored the worst, equal scores for ACE 
inhibitory activity and peptide size were obtained. This means that there were no peptides 
present for which there is a longer overlapping equivalent available or that there was a longer 
equivalent in the protein sequence present, but that it is less active than one of its shorter 
constituents. The highest number of ACE inhibitory peptide sequences was present in 
convicilin (Q9M3X6), the longest pea protein sequence. The different genetic variants of 
respectively legumin and convicilin displayed similar scores. 
The different whey proteins exhibited larger differences in scores compared to pea.         
β-lactoglobulin (LACB_BOVIN) had the highest scores on total ACE inhibitory activity and 
shortest ACE inhibitory peptide sequence, not only of the whey proteins, but of all the 
proteins screened by the database. The iron-binding transferrins (TRFE_BOVIN, 
TRFL_BOVIN) scored high on total ACE inhibitory activity, but their scores on shortest 
peptide sequence were considerably lower. Apparently these proteins contained potent ACE 
inhibitory peptide sequences that included smaller peptides with lower activity. The other 
whey proteins screened had scores that were comparable with pea. The amino acid 
sequences of α-lactalbumin (LCA_BOVIN) and lysozyme (LYCN_BOVIN) are alike (Wong et 
al., 1996) and therefore both proteins succeeded each other in the ACE inhibitory peptide 
scoring.  
The caseins were also analysed by the ACE inhibitory peptide database, as casein-
derived ACE inhibitory peptides have been well characterised (Fitzgerald and Meisel, 2000; 
Pihlanto-Leppälä, 2001). β-casein (CASB_BOVIN) scored best among the caseins and had a 
relatively high score on total ACE inhibitory activity, while its score on peptide size was 
substantially lower. The same phenomenon was observed for αs1-casein. Both proteins had 
relatively large, high ACE inhibitory peptides that were composed of smaller, less active 
peptides. 
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Table 3. Scoring of different proteins in pea, whey and casein by the ACE inhibitory peptide 
database. 
Protein Number 
of AA 
Score on highest 
ACE inhibitory 
activity 
Score on shortest 
peptide sequence 
and then on highest 
activity 
  
Max. 
number of 
ACE 
inhibitory 
peptides Score Score/AA Score Score/AA 
PEA       
vicilin 431 59 4.270 9.906 4.264 9.892 
legumin J 481 72 3.394 7.056 3.009 6.255 
legumin A2 498 76 2.781 5.584 2.771 5.564 
legumin A 496 78 2.759 5.563 2.749 5.543 
legumin B 544 78 3.502 6.438 2.879 5.292 
legumin K 500 77 2.710 5.421 2.321 4.641 
albumin PA2 231 43 2.401 10.395 1.014 4.391 
vicilin 47 kDa 438 56 2.444 5.580 1.816 4.146 
vicilin 14 kDa 124 14 0.403 3.248 0.403 3.248 
convicilin 584 86 2.021 3.460 1.684 2.883 
convicilin A 543 70 1.339 2.465 1.291 2.377 
albumin PA1B 52 5 0.094 1.801 0.094 1.801 
albumin PA1A 37 6 0.013 0.354 0.013 0.354 
WHEY       
β-lactoglobulin 162 25 4.238 26.160 4.241 26.181 
β2-microglobulin 98 12 1.329 13.557 1.329 13.557 
serotransferrin 685 105 10.825 15.803 6.995 10.211 
lactotransferrin 689 121 17.950 26.052 5.463 7.929 
BSA 583 60 4.489 7.699 4.176 7.163 
proteose peptone 
C5/C8 
107 14 1.184 11.064 0.749 6.998 
lactoperoxidase 612 94 5.472 8.941 4.056 6.627 
α-lactalbumin 123 14 0.814 6.614 0.814 6.614 
lysozyme 130 20 0.546 4.203 0.492 3.781 
IgG1/2 Hc precursor 470 63 3.107 6.611 1.620 3.446 
proteose peptone C3 135 13 0.342 2.534 0.247 1.830 
CMP 64 4 0.209 3.260 0.016 0.255 
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Table 3. Scoring of different proteins in pea, whey and casein by the ACE inhibitory peptide 
database (continued). 
Protein Number 
of AA 
Score on highest 
ACE inhibitory 
activity 
Score on shortest 
peptide sequence 
and then on highest 
activity 
  
Max. 
number of 
ACE 
inhibitory 
peptides Score Score/AA Score Score/AA 
CASEIN       
β-casein 209 32 3.402 16.277 0.947 4.532 
αs2-casein 207 28 0.709 3.425 0.708 3.422 
αs1-casein 199 37 2.159 10.851 0.562 2.822 
κ-casein 169 19 0.636 3.763 0.147 0.869 
 
The protein sequences with the highest scores for pea and whey were cleaved in silico by 
the gastrointestinal proteases pepsin, trypsin and α-chymotrypsin by means of the software 
program PeptideCutter (http://www.expasy.org/). Figure 3, 4 and 5 show the ACE inhibitory 
peptide sequences and the cleavage sites of the gastrointestinal enzymes in the amino acid 
sequences of albumin PA2, vicilin and β-lactoglobulin respectively.  
For pea albumin PA2, 67 ACE inhibitory peptide sequences were found; as some of these 
were overlapping only 43 were detected in the scoring (Table 3, Figure 3). Most of these 
were dipeptides and had very potent ACE inhibitory activities: 77% of the peptides scored on 
highest ACE inhibitory activity demonstrated an IC50 value lower than 1000 µM and 40% had 
an IC50 value lower than 100 µM. The difference between the two scoring methods was due 
to the substitution of the tripeptide Leu-Gly-Pro (IC50 = 0.72 µM) by the more than 600 times 
less active dipeptide Gly-Pro (IC50 = 450 µM) when scoring on peptide size. Because of the 
large difference in ACE inhibitory activity, the substitution of only one peptide resulted in a 
substantial difference in score. By in silico hydrolysis, 69 peptide bonds could be cleaved by 
pepsin, 26 by trypsin and 50 by α-chymotrypsin, but some of the pepsin cleavage sites 
overlapped with the ones of α-chymotrypsin and trypsin. In total, 38% of the peptide bonds 
were cleaved by the gastrointestinal enzymes (at least 60% probability for trypsin and          
α-chymotrypsin). The less probable cleavage sites were interpreted as being cleaved in less 
than 60% of the protein molecules and left intact in the others. Four known ACE inhibitory 
dipeptides could be directly released by in silico digestion of albumin PA2: Leu-Tyr  (IC50 = 
18 µM), Gly-Ser (IC50 = 3800 µM), Gly-Lys (IC50 = 2500 µM) and Tyr-Trp (IC50 = 10 µM). 
Moreover, 19 precursors of ACE inhibitory peptide sequences were formed. By this way, at 
most 22 other ACE inhibitory peptides could be freed, the most active ones being Asp-Gly 
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(IC50 = 12 µM) (2 moles per mole of protein), Leu-Gly-Pro (IC50 = 0.72 µM), Met-Phe (IC50 = 
45 µM) and Val-Tyr (IC50 = 10 µM). 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Amino acid sequence of albumin PA2 with the ACE inhibitory peptide sequences 
(bold, when overlapping: sequences underlined) and the cleavage sites of pepsin, 
trypsin and/or α-chymotrypsin (less than 60% probability cleavage sites for trypsin 
and α-chymotrypsin are indicated with dotted arrows). The ACE inhibitory peptides 
that are directly released are in yellow. 
 
For pea vicilin, 88 ACE inhibitory peptide sequences were indicated compared to 59 in the 
scoring (Figure 4). All of the detected ACE inhibitory sequences were di- or tripeptides. Five 
tripeptides were composed of or overlapped with ACE inhibitory dipeptides, but only in the 
case of Phe-Gly-Lys (IC50 = 160 µM), the substituted dipeptide Phe-Gly (IC50 = 3700 µM) 
showed a lower ACE inhibitory activity. This explains the similar scores on highest ACE 
inhibitory activity and shortest peptide sequence. When scoring on highest ACE inhibitory 
activity, 64% of the ACE inhibitory peptide sequences had an IC50 lower than 1000 µM and 
27% even possessed an IC50 lower than 100 µM. The most potent ACE inhibitory peptide 
sequence in vicilin was Leu-Lys-Pro with an IC50 of 0.32 µM. Pepsin could cleave vicilin at 
112, trypsin at 52 and α-chymotrypsin at 74 positions. Vicilin had a theoretical digestibility of 
37% (only cleavage sites with at least 60% probability for trypsin and α-chymotrypsin). 
Digestion of vicilin by gastrointestinal proteases predicted the release of 5 ACE inhibitory 
1   MTKTGYINA AFRSSQNNEAY LFINDKYVLL DYAPGTSNDK VLYGPTPVRD    
 
51    GFKSLNQTVF GSYGVDCSFD TDNDEAFIFY EKFCALIDYA PHSNKDKIIL        
 
101  GPKKIADMFP FFEGTVFENG IDAAYRSTRG KEVYLFKGDQ YARIDYETNS  
 
151  MVNKEIKSIR NGFPCFRNTI FESGTDAAFA SHKTNEVYFF KGDYYARVTV  
 
201   TPGATDDQIM  DGVRKTLDYW  PSLRGIIPLE N 
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dipeptides: Ile-Arg (IC50 = 696 µM), Gln-Lys (IC50 = 885 µM), Ser-Gly (IC50 = 8500 µM), Gly-
Lys (IC50 = 2500 µM) and Ala-Phe (IC50 = 15.2 µM). Further degradation by brush border, 
intracellular and serum peptidases could free maximally 33 ACE inhibitory peptides from 25 
precursor peptides. The most active peptides present in precursors were Ile-Tyr (IC50 = 2.1 
µM) and Val-Lys (IC50 = 13 µM) (3 moles per mole of protein). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Amino acid sequence of vicilin with the ACE inhibitory peptide sequences (bold, 
when overlapping: sequences underlined) and the cleavage sites of pepsin, trypsin 
and/or α-chymotrypsin (less than 60% probability cleavage sites for trypsin and    
α-chymotrypsin are indicated with dotted arrows). The ACE inhibitory peptides that 
are directly released are in yellow. 
1  RSDPQNPFIF KSNKFQTLFE NENGHIRLLQ KFDQRSKIFE NLQNYRLLEY       
 
51 KSKPHTIFLP QHTDADYILV VLSGKAILTV LKPDDRNSFN LERGDTIKLP        
 
101 AGTIAYLVNR DDNEELRVLD LAIPVNRPGQ LQSFLLSGNQ NQQNYLSGFS   
 
151  KNILEASFNT DYEEIEKVLL EEHEKETQHR RSLKDKRQQS QEENVIVKLS     
 
201  RGQIEELSKN AKSTSKKSVS SESEPFNLRS RGPIYSNEFG KFFEITPEKN     
 
251  PQLQDLDIFV NSVEIKEGSL LLPHYNSRAI VIVTVNEGKG DFELVGQRNE      
 
301  NQQEQRKEDD EEEEQGEEEI NKQVQNYKAK LSSGDVFVIP AGHPVAVKAS  
 
351  SNLDLLGFGI NAENNQRNFL AGDEDNVISQ IQRPVKELAF PGSAQEVDRI    
 
401  LENQKQSHFA DAQPQQRERG SRETRDRLSS V 
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Although the scoring was done with 25 non-overlapping ACE inhibitory peptide 
sequences, in total 50 different ACE inhibitory peptide sequences were present in the amino 
acid sequence of β-lactoglobulin (Figure 5). Some longer ACE inhibitory peptide sequences 
were present and four of them had a slightly higher ACE inhibitory activity than their partial 
peptides: Gly-Leu-Asp-Ile-Gln-Lys (IC50 = 580 µM), Val-Ala-Gly-Thr-Trp-Tyr (IC50 = 1682), 
Leu-Leu-Phe (IC50 = 80 µM) and Ala-Leu-Pro-Met-His-Ile-Arg (IC50 = 43 µM). This resulted in 
a slightly lower score on shortest peptide sequence compared to the one on highest ACE 
inhibitory activity. The very high score of β-lactoglobulin can be explained by the high number 
of ACE inhibitory peptides per amino acid and by the fact that 80% of the ACE inhibitory 
peptide sequences had an IC50 value lower than 1000 µM, while 36% of them exhibited an 
IC50 lower than 100 µM. The two most potent ACE inhibitory peptides present in the amino 
acid sequence of β-lactoglobulin were Lys-Trp (IC50 = 1.63 µM) and Leu-Lys-Pro (IC50 =    
0.32 µM). In this whey protein, 37 cleavage sites for α-chymotrypsin, 48 for pepsin and 17 for 
trypsin were observed. In total, 39% of the peptide bonds were cleaved by the 
gastrointestinal enzymes (at least 60% probability for trypsin and α-chymotrypsin). Six ACE 
inhibitory peptides were directly produced by the combined action of pepsin, trypsin and      
α-chymotrypsin: Gln-Lys (IC50 = 885 µM), Ala-Leu-Pro-Met-His-Ile-Arg (IC50 = 43 µM), Ala-
Leu-Pro-Met-His (IC50 = 521 µM), His-Ile-Arg (IC50 = 953 µM), Ile-Arg (IC50 = 696 µM) and 
Ser-Phe (IC50 = 130 µM). In addition, 8 precursor peptide sequences were released that 
contained 13 ACE inhibitory peptides, the most potent being Ile-Ala-Glu (IC50 = 35 µM).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Amino acid sequence of β-lactoglobulin with the ACE inhibitory peptide sequences 
(bold, when overlapping: sequences underlined) and the cleavage sites of pepsin, 
trypsin and/or α-chymotrypsin (less than 60% probability cleavage sites for trypsin 
and α-chymotrypsin are indicated with dotted arrows). The ACE inhibitory peptides 
that are directly released are in yellow.  
1  LIVTQTMKGL DIQKVAGTWY SLAMAASDIS LLDAQSAPLR VYVEELKPTP  
 
51  EGDLEILLQK WENGECAQKK IIAEKTKIPA VFKIDALNEN KVLVLDTDYK  
 
101  KYLLFCMENS AEPEQSLACQ CLVRTPEVDD EALEKFDKAL KALPMHIRLS  
 
151  FNPTQLEEQC HI 
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DISCUSSION 
 
Gastrointestinal digestion constitutes a major barrier to the bioavailability of ACE inhibitory 
peptides (Pihlanto-Leppälä, 2001). In a previous study, high ACE inhibitory activity is 
obtained upon in vitro gastrointestinal digestion of pea and whey protein (Vermeirssen et al., 
2003b). In order to further elucidate the relative importance of the different enzymes and 
proteins in the release of ACE inhibitory peptides, the evolution of the ACE inhibitory activity 
during the in vitro physiological digestion of pea and whey protein was investigated. In 
addition, the stability of the ACE inhibitory digests to brush border peptidases was examined. 
Although in some studies the stability of isolated ACE inhibitory peptides towards 
gastrointestinal proteases is considered (Choi et al., 2001; Kim et al., 1999), the possible 
degradation by brush border peptidases is largely neglected. Protein degradation in the 
different phases of digestion was followed by SDS-PAGE and HPLC. This information was 
supplemented with theoretical data obtained by screening different protein sequences from 
pea and whey using an ACE inhibitory peptide database and data-mining software. Besides, 
these proteins were cleaved in silico by pepsin, trypsin and α-chymotrypsin. Hence, the 
theoretical release of ACE inhibitory peptides during gastrointestinal digestion could be 
indicated. The application of high throughput techniques in biology has increased the amount 
of information tremendously and the usefulness of databases has been demonstrated in this 
field (Vidal, 2001). Furthermore, this may change the way biological questions are formulated 
and addressed. In parallel, a database of ACE inhibitory peptide sequences may have 
important value in nutrition science. Instead of trying to isolate ACE inhibitory peptides blindly 
from food proteins by applying certain enzymes, a food protein known to contain several 
potent ACE inhibitory peptide sequences may be chosen to be digested by an enzyme that 
specifically releases these bioactive fragments. 
 
Formation of ACE inhibitory activity over time 
When the physiological digestion was studied over time and followed by a rat intestinal 
acetone extract digestion, the degree of proteolysis evolved differently than the ACE 
inhibitory activity. In the early stages of stomach, small intestine and mucosal phase 
digestion, the degree of proteolysis augmented first to level off in the later stage of the 
digestion phase. As the formed peptides and amino acids resided in the same medium as 
the protein and proteases, product inhibition may have occurred. Digestion in a dialysis bag 
or ultrafiltration membrane reactor may overcome this problem (Bordenave et al., 2000; 
Gauthier et al., 1986). The higher susceptibility to hydrolysis of pea protein, when compared 
to whey, was observed in the stomach and small intestine phase, but in the mucosal phase 
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the degree of proteolysis of the pea protein increased only slightly, while for the whey protein 
this increase was substantial. However, the increase in degree of proteolysis indicates only 
the release of 6% (w/v) TCA soluble peptides and amino acids from non-soluble proteins. As 
the brush border peptidases in the rat intestinal acetone extract tend to splice more 
oligopeptides rather than large proteins (Ganapathy and Leibach, 1999), the hydrolysis will 
not be reflected in the degree of proteolysis, but it will in the TNBS free α-amino-groups and 
this was the case in our experiments.  
The ACE inhibitory activity of the pea protein reached 100% already after the first half 
hour of digestion, while for the whey protein this happened only in the small intestine phase. 
For the remainder of the digestion, 100% ACE inhibitory activity was maintained. Pihlanto-
Leppälä et al. (2000) reported that pepsin hydrolysis for 3 h at pH 2 and 37°C in an E/S of 
1/200 (w/w) is insufficient to release ACE inhibitory peptides from α-lactalbumin and            
β-lactoglobulin and that trypsin is necessary for the formation of high ACE inhibitory activity 
from whey proteins. Mullally et al. (1997a), on the other hand, found a similar and rather high 
percent ACE inhibitory activity after digestion of whey proteins with pepsin at pH 3 or trypsin 
at pH 8 or the combination for a total of 4 h at 50°C in an E/S of 3/1000 (w/w). When 
characterising goat whey peptic hydrolysate, Bordenave et al. (2000) concluded that a 
residence time of 1 h in an ultrafiltration reactor at pH 2 and 40°C is enough to ensure total 
degradation of α-lactalbumin by pepsin in an E/S of 1/50 (w/w). From the evolution of the 
ACE inhibitory activity of the whey protein in the stomach phase it is very likely that a longer 
incubation time with pepsin could lead to 100% ACE inhibitory activity. However, to obtain a 
low IC50, additional hydrolysis by trypsin and α-chymotrypsin would be essential, as is 
indicated by the large drop in IC50 from the end of the stomach to the small intestine phase. 
Remarkably, the decrease in IC50 during this digestion phase was more pronounced for 
whey, while at the same time this protein displayed a smaller increase in the degree of 
proteolysis. The latter supports the observation of Mullally et al. (1997a) that there is no 
direct relationship between the degree of proteolysis and the ACE inhibitory activity. At the 
end of the small intestine phase, the IC50 of the pea digest was also significantly lower than 
at the end of the stomach phase, but the change was not as extreme as for the whey protein. 
As the pea and whey physiological digest were hydrolysed by brush border peptidases, the 
IC50 value increased again, signifying that degradation of ACE inhibitory peptides started to 
dominate or that conversion into less active ACE inhibitory peptides occurred, diluting the 
total activity. Moreover, the ACE present in the rat intestinal extract could have resulted in an 
underestimation of the ACE inhibitory activity. Considering a 25% overestimation of the IC50 
value, this may explain the higher IC50 after the brush border phase compared to the small 
intestine phase for the pea protein. However, for the whey protein, the more substantial 
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increase of the IC50 after the brush border phase cannot be explained solely by the presence 
of ACE in the sample. Nevertheless, high ACE inhibitory activity was still present at the end 
of the digestion, both for pea and whey protein, increasing the potential for these 
hydrolysates to reduce the blood pressure in vivo.  
 
Follow-up of the protein degradation over time 
SDS-PAGE visualised the proteins with a molecular weight of 14 to 94 kDa present in the 
proteins. Because β-mercapto-ethanol disrupts disulphide bounds, not only the albumin 
fraction, but also the globulin fraction of the pea protein was visible on the gel. The high 
sensitivity of the pea protein for hydrolysis was noticeable as well: after the stomach phase, 
bands with molecular weight higher than 20 kDa faded away, and after the small intestine 
and mucosal phase only a light spot around 10 kDa remained, indicating that most proteins 
were degraded to small peptides. Convicilin, PA2 and to a lesser extent vicilin and legumin β 
seemed to resist the stomach digestion, but all these proteins were completely broken down 
during the subsequent phases of in vitro digestion. Convicilin, vicilin and legumin α are 
reported to be sensitive to hydrolysis, while legumin β due to its highly ordered structure and 
high hydrophobicity resists enzyme hydrolysis (Crevieu et al., 1997; Nielsen et al., 1988). 
Albumins are on average less digestible than globulins, with PA2 having a relatively high 
cysteine content and consequently a lot of disulphide bonds (Crevieu et al., 1997).  
For the whey protein, α-lactalbumin was degraded during the stomach digestion, while the 
band of β-lactoglobulin remained present untill the end of digestion. β-lactoglobulin resists 
pepsin and largely trypsin hydrolysis (Guo et al., 1995), while it is hydrolysed by                  
α-chymotrypsin to a limited extent (Schmidt and Poll, 1991). Bovine serum albumin and the 
immunoglobulin fraction were also broken down during the stomach phase. Although some 
bovine immunoglobulins appear in the ileum of human adults after oral ingestion of an 
immunoglobulin concentrate (Roos et al., 1995), they seemed to be completely degraded in 
the in vitro physiological digestion of whey protein isolate. In a study where the hydrolysis of 
whey protein concentrate is followed by gel filtration, trypsin and to a lesser extent               
α-chymotrypsin degrade the four major whey proteins, immunoglobulins, BSA,                  
β-lactoglobulin and α-lactalbumin in relatively large molecular weight fractions (Angelo et al., 
1982). This is confirmed by the appearance of the three bands, which are assumed to be 
fragments of β-lactoglobulin, after the small intestine phase. 
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In silico screening of the ACE inhibitory peptide potential and release 
Protein sequences from pea and whey protein were obtained from the protein databases 
SwissProt, TrEMBL and NCBI. For pea, each type of protein is present in the database and 
for some even different genetic variants are reported. For whey, the complete amino acid 
sequences of the major proteins and some minor enzymes are also found. These protein 
sequences were screened by the ATO ACE inhibitory peptide database, containing 498 ACE 
inhibitory peptide sequences with their IC50 value from literature, by means of the data-mining 
software. A database of biologically active peptide sequences has already been reported by 
Dziuba et al. (1999b), although it consisted of only 201 ACE inhibitory peptides. This is 
however the first study to attribute ACE inhibitory peptide potential scores to proteins and to 
investigate the in silico release of these ACE inhibitory peptide sequences.  
The different proteins were scored on ACE inhibitory activity in two ways. This provided 
information on the theoretical content of ACE inhibitory peptide sequences and whether they 
included some smaller active fragments. The latter is important as di- and tripeptides are 
more easily absorbed intact (Webb, 1990). In order to facilitate the interpretation of these 
scores, the caseins were also screened by the database, as a lot of potent ACE inhibitory 
peptides have already been released from these proteins (Fitzgerald and Meisel, 2000). This 
scoring was confirmed for the proteins albumin PA2, vicilin and β-lactoglobulin, respectively 
the pea and whey proteins with the highest scores. The scores of all pea globulins were in 
the narrow range of 2 to 10. This may be explained by the fact that the amino acid sequence 
of all pea globulins shows some similarity. Vicilins and legumins have evolved from the 
duplication of the same ancestral gene, but in legumins a novel N-terminal domain has been 
recruited somewhere in evolution (Gibbs et al., 1989). Convicilin on the other hand, differs 
only from vicilin by the insertion of a 121 amino acid sequence near the N-terminus of the 
protein (Bown et al., 1988). β-lactoglobulin, the major whey protein, and lactotransferrin had 
the highest scores on ACE inhibitory activity. The latter is known to exert different biological 
activities like antibacterial, immunomodulatory, anti-tumour and antioxidant activity and to 
contain a number of bioactive peptide sequences with antimicrobial activity (Baker et al., 
2002). β-casein and αs1-casein scored higher on ACE inhibitory activity than the pea proteins 
and α-lactalbumin and BSA, but much lower than β-lactoglobulin. Caseins are known to 
contain a lot of proline, which may provide resistance to complete degradation by human 
proteases. Though, the proline content cannot be related to high ACE inhibitory potential of a 
protein: although bovine serum albumin contains as much proline as β-casein, it had a lower 
ACE inhibitory activity score. However, it must be taken into account that the scoring was 
performed by means of IC50 from literature, that were probably in some cases obtained by 
different ACE inhibition assays, which may result in slightly different values. Moreover, the 
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database can only search for the ACE inhibitory peptide sequences it contains. As this 
database was very recently updated and contained a substantial amount of ACE inhibitory 
peptides, its predictive value is significant. Hence, this database is a powerful tool to screen 
the ACE inhibitory potential of proteins, provided their amino acid sequence is available.  
 Subsequently, the proteins were hydrolysed in silico by pepsin, trypsin and                  
α-chymotrypsin. This procedure possessed some limitations as well. During gastrointestinal 
digestion, proteins are first cleaved by pepsin in the stomach and then by trypsin and            
α-chymotrypsin in the small intestine. During the in silico digestion, these three proteases 
cleaved at the same time, which means that neighbouring amino acids that were eliminated 
by the action of pepsin, may have exerted some favourable or unfavourable effects on the 
cleavage by trypsin and α-chymotrypsin in silico. Furthermore, the program takes a specified 
cleavage preference into account. This may not include all the exceptions that occur upon 
the presence of a certain amino acid in a certain position relative to the spliced peptide bond. 
Finally and most importantly, the protein conformation is totally neglected during in silico 
digestion. This may result in a higher number of cleavages predicted compared to the in vitro 
or in vivo situation. In silico, the digestibility of albumin PA2, vicilin and β-lactoglobulin was 
very similar. During in vitro digestion, however, the pea proteins are more easily degraded by 
pepsin than β-lactoglobulin. This is due to the compact native structure of β-lactoglobulin 
(Kinsella and Whitehead, 1989). Hydrophobic amino acid residues forming bonds susceptible 
to proteolysis by pepsin, are buried inside the molecule and are inaccessible for the enzyme. 
Overall, the in silico digestion is more pronounced than in reality, because it indicates where 
the protein can be hydrolysed. The in vitro and in vivo digestion conditions determine 
whether the hydrolysis at a certain position in the protein sequence will occur or not. For 
example, β-lactorphin, Tyr-Leu-Leu-Phe, is released from β-lactoglobulin upon in vitro 
digestion by pepsin, trypsin and α-chymotrypsin (Antila et al., 1991). During the in silico 
digestion of β-lactoglobulin, however, this peptide was degraded. The lactokinin Ala-Leu-Pro-
Met-His-Ile-Arg was theoretically released from β-lactoglobulin. Some minor degradation by 
α-chymotrypsin took place, which is confirmed by experimental data (Mullally et al., 1997b) 
and by our study on the in vitro gastrointestinal digestion of this peptide (Chapter 3). 
However, the major degradation product formed, His-Ile-Arg, is also ACE inhibitory active 
(Mullally et al., 1997b). The RP-HPLC chromatograms of the physiological whey digest did 
not exclude the release of the heptapeptide or its α-chymotrypsin degradation products. In 
the study of Pihlanto-Leppälä et al. (1997), only digestion of β-lactoglobulin by trypsin 
releases the heptapeptide, while digestion by a combination of pepsin, trypsin and               
α-chymotrypsin releases His-Ile-Arg. The period of digestion here is 24 h, which is very long. 
The same authors detect the ACE inhibitory active fragment Ala-Leu-Pro-Met-His and the 
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fragment Leu-Pro-Met-His-Ile-Arg in the digest of β-lactoglobulin obtained by 3 h pepsin, then 
7 h trypsin and α-chymotrypsin hydrolysis (Pihlanto-Leppälä et al., 2000). Other ACE 
inhibitory peptides released in this study are Cys-Met-Glu-Asn-Ser-Ala and Val-Leu-Asp-Thr-
Asp-Tyr-Lys. Moreover, the fragment Val-Ala-Gly-Thr-Trp is found. RP-HPLC combined with 
mass spectrometry of the pea and whey digests could confirm the formation of the 
theoretically released ACE inhibitory peptide sequences during the in vitro physiological 
digestion in our study.  
 When combining the theoretical data with our experimental results, the evolution in IC50 
during the physiological digestion can be related to the ACE inhibitory potential of the 
degraded proteins. For pea, most proteins were already broken down to molecular masses 
lower than 10 kDa after the stomach phase and were further degraded during the small 
intestine phase. All these proteins had similar scores in the in silico screening. This 
corresponds to the high ACE inhibitory activity already observed after the stomach phase 
and which further increased in the small intestine phase. The protein with the highest score 
on ACE inhibitory activity and the major whey protein, β-lactoglobulin, was only degraded 
from the small intestine phase on, theoretically releasing ACE inhibitory peptides like Ala-
Leu-Pro-Met-His-Ile-Arg. This is consistent with the fact that the IC50 value of whey protein 
decreased substantially during hydrolysis with trypsin and α-chymotrypsin. Hence, for whey, 
it could be useful to concentrate on the release of ACE inhibitory peptides from                     
β-lactoglobulin.  
  
In conclusion, this paper demonstrates the evolution of the ACE inhibitory activity during 
physiological digestion followed by a brush border phase. It further indicates how the IC50 
and the protein degradation can be related to each other by means of an ACE inhibitory 
peptide database. 
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Fractionation, in vitro intestinal transport and  
antihypertensive activity of pea and whey digests 
 
ABSTRACT 
 
The ACE inhibitory activity of pea and whey hydrolysate, obtained by in vitro 
gastrointestinal digestion, was further increased upon purification by ultrafiltration-
centrifugation and RP-HPLC. The most active RP-HPLC fractions of the permeates had IC50 
values as low as 0.016 mg P (protein)/ml for pea and 0.003 mg P/ml for whey, which signifies 
that the ACE inhibitory activity of the pea digest was more than 4 times enriched, while that 
of the whey digest was more than 13 times augmented. The intestinal transport of active 
compounds in the digests and permeates was investigated in Caco-2 cell monolayers. 
Although the samples retained relatively high ACE inhibitory activity after 2 h incubation in 
the presence of Caco-2 homogenates, no or only little ACE inhibitory activity was detected in 
the basolateral compartments of the Caco-2 cell monolayers after 1 h transport experiment, 
even after concentration of the samples. Some ACE inhibitory activity was observed in the 
transport experiments at high concentrations (45 mg P/ml digest, 50 mg P/ml permeate), but 
these were associated with compromised cell monolayer integrity as indicated by decreased 
TEER and increased sodium fluorescein fluxes. Taking into account that the Caco-2 model is 
tighter than intestinal mammalian tissue and that the ACE inhibitory activity of pea and whey 
hydrolysates resisted intestinal peptidase activity well, absorption of these peptides in 
substantial quantities might still take place in vivo. After intravenous administration of a dose 
of 50 mg P/kg BW in spontaneously hypertensive rats (SHR), pea permeate exerted a 
transient, but strong antihypertensive effect of 44.4 mmHg. As it was immediately followed by 
an increase in blood pressure above the initial value, this result has to be interpreted with 
caution and further research is necessary. Whey permeate exerted no effect at a dose of     
50 mg P/kg BW.  
 
Keywords: ACE inhibitory peptides, Caco-2, intestinal transport, SHR 
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INTRODUCTION 
 
Angiotensin I converting enzyme (ACE, EC 3.4.15.1) inhibitory peptides may result in a 
lowering of the blood pressure by inhibition of the ACE enzyme, which results in a decrease 
of the vasoconstrictor angiotensin II and an increase in the vasodilator bradykinin (Eriksson 
et al., 2002). ACE inhibitory peptides have already been found in several food protein 
hydrolysates and ferments (Dziuba et al., 1999; Yamamoto, 1997). Foods containing ACE 
inhibitory peptides have shown to be effective in both the prevention and treatment of 
hypertension (Sipola et al., 2002; Takano, 1998). As ACE inhibitory peptides have not 
revealed any side effects yet, they may represent an alternative for or an additional treatment 
to antihypertensive drugs and may be applied in the prevention of a high blood pressure as 
well (Fitzgerald and Meisel, 2000).  
Purification of ACE inhibitory active food protein hydrolysates may lead to more active 
fractions or ultimately a potent ACE inhibitory peptide. The studies of Mullally et al. (1997) 
and Pihlanto-Leppälä et al. (2000) suggest that ultrafiltration may be exploited to enrich ACE 
inhibitory peptides from whey proteins. Additional purification by ion chromatography and 
RP-HPLC augments substantially the ACE inhibitory activity from wheat germ hydrolysate: 
the IC50 value of the digest is 0.67 mg/ml, while the IC50 of the pure peptide Ile-Val-Tyr is   
0.48 µM or 0.189 µg/ml (Matsui et al., 1999). 
ACE inhibitory peptides exert an antihypertensive effect in vivo if they reach the 
cardiovascular system in an active form. Upon oral administration, they therefore need to 
resist complete degradation by gastrointestinal proteases and brush border peptidases and 
they have to be absorbed through the intestinal wall with preservation of their physiological 
activity. During this oral delivery route, degradation of peptides can take place, which results 
in an activation or inactivation of their biological activity (Fitzgerald and Meisel, 2000; 
Pihlanto-Leppälä, 2001). This partially explains the discrepancy between the ACE inhibitory 
activity and the antihypertensive effect after oral administration of a food protein hydrolysate, 
as observed in the study of Abubakar et al. (1998). Few studies on ACE inhibitory peptides 
consider the stability during digestion and absorption in the gastrointestinal tract. After oral 
administration of Calpis sour milk, containing the antihypertensive peptides Val-Pro-Pro 
and Ile-Pro-Pro, these peptides are detected in the abdominal aorta of spontaneously 
hypertensive rats (SHR), suggesting that these casokinins are directly absorbed without 
being decomposed by the digestive enzymes (Masuda et al., 1996). When the transport of 
the antihypertensive peptide Val-Pro-Pro is investigated in Caco-2 cell monolayers, which 
are a representative model of the human intestinal epithelial cell barrier (Wilson et al., 1990), 
uptake of the intact peptide is suggested to occur by the paracellular route (Satake et al., 
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2002). After a single oral administration of the ACE inhibitory dipeptide Val-Tyr, this peptide 
is dose-dependently detected in the plasma of normotensive and mild hypertensive subjects 
(Matsui et al., 2002a; Matsui et al., 2002b). Although it exerts a 10% systolic blood pressure 
reduction after intravenous administration of 50 mg/kg BW in SHR (Matsufuji et al., 1995), it 
fails to exert an antihypertensive effect at a single oral dose of 12 mg in mild hypertensive 
subjects (Matsui et al., 2002b). 
In previous studies, high ACE inhibitory activity is produced by in vitro gastrointestinal 
digestion of pea and whey protein (Vermeirssen et al., 2003a; Vermeirssen et al., 2003b). An 
in vitro digestion simulating the physiological conditions in vivo is adequate for the formation 
of maximal ACE inhibitory activity. Moreover, whey hydrolysates are more ACE inhibitory 
active than pea hydrolysates (Vermeirssen et al., 2003b). The aim of this study was to obtain 
more active fractions from pea and whey protein hydrolysates by means of ultrafiltration and 
RP-HPLC. Subsequently, the intestinal absorption of the active compounds present in the 
digests and permeates obtained by ultrafiltration was investigated in the Caco-2 cell system. 
Finally, the permeates were injected intravenously in SHR to measure potential 
antihypertensive effects. 
 
 
MATERIALS AND METHODS 
 
Products 
The products used during in vitro gastrointestinal digestion and HPLC analysis are 
described in Chapter 5. Transport buffer (pH 7.4) consisted of Hanks’ Balanced Salt Solution 
(HBSS) supplemented with HEPES (both from Invitrogen Life Technologies, Carlsbad, CA, 
USA) and D-glucose (G 7021, Sigma-Aldrich, St.-Louis, MO, USA) at final concentrations of 
10 mM and 25 mM, respectively. When explicitly mentioned, transport buffer at pH 6 was 
used, which contained HBSS supplemented with 10 mM MES (Invitrogen Life Technologies) 
and 25 mM D-glucose. Dulbecco’s Modified Eagle Medium (DMEM) containing GlutaMAX, 
non-essential amino acids, penicillin (10 000 IU/ml), streptomycin (10 000 µg/ml) and fetal 
bovine serum were also from Invitrogen Life Technologies. Non-specified products were 
analytical grade from VWR International (Zaventem, Belgium). 
 
In vitro gastrointestinal digestion  
The experimental conditions of the in vitro physiological digestion are mentioned in 
Chapter 5.  
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ACE inhibitory activity 
The treatment of the samples is described in Chapter 4. ACE inhibition assay 3 in   
Chapter 2 was used to determine the ACE inhibitory activity. 
 
Protein content 
Protein content was determined by the Bio-Rad DC protein standard assay (Bio-Rad 
Laboratories S.A.-N.V., Nazareth Eke, Belgium) with BSA as standard, based on the method 
of Lowry (Lowry et al., 1951), according to the procedures of the manufacturer. 
 
 Ultrafiltration-centrifugation  
Eighty milligram lyophilised digest was dissolved in 2 ml milliQ water (Millipore, Bedford, 
MA, USA) and ultrafiltrated-centrifuged in Centricon YM-3000 tubes (MWCO = 3000 Da) 
(Millipore) (low adsorption, hydrophilic, regenerated cellulose membranes) for 2 h at 7500 g. 
Permeate and retentate were lyophilised and dissolved in demineralised water or buffer to 
determine the ACE inhibitory activity.  
 
HPLC 
The permeate was fractionated using preparative RP-HPLC by injecting repetitively 1 ml 
of a 35 to 40 mg P (protein)/ml solution on a Vydac C18 column (250 x 10 mm) and ABI Model 
783A Gradient Controller and Absorbance Detector at 210 nm with an ABI Model 400A 
Solvent Delivery System and 491 Dynamic Mixer/Injector (Applied Biosystems, Foster City, 
CA, USA) operating at room temperature. The flow rate amounted to 4 ml/min. A linear 
gradient from 95% solvent A (H2O + 0.1% (w/v) TFA) to 40% solvent B (acetonitrile +   
0.085% (w/v) TFA) in 30 min was applied, thereafter the gradient increased linearly to 95% 
solvent A in 10 min and remained at 95% solvent A during the last 10 min. Two minutes after 
the start of the elution, fractions were collected every 6 min (Figure 1). The five fractions 
were lyophilised and dissolved in demineralised water to determine the ACE inhibitory 
activity. 
The profiles of the permeates were obtained by analytical RP-HPLC by injecting 100 µl of 
a 10 mg P/ml solution on a Prosphere 300 Å C18 column (250 x 4.6 mm, 5 µm) (Alltech 
Associates, Deerfield, IL, USA) and a Dionex (Sunnyvale, CA, USA) HPLC with an 
autosampler ASI-100, pump series P580, STH585 column oven, UV-VIS detector UVD340S 
operating at 210 nm and Chromeleon 6.0 software. The same programs as for the 
preparative RP-HPLC were applied. 
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Caco-2 cell culture 
Caco-2 cells were obtained from the American Type Culture Collection (Rockville, MD, 
USA). Cells were grown in 75 cm2 tissue culture flasks (Nunc, Roskilde, Denmark) in an 
atmosphere of 5% CO2 and 90% relative humidity at 37°C. Cells were passaged every         
3-4 days (at 70-80% confluence) at a split ratio of 1:7. The Caco-2 cells were maintained in 
high glucose (4.5 g/l) DMEM containing glutaMAX, 100 U/ml of penicillin, 100 µg/l of 
streptomycin, 1% (v/v) non-essential amino acids and 10% (v/v) fetal bovine serum. Cells 
were negative for Mycoplasma infection. 
 
Stability experiments with Caco-2 homogenates 
The Caco-2 homogenates were prepared as described in Chapter 3. Pea and whey digest 
and permeate at a concentration of 1 mg P/ml dissolved in transport buffer were incubated 
with the Caco-2 homogenates in an E/S ratio of 1/6 (w/w) at 37°C. The IC50 value was 
determined before the experiment, at the start, after 1 and 2 h. The percent ACE inhibitory 
activity was also assessed after 0.5 h and 1.5 h. A control sample containing only the Caco-2 
homogenate in transport buffer was also analysed for ACE activity and ACE inhibitory 
activity.  
 
Caco-2 transport study  
 For the transport studies, Caco-2 cells were plated at a density of 40 000 cells/cm2 on 
Transwell membrane inserts (3 µm pore diameter, 12 mm diameter, Costar, Cambridge, MA, 
USA). Confluence was reached within 3-4 days after seeding and the monolayers (cell 
passage 90-110) were used for the experiments between days 18-24 post-seeding. The 
Caco-2 cell system was validated as described by Augustijns et al. (1998). Before the 
experiments, the monolayers were rinsed with transport buffer and preincubated for 30 min 
at 37°C. Thereafter, transepithelial electrical resistance (TEER) of the monolayers was 
measured at 37°C using a Millicel ERS apparatus (Millipore) to check cell monolayer 
integrity. Only monolayers with TEER values above 300 Ω.cm2 were used in the 
experiments. The transport buffer was then replaced by 0.5 ml transport buffer containing the 
test compound (pH 7.4 or pH 6) at the apical or mucosal side, while 1 ml transport buffer    
(pH 7.4) was added to the basolateral or serosal side. After 1 h incubation at 37°C, the 
basolateral medium was withdrawn and analysed for ACE inhibitory activity. The TEER was 
measured again and 1.5 ml fresh transport medium was added to the basolateral side, while 
the apical compartment was replaced by a solution of sodium fluorescein (0.5 ml; 1 mg/ml). 
After 1 h incubation at 37°C, the basolateral medium was collected and analysed for sodium 
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fluorescein transport. Sodium fluorescein was used as a hydrophilic marker for cell 
monolayer integrity. Typical sodium fluorescein flux values, measured by UV absorption of 
the basolateral solution at 490 nm, across Caco-2 monolayers after the transport experiment 
should be lower than 1% h-1 (Augustijns et al., 1998). Donor and basolateral samples were 
both analysed for ACE inhibitory activity, immediately and in the basolateral samples also 
after concentrating (usually 4 times) by lyophilisation. The effect of concentrated transport 
buffer on the ACE inhibitory activity of the concentrated samples was taken into account. The 
following solutions were supplemented to the apical side of the Caco-2 cell monolayer: pea 
and whey digest at 45 and 9 mg P/ml, pea and whey permeate at 10 mg P/ml, pea digest 
heat treated at 98°C for 5 min at 33 mg P/ml. In one experiment, transport buffer at pH 6 was 
applied to the apical compartment and the transport of the following samples was 
investigated: pea digest heat treated at 98°C for 5 min at 45 mg P/ml, pea and whey digest at 
9 mg P/ml, pea permeate at 10 mg P/ml, pea and whey permeate at 50 mg P/ml. Results are 
presented as mean ± standard error (SE) (if more than one experiment) of two to four 
experiments, with two to three repetitions for each condition per experiment.  
 
Osmolarity 
 The osmotic concentration was determined by measuring the freezing point depression on 
a model 3D3 Osmometer (Advanced Instruments, Inc., Norwood, MA, USA). 
 
SHR experiments 
SHR, 12 weeks old, were supplied by Janvier (Le Genest-St.-Isle, France). Twenty-one 
SHR (290-345 g) with tail SBP of > 180 mmHg were used, and were divided in 4 groups: 6 
control animals and 5 animals in the other groups. The SHR was anesthetised with 1 ml/kg 
Nembutal (60 mg/ml pentobarbital) (Sanofi Santé Animale, Brussel, Belgium), and the 
femoral artery was cannulated for recording the mean arterial blood pressure with a Druck 
Blood Pressure Transducer PDCR 75/1 (Orecon, Leuven, Belgium) and Kipp & Zonen BD40 
pen recorder (Kipp & Zonen B.V., Delft, The Netherlands). PE50 and PE10 type catheters 
were used for the femoral artery and vein, respectively. The rats were allowed to stabilise for 
5 min after the surgery. Pea and whey permeate, dissolved in physiological saline, were 
injected at a dose of 50 mg P/kg BW in the femoral vein. Physiological saline (500 µl) and 
captopril dissolved in physiological saline (5 mg/kg BW) were used as negative and positive 
controls, respectively. All experiments were carried out in accordance to national guidelines. 
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Statistical analysis 
 All values are reported as mean ± standard error of the mean (nmin = 3). A Student t-test 
was used to compare the ACE inhibitory activity (log IC50) of the permeate and the retentate 
with the one of the digest. It was also investigated if the collected fractions exhibited a higher 
or lower ACE inhibitory activity than the permeate. For the SHR experiments, the blood 
pressure after injection was compared to the initial blood pressure by a Student t-test. 
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RESULTS 
 
Fractionation of pea and whey digests 
A 44.4 mg/ml pea and whey protein solution (90% protein content) exhibited an IC50 value 
of 16 mg/ml and 18 mg/ml, respectively. An in vitro physiological digestion that simulated the 
conditions of protein digestion in vivo, produced hydrolysates from pea and whey protein with 
high ACE inhibitory activity. The IC50 values amounted to 0.076 mg/ml and 0.048 mg/ml, 
respectively (see Chapter 5). The protein content of pea and whey digest was 92 ± 2% and 
86 ± 3%, respectively.  
A first enrichment of ACE inhibitory peptides was obtained by ultrafiltration-centrifugation 
with a MWCO of 3000 Da. The permeate, the low molecular weight fraction, was highly 
hygroscopic and its ACE inhibitory activity was more accurately expressed relative to the 
protein content. A further purification of this permeate was performed by RP-HPLC. Figure 1 
shows the RP-HPLC profile of the pea and whey permeate and indicates the 5 different 
fractions that were collected. The first fraction remained a gel even after extensive 
lyophilisation. For this reason and, because only a small amount of sample was wasted for 
protein determination, the ACE inhibitory activity was expressed relative to the protein 
content for comparison of the different samples. For the whey permeate sharp individual 
peaks could be observed, while for the pea permeate on the other hand, most of the peaks 
merged. 
An overview of the different ACE inhibitory activities obtained by ultrafiltration-
centrifugation of the digests and RP-HPLC fractionation of the permeates is depicted in 
Figure 2. The permeate of both pea and whey had a higher ACE inhibitory activity than the 
digest, while the IC50 value of the retentate did not differ significantly from the corresponding 
digests’ IC50. The former effect was more pronounced for whey, where the IC50 value in the 
molecular weight fraction lower than 3000 Da was one third of the IC50 of the digest. A further 
increase in ACE inhibitory activity was obtained by RP-HPLC fractionation of the permeate. 
Both for pea and whey protein, the ACE inhibitory activity in the first fraction was lower than 
in the permeate. In fraction II, III an IV of the pea permeate a higher ACE inhibitory activity 
was observed. The lowest IC50 value of 0.016 mg P/ml was found in fraction IV, which was 
more than four times lower than the IC50 value of pea digest. For whey, the fractionation 
resulted in an even higher enrichment of ACE inhibitory activity. Fraction III, IV and V had 
higher ACE inhibitory activities compared to the permeate. The lowest IC50 value,            
0.003 mg P/ml found in fraction III, was more than thirteen times lower than the IC50 value of 
the whey digest.  
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Figure 1. HPLC profile of pea and whey permeate and the different fractions (I, II, III, IV, V) 
that were collected. 
 
 The yield of the three most active fractions was estimated for pea and whey protein   
(Table 1). For the fractions II, III and IV from pea, a yield of about 5% was observed. For the 
fractions III, IV and V from whey, the yield was approximated 2%.  
 
Table 1. Estimated yields (g) of digest, permeate and the three most active fractions from 4% 
(w/v) pea and whey. 
 Pea Whey 
Protein 4.44 g  4 g P 4.44 g  4 g P  
Digest 3.50 3.20 4.44 3.81 
Permeate 1.18 0.61 1.23 0.51 
Fractions 0.25 0.19 0.11 0.08 
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Figure 2. Log IC50 and IC50 (mg P/ml) of the pea and whey digest, permeate and retentate 
and the fractions I, II, III, IV and V collected after RP-HPLC fractionation of the 
permeate (nmin = 3).  
 Significantly different from the digest: +p < 0.05, ++p < 0.01. 
 Significantly different from the permeate: *p < 0.05, **p < 0.01, ***p < 0.001. 
 
Stability experiments with Caco-2 homogenates 
A 1 mg P/ml solution of pea and whey digest and permeate respectively, was incubated at 
37°C in the presence of Caco-2 homogenates. At regular intervals, the ACE inhibitory activity 
of these solutions was analysed and the IC50 was determined before the experiment, 
immediately after the addition of the Caco-2 homogenates and after 1 and 2 h incubation 
(Figure 3). The ACE inhibitory activity decreased, and consequently the IC50 value increased, 
in all solutions over time. The ACE inhibitory activity diminished substantially more in whey 
than pea digests and permeates. At the end of the experiment, the 1 mg P/ml pea digest still 
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retained 90% of its initial ACE inhibitory activity, while for the pea permeate this was 89%. 
The activities of the whey digest and permeate reduced to 72% and 69%, respectively. 
Figure 3. ACE inhibitory activity (%) of a 1 mg P/ml solution and IC50 value (mg P/ml) of the 
digest and the permeate of pea and whey protein before and during incubation 
with Caco-2 homogenates. 
 
For the pea digest the IC50 value increased one and a half times, while the IC50 value of 
the pea permeate almost doubled upon 2 h incubation with Caco-2 homogenates. The IC50 
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value of the whey digest at the end of the experiment was three times its initial value. The 
most pronounced effect was observed for the whey permeate, for which the IC50 value 
augmented thirteen times. Nevertheless, all samples still had high ACE inhibitory activity 
after 2 h incubation with Caco-2 homogenates. Solutions with only Caco-2 homogenates 
failed to show any ACE activity or significant ACE inhibitory activity.  
 
Caco-2 transport study  
 In a first set of experiments, the intestinal transport of pea and whey digest at 45 and        
9 mg P/ml concentration (P45, P9, W45, W9) and of pea and whey permeate at 10 mg P/ml 
concentration (Pperm10, Wperm10) was investigated in the Caco-2 cell system. The 
transepithelial electrical resistance (TEER) was measured after an incubation period of 1 h 
with test solution and after an additional hour of incubation with sodium fluorescein       
(Figure 4). TEER values are expressed as percent of the initial value, which was at least 300 
Ω.cm2. For the control condition, where just transport buffer was added at the apical side 
during the first hour, the TEER decreased only slightly after 2 h at 37°C. The integrity of this 
cell monolayer was not compromised. Upon incubation with pea and whey digest at the 
highest concentration, hardly a stable TEER measurement could be obtained after 1 h and 
only about 20% of the initial TEER remained after the sodium fluorescein transport. This 
damage to the cell monolayer was also reflected in the sodium fluorescein flux, which was 
substantially higher for the 45 mg P/ml pea and whey digest than the value of 0.40% h-1 for 
the control, and even higher than the reference of 1% h-1 (Figure 4). Sodium fluorescein is a 
hydrophilic compound, which is supposed to cross the cell monolayer via the paracellular 
route with typical fluxes lower than 1% h-1 (Augustijns et al., 1998). Acceptable transport 
validation parameters were obtained for 9 mg P/ml pea and whey digest and 10 mg P/ml pea 
and whey permeate. The IC50 values of the donor samples were comparable with the values 
mentioned in Figure 2. Hence, at the start of the experiment the ACE inhibitory activity at the 
apical side was 100% in all samples. When the basolateral samples were analysed 
immediately after the transport experiment, the 45 mg P/ml whey digest was the only sample 
for which significant ACE inhibitory activity was detected (Figure 5). Concentrating the control 
resulted in an apparent higher, although still non-significant, ACE inhibitory activity, which 
can be explained by a higher chloride concentration than the optimal one needed for 
maximal ACE activity (Chapter 1). Substantial ACE inhibitory activity was found in the 
concentrated basolateral samples for the 45 mg P/ml pea and whey digests conditions. The 
digests at the lower concentration and the whey permeate at 10 mg P/ml did not result in 
ACE inhibitory activity of the basolateral samples, while for the 10 mg P/ml pea permeate 
little ACE inhibitory activity was observed. 
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Figure 4. Transport validation parameters: TEER (%), after a 1 h incubation with test solution 
and after an additional 1 h incubation with sodium fluorescein solution; and sodium 
fluorescein flux (% h-1). P, W, Pperm and Wperm: pea and whey digest and 
permeate respectively, the number is the concentration in mg P/ml, heat: 5 min at 
98°C, pH 6: apical transport medium at pH 6 (single and repeated experiments).  
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Figure 5. ACE inhibitory activity (%) in the basolateral compartment upon immediate 
analysis and in 4 times concentrated samples (no immediate analysis and 3 times 
concentrated in P45_heat pH6, Pperm50_pH6 and Wperm50_pH6). P, W, Pperm 
and Wperm: pea and whey digest and permeate respectively, the number is the 
concentration in mg P/ml, heat: 5 min at 98°C, pH 6: apical transport medium at 
pH 6 (single and repeated experiments).  
 
In a second set of experiments, the pea digest at high concentration was heat treated 
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the end of the experiment and the very high sodium fluorescein fluxes. ACE inhibitory activity 
was only observed after concentrating the basolateral samples (Figure 5). Lower ACE 
inhibitory activity was noticed in the heat treated pea digests compared to the untreated      
45 mg P/ml pea digest. Pea digest at 9 mg P/ml and pea permeate at 10 mg P/ml at pH 6 
had little, but significant ACE inhibitory activity after concentration, while whey digest at         
9 mg P/ml at pH 6 showed no activity. The concentrated basolateral samples of 50 mg P/ml 
pea and whey permeate at pH 6 demonstrated significant ACE inhibitory activity as well.  
The osmolarity of some donor samples was determined (T able 2). As an isotonic 9 g/l 
NaCl solution exhibits an osmolarity of about 300 mOsm, all these solutions, except the pea 
and whey digest at a concentration of 9 mg P/ml at pH 6, were hypertonic.  
 
Table 2. Osmolarity (mOsm) of some donor samples in different concentrations.  
 Pea Whey 
Digest 45 mg P/ml 573 472 
Heat treated 33 mg P/ml 466 / 
Digest 9 mg P/ml pH 6 377 353 
Permeate 50 mg P/ml 1417 1498 
Permeate 30 mg P/ml 957 1063 
Permeate 10 mg P/ml 522 533 
Permeate 10 mg P/ml pH 6 524 544 
/ = not determined. 
 
SHR experiments 
 To investigate the biological activity of the ACE inhibitory pea and whey permeates in 
vivo, doses of 50 mg P/kg BW were injected into the femoral vein of SHR. Physiological 
saline in an equal volume and captopril (5 mg/kg BW) served as negative and positive 
control, respectively. The evolution of the mean arterial blood pressure during 15 min from 
the start of the injection is depicted in Figure 6. The maximal drop in blood pressure occurred 
at different times in the different animals, partially due to variations in injection time. This 
caused less pronounced effects of the average over time. Therefore, the overall mean 
minimal blood pressure and blood pressure reduction ratio is mentioned in Table 3. In the 
control animals, the blood pressure remained at 141 ± 1 mmHg throughout the experiment. 
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Captopril exerted a significant blood pressure lowering effect from 40 s onwards, when on 
average the injection was completed, and reached a minimum level after 1 min 30 s. After 4 
min the blood pressure increased again, showing in some rats the tendency to return to its 
initial value, while remaining at a reduced level in others, which explained the large standard 
error bars after 10 min. Captopril resulted in a maximal reduction ratio of 41%.  
 As the solutions of pea and whey permeate were more concentrated than the captopril 
and control test solutions, they were injected more slowly. Intravenous administration of pea 
permeate immediately caused a sharp and short blood pressure reduction. Only 20 and 25 s 
after the start of the injection the blood pressure was significantly lower than the start value, 
but this was largely due to variations in injection time. The maximal reduction ratio of pea 
permeate was 32%. At 2 min, when the total amount of pea permeate had been injected, the 
blood pressure increased above the initial value, but returned to it after 10 min. When whey 
permeate was injected in the femoral vein, a similar course in blood pressure could be 
observed, but the slight changes were non-significant.  
 The heart rate of the animals was not affected by any of the treatments. 
 
Table 3. Initial and minimal mean arterial blood pressure (BP) (mmHg) and reduction ratio 
(%) after intravenous administration of captopril, pea and whey permeate. 
 Initial BP  Minimal BP  Reduction ratio (%) 
Captopril 5 mg/kg 141.0 ± 2.2   82.8 ± 1.1*** 41 
Pea permeate 50 mg P/kg  136.8 ± 4.2   92.4 ± 4.8*** 32 
Whey permeate 50 mg P/kg 140.0 ± 2.0   133.4 ± 2.5 / 
Significantly different from the initial blood pressure : ***p < 0.001 (n = 5). 
/ = not applicable. 
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Figure 6. Evolution of the mean arterial blood pressure (mmHg) after injection of 
physiological saline (control), 5 mg/kg BW captopril, 50 mg P/kg BW pea permeate 
and 50 mg P/kg BW whey permeate during 15 min upon injection and during the 
first 2 min in detail (n = 5). The injection time (min) is also indicated.  
*p < 0.05, **p < 0.01, ***p < 0.001 significantly different from the initial blood 
pressure.  
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DISCUSSION 
 
Fractionation of pea and whey digests 
Firstly, ultrafiltration was applied to pea and whey hydrolysates. This is a simple and 
reliable technique to separate peptides on molecular weight, while removing proteins. 
Moreover, it presents an effective sample preparation and clean-up technique for RP-HPLC 
(Herraiz, 1997). Bioactive peptides usually contain 2-20 amino acid residues per molecule 
(Pihlanto-Leppälä, 2001) and the lower their molecular weight, the higher their chance to 
cross the intestinal barrier and exert a biological effect (Roberts et al., 1999). The MWCO in 
our study was 3000 Da, which corresponds to oligopeptides of about 25 amino acids. 
Ultrafiltration led to an enrichment of ACE inhibitory activity in the permeate of both pea and 
whey hydrolysate. In whey, the ACE inhibitory activity was even increased threefold by this 
treatment step. Compared to pea, whey hydrolysate seemed to contain a higher proportion of 
large peptides with lower ACE inhibitory activity. β-lactoglobulin, which is still partially present 
after in vitro gastrointestinal digestion as observed in Chapter 5 and 6, may bind low 
molecular weight ACE inhibitory peptides, preventing them from crossing the ultrafiltration 
membrane (Noiseux et al., 2002). When fractionating ACE inhibitory peptides from whey 
hydrolysate, Pihlanto-Leppälä et al. (2000) found higher ACE inhibitory activity in the < 1 kDa 
fraction than in the other fractions. However, Mullally et al. (1997) reported that the 
permeates of tryptic digests of whey protein hydrolysates and β-lactoglobulin obtained after 
ultrafiltration through 3 kDa, as opposed to 1 kDa membranes, are more potent inhibitors of 
ACE. In a three-step recycling ultrafiltration membrane reactor, the gelatine hydrolysate 
fraction gained after the third hydrolysis with an ultrafiltration membrane of 1 kDa MWCO 
shows a higher ACE inhibitory activity than after the first and second hydrolysis steps with 
ultrafiltration membranes of 10 and 5 kDa respectively (Byun and Kim, 2001). Hence, our 
results confirm the observation that ultrafiltration may separate high ACE inhibitory activity.  
Secondly, the permeates obtained by ultrafiltration-centrifugation were fractionated by    
RP-HPLC. This separates the peptides by molecular weight and hydrophobicity. The highest 
ACE inhibitory activity was found in fraction IV for pea and fraction III for whey, which 
corresponded with a gradient of about 24-28% acetonitrile. Hence, these fractions contained 
probably hydrophobic peptides, which are more likely to exert an ACE inhibitory effect 
according to the structure-activity relationship of ACE inhibitory peptides (Fitzgerald and 
Meisel, 2000). The first fractions showed a lower ACE inhibitory activity than the permeates 
and digests they originated from. Most likely, this can be attributed to the presence of amino 
acids and short hydrophilic peptides with low ACE inhibitory activity. The treatment was 
again more effective for whey than for pea. This may suggest that in whey hydrolysate very 
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potent ACE inhibitory peptides were present next to low active peptides, while in pea digest 
all peptides had more or less the same ACE inhibitory activity.  
 
Caco-2 transport study 
 For the bioavailability of ACE inhibitory peptides, transport through the intestinal brush 
border forms a major issue, in addition to stability towards peptidases (Fitzgerald and Meisel, 
2000).  After addition of pea and whey digests or permeates to the apical compartment of a 
Caco-2 cell monolayer, no or only little ACE inhibitory activity was detected even in 
concentrated basolateral samples after 1 h at 37°C. It is very unlikely that this was caused by 
degradation by Caco-2 peptidases, as high ACE inhibitory activity was still recovered after    
2 h incubation of pea and whey digests and permeates with Caco-2 homogenates at 37°C, 
although some decrease in activity could be observed. Whey digest and permeate seemed 
more susceptible to degradation by these peptidases than pea, or it can be that in pea digest 
and permeate ACE inhibitory peptides were broken down to other active peptides with the 
same total ACE inhibitory activity. This corresponds well with the observation in Chapter 6, 
where the ACE inhibitory activity of whey digest decreased more than the one of pea upon 
incubation with a rat intestinal acetone powder extract. Furthermore, this rules out the 
possibility that the change in ACE inhibitory activity in the digests in these experiments was 
solely due to the further action of the gastrointestinal proteases, as it also occurred in the 
permeates. In this respect, it was noticed that in a solution containing pepsin, trypsin and    
α-chymotrypsin in concentrations as supplemented during digestion, these enzymes were 
largely precipitated during the centrifugation step. 
 The intestinal transport of pea and whey digest at 45 and 9 mg P/ml concentration and of 
pea and whey permeate at 50 and 10 mg P/ml concentration was investigated in the Caco-2 
cell model. These concentrations were first of all chosen to facilitate the detection of 
intestinal transport of active compounds. Similar concentrations to 10 mg P/ml or 5 mg P/well 
are reported in transport experiments in literature (Rubio and Seiquer, 2002; Winckler et al., 
1999). Considering that the ACE inhibitory peptides Val-Pro-Pro and Ile-Pro-Pro reach the 
intestinal brush border undegraded, consumption of 95 ml Calpis milk or 150 ml Evolus milk 
delivers respectively about 2.6 mg or 5.3 mg ACE inhibitory peptides to the intestinal barrier 
(Hata et al., 1996; Seppo et al., 2003). Hence, our lower concentrations are rather 
physiologically relevant.  
There was a strong indication that the ACE inhibitory peptides in our samples were not 
transported through the Caco-2 cell monolayer, although the sensitivity of the ACE inhibition 
assay may have been too low to detect active compounds in the basolateral samples. The   
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45 mg P/ml digests and 50 mg P/ml permeates showed the highest ACE inhibitory activity in 
the basolateral compartments, but they compromised the integrity of the monolayer as 
indicated by the large decreases in TEER and the high sodium fluorescein transport. The 
hypertonicity of these solutions may be responsible for these harmful effects. The permeates 
showed a higher osmolarity than the digests at similar concentrations: due to the low 
molecular weight of the peptides in these samples, they contained at least the amount of 
solute particles present in the digests at the same protein concentration. Heat treatment 
alleviated the damaging of the cell monolayer and probably decreased the concentration of 
‘active solute particles’ present. Despite having an osmolarity as high as the 45 mg P/ml 
digests, the 10 mg P/ml permeates did not evoke significant decreases in TEER or increased 
sodium fluorescein transport. As the osmolarity of the permeates was measured at a different 
point in time than that of the digests, this may be explained by a variation in the 
measurement. Another mechanism than hypertonicity may also have contributed to the 
harmful effects of the 45 mg P/ml digests. Applying transport buffer at pH 6 in the apical 
compartment did not result in increased transport of pea and whey digests and permeates. It 
has been shown that in the intestinal mucosa an acid microclimate region is present in the 
absorptive zone of the villus (Daniel and Herget, 1998). As a proton-motive force efficiently 
energises di- and tripeptide transport in the PepT1 transporter (Walker et al., 1998), a lower 
mucosal pH may increase peptide uptake. In vitro studies with various tissue preparations 
reveal that there are only minor effects, if any, on peptide uptake when the pH of the 
incubation buffer is changed from neutral to acidic values. Hydrolysis of dipeptides appears 
to be reduced more significantly than the transport is increased. The Caco-2 cell monolayer 
however, lacks a three-dimensional structure and different cell types and may therefore not 
have a microclimate pH that differs significantly from bulk-phase pH (Daniel and Herget, 
1998). Therefore lowering of the pH in the mucosal bathing solution results in an increased 
uptake of di- and tripeptides by PepT1 in the Caco-2 model (Winckler et al., 1999; Yang et 
al., 1999). As this effect was not observed, ACE inhibitory peptides may not present a 
substrate for the PepT1 transporter. When studying the transport mechanism of the ACE 
inhibitory peptide Val-Pro-Pro, addition of a competitive substrate for PepT1 or endocytosis 
inhibitors, like Gly-Pro, does not inhibit the transport of intact tripeptide across Caco-2 cell 
monolayers (Satake et al., 2002). Although Val-Pro-Pro is composed out of hydrophobic 
amino acids, a peptide with only three amino acid residues may not be hydrophobic enough 
to be transported by passive diffusion or endocytosis. In order to cross the epithelial barrier 
transcellularly, a peptide must both have a low hydrogen bonding potential and a favourable 
octanol-water partition coefficient (Burton et al., 1996). Therefore the paracellular route is 
suggested as the major pathway for intact transport of Val-Pro-Pro. This bioactive peptide 
has a flux of less than 2% h-1 in the Caco-2 cell monolayer, although it has been shown to be 
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present in the abdominal aorta and exerts an antihypertensive effect after oral intake in SHR 
(Masuda et al., 1996). In another paper, where the transepithelial transport of bioactive 
oligopeptides in Caco-2 cell monolayers is investigated, susceptibility to peptidases is 
observed to be one of the primary factors that determine transport (Shimizu et al., 1997). 
Adsorptive transcytosis, depending on the hydrophobicity of the peptides, is suggested to be 
involved in the transport of bradykinin, while the tetrapeptide Gly-Gly-Tyr-Arg would be 
transported mainly via the paracellular pathway.  
Paracellular transport is regulated by the tight junctions, which are associated with a 
cytoskeletal structure and are therefore influenced by various factors that affect cellular 
structure and function (Nusrat et al., 2000). During rapid fluid absorption (solvent drag) 
associated with sodium coupled transport of hexoses and amino acids in the small intestine, 
the tight junctions become dilated and allow the passage of solutes with theoretical molecular 
weight up to 1000 Da or more between absorptive cells. It has been shown that 
undegradable, mainly hydrophilic oligopeptides are transported in this way in substantial 
quantities (Pappenheimer et al., 1997). The tight junction permeability can be estimated by 
measuring the TEER. As the resistance of the paracellular route is much lower than that of 
the transcellular one, the TEER across the epithelial monolayers reflects mainly the 
resistance offered by the tight junctions. Specific food ingredients, like extracts of sweet 
pepper, horse radish and some mushrooms, have demonstrated to decrease the TEER and 
hence increase the paracellular permeability in Caco-2 cell monolayers, without affecting the 
viability of the cells (Hashimoto et al., 1994; Shimizu, 1999). By the same mechanism, 
sodium salts of medium-chained fatty acids derived from dairy products, sodium caprate 
(C10) in particular, can promote the intestinal absorption of undegradable oligopeptides 
without causing detrimental alterations of the intestinal mucosa (Chao et al., 1999). 
Moreover, Caco-2 cell monolayers are known to be tighter than mammalian intestinal tissues 
(Boisset et al., 2000). These findings suggest that the amount of bioactive peptides 
paracellularly absorbed during food intake in vivo could be higher than expected from the 
results of in vitro transport experiments. As the ACE inhibitory activity in our digests and 
permeates was relatively resistant towards peptidase activity, it is still possible that the 
bioactive peptides are transported in vivo in sufficient quantities to exert an antihypertensive 
effect.  
 
SHR experiments 
The intravenous administration experiments in SHR were validated by the use of 
physiological saline and captopril as negative and positive controls respectively. Captopril, as 
antihypertensive drug, exerted a strong reduction in blood pressure that was maintained for 
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several minutes. A similar observation is made by French et al. (1995), where after 
intravenous administration of captopril at a dose of 5 mg/kg BW to conscious SHR, the blood 
pressure, monitored in the carotid artery, has returned to the baseline level after 60 min. A 
reduction in the mean arterial blood pressure of 17 mmHg is obtained after 30 min. In 
another study, intravenous injection of captopril at a dose of 5 mg/kg BW immediately lowers 
the systolic blood pressure, monitored in the carotid artery, in SHR. Twenty minutes after 
injection a reduction of 75 mmHg is obtained and maintained for another 40 min till the end of 
the experiment (Shin et al., 2001). However, it is difficult to compare the change in systolic 
blood pressure with the change in mean arterial blood pressure, as these are influenced by 
blood pressure-lowering agents differently (Fuglsang et al., 2002).  
Pea permeate at a dose of 50 mg/kg BW showed a transient and sharp antihypertensive 
effect that was immediately followed by an increase in blood pressure above the initial value. 
Later on, the blood pressure returned to the initial level. Whey permeate tended to follow the 
same course, but no significant changes were observed. These are both mixtures of 
unknown peptides dissolved in physiological saline at concentrations of about 30 mg P/ml. 
Permeates dissolved in transport buffer at this concentration were hypertonic. Hence, one 
possible explanation for the change in blood pressure observed could be the administration 
of hypertonic solutions. However, these solutions were injected slowly and injection of a 
hypertonic saline solution of about 410 mOsm in the femoral artery did not change the blood 
pressure (data not shown). Moreover, there was a substantial difference in the effect 
between pea and whey permeate. A more plausible clarification for the combination of an 
increase and a decrease in blood pressure would be the presence of both vasodilating or 
ACE inhibitory peptides and vasoconstricting peptides in the permeates. In addition to the 
ACE inhibition, food derived peptides may exert an antihypertensive effect by other 
mechanisms. From albumin, for example, two peptides have been isolated with vasorelaxing 
properties (Fujita et al., 1995; Matoba et al., 1999). Finally, the increase in blood pressure 
following the decrease may be explained by an unknown compensation mechanism in the 
animal. Peptides are rapidly degraded in plasma and some of them have half-lives in the 
order of minutes and even seconds (Gardner, 1998; Moskowitz, 2003). In this respect, the 
ACE inhibitory peptides in pea permeate, showing a higher stability to peptidases than whey 
permeate, might exert a transient antihypertensive effect before being broken down in the 
plasma.  
In only one other study a mixture of peptides is intravenously administered to SHR. When 
wheat germ hydrolysate, dissolved in physiological saline, is injected at a dose of 50 mg/kg 
BW in the tail vein of SHR, a short decrease in mean arterial blood pressure, monitored in 
the carotid artery, of only 5% is obtained 13 min after injection (Matsui et al., 2000). The 
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injection of Ile-Val-Tyr, a potent ACE inhibitory peptide isolated from wheat germ hydrolysate, 
at 5 mg/kg BW results in a more pronounced transient antihypertensive effect of 10% after   
8 min. This peptide is found to be metabolised in plasma to form a subsequent ACE inhibitor, 
Val-Tyr. The absence of an antihypertensive effect after intravenous administration of ACE 
inhibitory peptides cannot exclude a protective role of these peptides in the long term or at a 
higher dose after single administration. For example, when a soy protein hydrolysate is fed 
daily to SHR, a dose of 100 mg/kg BW decreases the systolic blood pressure of SHR only 
after 12 days (Wu and Ding, 2001). Oligopeptides of 1 kDa or less, obtained from chicken 
egg yolk hydrolysate, suppress the development of hypertension in SHR after daily oral 
administration at 20 mg/kg BW for 12 weeks (Yoshii et al., 2001). 
Further research needs to elucidate the biological effects of pea and whey permeate in 
vivo. 
 
In conclusion, the ACE inhibitory activity of pea and whey hydrolysates could be increased 
upon purification by ultrafiltration-centrifugation and RP-HPLC. When examining the 
intestinal transport of active compounds in pea and whey digests and permeates, only minor 
ACE inhibitory activity was observed to cross the Caco-2 cell monolayer. After intravenous 
administration in SHR, pea permeate exerted an antihypertensive effect that merits further 
research. 
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General discussion, conclusions  and perspectives 
 
PROBLEM STATEMENT AND RELEVANCE OF THIS WORK 
 
Hypertension is a significant public health problem worldwide that is associated with 
an increased risk for coronary heart disease, congestive heart failure, stroke and renal 
disease. It is estimated that 20% of the world’s adult population suffers from hypertension. 
The incidence of hypertension becomes more prevalent with age and hypertension is found 
in about 65% of individuals above 65 years in many industrialised countries (Alper et al., 
2001). Moreover, the World Health Organisation (WHO) attributes 30% of all global deaths in 
1998 to cardiovascular diseases (CVD) (WHO, 1999). In Belgium, the share of 
cardiovascular diseases in mortality is even bigger (Figure 1). 
 
Figure 1. Proportional mortality of cardiovascular diseases (CVD) in Belgium, 1995 (Country 
profile for diseases of the circulatory system, www.who.org). 
 
Lifestyle modifications and diet therapy are one of the most important tools for effective 
lowering of blood pressure (Hermansen, 2000). Moreover, even small decreases in blood 
pressure result in significantly lower risks for cardiovascular diseases (Van der Niepen, 
2000). A higher dietary protein intake seems to have favourable influences on the blood 
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pressure in hypertensive individuals. Also the Dietary Approaches to Stop Hypertension trial 
(DASH), a diet rich in fruits, vegetables and low-fat dairy products, is associated with an 
effective reduction of the blood pressure (Hermansen, 2000). Although other mechanisms 
may play a role, ACE inhibition by bioactive peptide release from food proteins may have 
caused these antihypertensive effects. Indeed, a number of research reports have 
demonstrated the antihypertensive effect of ACE inhibitory peptides or foods containing 
these bioactive compounds in hypertensive patients, even when they received 
antihypertensive medication (Hata et al., 1996; Itakura et al., 2001; Pins and Keenan, 2002; 
Seppo et al., 2002; Seppo et al., 2003). In addition, several studies in spontaneously 
hypertensive rats (SHR) suggest a significant suppression of the development of 
hypertension upon receiving a diet rich in ACE inhibitory peptides (Sipola et al., 2002; Yoshii 
et al., 2001). Overall, this points out to the fact that ACE inhibitory peptides, as part of a 
food product or as nutraceutical, may be of functional interest in both the treatment 
and the prevention of hypertension. Compared to ACE inhibitory drugs, food derived 
peptides have certain advantages. As they usually have a lower activity and specificity, they 
do not demonstrate any side effects. They also represent a much lower cost to health care. 
As part of the daily diet, they appear more natural and safe to the consumer. However, ACE 
inhibitory drugs have proven their usefulness and it is not the intention to completely replace 
them, but in a number of cases, especially in the prevention of hypertension and as initial 
treatment in mild hypertensive individuals, food derived ACE inhibitory peptides could be 
applied, while in others they could function as an additional treatment.  
Food derived ACE inhibitory peptides fit well in the new nutrition concept that 
emphasises the relation between nutrition and human health. The market for functional 
foods is increasing. According to a study from Business Communications Company, Inc., 
RGA-109 Functional/Nutraceutical/Welness Foods and Beverages, the sales of functional 
foods and beverages marketed in the US is estimated at $20 per person in 1999 (Rajan, 
2000). Growing at an average annual growth rate of 12.8%, it is projected that the total 
market will increase to $36 per person in 2004. The larger share will be for functional 
beverages, although a faster growth is projected for functional snacks and meal items. 
However, defining the market for functional foods has proven problematic for market analysts 
since it is highly fragmented and covers a multitude of products with proven and unproven 
benefits. In this respect, functional foods are defined as those foods that are marketed on a 
health benefit and it does not necessarily include natural foods containing bioactive 
compounds. 
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Some functional foods containing ACE inhibitory peptides are already on the 
market. Calpis sour milk from The Calpis Food Industry Co., Ltd. (Tokyo, Japan) bears the 
FOSHU label in Japan (Takano, 2002) and is patented (Nakamura and Takano, 1995). 
Evolus from Valio Ltd. (Helsinki, Finland) is a similar milk fermented by Lactobacillus 
helveticus LBK-16 H, but this strain is still alive in the fermented milk, the concentrations of 
the two ACE inhibitory tripeptides Val-Pro-Pro and Ile-Pro-Pro are doubled and the milk has 
a favourable electrolyte composition (Seppo et al., 2003; Sipola et al., 2002). Davisco Foods 
International, Inc. (Eden Prairie, MN, USA) brought BioZate 1, a hydrolysed whey protein 
isolate supplement, on the market in the USA (Pins and Keenan, 2002). Katsuo-bushi 
oligopeptide, a thermolysin digest of dried bonito has also been approved as FOSHU in 
Japan (Fujita and Yoshikawa, 1999). 
 
Figure 2. Functional foods containing ACE inhibitory peptides on the market. 
 
 Although ACE inhibitory peptides have been characterised from various food proteins 
from vegetable or animal origin, pea protein has never been investigated. Pea is a long 
established and significant crop in Europe and has some advantages for human nutrition. 
Pea protein has a well balanced profile of amino acids, and especially a high content in the 
essential amino acid lysine. Moreover, in accordance with today’s consumer demands, it is 
environment-friendly produced: it may not only present a non-GMO alternative to soy protein, 
but it is a low input crop due to symbiotic nitrogen fixation (Schneider and Lacampagne, 
2000). Therefore, pea protein was the subject of our study and was compared to whey 
protein, a high valuable protein, which originates as by-product from milk during the cheese 
making process.  
 This work aimed to study the formation of ACE inhibitory activity from pea and 
whey protein and to investigate in vitro the maintenance of this activity after oral 
administration in the human body, from the gastrointestinal tract to the site of action, 
the cardiovascular system. Compared to most ACE inhibitory peptide studies, where 
emphasis is put on the isolation of peptides, their in vitro ACE inhibitory activity and in vivo 
antihypertensive effect in SHR, this thesis stressed the importance of the gastrointestinal 
BioZate 1 
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proteases and peptidases in the formation and degradation of ACE inhibitory peptides and 
the need for intestinal transport of intact peptides. Gastrointestinal digestion and intestinal 
transport are the major barriers in the bioavailability of ACE inhibitory peptides (Pihlanto-
Leppälä, 2001). We chose not to isolate one or a few peptides with high ACE inhibitory 
activity. In protein hydrolysates, the ACE inhibition measured is the result of various 
peptides, while the nutritional value of the protein is preserved. Moreover, it is suggested that 
peptide mixtures may exert a synergistic ACE inhibitory effect (Gobbetti et al., 2000). 
  An overview of the major accomplishments of this work is given in Figure 3. In brief: 
• An ACE inhibition assay was developed, optimised and validated (Chapter 2). 
• Ala-Leu-Pro-Met-His-Ile-Arg, one of the most potent ACE inhibitory peptides isolated 
from whey protein up to date, resisted in vitro gastrointestinal digestion and was 
transported intact through a Caco-2 Bbe cell monolayer. However, this peptide was 
degraded in the presence of rat intestinal tissue and failed to reduce the blood 
pressure after intravenous administration in SHR at a dose of 5 mg/kg (Chapter 3). 
• Fermentation by lactic acid bacteria and the yeast Saccharomyces cerevisiae was 
rather ineffective in releasing ACE inhibitory activity from pea and whey protein. In 
vitro gastrointestinal digestion seemed to be the predominant factor controlling the 
formation of ACE inhibitory activity from these food proteins (Chapter 4).  
• In vitro gastrointestinal digestion of pea and whey protein released high ACE 
inhibitory activity. Comparison of three different in vitro digestions in batch, revealed 
that a digestion simulating the physiological conditions of protein hydrolysis was 
sufficient to obtain maximal ACE inhibitory activity. In a semi-continuous reactor 
model of the gastrointestinal digestion of pea protein, response surface methodology 
indicated that maximal ACE inhibitory activity was achieved at the longest incubation 
times in the stomach and small intestine phase within the model (Chapter 5). 
• A time course study of the in vitro gastrointestinal digestion observed for pea protein 
high ACE inhibitory activity already in the stomach phase, while high ACE inhibitory 
activity was only attained in the small intestine phase for whey protein. SDS-PAGE 
showed that the major part of the proteins in pea was already broken down after the 
stomach phase digestion, while the major whey protein β-lactoglobulin was only 
degraded from the small intestine phase onwards. Supplementation of a rat intestinal 
acetone extract, simulating the intestinal brush border phase digestion, slightly 
decreased the ACE inhibitory activity and more for whey than pea digest (Chapter 6).  
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• An ACE inhibitory peptide database predicted very high ACE inhibitory peptide 
potency for β-lactoglobulin, that exceeded all other pea and whey proteins, and even 
above β-casein, a known source of potent ACE inhibitory peptides. In silico 
gastrointestinal digestion of the pea and whey proteins with the highest potencies 
characterised the release of ACE inhibitory peptide sequences (Chapter 6). 
• The ACE inhibitory activity of pea and whey digest could be enriched by ultrafiltration-
centrifugation and subsequent RP-HPLC fractionation of the permeate. Larger 
differences were obtained for whey than pea protein (Chapter 7). 
• Although high ACE inhibitory activity was maintained after incubation of pea and 
whey digest and permeate with Caco-2 homogenates, no or only little ACE inhibitory 
activity was transported through Caco-2 cell monolayers (Chapter 7).  
• After intravenous administration of a dose of 50 mg P/kg BW in SHR, pea permeate 
exerted a transient, but strong antihypertensive effect. Whey permeate exerted no 
effect at a dose of 50 mg P/kg BW (Chapter 7). 
 
The importance of our findings is briefly discussed in the following section.  
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Figure 3. Schematic overview of the major accomplishments of this work. Red: high(er), 
blue: low(er) ACE inhibitory activity as determined by the ACE inhibition assay. 
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GENERAL DISCUSSION AND CONCLUSIONS 
 
In vitro models 
The maintenance of ACE inhibitory activity derived from pea and whey protein after oral 
administration in the human body was investigated by a combination of different in vitro 
models. In vitro models are commonly used as alternatives in the screening procedure of 
bioactive compounds, whether derived from food or plants or chemically synthesised. They 
contribute to the 3R concept of Replace, Reduce and Refine experiments with animals and 
humans. In vitro models have several advantages over in vivo experiments with laboratory 
animals and clinical trials in humans: they pose no ethical constraints, are more reproducible 
and suited for standardised operation, have lower costs, allow fast screening of numerous 
samples and are easier to investigate underlying mechanisms. The drawbacks inherent to 
these models are that they are less representative than the in vivo situation and that no 
conclusions can be made in the long term. All in vitro models have limitations and these need 
to be recognised. In vitro models are only useful if they are well validated so that a reliable 
predictive value is obtained. More sophisticated models may increase the similarity with the 
in vivo situation, but will be more complex at the same time. Depending on the goal of the 
research, the appropriate in vitro model should be selected. 
 
ACE inhibitory activity in vitro 
In this work, an ACE inhibition assay was developed from a diagnostic ACE activity test, 
further optimised and validated. It provided a more rapid and straightforward measurement of 
the ACE inhibitory activity compared to the widely used method of Cushman & Cheung and 
derivatives. Both methods may result in a slight overestimation of the ACE inhibitory activity 
of food protein hydrolysates, as peptide substrates of ACE also display ACE inhibitory 
activity in the assay. This can be circumvented on the pure peptide level by measuring the 
ACE inhibitory activity before and after pre-incubation of the peptide with ACE, where the 
ACE of the pre-incubation needs to be inactivated first, and a follow up of the degradation of 
the peptide by pre-incubation with ACE on HPLC (Fujita et al., 2000). As we focussed on 
food peptide mixtures, this approach was far too difficult for the purpose of our research and 
we just took this limitation into account. In literature, the majority of the ACE inhibitory 
peptide studies never mention this fact. Substrates for ACE are anyhow eliminated in the oral 
delivery route: if they already resist the gastrointestinal proteases, they are either degraded 
by ACE in the intestinal brush border membrane or by ACE in the plasma. The small 
increase in IC50 observed upon incubation of pea and whey digest with rat intestinal acetone 
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powder may have been partially due to substrates of ACE that were degraded. As the effect 
was more pronounced for pea than whey, it could be speculated that more substrates for 
ACE were present in the whey compared to the pea digests. Nevertheless, still high ACE 
inhibitory activity was found after this hydrolysis phase, indicating that a substantial amount 
of real ACE inhibitors was present in the digests. Further optimisation suggestions for the 
ACE inhibition assay are decreasing the sample volume of the inhibitory sample, which could 
be very useful in profound fractionation and isolation of ACE inhibitory peptides, and 
transforming the test to a multi-well plate assay, which will make the measurement even less 
labour intensive. A similar ACE inhibition assay, using FAPGG as substrate and measured in 
96 well plates during 15 min at 340 nm, was recently mentioned in a study of van der Ven et 
al. (2002). 
 
Antihypertensive effect in vivo 
It is difficult to establish a direct relation between the ACE inhibitory activity in vitro and the 
antihypertensive activity in vivo. Not only does the bioavailability after oral administration play 
a major role, but also other antihypertensive mechanisms than ACE inhibition may be of 
interest e.g. in the case of multifunctional peptides with additional opiate or vasorelaxing 
properties. In addition, different ACE inhibition assays, where other substrates and 
calculations for the IC50 are used, hamper the comparison of ACE inhibitory activities. Also in 
in vivo experiments and clinical trials, different experimental designs (measurement of the 
mean arterial or systolic and/or diastolic blood pressure; intravenous, subcutaneous or oral 
administration; other doses) and the use of the SHR model versus the hypertensive patient, 
hinder stating an unequivocal effect. Although the IC50 of captopril is about thousand fold 
lower than that of food derived ACE inhibitory peptides, there is not such a discrepancy 
observed in the antihypertensive effect. Indeed, oral administration of 200 mg/kg BW 
dipeptide isolated from garlic results in a reduction of blood pressure in SHR of about           
30 mmHg, while captopril at a dose of 10 mg/kg BW exerts an antihypertensive effect of 
about 50 mmHg (Suetsuna, 1998). There are no substantial differences in duration of the 
effect. When compared on molar basis, the antihypertensive activity of Leu-Lys-Pro after oral 
and intravenous administration in SHR, amounted to 91% and 20% respectively to that of 
captopril, whereas the in vitro ACE inhibitory activity was 7.73% compared to captopril (Fujita 
and Yoshikawa, 1999). Hence, these findings indicate that compared to antihypertensive 
drugs, food derived ACE inhibitory peptides with antihypertensive activity possess higher in 
vivo activity than what would be expected from their in vitro activity. A sound explanation for 
this observation cannot be proposed yet, but in addition to the reasons mentioned above, it is 
suggested that food derived peptides have higher affinities for tissues and are more slowly 
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eliminated than the synthetic captopril (Fujita and Yoshikawa, 1999). Moreover, it is plausible 
that the access to the ACE enzyme in vivo is limited so that above a certain affinity 
substances inhibit ACE in vivo to a similar extent. After feeding of a soy protein hydrolysate 
at 100 mg/kg BW in SHR during one month, the blood pressure decreased by 38 mmHg, 
compared to 46 mmHg for 50 mg/kg BW captopril (Wu and Ding, 2001). When assessing the 
ACE activity in serum, aorta and lung of these rats, the soy ACE inhibitory peptides did not 
show any significant effect compared to the control, whereas captopril greatly enhanced the 
ACE activity in serum and reduced the ACE activity in the aorta. Although the real causes of 
these observations remain unknown, these different responses might indicate that food 
derived ACE inhibitory peptides and captopril act via different antihypertensive mechanisms.  
Another remarkable effect is that an antihypertensive effect of ACE inhibitory peptides is 
only detected in SHR and hypertensive individuals and not in Wistar Kyoto rats (WKY) and 
normotensive individuals (Itakura et al., 2001; Nakamura et al., 1995b). This is directly 
related to their mechanism of action, because the opiate peptide α-lactorphin, although it has 
some ACE inhibitory activity, lowered the blood pressure in both SHR and WKY and this 
effect could be abolished by naloxone, a specific opiate receptor antagonist (Nurminen et al., 
2000).  
Hence, further investigation into the antihypertensive effect of food derived ACE inhibitory 
peptides is necessary. Yet, the showing of in vitro ACE inhibitory activity is a good starting 
point, because it is based on a biological mechanism. As ACE exhibits several functions in 
the human body, ACE inhibition may have additional or other implications than 
antihypertensive effects (Moskowitz, 2002). 
 
Intestinal transport  
Few studies on the transport of ACE inhibitory peptides have been undertaken in 
literature, although it is important for the bioavailability of these peptides to investigate if they 
are transported and what the transport mechanism is. The Caco-2 cell monolayer was used 
to investigate intestinal transport in this work. This confluent cell monolayer displays several 
properties typical for differentiated intestinal epithelial cells (Wilson et al., 1990) and is widely 
used as model in transport studies of drugs (Augustijns et al., 1998; Boisset et al., 2000) and 
food compounds (Rubio and Seiquer, 2002). Caco-2 cell monolayers are known to be tighter 
than mammalian intestinal tissues (Boisset et al., 2000), while brush border membrane 
associated enzyme activities are generally lower (Bolte et al., 1998). Species-specific 
differences in intestinal brush border enzyme activity have been observed (Drucker et al., 
1997). For example, esterase activities in homogenates prepared from freshly scraped 
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intestinal mucosa of rat is up to six times higher than that of pig, the latter considered more 
representative for the human small intestine (Augustijns et al., 1998). In order to get a total 
overview of the transport possibilities and limitations of a certain compound, it is advised to 
apply different absorption models. Considering the information above, Ala-Leu-Pro-Met-His-
Ile-Arg may be degraded in the human intestine to a lesser extent than in the rat intestinal 
tissue homogenates and it may be transported in higher concentrations than observed in the 
Caco-2 Bbe cell monolayer. Likewise, pea and whey digests and permeates may be 
absorbed in vivo, although in the Caco-2 model almost no transport of their ACE inhibitory 
activity is observed. Moreover, the digests and permeates have the advantage of showing 
resistance to degradation by intestinal peptidases from Caco-2 homogenates and rat 
intestinal acetone powder. It is believed that resistance to the brush border peptidases is the 
predominant factor for transport. Besides, during oral consumption of ACE inhibitory 
peptides, the presence of other food compounds may have important consequences on the 
susceptibility to peptidase degradation and intestinal transport (Charman et al., 1997). While 
some specific food compounds have been observed to decrease the TEER in the Caco-2 cell 
monolayer (Shimizu, 1999), active transport of sugars and amino acids initiates a solvent 
drag through the tight junctions in rat intestine, by which oligopeptides may be absorbed 
(Pappenheimer and Volpp, 1992). This could be an additional advantage of protein 
hydrolysates containing amino acids, compared to pure peptides.  
 
Pea versus whey protein 
In our study, pea and whey protein demonstrated some different characteristics, which 
can be related to their amino acid sequence and protein structure. Although pea protein was 
more susceptible to gastrointestinal proteases than whey, the latter had a lower IC50 value 
after in vitro physiological digestion, but this was only reached after the small intestine phase. 
After enrichment of ACE inhibitory peptides from the digests by ultrafiltration-centrifugation 
and RP-HPLC, the increases in ACE inhibitory activity were more substantial in whey 
compared to pea. While pea digest seemed to contain peptides with more or less similar 
ACE inhibitory activity, in whey digest potent ACE inhibitory peptides were present next to 
low active peptides. Combining SDS-PAGE and RP-HPLC experimental data with theoretical 
data from an ACE inhibitory peptide database and data-mining program revealed that           
β-lactoglobulin, the main whey protein, was responsible for these phenomena. This protein 
exhibited high ACE inhibitory peptide potential and resisted digestion by pepsin. The different 
pea proteins on the other hand were all rather easily digested and showed similar ACE 
inhibitory potential, which was lower than β-lactoglobulin. Moreover, in silico gastrointestinal 
digestion directly released Ala-Leu-Pro-Met-His-Ile-Arg from β-lactoglobulin, which could also 
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be released in the in vitro experiments. To our knowledge, this is the first study that applied a 
large ACE inhibitory peptide database to predict potentials of protein sequences. Such a 
database may prove to be particularly useful in nutrition science: instead of a ‘trial and error’ 
approach where ACE inhibitory peptides can be isolated from food proteins by applying 
certain enzymes, a food protein knowing to contain a lot of potent ACE inhibitory peptide 
sequences may be chosen to be digested by an enzyme that specifically will release these 
bioactive fragments. 
Pea digest and permeate exhibited higher ACE inhibitory activity than whey upon 
incubation with rat intestinal acetone powder or Caco-2 homogenates, due to a higher 
resistance towards brush border peptidases. The susceptibility to plasma peptidases may 
also have been the reason why pea permeate exerted a certain antihypertensive effect upon 
intravenous administration in SHR, while whey permeate was ineffective. However, further 
SHR experiments such as the daily oral administration of different doses over a longer period 
of time, need to further substantiate the possible antihypertensive effect of pea and whey 
permeate or digest.  
This thesis indicates some important physiological implications for the release of ACE 
inhibitory activity in vivo during gastrointestinal digestion of pea and whey protein. In healthy 
subjects maximal ACE inhibitory activity release after gastrointestinal digestion of pea and 
whey protein can be expected. In older persons that have a higher non-optimal pH in the 
stomach (Morihara et al., 2001), it is suggested that considerably lower ACE inhibitory 
activity is released, even more for whey than pea protein. In this respect, a production 
process based on the gastrointestinal digestion, like in the semi-continuous reactor model, 
has the advantage that potent ACE inhibitory hydrolysates that resist the physiological 
digestion, are orally administered. The results obtained by response surface modelling 
indicate that factors that prolonge the residence time in stomach and small intestine may 
enhance the release of ACE inhibitory activity. Examples are protein-rich, fat and 
hyperosmolalic food and sensations of fear (Ganong, 1997a). In this respect, peptides 
present in a food matrix may react with other food components, which can influence both the 
activity and the bioavailability of ACE inhibitory peptides. This, together with the effect of 
processing conditions, needs to be investigated when developing a food process technology 
for ACE inhibitory products.  
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PERSPECTIVES 
 
New approaches for production and bioavailability of ACE inhibitory peptides 
 In addition to the exploration of new proteins in this field, a more purposeful approach is 
the screening of the protein sequence, if available, against an ACE inhibitory peptide 
database as described in Chapter 6. Hence, proteins with high ACE inhibitory peptide 
potential can be selected a priori and specific enzymes that will release the active sequences 
can be chosen.  
 ACE inhibitory peptides may be chemically synthesised based on known peptide 
sequences. Although high costs and low quantities are generally associated with this 
production process, recent advantages in the design and construction of synthetic 
peptides make this approach more attractive. Standard solid-phase approaches using 
fluorenyl-methoxycarbonyl (FMOC) chemistry can synthesise routinely peptides to lengths of 
about 40-50 amino acids. Chemical ligation, the chemoselective reaction of unprotected 
peptide segments, is a more novel approach that has made the total synthesis of longer 
polypeptides possible even in water, at a pH of 7 (Muir et al., 1997). At present, one is able 
to design peptides with specific folding motifs to obtain more thermodynamically stable 
molecules and even more interestingly, to design peptides with specific functions. To 
accomplish this, one must first have an understanding of the spatial relationship amongst 
residues that will promote the desired activity. This usually requires knowledge of the X-ray 
crystal or NMR solution structure of the protein or peptide and deriving structure-activity 
relationships (SARs). For ACE inhibitory peptides, mostly short sequences without a tertiary 
structure, only the latter is of importance. SARs are generally developed by substituting 
residues in the native sequence and assessing the subsequent effects on structure and 
activity. Bioactivities of short peptides can be optimised by using combinatorial libraries 
(Dooley and Houghten, 1999; Mayo, 2000). A more detailed knowledge on the structure-
activity relationship of ACE inhibitory peptides and the crystallisation and mechanism of 
action of ACE will both contribute to and benefit from this approach. In addition, it may be 
investigated if amino acids that resist proteolysis in vivo, e.g. D-amino acids, can be 
incorporated with the maintenance of biological activity. Computer programs are also 
available that investigate the permeability of peptides (Brayden and O'Mahony, 1998). 
Finally, in this way an ACE inhibitory peptide database can be created and extended. 
 Some peptides, however, are still difficult to chemically synthesise. Genetic engineering 
may represent an alternative tool to produce these and other ACE inhibitory peptides in large 
amounts. The chemical synthesis of DNA provides the opportunity to construct and modify 
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natural genes, thereby making it possible to create an artificial gene coding for a specific 
ACE inhibitory peptide or a combination of peptides. However, in order to be applied as 
functional food or nutraceutical, these peptides must be produced with a high yield by 
recombinant DNA technology. Recently, the expression and purification of an ACE inhibitory 
peptide multimer in Escherichia coli containing the ACE inhibitory peptides Ile-Tyr and Val-
Lys-Tyr, was described (Oh et al., 2002). Artificial genes were designed based on the 
oligonucleotide sequence of the decapeptide Asp-Phe-Ile-Tyr-Val-Lys-Tyr-Gly-Pro-Gly. 
Degenerative codons for amino acids were used to avoid limitation of supply. The presence 
of Asp-Phe can counteract the positive charge of lysine, providing a more stable and less 
toxic peptide in the host cell. Phenylalanine and tyrosine make the peptide cleavable by       
α-chymotrypsin for the release of the ACE inhibitory peptide sequences. Two ligated 
repeated sequences were cloned into a plasmid vector and after isolation of the fragment it 
was recloned in pAP1, a plasmid vector already containing the synthetic DNA fragment. This 
step was repeated once more to end up with clones containing genes encoding up to 6 
repeats of the decapeptide, pAP3. Hence, the sequence was long enough to study the 
expression of the artificial protein. After isolation of this DNA fragment, it was cloned into 
another plasmid that was used to transform an E. coli strain. In this way, the artifical protein 
PA3 was expressed as a fusion protein, GST-AP3-6His. After recovering the inclusion bodies 
from the cells, the protein was easily purified with affinity chromatography on a glutathione 
sepharose column, due to the His-tag. The resin-bound fusion protein was cleaved with 
thrombin and the peptide AP3-6His was further purified on RP-HPLC. A yield of 7.9% of this 
oligopeptide was obtained after purification. After α-chymotrypsin hydrolysis and fractionation 
on RP-HPLC, two potent ACE inhibitory peptide fractions containing the peptides Ile-Tyr and 
Val-Lys-Tyr could be isolated. They constituted approximately 35% of the total AP3-
hydrolysate.  
 Several expression vector systems are commercially available to yield substantial 
amounts of designed proteins. Most of them, however, make the subsequent purification of 
the artificial protein necessary because the expressed protein resides in the host cell, as 
described in the above study. In the same way as therapeutic compounds are delivered in 
situ (Krüger et al., 2002; Steidler, 2002), ACE inhibitory propeptides could be delivered via 
microorganisms to the small intestine, where they could be expressed and exported outside 
the cell, cleaved into active peptides by the action of proteases and/or peptidases and finally 
transported into the blood stream. A GRAS microorganism that is able to survive the 
gastrointestinal transit and has additional probiotic properties, could be selected. This 
bacterium should be genetically engineered to express upon induction the ACE inhibitory 
propeptide, coupled to a signal peptide to direct the translocation of the protein through the 
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cell membrane. An inducible promoter should increase ACE inhibitory peptide release in the 
small intestine and prevent the expression of the polypeptide in the large intestine, where it is 
of no use and could eventually lead to the formation of harmful nitrogen compounds. When 
genetically modified organisms (GMO) are more understood and accepted, a functional food 
based on this concept might have great value, because it not only would enhance the oral 
delivery of ACE inhibitory peptides, but it also would enable the combination of different 
functional effects in one food. In addition to microorganisms, genetical engineering may also 
be applied to plants and animals, where modified proteins, rich in ACE inhibitory peptide 
sequences, could be obtained. 
 Despite their susceptibility to metabolisation and sometimes low membrane permeability, 
peptides have been recognised as important therapeutic compounds and therefore several 
approaches have been designed to increase the oral delivery of peptides. In addition to in 
situ delivery and modification of the peptide to obtain higher stability, the bioavailability of 
ACE inhibitory peptides may be increased by cross linking the target peptide to protein 
transduction domains or by means of specific peptide carriers like Pep-1 that are able to 
deliver biologically active proteins and peptides into mammalian cells (Morris et al., 2001). 
Peptide permeation may also be achieved by chemical enhancers and surfactant-like agents, 
provided the tissue recovers in vivo after temporary exposure. Receptor targeting and 
mucoadhesion represent some other strategies that may increase the delivery of peptides 
(Brayden and O'Mahony, 1998). 
 ACE affinity chromatography was applied to isolate an ACE binding protein of about    
14 kDa from human serum (Thevananther and Brecher, 1999). This technology might also 
be further explored for a more straightforward fractionation of ACE inhibitory peptides. A 
detailed knowledge about the structures of the active domains of ACE would allow coating 
columns with smaller particles for a specific methodology. 
 
ACE has more in store 
 The literature review already pointed out to the many different functions of the ACE 
enzyme. Moreover, relative overactivity of ACE (D/D genotype) appears to be associated 
with many age-dependent common diseases in humans, including cardiovascular disease, 
cancer and psychiatric disease (Moskowitz, 2002). ACE inhibitors are common treatments 
for direct hypertension related diseases like congestive heart failure, myocardial infarction, 
diabetes, chronic renal insufficiency and atherosclerotic cardiovascular diseases. However, 
hypertension is also significantly associated with cerebrovascular disease, neoplasms, 
endocrine disorders, gastrointestinal diseases, psychiatric disorders, dementia, skin 
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problems and blood diseases (Bunk, 2002). Besides, the successful application of ACE 
inhibitors in a number of these diseases suggests that ACE is an early rate-limiting step for 
multiple disease pathways (Figure 4). Since ACE inhibitors have superior, although not yet 
fully explained, clinically efficacy and an established safety profile, many additional disease 
targets might benefit from the administration of ACE inhibitors (Moskowitz, 2002). The broad 
functionality of ACE also increases the application possibility of food derived ACE inhibitory 
peptides.  
 
Figure 4.  ACE at the start of a disease pathway of common diseases (Moskowitz, 2002). 
 
Recently, a model has been designed for the active site of ACE and the functional and 
structural differences in the C- and N-domain (Moskowitz, 2003). The ancestral ACE gene 
underwent duplication at the origin of Chordata, at the same time that the circulation became 
closed, resulting in increased systemic pressure. Moskowitz (2003) suggests that the 
duplicated ACE, ‘somatic’ ACE, functions as a mechanosensor, defending downstream 
vessels and tissues from an increase in pressure. In this model, ACE senses shear stress 
(blood velocity) on vessel walls in regions of turbulent blood flow (Figure 5). This occurs in 
plaque containing regions or when cholesterol and fatty acids thicken membrane fluidity, so 
that ACE spins too slowly to orient itself in the direction of the blood flow. Both N- and C-
domains have an evolutionary conserved tripeptide Phe-X-Pro that is positioned near the 
active site and contains a charged middle amino acid in the C-terminal and a neutral middle 
amino acid in the N-terminal domain. An increase in shear stress strips this autoinhibitor 
tripeptide, Phe-Gln-Pro, from the N-terminal active site, thereby activating it. The C-terminal 
domain is constitutively activated by chloride. Crystallisation of the duplicated holoenzyme 
must validate this hypothesis.  
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Figure 5. Model of somatic ACE with the active C- and N-domains under laminar blood flow 
(left) and turbulent blood flow (right) conditions. Arrow with v = blood velocity 
vector, solid circle = zinc ion, open circle = chloride ion, @ = stop feature at active 
site preventing protrusion of more than two or three amino acids past the active 
site, N = N-terminal domain, C = C-terminal domain, R, P, K, Q, F = one letter 
amino acid code. The C-terminal active site has been opened by chloride ion. The 
N-terminal active site is occluded in a region of laminar blood flow. In a region of 
turbulent blood flow, the N-terminal active site is opened by a mechanical shearing 
force (Moskowitz, 2003).  
 
Hence, the N-terminal active domain of ACE may regulate ACE in vivo. Moskowitz (2003) 
proposes that the systemic blood pressure may be regulated by the C-domain, while local 
signals may be due to the activation of the N-terminal active site, e.g. target organ damage.  
This model also explains the clinical superiority of hydrophobic ACE inhibitors relative to 
hydrophilic ones. All ACE inhibitors bind to C-terminal sites, but only hydrophobic ones like 
captopril, quinapril and ramipril bind the occluded N-site and are therefore better at blocking 
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angiotensin II production. Moreover, it can explain why these inhibitors have specific local 
benefits in addition to a reduction in the systemic blood pressure (Moskowitz, 2003). 
This new information may have important implications for food derived ACE inhibitory 
peptides as well. Based on their structure, hydrophobic or hydrophilic, they will show a 
different inhibition of the ACE enzyme, resulting in different effects in the human body.  
 
Systems biology will change nutrition research 
In applying biomarkers in human studies, the relationship between nutritional intervention, 
the biomarkers and the supposed health effect, in many instances, has not been 
straightforward. This is also the case for the relation of ACE inhibitory activity in vitro and an 
antihypertensive effect in vivo. New biological methods can offer new perspectives in this 
respect. Genomics, genotyping, transcriptomics, proteomics and metabolomics, together with 
bioinformatics, constitute the discipline of functional genomics, which is also referred to as 
systems biology. Instead of focussing on a single gene or protein only, systems biology 
studies the whole tissue, organ or organism. In theory, the a priori knowledge of the 
molecular mechanism is not necessary, but will be revealed from the complex dataset. The 
integration of systems biology into nutrition research is termed nutritional genomics or 
nutrigenomics (van Ommen and Stierum, 2002; Verrips et al., 2001). This describes a new 
approach to food and nutrition research, in which these powerful functional genomic 
technologies are used in combination with established nutritional and biochemical techniques 
to determine the mechanisms by which foods and their individual components modulate 
processes occurring in the human body. Moreover, answers can be formulated on questions 
related to dose effects and individual requirements according to genetic profile, age, gender 
and lifestyle. Individual genetic differences in response to dietary components have been 
evident for years: lactose intolerance, alcohol dehydrogenase deficiency, individual and 
population differences in blood lipid profiles and health outcomes after consumption of high 
fat diets.  
In the respect of our work, the expression of hypertension related genes may be screened 
with several ACE inhibitory peptides to reveal the overall mechanisms by which ACE 
inhibitory peptides exert effects. This methodology may also provide answers to what roles 
gender, ethnicity and age play in ACE activity and its inhibition. Furthermore, the successful 
application of ACE inhibitors in a number of diseases may be mechanistically explained.  
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Addendum 
 
 
Composition of Pisane (Cosucra), pea protein isolate and Lacprodan DI-9213 
(Acatris), whey protein isolate 
Component Content (% of dry matter) *(UTI/mg dry matter) 
 PEA WHEY 
protein (N x 6.25) 90 ± 2 min. 90 
fat (petroleum ether method) 0.2 max. 0.2 
fibres 1.8  
starch 0.7  
sugars 1 max. 0.2 
ash  max. 5 (mainly K, Na, P) 5 (mainly P) 
water  max. 6 max. 5 
anti-nutritional factors:   
 α-galactosides 0.9  
 trypsin inhibitors 1.25*  
 phytic acid 1.5  
 lectins 0  
 
 
 
Physical specifications 
 PEA WHEY 
pH (5% solution) 6.8-7.5 2.8-3.5 
density 0.33 g/cm3 0.45 g/cm3 
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Amino acid composition 
Amino acid Content (% of total nitrogen content) 
 PEA WHEY 
alanine 4.7 4.7 
arginine 9.0 1.9 
aspartate 12.3 11.0 
cysteine 1.2 2.4 
glutamate 19.8 16.7 
glycine 4.6 1.7 
histidine* 2.8 1.9 
isoleucine* 4.6 6.1 
leucine* 8.0 10.2 
lysine* 8.2 9.2 
methionine* 1.1 1.8 
phenylalanine* 5.5 3.0 
proline 4.5 5.8 
serine 5.4 5.0 
threonine* 4.1 7.3 
tryptophan* 1.0 1.7 
tyrosine 4.1 3.7 
valine* 5.2 5.9 
* dietary essential amino acids 
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